var images_info;if (!images_info) images_info =[]; images_info["106"]={"106010":{"type":"graphic_algorithm","displayName":"Treatment of pediatric hypercholesterolemia","title":"Overview of management of hypercholesterolemia in children 10 years and older","html":"<div class=\"graphic\"><div style=\"width: 830px\" class=\"figure\"><div class=\"ttl\">Overview of management of hypercholesterolemia in children 10 years and older</div><div class=\"cntnt\"><img style=\"width:810px; height:692px;\" src=\"images/PEDS/106010_Tx_ped_hypercholesterolemia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;algorithm summarizes the management of hypercholesterolemia in children 10 years and older. Refer to the UpToDate topic on management of pediatric dyslipidemia for details of management in children &lt;10 years.<br />LDL-C units are mg/dL; divide by 38.67 to convert to mmol/L.</div><div class=\"graphic_footnotes\">LDL-C: low-density lipoprotein cholesterol; CVD: cardiovascular disease; NHLBI: National Heart, Lung, and Blood Institute; BMI: body mass index; HIV: human immunodeficiency virus.<br />* LDL-C values should be based on averaging the results of two fasting lipid profiles obtained two weeks to three months apart. For LDL-C levels ≥250, refer to a pediatric lipid specialist. Refer to the UpToDate topic on management of dyslipidemia in children for additional details.<br />¶ Consultation with a registered dietician may be warranted for implementation of dietary changes. Refer to the UpToDate topic on management of pediatric dyslipidemia for further details of nonpharmacologic management of hypercholesterolemia.<br />Δ Targeted values of LDL-C and depend on the presence of associated risk factors. Generally, the minimal value is &lt;130 mg/dL (3.36 mmol/L). The optimal value is &lt;110 mg/dL (2.84 mmol/L). In high risk patients (eg, children with diabetes mellitus or chronic renal insufficiency), target values of &lt;100 mg/dL (2.59 mmol/L) are used.<br /><FONT class=lozenge>◊</FONT> Risk factors for premature CVD, as defined by the NHLBI expert panel are: high-risk conditions and comorbidities (including type 1 and 2 diabetes mellitus, chronic kidney disease, hypertension requiring drug therapy [ie, blood pressure ≥99<SUP>th</SUP> percentile + 5 mmHg], current cigarette smoker, BMI ≥97<SUP>th</SUP> percentile, heart transplant recipient, and Kawasaki disease with current coronary aneurysms); moderate-risk conditions and comorbidities (including hypertension not requiring drug therapy, BMI ≥95<SUP>th</SUP> and &lt;97<SUP>th</SUP> percentile, HDL-C &lt;40 mg/dL [1.03 mmol/L], Kawasaki disease with regressed coronary aneurysms, chronic inflammatory diseases [eg, systemic lupus erythematosus, juvenile idiopathic arthritis], HIV infection, nephrotic syndrome, and adolescent depressive and bipolar disorders).<br />§ Family history of CVD includes heart attack, treated angina, interventions for coronary artery disease, stroke, or sudden cardiac disease in a first or second degree relative at age &lt;55 years for males or &lt;65 years for females. First- and second-degree relatives include parents, siblings, grandparents, aunts, and uncles.</div><div class=\"graphic_reference\">Adapted from: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.</div><div id=\"graphicVersion\">Graphic 106010 Version 1.0</div></div></div>"},"106011":{"type":"graphic_algorithm","displayName":"Overview of statin therapy in children","title":"Overview of statin therapy for hypercholesterolemia in children ≥10 years","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Overview of statin therapy for hypercholesterolemia in children &ge;10 years</div><div class=\"cntnt\"><img style=\"width:566px; height:736px;\" src=\"images/PEDS/106011_Overview_statin_thrpy_child.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure summarizes the management of statin therapy in children 10 years and older. Children &lt;10 years who require statin therapy should be managed by a pediatric lipid specialist. Refer to the UpToDate topic on management of dyslipidemia in children for more details.<br />Prior to initiating statin therapy, potential drug interactions should be reviewed if the child is taking other medications (specific drug interactions may be determined by using Lexi-Interact). Female patients should be advised about concerns with pregnancy and the need for appropriate contraception.</div><div class=\"graphic_footnotes\">LDL-C: low-density lipoprotein cholesterol; CK: creatine kinase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CVD: cardiovascular disease; NHLBI: National Heart, Lung, and Blood Institute.<br />* Criteria for initiating statin therapy are based upon the LDL-C level and the presence of additional CVD risk factors. Refer to the UpToDate topic on management of dyslipidemia in children for more details.<br />¶ The recommendations for laboratory monitoring presented here are based upon the NHLBI expert panel guidelines. Individual practice may vary. Refer to the UpToDate topic on management of pediatric dyslipidemia for further details.<br />Δ Refer to Lexicomp for information on dosing of individual statin medications in children. The initial choice of agent is generally based on potential drug interactions, experience with the drug in children, price, and patient preference. Statin medications are usually given at bedtime, because most LDL-C synthesis occurs during nighttime hours.<br /><FONT class=lozenge>◊</FONT> Toxicity from statin therapy includes elevated liver enzymes (≥3 times the upper limit of normal), and myopathy (ie, elevated CK [≥10 times the upper limit of normal] or suggestive symptoms such as weakness, asthenia, and/or muscle cramps).<br />§ Targeted values of LDL-C and depend on the presence of associated risk factors. Generally, the minimal value is &lt;130 mg/dL (3.36 mmol/L). The optimal value is &lt;110 mg/dL (2.84 mmol/L). In high-risk patients (eg, children with diabetes mellitus or chronic renal insufficiency), target values of &lt;100 mg/dL (2.59 mmol/L) are used.</div><div class=\"graphic_reference\">Reference: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.</div><div id=\"graphicVersion\">Graphic 106011 Version 1.0</div></div></div>"},"106015":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of neonatal nephrocalcinosis","title":"Ultrasound demonstrating nephrocalcinosis in a neonate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound demonstrating nephrocalcinosis in a neonate</div><div class=\"cntnt\"><img style=\"width:448px; height:270px;\" src=\"images/PEDS/106015_US_neonatal_nephrocalcinos.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Patrick Niaudet, MD.</div><div id=\"graphicVersion\">Graphic 106015 Version 1.0</div></div></div>"},"106052":{"type":"graphic_picture","displayName":"Damage control shunting of iliac artery and ureter","title":"Damage control shunting of iliac artery and ureter","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Damage control shunting of iliac artery and ureter</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/106052_Dmg_cnt_shnt_iic_art_urtr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture shows damage control techniques used to manage injuries to the right iliac artery (arrowhead)&nbsp;and right ureter (arrow) following a gunshot wound. A vascular shunt has been placed into the injured iliac artery and tied into place with sutures above and below the tear (arrowhead). A drainage catheter has been placed into the damaged ureter (arrow) to divert urine externally.</div><div id=\"graphicVersion\">Graphic 106052 Version 1.0</div></div></div>"},"106065":{"type":"graphic_figure","displayName":"Resolution of comorbidities after adolescent WLS","title":"Resolution of comorbidities after weight loss surgery in adolescents","html":"<div class=\"graphic\"><div style=\"width: 697px\" class=\"figure\"><div class=\"ttl\">Resolution of comorbidities after weight loss surgery in adolescents</div><div class=\"cntnt\"><img style=\"width:677px; height:352px;\" src=\"images/PEDS/106065_Rsl_cmrbdt_aft_adls_WLS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Presence of comorbidities among 225 adolescents undergoing weight loss surgery, comparing data from baseline (preoperative) to three years after undergoing laparoscopic sleeve gastrectomy (SG) or roux-en-Y gastric bypass (RYGB). The percent with resolution refers to the patients that had the condition at baseline. Incident cases in the postoperative period are not included (diabetes 0%; dyslipidemia 7%, elevated blood pressure [BP] 4%; abnormal kidney function 10%).</div><div class=\"graphic_reference\">Data from: Inge TH, Courcoulas AP, Jenkins TM, et al. Weight Loss and Health Status 3 Years after Bariatric Surgery in Adolescents. N Engl J Med 2015.</div><div id=\"graphicVersion\">Graphic 106065 Version 1.0</div></div></div>"},"106069":{"type":"graphic_table","displayName":"Oral iron products","title":"Oral iron products","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral iron products</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Examples of US trade (brand) names</td> <td class=\"subtitle1\">Elemental iron content<br /> (mg iron per mg tablet or per mL liquid)*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"> <p><strong>Ferrous fumarate</strong></p> (contains 33% elemental iron per mg of mineral salt)</td> <td class=\"highlight_gray_text\"> <ul> <li>Tablets</li> </ul> </td> <td class=\"highlight_gray_text\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">Various over the counter and store brand products with \"iron\" in the name</td> <td>29.5 mg/90 mg</td> </tr> <tr> <td class=\"indent2\">Ferrimin 150</td> <td>150 mg elemental iron per tablet</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Ferretts, Ferrocite, Hemocyte</td> <td>106 mg/324 or 325 mg</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"> <p><strong>Ferrous gluconate</strong></p> (contains approximately 10 to 14% elemental iron per mg of mineral salt)</td> <td class=\"highlight_gray_text\"> <ul> <li>Tablets</li> </ul> </td> <td class=\"highlight_gray_text\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">Fergon, Ferrotabs</td> <td>27 mg/240 mg</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Various over the counter and store brand products with \"iron\" in the name</td> <td>28 mg/256 mg or 38 mg/324 or 325 mg</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\"> <p><strong>Ferrous sulfate</strong></p> (generally contains 20 to 30% elemental iron per mg of mineral salt, but can vary by manufacturer)</td> <td class=\"highlight_gray_text\"> <ul> <li>Liquids</li> </ul> </td> <td class=\"highlight_gray_text\">Multiple concentrations exist; check packaging closely</td> </tr> <tr> <td class=\"indent2\">BProtected Pedia, Fer-In-Sol, Fer-Iron</td> <td class=\"indent1\">15 mg/1 mL (\"drops\"; \"solution\")</td> </tr> <tr> <td class=\"indent2\">FeroSul</td> <td class=\"indent1\">44 mg/5 mL (\"elixir\"; \"liquid\")</td> </tr> <tr> <td class=\"indent2\">Various over the counter and store brand products with \"iron\" in the name</td> <td class=\"indent1\">60 mg/5 mL (\"syrup\")</td> </tr> <tr> <td class=\"highlight_gray_text\"> <ul> <li>Tablets</li> </ul> </td> <td class=\"highlight_gray_text\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">Feosol original</td> <td>65 mg/200 mg</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Ferro-Bob, FerrouSul</td> <td>65 mg/325 mg</td> </tr> <tr> <td rowspan=\"5\"> <p><strong>Polysaccharide-iron complex (PIC)</strong></p> (also available as PIC plus folic acid and PIC plus folic acid and vitamin B12)</td> <td class=\"highlight_gray_text\"> <ul> <li>Liquids</li> </ul> </td> <td class=\"highlight_gray_text\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">NovaFerrum</td> <td>15 mg/1 mL (\"drops\")</td> </tr> <tr> <td class=\"indent2\">NovaFerrum 125</td> <td>125 mg/5 mL (\"liquid\")</td> </tr> <tr> <td class=\"highlight_gray_text\"> <ul> <li>Capsules</li> </ul> </td> <td class=\"highlight_gray_text\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">EZFE 200, Ferrex 150, Ferric-X 150, iFerex 150, Myferon 150, NovaFerrum 50, Nu-Iron 150, PIC 200, Poly-Iron 150</td> <td>The number in the name is the mg of elemental iron (eg, NovaFerrum 50 contains 50 mg elemental iron per capsule)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Commonly available products are shown; other products are available by prescription or over the counter. Enteric coated and extended release formulations are also available for some products, but we generally do not advise use of these preparations because they are poorly absorbed. Refer to UpToDate content and Lexicomp drug monographs (included with UpToDate) for details of dosing, treatment of iron deficiency anemia, and management of acute iron poisoning.</div><div class=\"graphic_footnotes\">* Commonly available concentrations are listed, but other concentrations may be available and some brands may have been reformulated. Always refer to the latest available information on specific products.</div><div id=\"graphicVersion\">Graphic 106069 Version 3.0</div></div></div>"},"106070":{"type":"graphic_table","displayName":"Oral versus IV iron","title":"Advantages and disadvantages of oral versus IV iron","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of oral versus IV iron</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Oral iron</strong></td> <td> <ul> <li>Effective for most patients </li> <li>Extremely low risk of serious adverse events </li> <li>Initial costs very low&nbsp;</li> </ul> </td> <td> <ul> <li>Gastrointestinal side effects are common </li> <li>Compliance may be low </li> <li>May be inadequate for severe or ongoing&nbsp;blood loss </li> <li>May require administration for several months </li> <li>Total costs may be higher </li> </ul> </td> </tr> <tr> <td><strong>IV iron</strong></td> <td> <ul> <li>Effective for most patients </li> <li>More rapid correction of anemia and resolution of symptoms </li> <li>Ability to administer large doses (up to 1000 mg elemental iron) in a single infusion </li> <li>Compliance is assured </li> <li>No gastrointestinal side effects </li> </ul> </td> <td> <ul> <li>Requires monitored intravenous infusion </li> <li>Rare cases of allergic or infusion reactions </li> <li>Requires equipment and personnel to treat allergic or infusion reactions </li> <li>Initial costs may be higher </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content on the management of&nbsp;iron deficiency for further details. Advantages, disadvantages, costs, and burdens for any individual patient&nbsp;may depend on a number of factors.</div><div class=\"graphic_footnotes\">IV: intravenous.</div><div id=\"graphicVersion\">Graphic 106070 Version 1.0</div></div></div>"},"106077":{"type":"graphic_figure","displayName":"SCD distribution","title":"Countries with the highest incidence of sickle cell disease","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Countries with the highest incidence of sickle cell disease</div><div class=\"cntnt\"><img style=\"width:541px; height:362px;\" src=\"images/HEME/106077_SCD_distribution.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Half of the world's sickle cell disease population lives in these three countries.&nbsp;Refer to UpToDate content on sickle cell disease in sub-Saharan Africa for additional information.</div><div class=\"graphic_footnotes\">DR Congo: Democratic Republic of Congo</div><div id=\"graphicVersion\">Graphic 106077 Version 1.0</div></div></div>"},"106078":{"type":"graphic_picture","displayName":"Wilms tumor histology","title":"Wilms tumor histology","html":"<div class=\"graphic\"><div style=\"width: 761px\" class=\"figure\"><div class=\"ttl\">Wilms tumor histology</div><div class=\"cntnt\"><img style=\"width:741px; height:555px;\" src=\"images/PEDS/106078_Wlms_tmr_hstlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of Wilms tumor (hematoxylin-eosin stained) showing the triphasic nature of favorable histology, including epithelial cells, stromal cells, and blastemal cells.</div><div class=\"graphic_reference\">Courtesy of John Hicks, MD, Department of Pathology, Texas Children&rsquo;s Hospital and Baylor College of Medicine, Houston TX.</div><div id=\"graphicVersion\">Graphic 106078 Version 1.0</div></div></div>"},"106079":{"type":"graphic_picture","displayName":"Anaplastic Wilms tumor","title":"Anaplastic Wilms tumor","html":"<div class=\"graphic\"><div style=\"width: 758px\" class=\"figure\"><div class=\"ttl\">Anaplastic Wilms tumor</div><div class=\"cntnt\"><img style=\"width:738px; height:524px;\" src=\"images/PEDS/106079_Anplstc_wlms_tmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of anaplastic Wilms tumor (hematoxylin-eosin stained) showing hyperchromatic and enlarged tumor cells with bizarre mitotic figures (arrows).</div><div class=\"graphic_reference\">Courtesy of John Hicks, MD, Department of Pathology, Texas Children&rsquo;s Hospital and Baylor College of Medicine, Houston TX.</div><div id=\"graphicVersion\">Graphic 106079 Version 1.0</div></div></div>"},"106089":{"type":"graphic_table","displayName":"Muscle enzyme deficiencies","title":"Clinical and laboratory features of muscle enzyme deficiencies of glycogen metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and laboratory features of muscle enzyme deficiencies of glycogen metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"22%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Enzyme deficiency</td> <td class=\"subtitle1\">CPK</td> <td class=\"subtitle1\">Myoglobinuria</td> <td class=\"subtitle1\">Muscle glycogen present/abnormal</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td>Muscle glycogen synthase deficiency (GSD0b)</td> <td>Normal</td> <td>Not reported, present in an equine model</td> <td>Reduced glycogen content</td> <td> <p>Cardiomyopathy</p> Progressive weakness</td> </tr> <tr> <td>Lysosomal acid maltase deficiency (GSD II)</td> <td>Increased</td> <td>Absent</td> <td>Increased lysosomal glycogen</td> <td> <p>Hypotonia in infants</p> <p>Cardiomyopathy</p> Progressive weakness</td> </tr> <tr> <td>Glycogen debrancher deficiency (GSD III)</td> <td>Increased</td> <td>Absent</td> <td>Increased in &#62;90% of cases</td> <td> <p>Progressive weakness</p> Cardiomyopathy</td> </tr> <tr> <td>Glycogen branching enzyme deficiency (GSD IV)</td> <td>Normal</td> <td>Absent</td> <td>Polyglucosan</td> <td> <p>Highly variable age of onset</p> <p>Neurologic involvement</p> <p>Liver disease</p> Cardiomyopathy</td> </tr> <tr> <td>Muscle phosphorylase deficiency (GSD V)</td> <td>Increased</td> <td>Present</td> <td>Increased</td> <td> <p>Acute muscle pain</p> Progressive weakness</td> </tr> <tr> <td>Phosphofructokinase deficiency (GSD VII)</td> <td>Increased</td> <td>Present</td> <td> <p>Increased</p> Occasional polyglucosan</td> <td> <p>Exercise intolerance</p> Occasional gout</td> </tr> <tr> <td>Phosphoglycerate kinase deficiency</td> <td>Increased</td> <td>Present</td> <td>Increased</td> <td> <p>Exercise intolerance</p> <p>Variable neurologic involvement</p> Hemolysis</td> </tr> <tr> <td>Phosphorylase kinase deficiency (GSD IXd)</td> <td>Increased</td> <td>Absent</td> <td>Increased</td> <td>Exercise intolerance</td> </tr> <tr> <td>Phosphoglycerate mutase deficiency (GSD X)</td> <td>Increased</td> <td>Present</td> <td>Increased</td> <td> <p>Exercise intolerance</p> <p>Variable neurologic involvement</p> Hemolysis</td> </tr> <tr> <td>Lactate dehydrogenase A deficiency</td> <td>Increased</td> <td>Present</td> <td>Increased</td> <td>Exercise intolerance</td> </tr> <tr> <td>Aldolase A deficiency (GSD XII)</td> <td>Increased</td> <td>Present</td> <td>Increased</td> <td> <p>Myopathy</p> Variable hemolysis</td> </tr> <tr> <td>Beta-enolase deficiency (GSD XIII)</td> <td>Increased</td> <td>Present</td> <td>Increased or normal</td> <td>Exercise intolerance</td> </tr> <tr> <td>Phosphoglucomutase 1 deficiency (GSD XIV)</td> <td>Increased</td> <td>Present</td> <td>Increased or normal</td> <td> <p>Exercise intolerance</p> <p>Dilated cardiomyopathy</p> Protein glycosylation defects</td> </tr> <tr> <td>Glycogenin-1 deficiency (GSD XV)</td> <td>Normal</td> <td>Absent</td> <td>Polyglucosan/reduced normal glycogen</td> <td> <p>Cardiomyopathy</p> Progressive weakness</td> </tr> <tr> <td>RBCK1/ HOIL-1 deficiency</td> <td>Increased</td> <td>Absent</td> <td>Polyglucosan/reduced normal glycogen</td> <td> <p>Progressive weakness</p> <p>Cardiomyopathy</p> Increased infections</td> </tr> <tr> <td>Gamma subunit of AMP-activated protein kinase (PRKAG2) dysfunction</td> <td>Normal</td> <td>Absent</td> <td>Increased glycogen/variable polyglucosan</td> <td> <p>Cardiomyopathy</p> <p>Wolff-Parkinson-White syndrome</p> Atrioventricular conduction block</td> </tr> <tr> <td>LAMP 2 deficiency (formerly GSDIIb)</td> <td>Increased</td> <td>Absent</td> <td>Increased non-lysosomal glycogen</td> <td> <p>Cardiomyopathy</p> <p>Skeletal myopathy</p> <p>Neurologic involvement</p> Females also affected</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GSD: glycogen storage disease; CPK: creatinine phosphokinase;&nbsp;RBCK1:RanBP-type and C3HC4-type zinc finger containing 1;&nbsp;HOIL-1: heme-oxidized IRP2 ubiquitin ligase 1;&nbsp;AMP: adenosine monophosphate; LAMP 2: lysosome-associated membrane protein 2.</div><div class=\"graphic_reference\">Courtesy of William J Craigen, MD, PhD.</div><div id=\"graphicVersion\">Graphic 106089 Version 1.0</div></div></div>"},"106090":{"type":"graphic_picture","displayName":"Cloacal exstrophy","title":"Cloacal exstrophy in newborn infants","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Cloacal exstrophy in newborn infants</div><div class=\"cntnt\"><img style=\"width:726px; height:535px;\" src=\"images/PEDS/106090_Clcl_exstrphy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cloacal exstrophy in a male (A) and female (B) newborn infant. The anus is imperforate and the hindgut exits from the lower abdominal wall. In both patients, the bladder is split in half (seen best in the female; arrowheads), separated by the hindgut (asterisks). The umbilicus and omphalocele are seen superior to the split bladder and hindgut. The external genitalia are also split; the male has a small hemiphallus (arrows) associated with the scrotum.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 106090 Version 1.0</div></div></div>"},"106091":{"type":"graphic_diagnosticimage","displayName":"Mixed gonadal dysgenesis imaging","title":"Mixed gonadal dysgenesis (45,X/46,XY mosaicism)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mixed gonadal dysgenesis (45,X/46,XY mosaicism)</div><div class=\"cntnt\"><img style=\"width:283px; height:131px;\" src=\"images/PEDS/106091_Mxd_gndl_dysgns_img.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Imaging in a patient with mixed gonadal dysgenesis.<br />(A) Genitogram showing the M&uuml;llerian/uterine remnant on the patient's left side; the arrow points to the fallopian tube.<br />(B) Pelvic ultrasound showing the M&uuml;llerian/uterine remnant (arrow) behind the bladder.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 106091 Version 2.0</div></div></div>"},"106092":{"type":"graphic_diagnosticimage","displayName":"46,XX CAH Prader V","title":"Congenital adrenal hyperplasia with severe virilization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital adrenal hyperplasia with severe virilization</div><div class=\"cntnt\"><img style=\"width:414px; height:722px;\" src=\"images/PEDS/106092_46_XX_CAH_prdr_V.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infant with congenital adrenal hyperplasia (CAH) and severe virilization (Prader V).<br />(A): The phallus is fully developed, with a complete penile urethra.<br />(B): Genitogram demonstrating a high insertion of the vagina close to the bladder neck, representing a high confluence (arrow), and a long common&nbsp;urogenital sinus.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 106092 Version 1.0</div></div></div>"},"106093":{"type":"graphic_diagnosticimage","displayName":"Parotid gland ultrasonography in Sjögren's syndrome","title":"Parotid gland ultrasonography in Sjögren's syndrome","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Parotid gland ultrasonography in Sj&ouml;gren's syndrome</div><div class=\"cntnt\"><img style=\"width:728px; height:300px;\" src=\"images/RHEUM/106093_Prtd_glnd_ultrsn_sjgrn_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Longitudinal axis view of right parotid gland in a patient with sicca symptoms who did not fulfill criteria for Sj&ouml;gren's syndrome. Note the overall homogeneity in echotexture of the glandular parenchyma. This was interpreted as a normal study.<br />(B) Longitudinal axis view of right parotid gland in a patient with Sj&ouml;gren's syndrome. Note the numerous hypoechoic rounded areas, some of which are bounded by hyperechoic linear bands.</div><div class=\"graphic_reference\">Courtesy of Alan Baer, MD.</div><div id=\"graphicVersion\">Graphic 106093 Version 1.0</div></div></div>"},"106095":{"type":"graphic_table","displayName":"Prospective risk of fetal death in monoamniotic twin pregnancies","title":"Prospective risk of noniatrogenic fetal death in ongoing monoamniotic twin pregnancies by gestational age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prospective risk of noniatrogenic fetal death in ongoing monoamniotic twin pregnancies by gestational age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gestational age at baseline</td> <td class=\"subtitle1\">Rate of fetal death before delivery (percent)</td> </tr> <tr> <td>11 weeks</td> <td>16.3</td> </tr> <tr> <td>28 weeks</td> <td>1.4</td> </tr> <tr> <td>32 to 34 weeks</td> <td>5.1</td> </tr> <tr> <td>After 34 weeks</td> <td>0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data from a multicenter retrospective cohort study that included 193 monoamniotic twin pregnancies (386 fetuses) at 11 weeks of gestation. The mean gestational age of delivery for the 153 pregnancies with live born infants was 32.2 weeks of gestation.</div><div class=\"graphic_reference\">Data from: Van Mieghem T, De Heus R, Lewi L, et al. Prenatal management of monoamniotic twin pregnancies. Obstet Gynecol 2014; 124:498.</div><div id=\"graphicVersion\">Graphic 106095 Version 2.0</div></div></div>"},"106096":{"type":"graphic_diagnosticimage","displayName":"SPECT-CT in melanoma","title":"SPECT-CT in melanoma","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">SPECT-CT in melanoma</div><div class=\"cntnt\"><img style=\"width:725px; height:714px;\" src=\"images/ONC/106096_SPECT_CT_mlnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A): Planar images show the injection site (arrow) as well as tracer migrating toward both axillae. The location of the focal tracer uptake (arrowhead and dashed arrow) might be assumed to be bilateral axillary uptake, but it is difficult to determine on planar images alone.<br />(B): SPECT/CT shows focal tracer uptake in the left axilla (dashed arrow) as well as in a peri-scapular in-transit node (arrowhead) that was superimposed over the axilla on planar images.</div><div id=\"graphicVersion\">Graphic 106096 Version 1.0</div></div></div>"},"106098":{"type":"graphic_algorithm","displayName":"Atrial fibrillation anticoagulation algorithm","title":"Atrial fibrillation anticoagulation algorithm","html":"<div class=\"graphic\"><div style=\"width: 888px\" class=\"figure\"><div class=\"ttl\">Atrial fibrillation anticoagulation algorithm</div><div class=\"cntnt\"><img style=\"width:868px; height:634px;\" src=\"images/CARD/106098_Atrial_fib_antcg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TTR: time in therapeutic range; DAPT: dual antiplatelet therapy.<br />* The CHAD2S2-VASc score and estimated stroke risk based on the score are meant to provide guidance, but are not substitutes for clinical judgment.<br /><STRONG>Score 0 recommendation:</STRONG> For a patient with a CHA2DS2-VASc score of 0, the benefit-to-risk ratio generally does not favor anticoagulation. Nevertheless, patients who are not particularly stroke averse may reasonably choose anticoagulation.<br /><STRONG>Score 1 recommendation:</STRONG> The benefit-to-risk ratio varies depending on the patient's specific risk factor for thromboembolism and bleeding risk, but generally favors anticoagulation. Among those with a risk score of 1, patients between the ages of 65 and 74 years of age are at the highest risk for thromboembolism, followed by patients with heart failure, hypertension, or diabetes. Patients with vascular disease are at lower risk, and patients whose only risk factor is being female are at the lowest risk (but still at increased risk compared with an individual with no risk factors). A decision not to anticoagulant is a reasonable alternative for patients with a score of 1, particularly for patients at lower risk for thromboembolism (eg, women) or at increased risk for major bleeding.<br /><STRONG>Score 2+ recommendation:</STRONG> The benefit-to-risk ratio generally favors anticoagulation. The rare patient at very high risk of major bleeding, or an informed patient who is particularly averse to bleeding risk, may choose no anticoagulation.<br />¶ Some particularly stroke averse patients may reasonably choose anticoagulation.<br />Δ <STRONG>Reasons to avoid NOAC:</STRONG> Reasons not to use a non-vitamin K oral anticoagulant (NOAC) include (not an extensive list): &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Creatinine clearance &lt;30 mL/min</LI>&#xD;&#xA;<LI>Significant drug interactions, such as rifampin or enzyme-inducing antiepileptic drugs (eg, carbamazepine, phenytoin, some human immunodeficiency virus therapies)</LI>&#xD;&#xA;<LI>Patient has risk factors for NOAC accumulation, such as creatinine clearance ≤80 mL/min with low body weight</LI>&#xD;&#xA;<LI>Patient belongs to a group in which the use of NOACs has not been adequately studied, such as morbid obesity, weight &lt;60 kg, or age ≥80 years</LI>&#xD;&#xA;<LI>NOACs unavailable, not covered by the patient's insurance, or other cost concerns</LI>&#xD;&#xA;<LI>Concern about lack of a reversal agent for most of these (a reversal agent is available for dabigatran)</LI>&#xD;&#xA;<LI>Patient is pregnant or breast feeding (excretion unknown)</LI></UL><STRONG>Choice of NOAC:</STRONG> Evidence does not favor one NOAC over another. The choice of NOAC will depend on cost, availability, and clinician experience with the different agents. Edoxaban and rivaroxaban are given once daily and may be preferable in patients who are unlikely to comply with twice daily dosing.<br /><FONT class=lozenge>◊</FONT> Referral to a clinician experienced in counseling patients in the relative benefits and risks of anticoagulation therapy.</div><div id=\"graphicVersion\">Graphic 106098 Version 3.0</div></div></div>"},"106102":{"type":"graphic_table","displayName":"SIOP regimens for Wilms tumor","title":"Treatment regimens for Wilms tumor according to completed European* (SIOP) trials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment regimens for Wilms tumor according to completed European* (SIOP) trials</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"5%\"></colgroup><colgroup span=\"4\" width=\"23%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"5\">SIOP WT 2001 and 93-01</td> </tr> <tr> <td class=\"subtitle2\">Stage<sup>&#182;</sup></td> <td class=\"subtitle2\">Preoperative chemotherapy</td> <td class=\"subtitle2\">Histology<sup>&#916;</sup> (assessed after initial chemotherapy)</td> <td class=\"subtitle2\">Postoperative chemotherapy</td> <td class=\"subtitle2\">Radiation therapy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">I</td> <td class=\"divider_bottom\" rowspan=\"3\">Vincristine and dactinomycin for 4 weeks</td> <td>Low risk</td> <td>None</td> <td>None</td> </tr> <tr> <td>Intermediate risk</td> <td>Vincristine and dactinomycin for 4 weeks</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>High risk</td> <td>Vincristine, dactinomycin, and doxorubicin for 27 weeks</td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">II</td> <td class=\"divider_bottom\" rowspan=\"2\">Vincristine and dactinomycin for 4 weeks</td> <td>Low and intermediate risk</td> <td>Vincristine and dactinomycin for 27 weeks</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>High risk</td> <td>Doxorubicin, cyclophosphamide, carboplatin, and etoposide for 34 weeks</td> <td>25.2 Gy flank; 10.8-Gy boost for lymph node involvement or gross disease</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">III</td> <td class=\"divider_bottom\" rowspan=\"3\">Vincristine and dactinomycin for 4 weeks</td> <td>Low risk</td> <td>Vincristine and dactinomycin for 27 weeks</td> <td>None</td> </tr> <tr> <td>Intermediate risk</td> <td>Vincristine and dactinomycin for 27 weeks</td> <td>14.4 Gy flank; 10.8 Gy boost for lymph node involvement or gross disease</td> </tr> <tr class=\"divider_bottom\"> <td>High risk</td> <td>Doxorubicin, cyclophosphamide, carboplatin, and etoposide for 34 weeks</td> <td>25.2 Gy flank; 10.8-Gy boost for lymph node involvement or gross disease</td> </tr> <tr> <td rowspan=\"3\">IV</td> <td rowspan=\"3\">Vincristine, dactinomycin, and doxorubicin for 6 weeks</td> <td>Low and intermediate risk; lung nodule with complete response after initial chemotherapy</td> <td>Vincristine, dactinomycin, and doxorubicin for 27 weeks</td> <td>No lung XRT; flank XRT for local stage III<sup>&#9674;</sup></td> </tr> <tr> <td>Low and intermediate risk; lung nodule with incomplete response after initial chemotherapy</td> <td>Doxorubicin, cyclophosphamide, carboplatin, and etoposide for 34 weeks</td> <td>15Gy lung; flank XRT for local stage III<sup>&#9674;</sup></td> </tr> <tr> <td>High risk</td> <td>Doxorubicin, cyclophosphamide, carboplatin, and etoposide for 34 weeks</td> <td>15Gy lung; flank XRT for local stage III<sup>&#9674;</sup><sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SIOP: International Society of Pediatric Oncology; XRT: radiation therapy; NWTS: National Wilms Tumor Study; COG: Children's oncology group.<br />* The SIOP group primarily includes European pediatric oncology centers with additional centers located in South America and Australia.<br />¶ Note that the staging systems in SIOP and NWTS/COG protocols are not equivalent. SIOP stage is determined after preoperative chemotherapy and surgical resection; NWTS/COG stage is determined before surgical resection.<br />Δ According to SIOP protocols, Wilms tumors are classified based upon histology as follows: low risk (completely necrotic); intermediate risk (regressive type, mixed type, epithelial type, stromal type, and focal anaplasia); high risk (blastemal type and diffuse anaplasia).<br /><FONT class=lozenge>◊</FONT> Metastatic sites other than lung were also irradiated; XRT dose varied according to metastatic site.<br />§ Lung XRT is not required for patients with blastemal type histology who have complete response (ie, resolution of the lung nodule) with initial chemotherapy.</div><div class=\"graphic_reference\">Additional references: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Pritchard-Jones K, Bergeron C, de Camargo B, et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet 2015.</LI>&#xD;&#xA;<LI>Verschuur A, Van Tinteren H, Graf N, et al. Treatment of pulmonary metastases in children with stage IV nephroblastoma with risk-based use of pulmonary radiotherapy. J Clin Oncol 2012; 30:3533.</LI></OL>Adapted from: Dome JS, Graf N, Geller JI, et al. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J Clin Oncol 2015; 33:2999.</div><div id=\"graphicVersion\">Graphic 106102 Version 1.0</div></div></div>"},"106103":{"type":"graphic_table","displayName":"SIOP WT histologic classification","title":"International Society of Pediatric Oncology (SIOP) classification of Wilms tumors according to tumor histology as assessed after prenephrectomy chemotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International Society of Pediatric Oncology (SIOP) classification of Wilms tumors according to tumor histology as assessed after prenephrectomy chemotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Classification</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Low risk</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Completely necrotic</td> <td>No viable tumor persists (100% necrotic).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Intermediate risk</td> </tr> <tr> <td class=\"indent1\">Regressive type</td> <td>Chemotherapy-induced changes comprise more than two-thirds of the tumor; the remaining tumor comprises one, two, or three Wilms tumor components in any proportion.</td> </tr> <tr> <td class=\"indent1\">Mixed type*</td> <td>Two or three components present, none of which occupies more than two-thirds of the viable tumor.*</td> </tr> <tr> <td class=\"indent1\">Epithelial type*</td> <td>Epithelial component comprises more than two-thirds of the viable tumour; the remaining viable tumor comprises stromal (up to one-third) and blastemal (up to 10%) components.*</td> </tr> <tr> <td class=\"indent1\">Stromal type*</td> <td>Stromal component comprises more than two-thirds of the viable tumour; the remaining viable tumor comprises epithelial (up to one-third) and blastemal (up to 10%) components.*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Focal anaplasia*</td> <td>Localized anaplasia in any tumor type.*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">High risk</td> </tr> <tr> <td class=\"indent1\">Blastemal type*</td> <td>Blastemal component comprises more than two-thirds of the viable tumor; the remaining viable tumor comprises epithelial and/or stromal components in any proportion.*</td> </tr> <tr> <td class=\"indent1\">Diffuse anaplasia*</td> <td>Non-localized anaplasia in any tumor type, regardless of the extent of Necrosis.*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* More than one-third of the tumour is viable.</div><div class=\"graphic_reference\">Adapted from: Vujanić GM, Sandstedt B, Harms D, et al. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 2002; 38:79.</div><div id=\"graphicVersion\">Graphic 106103 Version 1.0</div></div></div>"},"106104":{"type":"graphic_picture","displayName":"Breast reduction inferior pedicle flap 2","title":"Breast reduction inferior pedicle flap 2","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Breast reduction inferior pedicle flap 2</div><div class=\"cntnt\"><img style=\"width:766px; height:719px;\" src=\"images/SURG/106104_Brst_rdct_infr_pdcl_flp2ed1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative (A,C) and postoperative (B,D) photos following inferior pedicle breast reduction. Resection weights are 1746 grams from right side and 1650 grams from left side.</div><div id=\"graphicVersion\">Graphic 106104 Version 2.0</div></div></div>"},"106105":{"type":"graphic_picture","displayName":"Breast reduction inferior pedicle flap 3","title":"Breast reduction inferior pedicle flap 3","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Breast reduction inferior pedicle flap 3</div><div class=\"cntnt\"><img style=\"width:727px; height:487px;\" src=\"images/SURG/106105_Brst_rdct_infr_pdcl_flp_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative (A,C) and postoperative (B,D)&nbsp;photos following inferior pedicle breast reduction. Resection weights are 994 grams from right side and 1024 grams from left side.</div><div id=\"graphicVersion\">Graphic 106105 Version 2.0</div></div></div>"},"106114":{"type":"graphic_diagnosticimage","displayName":"II and IH block probe and ultrasound","title":"II and IH block ultrasound probe placement and ultrasound image","html":"<div class=\"graphic\"><div style=\"width: 884px\" class=\"figure\"><div class=\"ttl\">II and IH block ultrasound probe placement and ultrasound image</div><div class=\"cntnt\"><img style=\"width:864px; height:337px;\" src=\"images/ANEST/106114_II_IH_blck_prb_ultrsnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the ilioinguinal and iliohypogastric nerve block, the ultrasound probe is placed just cephalad and medial to the ASIS, oriented along a line between the ASIS and the umbilicus. The internal oblique and transverse abdominis muscles are visualized, as in the image above. The needle is inserted in-plane to the transducer, and the tip is placed in the plane between these two muscles, as shown by the arrow in the image. After negative aspiration, 10 mL of LA is injected in 5-mL increments, with gentle aspiration between injections. LA may be seen expanding the fascial plane, as shown in the yellow ovals.</div><div class=\"graphic_footnotes\">II: ilioinguinal; IH: iliohypogastric; EO: external oblique muscle; IO: internal oblique muscle; TA: transverse abdominis muscle; ASIS: anterior superior iliac spine; LA: local anesthetic.</div><div class=\"graphic_reference\">Copyright &copy; 2012 Jens B&oslash;rglum and Kenneth Jensen. Originally published in Abdominal Surgery, Derbel F (Ed), InTech 2012, under <a href=\"http://creativecommons.org/licenses/by/3.0/\" spellcheck=\"true\" target=\"_blank\">CC BY 3.0 license</a>. Available from: <a href=\"http://www.intechopen.com/books/abdominal-surgery\" spellcheck=\"true\" target=\"_blank\">DOI: 10.5772/3020</a> (Accessed on January 7, 2016).</div><div id=\"graphicVersion\">Graphic 106114 Version 2.0</div></div></div>"},"106118":{"type":"graphic_waveform","displayName":"ECG in lower loop reentry flutter","title":"Electrocardiogram in lower loop reentry flutter","html":"<div class=\"graphic\"><div style=\"width: 810px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram in lower loop reentry flutter</div><div class=\"cntnt\"><img style=\"width:790px; height:434px;\" src=\"images/CARD/106118_ECG_lwr_lp_rntry_flttr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to flutter waves, which are positive in V1 and subtle but negative in the inferior leads.</div><div id=\"graphicVersion\">Graphic 106118 Version 1.0</div></div></div>"},"106119":{"type":"graphic_waveform","displayName":"ECG atriotomy-related right atrial flutter after mitral repair","title":"Electrocardiogram from a patient with an atriotomy-related right atrial flutter after mitral valve repair","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram from a patient with an atriotomy-related right atrial flutter after mitral valve repair</div><div class=\"cntnt\"><img style=\"width:788px; height:432px;\" src=\"images/CARD/106119_ECG_atrtmy_rlt_atrl_flt_mtrl_rpr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On electrophysiology study, the circuit was found to be wrapping around the atriotomy scar. The arrows point to the flutter waves, which are negative in the inferior leads.</div><div id=\"graphicVersion\">Graphic 106119 Version 1.0</div></div></div>"},"106120":{"type":"graphic_waveform","displayName":"ECG atypical left AFL through scar anterior septum prior AF","title":"Electrocardiogram of an atypical left atrial flutter occurring through a scar on the anterior septum in a patient with a prior atrial fibrillation ablation","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram of an atypical left atrial flutter occurring through a scar on the anterior septum in a patient with a prior atrial fibrillation ablation</div><div class=\"cntnt\"><img style=\"width:788px; height:425px;\" src=\"images/CARD/106120_ECG_atyp_lAFL_scr_ant_prr_AF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrows show the flutters waves, which are positive in V1.</div><div id=\"graphicVersion\">Graphic 106120 Version 1.0</div></div></div>"},"106121":{"type":"graphic_waveform","displayName":"ECG atypical roof dependent left AFL after AF ablation","title":"Electrocardiogram of an atypical roof dependent left atrial flutter after an atrial fibrillation ablation","html":"<div class=\"graphic\"><div style=\"width: 810px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram of an atypical roof dependent left atrial flutter after an atrial fibrillation ablation</div><div class=\"cntnt\"><img style=\"width:790px; height:432px;\" src=\"images/CARD/106121_ECG_atyp_rf_dpnd_AFL_AF_ablt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrows show positive flutter waves in V1 indicative of a left atrial focus. Flutter waves are isoelectric in the inferior leads.</div><div id=\"graphicVersion\">Graphic 106121 Version 2.0</div></div></div>"},"106122":{"type":"graphic_waveform","displayName":"ECG of a patient with clockwise mitral annular flutter","title":"Electrocardiogram of a patient with clockwise mitral annular flutter","html":"<div class=\"graphic\"><div style=\"width: 809px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram of a patient with clockwise mitral annular flutter</div><div class=\"cntnt\"><img style=\"width:789px; height:432px;\" src=\"images/CARD/106122_ECG_ptnt_clckws_mtrl_anlr_fltr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrows show the flutter waves, which are low amplitude and negative in the inferior leads. They are positive in V1-3, but become negative and then positive in V4-6.</div><div id=\"graphicVersion\">Graphic 106122 Version 1.0</div></div></div>"},"106124":{"type":"graphic_algorithm","displayName":"Management of neonates at risk for HSV","title":"Algorithm for the evaluation and management of asymptomatic neonates after vaginal or cesarean delivery to women with active genital herpes lesions","html":"<div class=\"graphic\"><div style=\"width: 956px\" class=\"figure\"><div class=\"ttl\">Algorithm for the evaluation and management of asymptomatic neonates after vaginal or cesarean delivery to women with active genital herpes lesions</div><div class=\"cntnt\"><img style=\"width:936px; height:952px;\" src=\"images/PEDS/106124_EvaluatneonatesriskHSV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm should be applied only in facilities where access to PCR and type-specific serologic testing is readily available and turnaround time for test results is appropriately short. In situations where this is not possible, the approach detailed in the algorithm will have limited, and perhaps no, applicability.</div><div class=\"graphic_footnotes\">HSV: herpes simplex virus; PCR: polymerase chain reaction; CSF: cerebrospinal fluid; ALT: alanine aminotransferase; IV: intravenous; SEM: skin, eye, and mouth; CNS: central nervous system.<br />* Evaluation and treatment is indicated prior to 24 hours of age if the infant develops signs and symptoms of neonatal HSV disease (eg, mucocutaneous vesicles, seizures, lethargy, respiratory distress, thrombocytopenia, coagulopathy, hypothermia, sepsis-like illness, hepatomegaly, ascites, or markedly elevated transaminases). In addition, immediate evaluation and treatment may be considered if there is prolonged rupture of membranes (&gt;4 to 6 hours) or if the infant is preterm (&le;37 weeks gestation).<br />&para; Surface cultures should be obtained from ALL of the following sites: conjunctivae, mouth, nasopharynx, and rectum. In addition, if the neonate had a scalp electrode placed, its site should be cultured.<br />&Delta; For details regarding determining maternal HSV infection classification, refer to UpToDate's content on genital HSV infection in pregnancy.<br /><span class=\"lozenge\">&loz;</span> Discharge after 48 hours of negative HSV cultures (and negative PCRs) is acceptable if other discharge criteria have been met, there is ready access to medical care, and a person who is able to comply fully with instructions for home observation will be present. If any of these conditions are not met, the infant should be observed in the hospital until HSV cultures are finalized as negative or are negative for 96 hours after being set up in cell culture, whichever is shorter.<br />&sect; The dose of acyclovir must be adjusted for neonates with renal impairment and/or weight &lt;1 kg. Refer to Lexicomp for additional dosing information. If IV acyclovir is not available, ganciclovir is an alternative. Refer to UpToDate's content on management of neonatal HSV infection for additional information.<br />&yen; Serum ALT values in neonates may be elevated due to noninfectious causes (eg, delivery-related perfusion). For this algorithm, ALT values &gt;2 times the upper limit of normal may be considered suggestive of neonatal disseminated HSV disease for HSV-exposed neonates.<br />&Dagger; Refer to UpToDate's content on clinical features and diagnosis of neonatal HSV infection for more details.<br />&dagger; Refer to UpToDate's content on diagnosis of neonatal HSV infection for details of distinguishing between the three disease categories (SEM, CNS, and disseminated disease).<br />** Consultation with a pediatric infectious disease specialist is warranted in cases of persistently positive CSF HSV PCR.</div><div class=\"graphic_reference\">Adapted with permission from Pediatrics, Vol. 131, Page e635, Copyright &copy; 2013 by the AAP.</div><div id=\"graphicVersion\">Graphic 106124 Version 6.0</div></div></div>"},"106126":{"type":"graphic_figure","displayName":"Delayed sleep-wake phase disorder","title":"Delayed sleep-wake phase disorder","html":"<div class=\"graphic\"><div style=\"width: 793px\" class=\"figure\"><div class=\"ttl\">Delayed sleep-wake phase disorder</div><div class=\"cntnt\"><img style=\"width:773px; height:498px;\" src=\"images/SLEEP/106126_Dly_slp_wk_phs_dsrdr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Actigram&nbsp;from a patient with delayed sleep-wake phase disorder (DSWPD). A 24-hour time interval (ranging from 6 PM to 6 PM) is depicted on the X axis; sequential dates are depicted on the Y axis. The actigram registers signal intensity (motion), and the contrast in signal activity serves to distinguish between wakefulness versus pronounced inactivity and/or sleepiness.<br />In this example, the individual appears to habitually fall asleep at approximately 4 AM nightly (arrow). During periods of unrestricted sleep, the estimated rise time occurs at 12 PM or later (arrowhead). There may be competing exogenous contributors with respect to the perpetuated delayed sleep-wake phase, as there are periods of pronounced inactivity apart from the consolidated sleep period, suggestive of napping (horizontal bars).</div><div id=\"graphicVersion\">Graphic 106126 Version 2.0</div></div></div>"},"106127":{"type":"graphic_table","displayName":"Worrisome features of peripheral lymphadenopathy in children","title":"Clinical features worrisome for malignancy or granulomatous disease in children with peripheral lymphadenopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features worrisome for malignancy or granulomatous disease in children with peripheral lymphadenopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Systemic symptoms (fever &#62;1 week, night sweats, weight loss [&#62;10% of body weight])</td> </tr> <tr> <td>Supraclavicular (lower cervical) nodes</td> </tr> <tr> <td>Generalized lymphadenopathy</td> </tr> <tr> <td>Fixed nontender nodes in the absence of other symptoms; matted nodes</td> </tr> <tr> <td>Lymph nodes &#62;1 cm with onset in the neonatal period</td> </tr> <tr> <td>Lymph nodes &#8805;2 cm in diameter that increase in size from baseline or do not respond to two weeks of antibiotic therapy</td> </tr> <tr> <td>Abnormal chest radiograph (particularly mediastinal mass or hilar adenopathy)</td> </tr> <tr> <td>Abnormal complete blood count (eg, lymphoblasts, cytopenias in more than one cell one)</td> </tr> <tr> <td>Absence of symptoms in the ear, nose, and throat regions</td> </tr> <tr> <td>Persistently elevated ESR/CRP or rising ESR/CRP despite antibiotic therapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lake AM, Oski FA. Peripheral lymphadenopathy in childhood. Ten-year experience with excisional biopsy. Am J Dis Child 1978; 132:357.</LI>&#xD;&#xA;<LI>Niedzielska G, Kotowski M, Niedzielski A, et al. Cervical lymphadenopathy in children--incidence and diagnostic management. Int J Pediatr Otorhinolaryngol 2007; 71:51.</LI>&#xD;&#xA;<LI>Oguz A, Karadeniz C, Temel EA, et al. Evaluation of peripheral lymphadenopathy in children. Pediatr Hematol Oncol 2006; 23:549.</LI>&#xD;&#xA;<LI>Slap GB, Brooks JS, Schwartz JS. When to perform biopsies of enlarged peripheral lymph nodes in young patients. JAMA 1984; 252:1321.</LI>&#xD;&#xA;<LI>Soldes OS, Younger JG, Hirschl RB. Predictors of malignancy in childhood peripheral lymphadenopathy. J Pediatr Surg 1999; 34:1447. </LI></OL></div><div id=\"graphicVersion\">Graphic 106127 Version 1.0</div></div></div>"},"106128":{"type":"graphic_table","displayName":"History peripheral lymphadenopathy child","title":"Important aspects of the history in a child with peripheral lymphadenopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the history in a child with peripheral lymphadenopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Historical feature</td> <td class=\"subtitle1\">Potential significance/examples</td> </tr> <tr> <td class=\"indent1\">Location, onset, adenopathy</td> <td>Affects the most likely etiologies</td> </tr> <tr> <td class=\"indent1\">Local symptoms of infection</td> <td> <ul> <li>Cough: Pneumonia (bacterial, viral, fungal) </li> <li>Sore throat: GAS, adenovirus, diphtheria </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Horner syndrome (miosis, ptosis, anhidrosis) or opsoclonus myoclonus</td> <td>Neuroblastoma, rhabdomyosarcoma</td> </tr> <tr> <td class=\"indent1\">Constitutional symptoms (eg, fever weight loss, night sweats, arthralgias, skin rash)</td> <td>May indicate malignancy, <em>Mycobacterium tuberculosis</em>, rheumatologic disease, or Kikuchi disease; fever is not helpful in discriminating infectious and noninfectious causes</td> </tr> <tr> <td class=\"indent1\">Dental problems or mouth sores</td> <td>Anaerobic infection, actinomycosis, enteroviral herpangina, HSV gingivostomatitis, Langerhans cell histiocytosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Skin lesions or trauma</td> <td><em>Staphylococcus aureus</em>, GAS, HSV, cat scratch disease (<em>Bartonella henselae</em>), tularemia, bubonic plague (<em>Yersinia pestis</em>), diphtheria</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Exposures</td> </tr> <tr> <td class=\"indent1\">Ill contacts</td> <td>Viral respiratory infections, CMV, EBV, GAS, <em>M. tuberculosis</em></td> </tr> <tr> <td class=\"indent1\">Unpasteurized animal milk</td> <td>Brucellosis, <em>Mycobacterium bovis</em></td> </tr> <tr> <td class=\"indent1\">Undercooked meats</td> <td>Toxoplasmosis, tularemia</td> </tr> <tr> <td class=\"indent1\">Animals:</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Cats </li> </ul> </td> <td>Cat scratch disease, toxoplasmosis</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Goats </li> </ul> </td> <td>Brucellosis</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Rabbits </li> </ul> </td> <td>Tularemia</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Prairie dogs </li> </ul> </td> <td>Bubonic plague</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Fish tanks </li> </ul> </td> <td><em>Mycobacterium marinum</em></td> </tr> <tr> <td class=\"indent1\">Tick bites, flea bites, biting flies or mosquitoes</td> <td>Lyme disease, bubonic plague, tularemia, filariasis</td> </tr> <tr> <td class=\"indent1\">Travel</td> <td>Depending on geographic region*, may increase risk of certain infections (eg, tularemia, bubonic plague, <em>M. tuberculosis</em>, measles, rubella, filariasis, leishmaniasis, typhoid fever)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sexual activity</td> <td>Sexually transmitted infections; hepatitis B infection</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Past medical history</td> </tr> <tr> <td class=\"indent1\">Medication history: Allopurinol, atenolol, captopril, carbamazepine, cephalosporins, gold, hydralazine, penicillin, phenytoin, primidone, pyrimethamine, quinidine, sulfonamides, sulindac</td> <td>Associated with lymphadenopathy</td> </tr> <tr> <td class=\"indent1\">History of asthma</td> <td>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</td> </tr> <tr> <td class=\"indent1\">History of recurrent infections, skin abscesses, suppurative adenitis</td> <td>Chronic granulomatous disease </td> </tr> <tr> <td class=\"indent1\">Autoimmune disease</td> <td>Autoimmune lymphoproliferative syndrome</td> </tr> <tr> <td class=\"indent1\">Immunization status</td> <td>Diphtheria, measles, rubella (if not immunized)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GAS: group A <em>Streptococcus</em>; HSV: herpes simplex virus; CMV: cytomegalovirus; EBV: Epstein-Barr virus.<br />* Refer to individual UpToDate topic reviews for the epidemiology of specific infections.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Greenfield S, Jordan MC. The clinical investigation of lymphadenopathy in primary care practice. JAMA 1978; 240:1388.</LI>&#xD;&#xA;<LI>Knight PJ, Mulne AF, Vassy LE. When is lymph node biopsy indicated in children with enlarged peripheral nodes? Pediatrics 1982; 69:391.</LI>&#xD;&#xA;<LI>Malley R. Lymphadenopathy. In: Textbook of Pediatric Emergency Medicine, 5<SUP>th</SUP> ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.421.</LI>&#xD;&#xA;<LI>Margileth AM. Sorting out the causes of lymphadenopathy. Contemp Pediatr 1995; 12:23.</LI>&#xD;&#xA;<LI>Morland B. Lymphadenopathy. Arch Dis Child 1995; 73:476.</LI>&#xD;&#xA;<LI>Pangalis GA, Vassilakopoulos TP, Boussiotis VA, Fessas P. Clinical approach to lymphadenopathy. Semin Oncol 1993; 20:570. </LI></OL></div><div id=\"graphicVersion\">Graphic 106128 Version 2.0</div></div></div>"},"106129":{"type":"graphic_table","displayName":"Renal angiomyolipoma staging University Medical Center Utrecht","title":"Renal angiomyolipoma staging criteria proposed by University Medical Center Utrecht","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Renal angiomyolipoma staging criteria proposed by University Medical Center Utrecht</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Number of angiomyolipoma</td> <td class=\"subtitle1\">Angiomyolipoma size</td> <td class=\"subtitle1\">Description of kidney anatomy</td> </tr> <tr> <td>None detected*</td> <td>None &#8805;1 cm in longest diameter</td> <td>&ndash;</td> <td>Normal</td> </tr> <tr> <td>1</td> <td>&#8804;5</td> <td>&#60;3.5 cm</td> <td>Normal</td> </tr> <tr> <td>2</td> <td>&#62;5</td> <td>&#60;3.5 cm</td> <td>Normal</td> </tr> <tr> <td>3</td> <td>&#8804;5</td> <td>At least 1 &#8805;3.5 cm</td> <td>Kidney intact</td> </tr> <tr> <td>4</td> <td>&#62;5</td> <td>1 to 4 &#8805;3.5 cm</td> <td>Kidney intact</td> </tr> <tr> <td>5</td> <td>&#62;5</td> <td>&#8805;5 &#8805;3.5 cm</td> <td>Kidney recognizable</td> </tr> <tr> <td>6</td> <td>&#62;5</td> <td>At least 1 &#8805;5 cm</td> <td>Kidney not recognizable</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Angiomyolipoma not detectable or lesions &lt;1 cm unidentifiable as angiomyolipoma.</div><div class=\"graphic_reference\">Reproduced from: Eijkemans MJ, van der Wal W, Reijnders LJ, et al. Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: An observational study in tuberous sclerosis complex patients in the Netherlands. Am J Kidney Dis 2015; 66:638. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 106129 Version 1.0</div></div></div>"},"106130":{"type":"graphic_table","displayName":"IV iron products","title":"Intravenous iron products (use in adults)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous iron products (use in adults)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Trade (brand) name</td> <td class=\"subtitle1\">Concentration of elemental iron</td> <td class=\"subtitle1\"> <p>Dosing</p> <p>(adults)</p> </td> <td class=\"subtitle1\">Test dose*</td> <td class=\"subtitle1\">Premedication&nbsp;</td> </tr> <tr> <td>Ferric carboxymaltose (FCM)</td> <td>Injectafer, Ferinject</td> <td>50 mg/mL</td> <td> <ul> <li>Weight &#8805;50 kg: Two doses of 750 mg, given&nbsp;seven or more days apart </li> <li>Weight &#60;50 kg: Two doses of 15 mg/kg, given&nbsp;seven or more days apart </li> </ul> </td> <td>Not required</td> <td rowspan=\"6\"> <ul id=\"_telerik_insertedList_id\"> <li>We do not routinely premedicate for any of the IV iron products. </li> </ul> <p>&nbsp;</p> <ul> <li>For patients with asthma, multiple drug allergies, or inflammatory arthritis, we often give methylprednisolone alone prior to the iron infusion. We do not give diphenhydramine. </li> </ul> </td> </tr> <tr> <td>Ferric gluconate (FG)</td> <td>Ferrlecit</td> <td>12.5 mg/mL</td> <td> <ul> <li>Multiple doses of 125 to 187.5 mg </li> </ul> </td> <td>Not required, but recommended if the patient has a history of multiple drug allergies</td> </tr> <tr> <td>Ferumoxytol<sup><span style=\"font-size: 13px;\">&#182;</span></sup></td> <td>Feraheme</td> <td>30 mg/mL</td> <td> <ul> <li>Two doses of 510 mg, given&nbsp;three to&nbsp;eight days apart, or </li> <li>Single dose of 1020 mg </li> </ul> </td> <td>Not required</td> </tr> <tr> <td>Iron dextran, low molecular weight (LMW ID)<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> <td>INFeD, CosmoFer</td> <td>50 mg/mL</td> <td> <ul> <li>Multiple doses of 100 mg, or </li> <li>Single dose of 1000 mg diluted in 250 mL normal saline) given over&nbsp;one hour </li> </ul> </td> <td>Yes, 25 mg (0.5 mL) prior to the first dose</td> </tr> <tr> <td>&nbsp;Iron isomaltoside<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> <td>Monofer</td> <td>100 mg/mL</td> <td> <ul> <li>Up to three doses of 500 mg, given over seven days, or </li> <li>Single dose of 20 mg/kg </li> </ul> </td> <td>&nbsp;Not required</td> </tr> <tr> <td>&nbsp;Iron sucrose (IS)</td> <td>Venofer</td> <td>20 mg/mL</td> <td> <ul> <li>Multiple doses of 200 to 300 mg </li> </ul> </td> <td>Not required, but recommended if the patient has a history of multiple drug allergies</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Dosing information in this table is for adults and includes some dosing not listed in the approved product information. Refer to UpToDate content on management of iron deficiency and most recent product labeling for additional information. Current US product labeling for all of the products available in the US is available on the US Food and Drug Administration website (<A spellcheck=true href=\"https://www.accessdata.fda.gov/scripts/cder/drugsatfda/\">https://www.accessdata.fda.gov/scripts/cder/drugsatfda/</A>) or the National Library of Medicine (<A spellcheck=true href=\"http://dailymed.nlm.nih.gov/dailymed/\">http://dailymed.nlm.nih.gov/dailymed/</A>). </div><div class=\"graphic_footnotes\">IV: intravenous.<br />* For all products, slow initial infusion is prudent; the&nbsp;patient is observed closely for infusion reactions.&nbsp;<br />¶ Notify radiologist if patient has a magnetic resonance imaging (MRI) scan within three months of administration.<br />Δ High molecular weight iron dextran (HMW ID) is no longer available. Iron isomaltoside (Monofer) is not available in the US.</div><div id=\"graphicVersion\">Graphic 106130 Version 3.0</div></div></div>"},"106132":{"type":"graphic_table","displayName":"Neonatal HSV diseases","title":"Summary of clinical, laboratory, radiographic findings, and treatment of neonatal herpes simplex virus (HSV) infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of clinical, laboratory, radiographic findings, and treatment of neonatal herpes simplex virus (HSV) infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup span=\"4\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">Proportion of cases</td> <td class=\"subtitle1\" rowspan=\"2\">Clinical manifestations</td> <td class=\"subtitle1\" colspan=\"4\">Diagnostic testing for HSV*</td> <td class=\"subtitle1\" rowspan=\"2\">Other laboratory and radiographic findings</td> <td class=\"subtitle1\" rowspan=\"2\">Recommended treatment</td> </tr> <tr> <td class=\"subtitle2\">Viral culture of surface specimens<sup>&#182;</sup></td> <td class=\"subtitle2\">Viral culture of skin lesion scrapings<sup>&#916;</sup></td> <td class=\"subtitle2\">Blood or plasma HSV PCR</td> <td class=\"subtitle2\">CSF HSV PCR</td> </tr> <tr class=\"divider_bottom\"> <td><strong>SEM disease</strong></td> <td>45%</td> <td> <ul> <li>Characteristic vesicular lesions </li> <li>Conjunctivitis, excessive tearing </li> <li>Ulcerative lesions of the mouth, palate, and tongue </li> </ul> </td> <td>Positive in &#62;90%</td> <td>Positive in &#62;90%</td> <td>Positive in approximately 75%</td> <td>Negative</td> <td> <ul> <li>Other laboratory and radiographic studies are typically normal </li> </ul> </td> <td> <p>Initial treatment: Acyclovir 60 mg/kg per day intravenously divided every 8 hours for 14 days<sup>&#9674;</sup></p> <p>Followed by:</p> <p>Oral suppressive therapy: Acyclovir 300 mg/m<sup>2</sup> per dose orally three times per day for six months<sup>&#9674;</sup></p> In addition, for ocular involvement: <ul class=\"decimal_heading\"> <li>Topical ophthalmic solution (eg, 1% trifluridine, 0.1% idoxuridine [iododeoxyuridine]<sup>&#167;</sup>, or 0.15% ganciclovir) </li> <li>Referral to an ophthalmologist </li> <li>Longer duration of oral suppressive therapy may be warranted </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>CNS disease</strong></td> <td>30%</td> <td> <ul> <li>Seizures </li> <li>Lethargy </li> <li>Irritability </li> <li>Tremors </li> <li>Poor feeding </li> <li>Skin lesions are present in 60 to 70% </li> </ul> </td> <td>Positive in &#62;90%</td> <td>Positive in &#62;90% if lesions are present; however, skin lesions are often not present at the onset of disease</td> <td>Positive in approximately 65%</td> <td>Positive in 75 to 100%</td> <td> <ul> <li>CSF analysis classically shows a mononuclear cell pleocytosis, normal or moderately low glucose concentration, and mildly elevated protein </li> <li>EEG may show focal or multifocal periodic epileptiform discharges </li> <li>Neuroimaging studies may show parenchymal brain edema or attenuation, hemorrhage, or destructive lesions involving the temporal, frontal, parietal, or brainstem regions of the brain </li> </ul> </td> <td> <p>Initial treatment: Acyclovir 60 mg/kg per day intravenously divided every 8 hours for a minimum of 21 days<sup>&#9674;</sup></p> <p>Followed by:</p> Oral suppressive therapy: Acyclovir 300 mg/m<sup>2</sup> per dose orally three times per day for six months<sup>&#9674;</sup></td> </tr> <tr> <td><strong>Disseminated disease</strong></td> <td>25%</td> <td> <ul> <li>Sepsis syndrome </li> <li>Fever or hypothermia </li> <li>Hepatitis </li> <li>Respiratory distress </li> <li>DIC </li> <li>Skin lesions are present in 60 to 80% </li> <li>CNS involvement occurs in 60 to 75% </li> </ul> </td> <td>Positive in &#62;90%</td> <td>Positive in &#62;90% if lesions are present; however, skin lesions are often not present at the onset of disease</td> <td>Positive in 100%</td> <td>Positive in &#62;90%</td> <td> <ul> <li>Elevated liver transaminases </li> <li>Thrombocytopenia </li> <li>Abnormal CSF, EEG, and neuroimaging studies as above </li> </ul> </td> <td> <p>Initial treatment: Acyclovir 60 mg/kg per day intravenously divided every 8 hours for a minimum of 21 days<sup>&#9674;</sup></p> <p>Followed by:</p> Oral suppressive therapy: Acyclovir 300 mg/m<sup>2</sup> per dose orally three times per day for six months<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HSV: herpes simplex virus; PCR: polymerase chain reaction; CSF: cerebrospinal fluid; SEM: skin, eyes, mouth; CNS: central nervous system; EEG: electroencephalogram; DIC: disseminated intravascular coagulopathy; DFA: direct immunofluorescence assay; BSA: body surface area.&nbsp;<br />* All of these diagnostic tests should be performed in any neonate with suspected HSV infection.<br />¶ Surface cultures are performed on swab specimens collected from the conjunctivae, mouth, nasopharynx, and rectum. Some experts suggest these be obtained with a single swab, starting with eyes and ending with the rectum, and placed in one viral transport media tube. Alternatively, they may be collected with multiple swabs, which are then placed in a single viral transport media tube.<br />Δ DFA permits rapid detection of HSV antigens in skin lesion scrapings; however, DFA is not as sensitive as culture and therefore viral culture should also be performed.<br /><FONT class=lozenge>◊</FONT> The dose of acyclovir must be adjusted for neonates with renal impairment and/or weight&nbsp;&lt;1kg. Refer to Lexicomp for additional dosing information. If IV acyclovir is not available, ganciclovir as an alternative. Refer to the UpToDate topic on management of neonatal HSV infection for additional information. Oral acyclovir dosing is based on BSA, which is calculated as follows: square root (Height [cm]&nbsp;* Weight [kg]&nbsp;/ 3600). The oral suppressive acyclovir dose should be adjusted each month to account for growth.<br />§ Idoxuridine (iododeoxyuridine) is not available in the United States.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>1. American Academy of Pediatrics. Herpes simplex. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.432. </li>&#xD;&#xA;    <li>2. Kimberlin DW, Gutierrez KM. Herpes simplex virus infections. In: Remington and Klein's infectious diseases of the fetus and newborn infant, 8th ed, Wilson CB, Nizet V, Maldonado YA, et al.&nbsp;(Eds), Saunders, Phildelphia, PA 2016. p.843.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 106132 Version 2.0</div></div></div>"},"106133":{"type":"graphic_table","displayName":"Causes of cerebral edema in children","title":"Causes of cerebral edema in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of cerebral edema in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Severe head trauma </li> <li>Brain tumor </li> <li>Hydrocephalus </li> <li>Hypoxic-ischemic encephalopathy </li> <li>Infectious <ul> <li>Cerebral abscess </li> <li>Meningitis </li> <li>Encephalitis </li> </ul> </li> <li>Diabetic ketoacidosis </li> <li>Stroke </li> <li>Venous thrombosis </li> <li>Arteriovenous malformations </li> <li>Vasculitis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*These conditions may result in one or more types of cerebral edema; cytotoxic, vasogenic, and/or interstitial. </div><div id=\"graphicVersion\">Graphic 106133 Version 2.0</div></div></div>"},"106135":{"type":"graphic_figure","displayName":"Cervical plexus 2","title":"Cervical plexus 2","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Cervical plexus 2</div><div class=\"cntnt\"><img style=\"width:520px; height:616px;\" src=\"images/ANEST/106135_Cervical_plexus_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cervical plexus is composed of the ventral rami of the first four cervical spinal nerves (ie, C1 through C4). The anterior rami of C2 through C4 emerge from the posterior border of the sternocleidomastoid muscle.</div><div id=\"graphicVersion\">Graphic 106135 Version 1.0</div></div></div>"},"106136":{"type":"graphic_picture","displayName":"Birt-Hogg-Dube syndrome face 1","title":"Fibrofolliculomas in Birt-Hogg-Dube syndrome","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Fibrofolliculomas in Birt-Hogg-Dube syndrome</div><div class=\"cntnt\"><img style=\"width:715px; height:508px;\" src=\"images/DERM/106136_Brt_Hgg_Db_sndrm_fc_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous white/gray papules are visible on the midface of this patient with Birt-Hogg-Dubé syndrome.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 106136 Version 1.0</div></div></div>"},"106137":{"type":"graphic_picture","displayName":"Provisional wound coverage of diabetic plantar infection","title":"Provisional wound coverage of diabetic plantar infection","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Provisional wound coverage of diabetic plantar infection</div><div class=\"cntnt\"><img style=\"width:617px; height:718px;\" src=\"images/SURG/106137_Prvsnl_cvr_dbt_plntr_infct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">​The pictures in the figure show the management of a diabetic patient with a chronic sinus draining from the plantar aspect of the foot that was present for over nine months. Following debridement (A), the wound was dressed and treated with an interim matrix wound dressing to create a neodermis to serve as wound bed for skin grafting (B). After two weeks, the overlying silicone layer was removed (C),&nbsp;and a skin graft was placed.</div><div id=\"graphicVersion\">Graphic 106137 Version 2.0</div></div></div>"},"106138":{"type":"graphic_picture","displayName":"Birt-Hogg-Dube syndrome face 2","title":"Birt-Hogg-Dubé syndrome","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Birt-Hogg-Dub&eacute; syndrome</div><div class=\"cntnt\"><img style=\"width:715px; height:466px;\" src=\"images/DERM/106138_Brt_Hgg_Db_sndrm_fc_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple whitish papules on the face of this patient with Birt-Hogg-Dub&eacute; syndrome.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 106138 Version 1.0</div></div></div>"},"106139":{"type":"graphic_picture","displayName":"Birt-Hogg-Dube syndrome ear","title":"Birt-Hogg-Dubé syndrome","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Birt-Hogg-Dub&eacute; syndrome</div><div class=\"cntnt\"><img style=\"width:459px; height:708px;\" src=\"images/DERM/106139_Brt_Hgg_Db_sndrm_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White papules representing fibrofolliculomas are present on the back of the ear of this patient with Birt-Hogg-Dubé syndrome.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 106139 Version 1.0</div></div></div>"},"106140":{"type":"graphic_picture","displayName":"Birt-Hogg-Dube syndrome neck","title":"Birt-Hogg-Dubé syndrome","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Birt-Hogg-Dub&eacute; syndrome</div><div class=\"cntnt\"><img style=\"width:716px; height:475px;\" src=\"images/DERM/106140_Brt_Hgg_Db_sndrm_nck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple fibrofolliculomas presenting as small, whitish papules on the neck of this patient with Birt-Hogg-Dubé syndrome. A few achrocorda (skin tags) of light-brown color are also present.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 106140 Version 1.0</div></div></div>"},"106141":{"type":"graphic_picture","displayName":"Birt-Hogg-Dube syndrome nose","title":"Birt-Hogg-Dubé syndrome","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Birt-Hogg-Dub&eacute; syndrome</div><div class=\"cntnt\"><img style=\"width:716px; height:463px;\" src=\"images/DERM/106141_Brt_Hgg_Db_sndrm_ns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple, near confluent white papules, representing fibrofolliculomas, on the face of this patient with Birt-Hogg-Dub&eacute; syndrome.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 106141 Version 1.0</div></div></div>"},"106149":{"type":"graphic_picture","displayName":"CAH Prader II-V","title":"Different degrees of virilization in 46,XX infants with congenital adrenal hyperplasia (CAH)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Different degrees of virilization in 46,XX infants with congenital adrenal hyperplasia (CAH)</div><div class=\"cntnt\"><img style=\"width:387px; height:794px;\" src=\"images/PEDS/106149_CAH_prdr_II_V.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of atypical external genitalia in 46,XX infants with congenital adrenal hyperplasia (CAH), ranging from&nbsp;mild virilization (Prader II) through severe virilization (Prader IV and V). Other 46,XX infants with CAH can have normal female genitalia (Prader I, not shown). None of these patients has palpable gonads, which is an&nbsp;important clue&nbsp;that CAH should be considered as a diagnosis.<br />(A) Mild virilization, Prader II<br />(B,C) Moderate virilization, Prader III<br />(D,E)&nbsp;Severe virilization, Prader IV <br />(F) Severe virilization,&nbsp;Prader V, with a complete penile urethra. This&nbsp;is very rare. Prior to the advent of newborn screening for this disorder, affected children may have been identified as&nbsp;male at birth,&nbsp;and the diagnosis&nbsp;was made later in childhood. </div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 106149 Version 3.0</div></div></div>"},"106152":{"type":"graphic_table","displayName":"Medicare guidelines hospice eligibility liver disease","title":"Medicare guidelines for hospice eligibility for patients with liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicare guidelines for hospice eligibility for patients with liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Liver disease</td> </tr> <tr> <td class=\"indent1\">Patients will be considered to be in the terminal stage of liver disease (life expectancy of six months or less) if they meet the following criteria (1 and 2 should be present; factors from 3 will lend supporting documentation):</td> </tr> <tr> <td class=\"indent2\"> <ol> <li>Both prolonged prothrombin time (more than five seconds over control, or INR &#62;1.5) <strong>AND</strong> serum albumin &#60;2.5 g/dL. </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ol start=\"2\"> <li>End stage liver disease with at least one of the following: Ascites, refractory to treatment or patient non-compliant; spontaneous bacterial peritonitis; hepatorenal syndrome (elevated creatinine and BUN with oliguria [&#60;400 mL/day] and urine sodium concentration &#60;10 mEq/L); hepatic encephalopathy refractory to treatment or patient non-compliant; recurrent variceal bleeding, despite intensive therapy. </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ol start=\"3\"> <li>Documentation of the following factors will support eligibility for hospice care: Progressive malnutrition; muscle wasting with reduced strength and endurance; continued active alcoholism (&#62;80 g ethanol/day); hepatocellular carcinoma; HBsAg; hepatitis C infection refractory to interferon treatment. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">INR: international normalized ratio; BUN: blood urea nitrogen; HBsAg: hepatitis B surface antigen positivity.</div><div class=\"graphic_reference\">Source: Centers for Medicare &amp; Medicaid Services. <a href=\"https://www.cms.gov/medicare-coverage-database/license/cpt-license.aspx?from=~/overview-and-quick-search.aspx&amp;npage=/medicare-coverage-database/details/lcd-details.aspx&amp;LCDId=33393&amp;ContrId=272&amp;ver=2&amp;ContrVer=1&amp;CntrctrSelected=272*1&amp;Cntrctr=272&amp;name=National+Government+Services%2c+Inc.+(06004%2c+HHH+MAC)&amp;DocType=All&amp;s=56&amp;bc=AggAAAIAAAAAAA%3d%3d&amp;amp;\" target=\"_blank\">Local Coverage Determination (LCD) for Hospice Determining Terminal Status (L33393)</a>. (Accessed on January 18, 2016).</div><div id=\"graphicVersion\">Graphic 106152 Version 1.0</div></div></div>"},"106154":{"type":"graphic_diagnosticimage","displayName":"Conjoined twins at 10 weeks of gestation","title":"Conjoined twins at 10 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 688px\" class=\"figure\"><div class=\"ttl\">Conjoined twins at 10 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:668px; height:434px;\" src=\"images/OBGYN/106154_Cnjn_twns_10_wks_gst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conjoined twins at 10 weeks of gestation. Heads are separate but body is shared. Each arrow points to a fetal head.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 106154 Version 2.0</div></div></div>"},"106155":{"type":"graphic_diagnosticimage","displayName":"Conjoined twins with shared heart","title":"Conjoined twins with shared heart","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Conjoined twins with shared heart</div><div class=\"cntnt\"><img style=\"width:726px; height:347px;\" src=\"images/OBGYN/106155_Cnjn_twns_shr_hrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coinjoined twins at 19 weeks of gestation.<br />(A) Shared heart.<br />(B) Shared bowel&nbsp;and separate bladders.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 106155 Version 2.0</div></div></div>"},"106156":{"type":"graphic_algorithm","displayName":"Empiric antimicrobial therapy uncomplicated ABRS","title":"Suggested approach to empiric antimicrobial therapy for outpatient treatment of uncomplicated acute bacterial rhinosinusitis (ABRS) in immunocompetent adults","html":"<div class=\"graphic\"><div style=\"width: 866px\" class=\"figure\"><div class=\"ttl\">Suggested approach to empiric antimicrobial therapy for outpatient treatment of uncomplicated acute bacterial rhinosinusitis (ABRS) in immunocompetent adults</div><div class=\"cntnt\"><img style=\"width:846px; height:608px;\" src=\"images/PC/106156_Antmcrbl_thpy_uncmplcd_ABRS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Indications for antibiotic therapy include lack of adequate follow-up, worsening symptoms during observation, and symptoms unchanged after 7 days of observation. Refer to the UpToDate topic on treatment of uncomplicated acute sinusitis and rhinosinusitis in adults for details.<br />¶ Refer to the UpToDate topics on penicillin allergy and cephalosporin allergy.<br />Δ Risk factors for resistance include: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Living in geographic regions with rates of penicillin-nonsusceptible <EM>S. pneumoniae</EM> exceeding 10%</LI>&#xD;&#xA;<LI>Age ≥65 years</LI>&#xD;&#xA;<LI>Hospitalization in the last 5 days</LI>&#xD;&#xA;<LI>Antibiotic use in the previous month</LI>&#xD;&#xA;<LI>Immunocompromise</LI>&#xD;&#xA;<LI>Multiple comorbidities (eg, diabetes or chronic cardiac, hepatic, or renal disease)</LI>&#xD;&#xA;<LI>Severe infection (eg, evidence of systemic toxicity with temperature of ≥102°F, threat of suppurative complications)</LI></UL><FONT class=lozenge>◊</FONT> Fluoroquinolones should be reserved for those who have no alternative treatment options as the serious adverse effects associated with fluoroquinolones generally outweigh the benefits for patients with acute sinusitis.<br />§ The diagnosis of ABRS can be confirmed clinically. In patients in whom there are concerns for complications, imaging should be obtained. In other patients in whom symptoms are not completely consistent with ABRS, imaging is reasonable to rule out sinusitis and/or evaluation for alternative diagnosis.<br />¥ Refer to the UpToDate topic on treatment of uncomplicated acute sinusitis and rhinosinusitis in adults for details.<br />‡ Choice of second-line agent will depend on initial therapy.<br />For patients not allergic to penicillin, options include: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Amoxicillin-clavulanate 2000 mg/125 extended-release tablets mg orally twice daily</LI>&#xD;&#xA;<LI>Levofloxacin 500 mg orally once daily</LI>&#xD;&#xA;<LI>Moxifloxacin 400 mg orally once daily</LI></UL>For penicillin-allergic patients options include: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Doxycycline 100 mg twice daily or 200 mg once daily</LI>&#xD;&#xA;<LI>Levofloxacin 500 mg orally once daily</LI>&#xD;&#xA;<LI>Moxifloxacin 400 mg orally once daily</LI></UL></div><div id=\"graphicVersion\">Graphic 106156 Version 3.0</div></div></div>"},"106157":{"type":"graphic_algorithm","displayName":"Observation versus antimicrobial therapy for ABRS","title":"Suggested approach to observation versus antimicrobial therapy for outpatient treatment of uncomplicated acute bacterial rhinosinusitis (ABRS) in immunocompetent adults","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Suggested approach to observation versus antimicrobial therapy for outpatient treatment of uncomplicated acute bacterial rhinosinusitis (ABRS) in immunocompetent adults</div><div class=\"cntnt\"><img style=\"width:532px; height:447px;\" src=\"images/PC/106157_Sgg_app_obsrv_vs_antmcrb_thrpy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Uncomplicated ABRS is ABRS without evidence of extension of infection beyond the paranasal sinuses and nasal cavity into the central nervous system, orbit, or surrounding tissues.<br />&para; Good follow-up: Assurance that antibiotic therapy can be started if symptoms worsen or if no improvement within 7 days.<br />&Delta; Decision will depend on patient presentation, comorbidities, and social factors. Refer to the UpToDate topic on treatment of uncomplicated acute sinusitis and rhinosinusitis in adults for details.</div><div id=\"graphicVersion\">Graphic 106157 Version 1.0</div></div></div>"},"106159":{"type":"graphic_picture","displayName":"Fibrous papule nose","title":"Fibrous papule of the nose","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Fibrous papule of the nose</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/106159_Fbrs_ppl_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A small, dome-shaped, skin-colored lesion with a central follicular opening is visible on the face of this patient.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 106159 Version 1.0</div></div></div>"},"106160":{"type":"graphic_picture","displayName":"Fibrous papule of the nose 2","title":"Fibrous papule of the nose","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Fibrous papule of the nose</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/106160_Fbrs_ppl_nose_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two small, skin-colored papules with a central follicular opening are visible on the nose of this patient.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 106160 Version 1.0</div></div></div>"},"106161":{"type":"graphic_picture","displayName":"Trichoepitelioma","title":"Trichoepiteliomas in Brooke-Spiegler syndrome","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Trichoepiteliomas in Brooke-Spiegler syndrome</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/106161_Trichoepitelioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple skin-colored papules representing trichoepitheliomas on the nasolabial sulcus in this patient with Brooke-Spiegler syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 106161 Version 1.0</div></div></div>"},"106163":{"type":"graphic_table","displayName":"Hard and soft signs of penetrating neck injury","title":"Hard and soft signs of penetrating neck injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hard and soft signs of penetrating neck injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Hard signs of vascular injury*</td> </tr> <tr> <td class=\"indent1\">Severe or uncontrolled hemorrhage</td> </tr> <tr> <td class=\"indent1\">Large, expanding, or pulsatile hematoma</td> </tr> <tr> <td class=\"indent1\">Thrills or bruits</td> </tr> <tr> <td class=\"indent1\">Shock unresponsive to IV fluid resuscitation</td> </tr> <tr> <td class=\"indent1\">Absent or diminished radial pulse</td> </tr> <tr> <td class=\"indent1\">Neurologic deficit (eg, hemiplegia) consistent with cerebral ischemia</td> </tr> <tr> <td class=\"subtitle1_single\">Hard signs of aerodigestive injury*</td> </tr> <tr> <td class=\"indent1\">Air bubbling from a wound</td> </tr> <tr> <td class=\"indent1\">Massive hemoptysis or hematemesis</td> </tr> <tr> <td class=\"indent1\">Respiratory distress</td> </tr> <tr> <td class=\"subtitle1_single\">Soft signs of injury</td> </tr> <tr> <td class=\"indent1\">Proximity wounds</td> </tr> <tr> <td class=\"indent1\">Minor hemorrhage</td> </tr> <tr> <td class=\"indent1\">Mild hypotension responsive to IV fluid resuscitation</td> </tr> <tr> <td class=\"indent1\">Minor hemoptysis or hematemesis</td> </tr> <tr> <td class=\"indent1\">Subcutaneous or mediastinal air</td> </tr> <tr> <td class=\"indent1\">Non-pulsatile, non-expanding hematoma</td> </tr> <tr> <td class=\"indent1\">Dysphonia</td> </tr> <tr> <td class=\"indent1\">Dysphagia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.<br />*Hard signs of injury reflect the presence of a serious injury that generally requires immediate transfer to the operating room.</div><div id=\"graphicVersion\">Graphic 106163 Version 2.0</div></div></div>"},"106164":{"type":"graphic_table","displayName":"Signs and symptoms of carboxyhemoglobin levels","title":"Signs and symptoms of various concentrations of carboxyhemoglobin levels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms of various concentrations of carboxyhemoglobin levels</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">CO-Hb, %</td> <td class=\"subtitle1\">Signs and symptoms</td> </tr> <tr> <td>0-10</td> <td>None</td> </tr> <tr> <td>10-20</td> <td>Tightness across forehead, slight headache, dilation of the cutaneous blood vessels</td> </tr> <tr> <td>20-30</td> <td>Headache and throbbing in the temples</td> </tr> <tr> <td>30-40</td> <td>Severe headache, weakness, dizziness, dimness of vision, nausea, vomiting, collapse</td> </tr> <tr> <td>40-50</td> <td>Same as above, greater possibility of collapse; syncope, increased pulse and respiratory rates</td> </tr> <tr> <td>50-60</td> <td>Syncope, increased respiratory and pulse rates, coma, intermittent convulsions, Cheyne-Stokes respiration</td> </tr> <tr> <td>60-70</td> <td>Coma, intermittent convulsions, depressed heart action and respiratory rate, possible death</td> </tr> <tr> <td>70-80</td> <td>Weak pulse, slow respiration leading to death within hours</td> </tr> <tr> <td>80-90</td> <td>Death in less than 1 hour</td> </tr> <tr> <td>&#62;90</td> <td>Death within minutes</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Einhorn IN. Physiological and toxicological aspects of smoke produced during the combustion of polymeric materials. Environ Health Perspect 1975; 11:163.</div><div id=\"graphicVersion\">Graphic 106164 Version 1.0</div></div></div>"},"106165":{"type":"graphic_table","displayName":"AIS for bronchoscopic gradation of inhalation injury","title":"Abbreviated injury score (AIS) for bronchoscopic gradation of inhalation injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Abbreviated injury score (AIS) for bronchoscopic gradation of inhalation injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> </tbody> <colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td class=\"centered\">0</td> <td>No injury</td> <td>Absence of carbonaceous deposits, erythema, edema, bronchorrhea or obstruction</td> </tr> <tr> <td class=\"centered\">1</td> <td>Mild injury</td> <td>Minor or patchy areas of erythema, carbonaceous deposits in proximal or distal bronchi*</td> </tr> <tr> <td class=\"centered\">2</td> <td>Moderate injury</td> <td>Moderate degree of erythema, carbonaceous deposits, bronchorrhea, or bronchial obstruction*</td> </tr> <tr> <td class=\"centered\">3</td> <td>Severe injury</td> <td>Severe inflammation with friability, copious carbonaceous deposits, bronchorrhea or obstruction*</td> </tr> <tr> <td class=\"centered\">4</td> <td>Massive injury</td> <td>Evidence of mucosal sloughing, necrosis, endoluminal obliteration*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Any or a combination of the findings.</div><div class=\"graphic_reference\">From: Endorf FW, Gamelli RL. Inhalation injury, pulmonary perturbations, and fluid resuscitation. J Burn Care Res 2007; 28:80. DOI: <a href=\"http://journals.lww.com/burncareresearch/pages/articleviewer.aspx?year=2007&amp;issue=01000&amp;article=00013&amp;type=abstract\" target=\"_blank\">10.1097/BCR.0B013E31802C889F</a>. Copyright &copy; 2007 American Burn Association. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 106165 Version 3.0</div></div></div>"},"106166":{"type":"graphic_table","displayName":"Inhalation injury protocol example in nonintubated adults","title":"Example of inhalation injury treatment protocol in nonintubated adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of inhalation injury treatment protocol in nonintubated adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Titrate humidified high-flow oxygen to maintain SaO<sub>2</sub> &#62;90%</td> </tr> <tr> <td>Cough, deep breathing exercises every two hours</td> </tr> <tr> <td>Turn patient side to side every two hours</td> </tr> <tr> <td>Chest physiotherapy every two hours</td> </tr> <tr> <td>Alternate mucolytic and heparin/saline nebulization:*</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Nebulize 3 mL of 20% N-acetylcysteine every four hours; add a bronchodilator if wheezing or bronchospasm occurs </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Alternate with nebulized unfractionated heparin<sup>&#182;</sup> 5000 to 10,000 units in 3 mL of normal saline every four hours </li> </ul> </td> </tr> <tr> <td>Nasotracheal suctioning, as needed</td> </tr> <tr> <td>Early ambulation</td> </tr> <tr> <td>Sputum cultures for intubated patients every Monday, Wednesday, and Friday</td> </tr> <tr> <td>Pulmonary function studies at discharge and at outpatient visits</td> </tr> <tr> <td>Patient/family education about the disease process</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PT: prothrombin time; PTT: partial thromboplastin time.<br />* This alternating regimen provides a nebulizer treatment every two hours and is usually continued for&nbsp;seven days.<br />¶ Preservative-free heparin is not required. Nebulized heparin typically does not affect systematic coagulation parameters; however, most clinicians managing burn patients monitor PT and PTT on a routine basis.</div><div class=\"graphic_reference\">Adapted from: Mlcak RP, Hegde SD, Herndon DN. Respiratory Care. In: Total Burn Care, 4th ed, Herndon DN (Ed), Saunders Elsevier, Philadelphia 2012.</div><div id=\"graphicVersion\">Graphic 106166 Version 1.0</div></div></div>"},"106171":{"type":"graphic_picture","displayName":"Fibrofolliculoma histo 2","title":"Histologic features of fibrofolliculoma","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Histologic features of fibrofolliculoma</div><div class=\"cntnt\"><img style=\"width:482px; height:726px;\" src=\"images/DERM/106171_Fbrfllclm_hst_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Epithelial proliferation emanating from a hair follicle with surrounding abnormal fibrous stroma.<br />(B) Multiple thin anastomosing epithelial strands extending from a dilated follicular cyst.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD MHSc.</div><div id=\"graphicVersion\">Graphic 106171 Version 1.0</div></div></div>"},"106178":{"type":"graphic_table","displayName":"Selection of pulmonary function tests","title":"Selection of pulmonary function tests","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection of pulmonary function tests</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Setting</td> <td class=\"subtitle1\">Tests to order in most patients</td> <td class=\"subtitle1\">Advanced testing</td> </tr> <tr class=\"divider_bottom\"> <td>Dyspnea at rest or on exertion</td> <td> <p>Spirometry before and after bronchodilator</p> <p>Lung volumes</p> <p>DLCO</p> Ambulatory oximetry with stair climb</td> <td>Cardiopulmonary exercise test</td> </tr> <tr class=\"divider_bottom\"> <td>Cough</td> <td>Spirometry before and after bronchodilator</td> <td>Bronchoprovocation challenge testing if spirometry normal and asthma suspected</td> </tr> <tr class=\"divider_bottom\"> <td>Asthma</td> <td>Spirometry before and after bronchodilator</td> <td>Bronchoprovocation challenge testing if spirometry normal and asthma suspected</td> </tr> <tr class=\"divider_bottom\"> <td>COPD</td> <td> <p>Spirometry before and after bronchodilator</p> Oximetry at rest</td> <td> <p>Lung volumes (can be ordered if FVC is low, chest radiograph shows hyperinflation, dyspnea is out of proportion to spirometric abnormalities)</p> <p>DLCO (can be ordered with initial spirometry or after irreversible airflow obstruction is identified)</p> <p>Ambulatory oximetry if resting oximetry is &#60;95%</p> Oximetry during sleep (to check adequacy of supplemental oxygen or in patients with awake, resting SpO<sub>2</sub> &#60;92%)</td> </tr> <tr class=\"divider_bottom\"> <td>Suspected bronchiectasis</td> <td> <p>Spirometry before and after bronchodilator</p> Lung volumes</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Suspected bronchiolitis</td> <td> <p>Spirometry before and after bronchodilator</p> <p>Lung volumes</p> DLCO</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Suspected upper airway obstruction (eg, stridor, hoarseness and dyspnea, unexplained dyspnea)</td> <td>Spirometry with flow volume loop (loop at shape of curves and also FIF50/FEF50)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Suspected ILD (eg, hypersensitivity pneumonitis, sarcoidosis, idiopathic pulmonary fibrosis, or abnormal chest radiograph)</td> <td> <p>Spirometry</p> <p>Lung volumes</p> <p>DLCO</p> <p>Oximetry at rest</p> Ambulatory oximetry or six-minute walk test</td> <td>Cardiopulmonary exercise test may be used in evaluation for lung transplantation</td> </tr> <tr class=\"divider_bottom\"> <td>Suspected neuromuscular or chest wall disease</td> <td> <p>Spirometry</p> <p>Lung volumes</p> <p>Maximal inspiratory force</p> Maximal expiratory force</td> <td>Arterial blood gas if FVC &#60;1 L</td> </tr> <tr> <td>Suspected diaphragmatic weakness</td> <td> <p>Spirometry upright and supine</p> <p>Lung volumes</p> <p>Maximal inspiratory force</p> Maximal expiratory force</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DLCO: diffusing capacity for carbon monoxide; COPD: chronic obstructive pulmonary disease; FVC: forced vital capacity; ILD: interstitial lung disease.</div><div id=\"graphicVersion\">Graphic 106178 Version 1.0</div></div></div>"},"106179":{"type":"graphic_diagnosticimage","displayName":"Kaposi’s sarcoma","title":"Chest radiograph and computed tomograms of Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph and computed tomograms of Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:366px; height:726px;\" src=\"images/PULM/106179_Kaposi_srcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph (A) and computed tomography (B and C) of patients with Kaposi's sarcoma show multiple nodules scattered throughout both lungs (arrows), some of which are poorly defined. A few nodules have a flame-shaped configuration.</div><div id=\"graphicVersion\">Graphic 106179 Version 1.0</div></div></div>"},"106180":{"type":"graphic_diagnosticimage","displayName":"Granulomatosis with polyangitis ","title":"Chest radiograph and computed tomograms of granulomatosis with polyangitis (formerly Wegener's granulomatosis)","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Chest radiograph and computed tomograms of granulomatosis with&nbsp;polyangitis (formerly Wegener's granulomatosis)</div><div class=\"cntnt\"><img style=\"width:726px; height:663px;\" src=\"images/PULM/106180_Grnlmtsvsclt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph (A) and computed tomographic images (coronal reformat [B], thin slab maximal intensity axial projection [C], and thin section axial reconstruction [D]) of patients who have granulomatosis with&nbsp;polyangitis (formerly Wegener's granulomatosis) are shown. Large, bilateral, central, perihilar pulmonary masses with spiculated lateral borders are seen with low attenuation centers and scattered air-bronchograms.</div><div id=\"graphicVersion\">Graphic 106180 Version 2.0</div></div></div>"},"106181":{"type":"graphic_diagnosticimage","displayName":"PAVM I","title":"Chest radiograph and computed tomograms of multiple pulmonary arteriovenous malformations with embolization coils","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph and computed tomograms of multiple pulmonary arteriovenous malformations with embolization coils</div><div class=\"cntnt\"><img style=\"width:249px; height:726px;\" src=\"images/PULM/106181_PAVM_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph (A) and computed tomographic coronal reformations (B and C) of patients with multiple pulmonary arteriovenous malformations (PAVMS). Bilateral PAVMS are seen with embolization coils in place after interventional treatment. The arrows on the CT images show multiple small, residual PAVMs that could not be embolized.</div><div id=\"graphicVersion\">Graphic 106181 Version 1.0</div></div></div>"},"106182":{"type":"graphic_diagnosticimage","displayName":"PAVM II","title":"Computed tomogram of a clustered pulmonary arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Computed tomogram of a clustered pulmonary arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:461px; height:714px;\" src=\"images/PULM/106182_PAVM_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic coronal reformations of a patient with a clustered right lower lobe pulmonary arteriovenous malformation show a lobulated mass (arrow) and a draining vein (arrowhead).</div><div id=\"graphicVersion\">Graphic 106182 Version 1.0</div></div></div>"},"106184":{"type":"graphic_table","displayName":"Effect of common lung conditions on DLCO, VA, and DLCO/VA (KCO)","title":"Effect of common lung conditions on DLCO, VA, and DLCO/VA (KCO)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effect of common lung conditions on DLCO, VA, and DLCO/VA (KCO)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">VA</td> <td class=\"subtitle1\">DLCO/VA (KCO)</td> <td class=\"subtitle1\">DLCO</td> </tr> <tr> <td>Incomplete lung expansion (eg, neuromuscular weakness or inadequate inspiration)</td> <td class=\"centered\">&#8595;&#8595;&#8595;</td> <td class=\"centered\">&#8593;&#8593;</td> <td class=\"centered\">&#8595;</td> </tr> <tr> <td>Discrete loss of alveolar units (eg, pneumonectomy)</td> <td class=\"centered\">&#8595;&#8595;&#8595;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8595;&#8595;</td> </tr> <tr> <td>Diffuse loss of alveolar units (eg, interstitial lung disease)</td> <td class=\"centered\">&#8595;&#8595;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595;&#8595;&#8595;</td> </tr> <tr> <td>Emphysema</td> <td class=\"centered\">Normal to &#8595;</td> <td class=\"centered\">&#8595;&#8595;</td> <td class=\"centered\">&#8595;&#8595;&#8595;</td> </tr> <tr> <td>Pulmonary vascular disease</td> <td class=\"centered\">Normal</td> <td class=\"centered\">&#8595;&#8595;</td> <td class=\"centered\">&#8595;&#8595;</td> </tr> <tr> <td>High pulmonary blood volume (eg, heart failure)</td> <td class=\"centered\">Normal</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> </tr> <tr> <td>Alveolar hemorrhage</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8593;&#8593;&#8593;</td> <td class=\"centered\">&#8593;&#8593;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DLCO: diffusing capacity for carbon monoxide; VA: alveolar volume measured during single breath DLCO; KCO: carbon monoxide transfer coefficient.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitting JW. Transfer factor for carbon monoxide: a glance behind the scene. Swiss Med Wkly 2004; 134:413. Copyright &copy; 2004 Jean-William Fitting.</div><div id=\"graphicVersion\">Graphic 106184 Version 1.0</div></div></div>"},"106185":{"type":"graphic_diagnosticimage","displayName":"CT hydrostatic pulmonary edema","title":"Computed tomography of hydrostatic pulmonary edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of hydrostatic pulmonary edema</div><div class=\"cntnt\"><img style=\"width:443px; height:725px;\" src=\"images/PULM/106185_CT_hydrsttc_plm_edm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial (A) and coronal (B) computed tomographic images of hydrostatic pulmonary edema in a patient with acute renal failure. Images show perihilar ground-glass opacities (arrows), lobular air-space nodules, and pleural effusions bilaterally (arrowheads).</div><div id=\"graphicVersion\">Graphic 106185 Version 1.0</div></div></div>"},"106186":{"type":"graphic_diagnosticimage","displayName":"CT ground-glass nodules","title":"Computed tomography of ground-glass nodules","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Computed tomography of ground-glass nodules</div><div class=\"cntnt\"><img style=\"width:474px; height:662px;\" src=\"images/PULM/106186_CT_grnd_glss_ndls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomographic image of atypical alveolar hyperplasia with multiple small ground-glass nodules in the anterior and posterior segments of the right upper lobe (arrows).</div><div id=\"graphicVersion\">Graphic 106186 Version 2.0</div></div></div>"},"106187":{"type":"graphic_diagnosticimage","displayName":"Computed tomography of microscopic polyangiitis","title":"Computed tomography of microscopic polyangiitis","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Computed tomography of microscopic polyangiitis</div><div class=\"cntnt\"><img style=\"width:595px; height:446px;\" src=\"images/PULM/106187_Cmpt_tmg_mcrscp_plngt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomographic image of a patient with pulmonary hemorrhage from microscopic polyangiitis. Ground-glass opacities and consolidation are seen throughout both lungs.</div><div id=\"graphicVersion\">Graphic 106187 Version 1.0</div></div></div>"},"106188":{"type":"graphic_diagnosticimage","displayName":"CT ILD from RA","title":"Computed tomography of interstitial lung involvement from rheumatid arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of interstitial lung involvement from rheumatid arthritis</div><div class=\"cntnt\"><img style=\"width:316px; height:696px;\" src=\"images/PULM/106188_CT_ILD_frm_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial (A and C) and coronal (B) computed tomographic images of rheumatoid arthritis-associated interstitial lung disease. Images show ground-glass and consolidative opacities involving the lower two-thirds of the lungs that spare the upper lobe. This pattern of lung involvement corresponds to cellular nonspecific interstitial pneumonia.</div><div id=\"graphicVersion\">Graphic 106188 Version 1.0</div></div></div>"},"106189":{"type":"graphic_diagnosticimage","displayName":"CT LIP","title":"Computed tomography of lymphocytic interstitial pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of lymphocytic interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:304px; height:747px;\" src=\"images/PULM/106189_CT_LIP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial (A and B) and coronal (C) computed tomographic images of a patient with chronic lymphocytic interstitial pneumonia from systemic lupus erythematosus (SLE). Images reveal upper lobe predominant ground-glass opacities and air-space nodules. Lower lobe predominant cystic disease is most likely related to follicular bronchiolitis from underlying SLE.</div><div id=\"graphicVersion\">Graphic 106189 Version 1.0</div></div></div>"},"106190":{"type":"graphic_diagnosticimage","displayName":"CT respiratory bronchiolitis","title":"Computed tomography of respiratory bronchiolitis","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Computed tomography of respiratory bronchiolitis</div><div class=\"cntnt\"><img style=\"width:467px; height:726px;\" src=\"images/PULM/106190_CT_rsprtry_brnchlt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT scans show multiple small solid and ground-glass centrilobular nodules with upper lobe predominance. Mild bibasal, subpleural, reticular opacities indicate age-related and smoking-related pulmonary fibrosis.</div><div id=\"graphicVersion\">Graphic 106190 Version 1.0</div></div></div>"},"106191":{"type":"graphic_diagnosticimage","displayName":"CT bronchiolitis obliterans","title":"Computed tomography of bronchiolitis obliterans","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Computed tomography of bronchiolitis obliterans</div><div class=\"cntnt\"><img style=\"width:596px; height:381px;\" src=\"images/PULM/106191_CT_brnchlt_obltrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial image shows a mosaic pattern consistent with bronchiolitis obliterans. Low-attenuation lung regions may represent hypoxic vasoconstriction and gas trapping. Ground-glass opacities are indicative of normal, hyperperfused lung parenchyma.</div><div id=\"graphicVersion\">Graphic 106191 Version 1.0</div></div></div>"},"106192":{"type":"graphic_diagnosticimage","displayName":"CT cryptogenic organizing pneumonia I","title":"Computed tomography of cryptogenic organizing pneumonia","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Computed tomography of cryptogenic organizing pneumonia</div><div class=\"cntnt\"><img style=\"width:597px; height:328px;\" src=\"images/PULM/106192_CT_crptgnc_orgnz_pnmn_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial image showing bilateral upper lobe parenchymal consolidation with clearly visible air-bronchograms.</div><div id=\"graphicVersion\">Graphic 106192 Version 1.0</div></div></div>"},"106194":{"type":"graphic_diagnosticimage","displayName":"CT cryptogenic organizing pneumonia II","title":"Computed tomography of cryptogenic organizing pneumonia in a patient with chronic lymphocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Computed tomography of cryptogenic organizing pneumonia in a patient with chronic lymphocytic leukemia</div><div class=\"cntnt\"><img style=\"width:596px; height:442px;\" src=\"images/PULM/106194_CT_crptg_orgnz_pnmn_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial image of a patient with chronic lymphocytic leukemia showing signs of cryptogenic organizing pneumonia. Bibasal subpleural consolidations are seen. In addition, left lower lobe perilobular pattern is seen forming arcades in the posterobasal segment.</div><div id=\"graphicVersion\">Graphic 106194 Version 1.0</div></div></div>"},"106195":{"type":"graphic_diagnosticimage","displayName":"CT bronchiolitis I","title":"Computed tomography of panbronchiolitis","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Computed tomography of panbronchiolitis</div><div class=\"cntnt\"><img style=\"width:596px; height:414px;\" src=\"images/PULM/106195_CT_brnchlt_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse panbronchiolitis in a Japanese-American patient. Extensive bilateral centrilobular nodules with a tree-in-bud pattern and bronchial wall thickening are seen, features that are typical of infectious bronchiolitis and bronchitis.</div><div id=\"graphicVersion\">Graphic 106195 Version 1.0</div></div></div>"},"106196":{"type":"graphic_diagnosticimage","displayName":"CT bronchiolitis II","title":"Computed tomography of infectious bronchiolitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of infectious bronchiolitis</div><div class=\"cntnt\"><img style=\"width:301px; height:650px;\" src=\"images/PULM/106196_CT_brnchlt_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A and B) Axial images from a patient with infectious bronchiolitis. Images show diffuse centrilobular nodules, tree-in-bud pattern, and mild bilateral lower lobe cylindrical bronchiectases. A mosaic pattern of attenuation is seen in both lungs, more conspicuous on the right than on the left. (C) Axial image from a patient with influenza-related bronchiolitis. Bilateral lower lobe predominant centrilobular nodules are seen with a tree-in-bud pattern, mucoid impaction of segmental lower lobe bronchi, and bronchial wall thickening.</div><div id=\"graphicVersion\">Graphic 106196 Version 1.0</div></div></div>"},"106199":{"type":"graphic_table","displayName":"Causes of right upper quadrant (RUQ) abdominal pain","title":"Causes of right upper quadrant (RUQ) abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of right upper quadrant (RUQ) abdominal pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">RUQ</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Biliary</td> </tr> <tr> <td class=\"indent1\">Biliary colic</td> <td>Intense, dull discomfort located in the RUQ or epigastrium. Associated with nausea, vomiting, and diaphoresis. Generally lasts at least 30 minutes, plateauing within&nbsp;one hour. Benign abdominal examination.</td> <td>Patients are generally well-appearing.</td> </tr> <tr> <td class=\"indent1\">Acute cholecystitis</td> <td>Prolonged (&#62;4 to 6 hours) RUQ or epigastric pain, fever. Patients will have abdominal guarding and Murphy's sign.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Acute cholangitis</td> <td>Fever, jaundice, RUQ pain.</td> <td>May have atypical presentation in older adults or immunosuppressed patients.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sphincter of Oddi dysfunction</td> <td>RUQ pain similar to other biliary pain.</td> <td>Biliary type pain without other apparent causes.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Hepatic</td> </tr> <tr> <td class=\"indent1\">Acute hepatitis</td> <td>RUQ pain with fatigue, malaise, nausea, vomiting, and anorexia. Patients may also have jaundice, dark urine, and light-colored stools.</td> <td>Variety of etiologies include hepatitis A, alcohol, and drug-induced.</td> </tr> <tr> <td class=\"indent1\">Perihepatitis (Fitz-Hugh-Curtis syndrome)</td> <td>RUQ pain with a pleuritic component, pain is sometimes referred to the right shoulder.</td> <td>Aminotransferases are usually normal or only slightly elevated.</td> </tr> <tr> <td class=\"indent1\">Liver abscess</td> <td>Fever and abdominal pain are the most common symptoms.</td> <td>Risk factors include diabetes, underlying hepatobiliary or pancreatic disease, or liver transplant.</td> </tr> <tr> <td class=\"indent1\">Budd-Chiari syndrome</td> <td>Symptoms include fever, abdominal pain, abdominal distention (from ascites), lower extremity edema, jaundice, gastrointestinal bleeding, and/or hepatic encephalopathy.</td> <td>Variety of causes.</td> </tr> <tr> <td class=\"indent1\">Portal vein thrombosis</td> <td>Symptoms include abdominal pain, dyspepsia, or gastrointestinal bleeding.</td> <td>Clinical manifestations depend on extent of obstruction and speed of development. Most commonly associated with cirrhosis.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 106199 Version 3.0</div></div></div>"},"106200":{"type":"graphic_table","displayName":"Causes of epigastric abdominal pain","title":"Causes of epigastric abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of epigastric abdominal pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Epigastric</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Acute myocardial infarction</td> <td>May be associated with shortness of breath and exertional symptoms.</td> <td>Consider particularly in patients with risk factors for coronary artery disease.</td> </tr> <tr> <td>Acute pancreatitis</td> <td>Acute-onset, persistent upper abdominal pain radiating to the back.</td> <td>&nbsp;</td> </tr> <tr> <td>Chronic pancreatitis</td> <td>Epigastric pain radiating to the back.</td> <td>Associated with pancreatic insufficiency.</td> </tr> <tr> <td>Peptic ulcer disease</td> <td>Epigastric pain or discomfort is the most prominent symptom.</td> <td>Occasionally, discomfort localizes to one side.</td> </tr> <tr> <td>Gastroesophageal reflux disease</td> <td>Associated with heartburn, regurgitation, and dysphagia.</td> <td>&nbsp;</td> </tr> <tr> <td>Gastritis/gastropathy</td> <td>Abdominal discomfort/pain, heartburn, nausea, vomiting, and hematemesis.</td> <td>Variety of etiologies including alcohol and nonsteroidal antiinflammatory drugs (NSAIDs).</td> </tr> <tr> <td>Functional dyspepsia</td> <td>The presence of one or more of the following: postprandial fullness, early satiation, epigastric pain, or burning.</td> <td>Patients have no evidence of structural disease.</td> </tr> <tr> <td>Gastroparesis</td> <td>Nausea, vomiting, abdominal pain, early satiety, postprandial fullness, and bloating.</td> <td>Most causes are idiopathic, diabetic, or postsurgical.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 106200 Version 2.0</div></div></div>"},"106201":{"type":"graphic_table","displayName":"Causes of left upper quadrant (LUQ) abdominal pain","title":"Causes of left upper quadrant (LUQ) abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of left upper quadrant (LUQ) abdominal pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">LUQ</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Splenomegaly</td> <td>Pain or discomfort in LUQ, left shoulder pain, and/or early satiety.</td> <td>Multiple etiologies.</td> </tr> <tr> <td>Splenic infarct</td> <td>Severe LUQ pain.</td> <td>Atypical presentations common. Associated with a variety of underlying conditions (eg, hypercoagulable state, atrial fibrillation, and splenomegaly).</td> </tr> <tr> <td>Splenic abscess</td> <td>Associated with fever and LUQ tenderness.</td> <td>Uncommon. May also be associated with splenic infarction.</td> </tr> <tr> <td>Splenic rupture</td> <td>May complain of LUQ, left chest wall, or left shoulder pain that is worse with inspiration.</td> <td>Most often associated with trauma.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 106201 Version 2.0</div></div></div>"},"106202":{"type":"graphic_table","displayName":"Causes of lower abdominal pain","title":"Causes of lower abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of lower abdominal pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Lower abdomen</td> <td class=\"subtitle1\">Localization</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Appendicitis</td> <td>Generally right lower quadrant</td> <td>Periumbilical pain initially that radiates to the right lower quadrant. Associated with anorexia, nausea, and vomiting.</td> <td>Occasional patients present with epigastric or generalized abdominal pain.</td> </tr> <tr> <td>Diverticulitis</td> <td>Generally left lower quadrant; right lower quadrant more common in Asian patients</td> <td>Pain usually constant and present for several days prior to presentation. May have associated nausea and vomiting.</td> <td>Clinical presentation depends on severity of underlying inflammatory process and whether or not complications are present.</td> </tr> <tr> <td>Nephrolithiasis</td> <td>Either</td> <td>Pain most common symptom, varies from mild to severe. Generally flank pain, but may have back or abdominal pain.</td> <td>Cause symptoms as stone passes from renal pelvis to ureter.</td> </tr> <tr> <td>Pyelonephritis</td> <td>Either</td> <td>Associated with dysuria, frequency, urgency, hematuria, fever, chills, flank pain, and costovertebral angle tenderness.</td> <td>&nbsp;</td> </tr> <tr> <td>Acute urinary retention </td> <td>Suprapubic</td> <td>Present with lower abdominal pain and discomfort; inability to urinate.</td> <td>&nbsp;</td> </tr> <tr> <td>Cystitis</td> <td>Suprapubic</td> <td>Associated with dysuria, frequency, urgency, and hematuria.</td> <td>&nbsp;</td> </tr> <tr> <td>Infectious colitis</td> <td>Either</td> <td>Diarrhea as the predominant symptom, but may also have associated abdominal pain, which may be severe.</td> <td>Patients with <em>Clostridium difficile</em> infection can present with an acute abdomen and peritoneal signs in the setting of perforation and fulminant colitis.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 106202 Version 2.0</div></div></div>"},"106203":{"type":"graphic_table","displayName":"Causes of diffuse abdominal pain","title":"Causes of diffuse abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of diffuse abdominal pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diffuse/poorly characterized</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Bowel obstruction</td> <td> <p>Most common symptoms are nausea, vomiting, crampy abdominal pain, and obstipation.</p> <p>Distended, tympanic abdomen with high-pitched or absent bowel sounds.</p> </td> <td>Multiple etiologies.</td> </tr> <tr> <td>Perforation of the gastrointestinal tract</td> <td>Severe abdominal pain, particularly following procedures.</td> <td>Can present acutely or in an indolent manner, particularly in immunosuppressed patients.</td> </tr> <tr> <td>Acute mesenteric ischemia</td> <td>Acute and severe onset of diffuse and persistent abdominal pain, often described as pain out of proportion to examination.</td> <td>May occur from either arterial or venous disease. Patients with aortic dissection can have abdominal pain related to mesenteric ischemia.</td> </tr> <tr> <td>Chronic mesenteric ischemia</td> <td>Abdominal pain after eating (\"intestinal angina\"), weight loss, nausea, vomiting, and diarrhea.</td> <td>May occur from either arterial or venous disease.</td> </tr> <tr> <td>Inflammatory bowel disease (ulcerative colitis/Crohn disease)</td> <td>Associated with bloody diarrhea, urgency, tenesmus, bowel incontinence, weight loss, and fevers.</td> <td>May have symptoms for years before diagnosis. Associated extraintestinal manifestations (eg, arthritis, uveitis).</td> </tr> <tr> <td>Viral gastroenteritis</td> <td>Diarrhea accompanied by nausea, vomiting, and abdominal pain.</td> <td>&nbsp;</td> </tr> <tr> <td>Spontaneous bacterial peritonitis</td> <td>Fever, abdominal pain, and/or altered mental status.</td> <td>Most often in cirrhotic patients with advanced liver disease and ascites.</td> </tr> <tr> <td>Dialysis related peritonitis</td> <td>Abdominal pain and cloudy peritoneal effluent. Other symptoms and signs include fever, nausea, diarrhea, abdominal tenderness, and rebound tenderness.</td> <td>Only in peritoneal dialysis patients.</td> </tr> <tr> <td>Colorectal cancer</td> <td>Variable presentation, including obstruction and perforation.</td> <td>&nbsp;</td> </tr> <tr> <td>Other malignancy</td> <td>Vary depending on malignancy.</td> <td>&nbsp;</td> </tr> <tr> <td>Celiac disease</td> <td>Abdominal pain in addition to including diarrhea with bulky, foul-smelling, floating stools due to steatorrhea and flatulence.</td> <td>&nbsp;</td> </tr> <tr> <td>Ketoacidosis</td> <td>Diffuse abdominal pain and nausea and vomiting.</td> <td>&nbsp;</td> </tr> <tr> <td>Adrenal insufficiency</td> <td>Diffuse abdominal pain and nausea and vomiting.</td> <td>Patients with adrenal crisis may present with shock and hypotension.</td> </tr> <tr> <td>Foodborne illness</td> <td>Mixture of nausea, vomiting, fever, abdominal pain and diarrhea.</td> <td>&nbsp;</td> </tr> <tr> <td>Irritable bowel syndrome</td> <td>Chronic abdominal pain with altered bowel habits.</td> <td>&nbsp;</td> </tr> <tr> <td>Constipation</td> <td>&nbsp;</td> <td>Associated with a variety of neurologic and metabolic disorders, obstruction lesions of the gastrointestinal tract, endocrine disorders, psychiatric disorders, and side effect of medications.</td> </tr> <tr> <td>Diverticulosis</td> <td>May have symptoms of abdominal pain and constipation.</td> <td>Often an asymptomatic and incidental finding on colonoscopy or sigmoidoscopy.</td> </tr> <tr> <td>Lactose intolerance</td> <td>Associated with abdominal pain, bloating, flatulence, and diarrhea. Abdominal pain may be cramping in nature.</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 106203 Version 2.0</div></div></div>"},"106204":{"type":"graphic_table","displayName":"Pelvic causes of abdominal pain in women","title":"Pelvic causes of abdominal pain in women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pelvic causes of abdominal pain in women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"55%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pelvic causes of abdominal pain in women</td> <td class=\"subtitle1\">Lateralization</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"indent1\">Ectopic pregnancy</td> <td>Either side or diffuse abdominal pain</td> <td>Vaginal bleeding with abdominal pain, typically six to eight weeks after last menstrual period.</td> <td>Patients can present with life-threatening hemorrhage if ruptured.</td> </tr> <tr> <td class=\"indent1\">Pelvic inflammatory disease</td> <td>Lateralization uncommon</td> <td>Characterized by the acute onset of lower abdominal or pelvic pain, pelvic organ tenderness, and evidence of inflammation of the genital tract. Often associated with cervical discharge.</td> <td>Wide spectrum of clinical presentations.</td> </tr> <tr> <td class=\"indent1\">Ovarian torsion</td> <td>Localized to one side</td> <td>Acute onset of moderate-to-severe pelvic pain, often with nausea and possibly vomiting, in a woman with an adnexal mass.</td> <td>Generally not associated with vaginal discharge.</td> </tr> <tr> <td class=\"indent1\">Ruptured ovarian cyst</td> <td>Localized to one side</td> <td>Sudden-onset unilateral lower abdominal pain. The classic presentation is sudden onset of severe focal lower quadrant pain following sexual intercourse.</td> <td>Generally not associated with vaginal discharge.</td> </tr> <tr> <td class=\"indent1\">Endometriosis </td> <td>&nbsp;</td> <td>Associated with dysmenorrhea, pelvic pain, dyspareunia, and/or infertility, but other symptoms may also be present (eg, bowel or bladder symptoms).</td> <td>Patients may present with one symptom or a combination of symptoms.</td> </tr> <tr> <td class=\"indent1\">Acute endometritis</td> <td>&nbsp;</td> <td>Most often preceded by pelvic inflammatory disease.</td> <td>Diagnostic criteria the same as pelvic inflammatory disease.</td> </tr> <tr> <td class=\"indent1\">Chronic endometritis</td> <td>&nbsp;</td> <td>Present with abnormal uterine bleeding, which may consist of intermenstrual bleeding, spotting, postcoital bleeding, menorrhagia, or amenorrhea. Vague, crampy lower abdominal pain accompanies the bleeding or may occur alone.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Leiomyomas (fibroids)</td> <td>&nbsp;</td> <td>Symptoms related to bulk or infrequently acute pain from degeneration or torsion of pedunculate tumor. Pain may be associated with a low-grade fever, uterine tenderness on palpation, elevated white blood cell count, or peritoneal signs.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ovarian hyperstimulation</td> <td>&nbsp;</td> <td>Abdominal distention/discomfort, nausea/vomiting, and diarrhea. More severe cases can have severe abdominal pain, ascites, intractable nausea, and vomiting.</td> <td>Women undergoing fertility treatment.</td> </tr> <tr> <td class=\"indent1\">Ovarian cancer</td> <td>&nbsp;</td> <td>Abdominal or pelvic pain. May have associated symptoms of bloating, urinary urgency or frequency, or difficulty eating/feeling full quickly.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ovulatory pain (Mittelsmerz)&nbsp;</td> <td>&nbsp;</td> <td>Occurs mid-cycle, coinciding with timing of ovulation.</td> <td>May be right- or left-sided, depending on site of ovulation during that cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Pregnancy and related complications*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to the UpToDate topics on abdominal pain.</div><div id=\"graphicVersion\">Graphic 106204 Version 3.0</div></div></div>"},"106205":{"type":"graphic_table","displayName":"Less common causes of abdominal pain","title":"Less common causes of abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Less common causes of abdominal pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"indent1\">Abdominal aortic aneurysm</td> </tr> <tr> <td class=\"indent1\">Abdominal compartment syndrome </td> </tr> <tr> <td class=\"indent1\">Abdominal migraine</td> </tr> <tr> <td class=\"indent1\">Acute intermittent porphyria</td> </tr> <tr> <td class=\"indent1\">Angioedema (either hereditary or angiotensin-converting enzyme [ACE] inhibitor-related)</td> </tr> <tr> <td class=\"indent1\">Celiac artery compression syndrome</td> </tr> <tr> <td class=\"indent1\">Chronic abdominal wall pain</td> </tr> <tr> <td class=\"indent1\">Colonic pseudo-obstruction (acute or chronic)</td> </tr> <tr> <td class=\"indent1\">Eosinophilic gastroenteritis</td> </tr> <tr> <td class=\"indent1\">Epiploic appendagitis</td> </tr> <tr> <td class=\"indent1\">Familial Mediterranean fever</td> </tr> <tr> <td class=\"indent1\">Helminthic infections</td> </tr> <tr> <td class=\"indent1\">Herpes zoster</td> </tr> <tr> <td class=\"indent1\">Hypercalcemia</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Lead poisoning</td> </tr> <tr> <td class=\"indent1\">Meckel's diverticulum</td> </tr> <tr> <td class=\"indent1\">Narcotic bowel syndrome</td> </tr> <tr> <td class=\"indent1\">Pseudoappendicitis</td> </tr> <tr> <td class=\"indent1\">Pulmonary etiologies</td> </tr> <tr> <td class=\"indent1\">Rectus sheath hematoma&nbsp;</td> </tr> <tr> <td class=\"indent1\">Renal infarction</td> </tr> <tr> <td class=\"indent1\">Rib pain</td> </tr> <tr> <td class=\"indent1\">Sclerosing mesenteritis</td> </tr> <tr> <td class=\"indent1\">Somatization</td> </tr> <tr> <td class=\"indent1\">Wandering spleen</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 106205 Version 4.0</div></div></div>"},"106206":{"type":"graphic_table","displayName":"USDA recommended daily or weekly caloric intake","title":"USDA recommended daily or weekly caloric intake of different food groups (USDA recommended average daily food intake)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">USDA recommended daily or weekly caloric intake of different food groups (USDA recommended average daily food intake)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"6\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Calorie level of pattern*</td> <td class=\"subtitle1\">1000</td> <td class=\"subtitle1\">1200</td> <td class=\"subtitle1\">1400</td> <td class=\"subtitle1\">1600</td> <td class=\"subtitle1\">1800</td> <td class=\"subtitle1\">2000</td> </tr> <tr class=\"divider_bottom highlight_blue_text\"> <td><strong>Food group</strong><sup>&#182;</sup></td> <td colspan=\"6\"><strong>Daily amount</strong><sup>&#916;</sup> of food from each group (vegetable and protein foods subgroup amounts are per week)</td> </tr> <tr> <td class=\"indent1\"><strong>Vegetables</strong></td> <td><strong>1 c-eq</strong></td> <td><strong>1&#189; c-eq</strong></td> <td><strong>1&#189; c-eq</strong></td> <td><strong>2 c-eq</strong></td> <td><strong>2&#189; c-eq</strong></td> <td><strong>2&#189; c-eq</strong></td> </tr> <tr> <td class=\"indent2\">Dark-green vegetables (c-eq/week)</td> <td>&#189;</td> <td>1</td> <td>1</td> <td>1&#189;</td> <td>1&#189;</td> <td>1&#189;</td> </tr> <tr> <td class=\"indent2\">Red and orange vegetables (c-eq/week)</td> <td>2&#189;</td> <td>3</td> <td>3</td> <td>4</td> <td>5&#189;</td> <td>5&#189;</td> </tr> <tr> <td class=\"indent2\">Legumes (beans and peas) (c-eq/week)</td> <td>&#189;</td> <td>&#189;</td> <td>&#189;</td> <td>1</td> <td>1&#189;</td> <td>1&#189;</td> </tr> <tr> <td class=\"indent2\">Starchy vegetables (c-eq/week)</td> <td>2</td> <td>3&#189;</td> <td>3&#189;</td> <td>4</td> <td>5</td> <td>5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Other vegetables (c-eq/week)</td> <td>1&#189;</td> <td>2&#189;</td> <td>2&#189;</td> <td>3&#189;</td> <td>4</td> <td>4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Fruits</strong></td> <td><strong>1 c-eq</strong></td> <td><strong>1 c-eq</strong></td> <td><strong>1&#189; c-eq</strong></td> <td><strong>1&#189; c-eq</strong></td> <td><strong>1&#189; c-eq</strong></td> <td><strong>2 c-eq</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Grains</strong></td> <td><strong>3 oz-eq</strong></td> <td><strong>4 oz-eq</strong></td> <td><strong>5 oz-eq</strong></td> <td><strong>5 oz-eq</strong></td> <td><strong>6 oz-eq</strong></td> <td><strong>6 oz-eq</strong></td> </tr> <tr> <td class=\"indent2\">Whole grains<sup>&#9674;</sup> (oz-eq/day)</td> <td>1&#189;</td> <td>2</td> <td>2&#189;</td> <td>3</td> <td>3</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Refined grains (oz-eq/day)</td> <td>1&#189;</td> <td>2</td> <td>2&#189;</td> <td>2</td> <td>3</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dairy</strong></td> <td><strong>2 c-eq</strong></td> <td><strong>2&#189; c-eq</strong></td> <td><strong>2&#189; c-eq</strong></td> <td><strong>3 c-eq</strong></td> <td><strong>3 c-eq</strong></td> <td><strong>3 c-eq</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Protein foods</strong></td> <td><strong>2 oz-eq</strong></td> <td><strong>3 oz-eq</strong></td> <td><strong>4 oz-eq</strong></td> <td><strong>5 oz-eq</strong></td> <td><strong>5 oz-eq</strong></td> <td><strong>5&#189; oz-eq</strong></td> </tr> <tr> <td class=\"indent2\">Seafood (oz-eq/week)</td> <td>3</td> <td>4</td> <td>6</td> <td>8</td> <td>8</td> <td>8</td> </tr> <tr> <td class=\"indent2\">Meats, poultry, eggs (oz-eq/week)</td> <td>10</td> <td>14</td> <td>19</td> <td>23</td> <td>23</td> <td>26</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Nuts seeds, soy products (oz-eq/week)</td> <td>2</td> <td>2</td> <td>3</td> <td>4</td> <td>4</td> <td>5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Oils</strong></td> <td><strong>15 g</strong></td> <td><strong>17 g</strong></td> <td><strong>17 g</strong></td> <td><strong>22 g</strong></td> <td><strong>24 g</strong></td> <td><strong>27 g</strong></td> </tr> <tr class=\"highlight_blue_text\"> <td><strong>Limit on calories for other uses, calories (% of calories)</strong><span style=\"white-space: nowrap;\"><sup>&#167;</sup><sup>&#165;</sup></span></td> <td>150 (15%)</td> <td>100 (8%)</td> <td>110 (8%)</td> <td>130 (8%)</td> <td>170 (9%)</td> <td>270 (14%)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">USDA: United States Department of Agriculture.<br />* Food intake patterns at 1000, 1200, and 1400 calories are designed to meet the nutritional needs of two- to eight-year-old children. Patterns from 1600 to 3200 calories are designed to meet the nutritional needs of children&nbsp;nine years and older and adults. If a child&nbsp;four to&nbsp;eight years of age needs more calories and, therefore, is following a pattern at 1600 calories or more, his/her recommended amount from the dairy group should be 2.5 cups per day. Children&nbsp;nine years and older and adults should not use the 1000-, 1200-, or 1400-calorie patterns.<br />¶ Foods in each group and subgroup are: &#xD;&#xA;<UL>&#xD;&#xA;<LI><STRONG>Vegetables</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Dark-green vegetables: All fresh, frozen, and canned dark-green leafy vegetables and broccoli, cooked or raw: for example, broccoli, spinach, romaine, kale, collard, turnip, and mustard greens.</LI>&#xD;&#xA;<LI>Red and orange vegetables: All fresh, frozen, and canned red and orange vegetables or juice, cooked or raw: for example, tomatoes, tomato juice, red peppers, carrots, sweet potatoes, winter squash, and pumpkin.</LI>&#xD;&#xA;<LI>Legumes (beans and peas): All cooked from dry or canned beans and peas: for example, kidney beans, white beans, black beans, lentils, chickpeas, pinto beans, split peas, and edamame (green soybeans). Does not include green beans or green peas.</LI>&#xD;&#xA;<LI>Starchy vegetables: All fresh, frozen, and canned starchy vegetables: for example, white potatoes, corn, green peas, green lima beans, plantains, and cassava.</LI>&#xD;&#xA;<LI>Other vegetables: All other fresh, frozen, and canned vegetables, cooked or raw: for example, iceberg lettuce, green beans, onions, cucumbers, cabbage, celery, zucchini, mushrooms, and green peppers.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Fruits</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>All fresh, frozen, canned, and dried fruits and fruit juices: for example, oranges and orange juice, apples and apple juice, bananas, grapes, melons, berries, and raisins.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Grains</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Whole grains: All whole-grain products and whole grains used as ingredients: for example, whole-wheat bread, whole-grain cereals and crackers, oatmeal, quinoa, popcorn, and brown rice.</LI>&#xD;&#xA;<LI>Refined grains: All refined-grain products and refined grains used as ingredients: for example, white breads, refined grain cereals and crackers, pasta, and white rice. Refined grain choices should be enriched.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Dairy</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>All milk, including lactose-free and lactose-reduced products and fortified soy beverages (soymilk), yogurt, frozen yogurt, dairy desserts, and cheeses. Most choices should be fat-free or low-fat. Cream, sour cream, and cream cheese are not included due to their low-calcium content.</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Protein foods</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>All seafood, meats, poultry, eggs, soy products, nuts, and seeds. Meats and poultry should be lean or low-fat and nuts should be unsalted. Legumes (beans and peas) can be considered part of this group as well as the vegetable group, but should be counted in one group only.</LI></UL></LI></UL>Δ Food group amounts shown in cup-(c) or ounce-equivalents (oz-eq). Oils are shown in grams (g). Quantity equivalents for each food group are: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Vegetables and fruits, 1 cup-equivalent is: 1 cup raw or cooked vegetable or fruit, 1 cup vegetable or fruit juice, 2 cups leafy salad greens, ½ cup dried fruit or vegetable.</LI>&#xD;&#xA;<LI>Grains, 1 ounce-equivalent is: ½ cup cooked rice, pasta, or cereal; 1 ounce dry pasta or rice; 1 medium (1 ounce) slice bread; 1 ounce of ready-to-eat cereal (about 1 cup of flaked cereal).</LI>&#xD;&#xA;<LI>Dairy, 1 cup-equivalent is: 1 cup milk, yogurt, or fortified soymilk; 1½ ounces natural cheese such as cheddar cheese or 2 ounces of processed cheese.</LI>&#xD;&#xA;<LI>Protein foods, 1 ounce-equivalent is: 1 ounce lean meat, poultry, or seafood; 1 egg; ¼ cup cooked beans or tofu; 1 Tbsp peanut butter; ½ ounce nuts or seeds.</LI></UL><FONT class=lozenge>◊</FONT> Amounts of whole grains in the patterns for children are less than the minimum of 3 oz-eq in all patterns recommended for adults.<br />§ All foods are assumed to be in nutrient-dense forms, lean or low-fat, and prepared without added fats, sugars, refined starches, or salt. If all food choices to meet food group recommendations are in nutrient-dense forms, a small number of calories remain within the overall calorie limit of the pattern (ie, limit on calories for other uses). The number of these calories depends on the overall calorie limit in the pattern and the amounts of food from each food group required to meet nutritional goals. Nutritional goals are higher for the 1200- to 1600-calorie patterns than for the 1000-calorie pattern, so the limit on calories for other uses is lower in the 1200- to 1600-calorie patterns. Calories up to the specified limit can be used for added sugars, added refined starches, solid fats, alcohol, or to eat more than the recommended amount of food in a food group. The overall eating pattern also should not exceed the limits of less than 10% of calories from added sugars and less than 10% of calories from saturated fats. At most calorie levels, amounts that can be accommodated are less than these limits. For adults of legal drinking age who choose to drink alcohol, a limit of up to&nbsp;one drink per day for women and up to&nbsp;two drinks per day for men within limits on calories for other uses applies; and calories from protein, carbohydrate, and total fats should be within the acceptable macronutrient distribution ranges (AMDRs).<br />¥ Values are rounded.</div><div class=\"graphic_reference\">Reproduced from: U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015&ndash;2020 Dietary Guidelines for Americans, 8th Edition, December 2015. Available at: <a href=\"http://health.gov/dietaryguidelines/2015/guidelines/\" target=\"_blank\">http://health.gov/dietaryguidelines/2015/guidelines/</a> (Accessed on January 13, 2016).</div><div id=\"graphicVersion\">Graphic 106206 Version 3.0</div></div></div>"},"106207":{"type":"graphic_table","displayName":"DRIs - Recommended dietary allowances and adequate intakes","title":"Dietary Reference Intakes (DRIs): Recommended dietary allowances and adequate intakes of several vitamins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary Reference Intakes (DRIs): Recommended dietary allowances and adequate intakes of several vitamins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Source of goal*</td> <td class=\"subtitle1\">Child<br /> 1 to 3</td> <td class=\"subtitle1\">Female<br /> 4 to 8</td> <td class=\"subtitle1\">Male<br /> 4 to 8</td> <td class=\"subtitle1\">Female<br /> 9 to 13</td> <td class=\"subtitle1\">Male<br /> 9 to 13</td> <td class=\"subtitle1\">Female<br /> 14 to 18</td> <td class=\"subtitle1\">Male<br /> 14 to 18</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Vitamins</td> </tr> <tr> <td class=\"indent1\">Vitamin A, mg RAE</td> <td>RDA</td> <td>300</td> <td>400</td> <td>400</td> <td>600</td> <td>600</td> <td>700</td> <td>900</td> </tr> <tr> <td class=\"indent1\">Vitamin E, mg AT</td> <td>RDA</td> <td>6</td> <td>7</td> <td>7</td> <td>11</td> <td>11</td> <td>15</td> <td>15</td> </tr> <tr> <td class=\"indent1\">Vitamin D, international units</td> <td>RDA</td> <td>600</td> <td>600</td> <td>600</td> <td>600</td> <td>600</td> <td>600</td> <td>600</td> </tr> <tr> <td class=\"indent1\">Vitamin C, mg</td> <td>RDA</td> <td>15</td> <td>25</td> <td>25</td> <td>45</td> <td>45</td> <td>65</td> <td>75</td> </tr> <tr> <td class=\"indent1\">Thiamin, mg</td> <td>RDA</td> <td>0.5</td> <td>0.6</td> <td>0.6</td> <td>0.9</td> <td>0.9</td> <td>1</td> <td>1.2</td> </tr> <tr> <td class=\"indent1\">Riboflavin, mg</td> <td>RDA</td> <td>0.5</td> <td>0.6</td> <td>0.6</td> <td>0.9</td> <td>0.9</td> <td>1</td> <td>1.3</td> </tr> <tr> <td class=\"indent1\">Niacin, mg</td> <td>RDA</td> <td>6</td> <td>8</td> <td>8</td> <td>12</td> <td>12</td> <td>14</td> <td>16</td> </tr> <tr> <td class=\"indent1\">Vitamin B6, mg</td> <td>RDA</td> <td>0.5</td> <td>0.6</td> <td>0.6</td> <td>1</td> <td>1</td> <td>1.2</td> <td>1.3</td> </tr> <tr> <td class=\"indent1\">Vitamin B12, mcg</td> <td>RDA</td> <td>0.9</td> <td>1.2</td> <td>1.2</td> <td>1.8</td> <td>1.8</td> <td>2.4</td> <td>2.4</td> </tr> <tr> <td class=\"indent1\">Choline, mg</td> <td>AI</td> <td>200</td> <td>250</td> <td>250</td> <td>375</td> <td>375</td> <td>400</td> <td>550</td> </tr> <tr> <td class=\"indent1\">Vitamin K, mcg</td> <td>AI</td> <td>30</td> <td>55</td> <td>55</td> <td>60</td> <td>60</td> <td>75</td> <td>75</td> </tr> <tr> <td class=\"indent1\">Folate, mcg DFE</td> <td>RDA</td> <td>150</td> <td>200</td> <td>200</td> <td>300</td> <td>300</td> <td>400</td> <td>400</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><SPAN style=\"COLOR: black\">RAE: retinol activity equivalents;</SPAN><SPAN style=\"COLOR: black\"> RDA: recommended dietary allowance; AT: alpha-tocopherol; AI: adequate intake; DFE: dietary folate equivalents.</SPAN><br />* 14 g fiber per 1000 kcal = basis for AI for fiber.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Institute of Medicine. Dietary Reference Intakes: The essential guide to nutrient requirements. Washington (DC): The National Academies Press, 2006.</li>&#xD;&#xA;    <li>Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): The National Academies Press, 2010.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015&ndash;2020 Dietary Guidelines for Americans, 8th Edition, December 2015. Available at: <a href=\"http://health.gov/dietaryguidelines/2015/guidelines/\" target=\"_blank\">http://health.gov/dietaryguidelines/2015/guidelines/</a> (Accessed on January 13, 2016).</div><div id=\"graphicVersion\">Graphic 106207 Version 2.0</div></div></div>"},"106208":{"type":"graphic_table","displayName":"Checklists for airway management in adult trauma","title":"Checklists for airway management in adult trauma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Checklists for airway management in adult trauma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pre-arrival checklist in preparation for airway management of adult trauma patient*</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Oxygen mask and nasal cannula available and connected to oxygen </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Bag-valve mask with ETCO2 attachment available </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Oral airways available </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Suction available and working </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Direct laryngoscope handle and blades available and functional (light works) </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Tracheal tubes (multiple sizes) and stylet available; tube shaped straight to cuff </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Tracheal tube introducer (\"bougie\") available </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Rescue airway devices available (eg, laryngeal mask airway, King airway) </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Cricothyrotomy kit available </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Video laryngoscope available; monitor positioned appropriately </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>IV catheters and isotonic fluids available </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Individuals designated to provide cervical spine stabilization and airway assistance </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Airway plan verbalized (primary plan and back-up plan) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Respiratory therapist notified; mechanical ventilator brought to bedside </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Pre-induction checklist for intubation of adult trauma patient*</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Pre-arrival checklist completed </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Airway plan confirmed between trauma and ED attending physicians (if necessary) </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>IV lines functioning </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Induction and NMBA medications and doses confirmed, and drawn up in labeled syringes </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Cervical spine stabilization initiated (if necessary) </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Pre-oxygenation underway: mask at 15 L/minute and nasal cannula at 5 L/minute </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Patient positioning optimized </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Blood pressure cuff placed on arm opposite that of IV line and pulse oximetry probe </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ETCO2: end-tidal carbon dioxide; IV: intravenous; NMBA: neuromuscular blocking agent; ED: emergency department.<br />* All items must be verbalized by the Nurse Scribe and confirmed by the physician or clinician responsible for airway management.</div><div class=\"graphic_reference\">Adapted from: Smith KA, High K, Collins SP, Self WH. A preprocedural checklist improves the safety of emergency department intubation of trauma patients. Acad Emerg Med 2015; 22:989.</div><div id=\"graphicVersion\">Graphic 106208 Version 1.0</div></div></div>"},"106210":{"type":"graphic_picture","displayName":"Primary effusion lymphoma histology","title":"Primary effusion lymphoma histology","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Primary effusion lymphoma histology</div><div class=\"cntnt\"><img style=\"width:599px; height:414px;\" src=\"images/HEME/106210_Prmry_effsn_lmphm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary effusion lymphoma, Wright-Giemsa stained smear of pleural fluid, original magnification 1000X.</div><div class=\"graphic_reference\">Courtesy of Patrick Treseler, MD, PhD.</div><div id=\"graphicVersion\">Graphic 106210 Version 1.0</div></div></div>"},"106211":{"type":"graphic_table","displayName":"Causes of delayed emergence or hypoactive emergence delirium","title":"Possible causes of delayed emergence or hypoactive emergence delirium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible causes of delayed emergence or hypoactive emergence delirium</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug effects</td> <td class=\"subtitle1\">Metabolic or temperature derangements</td> <td class=\"subtitle1\">Neurologic disorders</td> </tr> <tr> <td> <ul> <li>Opioids </li> <li>Benzodiazepines </li> <li>Sedative-hypnotic&nbsp;agents </li> <li>Volatile inhalational anesthetics </li> <li>Anticholinergic agents&nbsp; </li> <li>Neuromuscular blockers </li> <li>Preoperative&nbsp;self-administered prescription or illicit drugs or alcohol</li> </ul> </td> <td> <ul> <li>Hypoxemia </li> <li>Hypercapnia </li> <li>Hypothermia </li> <li>Hyperthermia </li> <li>Hypoglycemia </li> <li>Hyperglycemia </li> <li>Electrolyte imbalance <ul> <li>Hyponatremia </li> <li>Hypernatremia </li> <li>Hypermagnesemia </li> <li>Hypercalcemia </li> </ul> </li> <li>Hypothyrodism&nbsp;</li> </ul> </td> <td> <ul> <li>Acute&nbsp;stroke </li> <li>Seizures </li> <li>Elevated intracranial pressure </li> <li>Hypoxic-ischemic encephalopathy </li> <li>Hyperperfusion syndrome </li> </ul> <p>&nbsp;</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Black S, Enneking FK, Cucchiara RF. Failure to awaken after general anesthesia due to cerebrovascular events. J Neurosurg Anesthesiol 1998; 10:10.</div><div id=\"graphicVersion\">Graphic 106211 Version 5.0</div></div></div>"},"106215":{"type":"graphic_table","displayName":"Reversal agents for opioids, benzodiazepines, anticholinergics","title":"Reversal agents for opioids, benzodiazepines, and anticholinergic agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reversal agents for opioids, benzodiazepines, and anticholinergic agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"14%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug class</td> <td class=\"subtitle1\">Reversal agent</td> <td class=\"subtitle1\">Dose of reversal agent (IV)</td> <td class=\"subtitle1\">Time between repeat doses</td> <td class=\"subtitle1\">Maximum cumulative initial dose</td> <td class=\"subtitle1\">Additional dosing if necessary</td> </tr> <tr class=\"divider_bottom\"> <td>Opioids</td> <td>Naloxone</td> <td>40 mcg</td> <td>2 to 5 minutes</td> <td>10 mcg/kg</td> <td> <p>Infusion at 1 to 10&nbsp;mcg/kg per hour, with careful titration of the infusion rate according to patient response.&nbsp;</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Benzodiazepine</td> <td>Flumazenil</td> <td>0.2 mg</td> <td>1 minute</td> <td>1 mg</td> <td>After a 20 minute interval, if sedation is evident, additional 0.2 mg doses may be administered to a maximum of 1 mg. After another 20 minute interval, this dosing may be repeated. No more than 3 mg should be administered in a single hour.</td> </tr> <tr> <td>Anticholinergic agent</td> <td>Physostigmine</td> <td>0.5 to 1 mg (slow IV push)</td> <td>5 to 10 minutes</td> <td>2 mg</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Nicodemus HF, Rose JB. Delayed emergence in pediatric patients. In: Complications in Anesthesia, 1st ed, Atlee JL (Ed), Saunders, Philadelphia 1999.</li>&#xD;&#xA;    <li>Anderson JA. Reversal agents in sedation and anesthesia: a review. Anesth Prog 1988; 35:43.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 106215 Version 3.0</div></div></div>"},"106221":{"type":"graphic_figure","displayName":"Sensory distribution scalp block","title":"Sensory distribution scalp block","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Sensory distribution scalp block</div><div class=\"cntnt\"><img style=\"width:501px; height:461px;\" src=\"images/ANEST/106221_Sensory_distribution_scalp_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The purple-shaded areas show the extent of sensory anesthesia after scalp block.</div><div id=\"graphicVersion\">Graphic 106221 Version 1.0</div></div></div>"},"106222":{"type":"graphic_figure","displayName":"Sensory distribution cervical plexus block","title":"Sensory distribution cervical plexus block","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Sensory distribution cervical plexus block</div><div class=\"cntnt\"><img style=\"width:501px; height:461px;\" src=\"images/ANEST/106222_Sensory_distribution_cervical_plexus_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The purple-shaded area shows the extent of sensory anesthesia after cervical plexus block.</div><div id=\"graphicVersion\">Graphic 106222 Version 1.0</div></div></div>"},"106223":{"type":"graphic_table","displayName":"Evaluation and management of delayed emergence","title":"Evaluation and management of delayed emergence in the operating room or PACU","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation and management of delayed emergence in the operating room or PACU</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Evaluation</td> <td class=\"subtitle1\">Possible treatment</td> </tr> <tr class=\"divider_bottom\"> <td>Confirm that all anesthetic agents have been discontinued (inhalation and intravenous). Assess doses and timing of last administration of all agents.</td> <td>Continue supportive care (eg,&nbsp;O<sub>2</sub> administration, as well as&nbsp;controlled ventilation and/or blood pressure support if necessary).</td> </tr> <tr class=\"divider_bottom\"> <td>Consider residual effects of opioids, benzodiazepines,&nbsp;sedative-hypnotic agents, inhalation agents, or anticholinergic agents.</td> <td>Consider reversal medications (eg, naloxone for opioid overdose, flumazenil for benzodiazepine overdose, physostigmine for anticholinergic agent toxicity).</td> </tr> <tr class=\"divider_bottom\"> <td>Check for residual effects of neuromuscular blocking agents with a peripheral nerve stimulator.</td> <td>Administer pharmacologic reversal agents (eg, neostigmine [up to 5 mg] with glycopyrrolate [up to 1 mg]&nbsp;or sugammadex 2 mg/kg)&nbsp;if appropriate.</td> </tr> <tr class=\"divider_bottom\"> <td>Obtain&nbsp;ABG to rule out hypoxemia and/or hypercapnia with CO<sub>2</sub> narcosis.</td> <td>&nbsp;Correct hypoxemia and hypercapnia.</td> </tr> <tr class=\"divider_bottom\"> <td>Measure temperature to rule out hypothermia or hyperthermia.</td> <td class=\"divider_bottom\">Correct hypothermia or hyperthermia.</td> </tr> <tr class=\"divider_bottom\"> <td>Measure glucose to rule out hypoglycemia or hyperglycemia and electrolytes to rule out severe abnormalities (eg, hyponatremia or hypernatremia).</td> <td class=\"divider_bottom\">&nbsp;Correct abnormalities.</td> </tr> <tr> <td>Perform basic neurologic examination (eg, the NIH stroke scale and/or the Glasgow coma scale).</td> <td>Consult neurology if acute neurologic event is suspected, notify surgeon, continue supportive care (eg, oxygenation, ventilation, maintenance of cerebral perfusion pressure).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PACU: Post-anesthesia care unit; O<SUB>2</SUB>: oxygen; ABG: arterial blood gas;&nbsp;CO<SUB>2</SUB>: carbon dioxide; NIH: National Institutes of Health.</div><div id=\"graphicVersion\">Graphic 106223 Version 2.0</div></div></div>"},"106226":{"type":"graphic_figure","displayName":"Pancreaticojejunostomy techniques","title":"Pancreaticojejunostomy techniques","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Pancreaticojejunostomy techniques</div><div class=\"cntnt\"><img style=\"width:538px; height:236px;\" src=\"images/SURG/106226_Pancreaticojejunostomy_techniques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For pancreaticojejunostomy, there are two predominant methods of reconstruction: end-to-side duct-to-mucosa anastomosis (A) or invagination of the pancreatic remnant. The invagination method can be performed either end-to-side (B) or end-to-end (C). The choice of the method is determined by surgeon preference, as there is no conclusive evidence to favor one method over another.</div><div id=\"graphicVersion\">Graphic 106226 Version 1.0</div></div></div>"},"106229":{"type":"graphic_table","displayName":"Checklist for blood product refusal","title":"Blood product and extracorporeal procedure informed consent checklist","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blood product and extracorporeal procedure informed consent checklist</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"3\">The following points can be documented:</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Discussed the risks and benefits of accepting blood product transfusion.</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Discussed the risks and benefits of NOT accepting blood product transfusion.</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Discussed the risks and benefits of extracorporeal circulatory and salvage techniques.</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Specify whether consent was obtained privately or with family members/others present.</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Patient understands that if clinically significant bleeding cannot be stopped then the patient will eventually die.</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Patient is aware that blood product refusal may result in organ or tissue damage or even death.</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Patient adamantly refuses the blood component therapies indicated below, even if faced with death.</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Patient realizes that with these restrictions the care team may be forced to proceed more quickly to definitive procedures that have a chance of stopping the bleeding (bowel resection, caesarian section, hysterectomy, amputation, etc) [this is due to the lack of a blood \"buffer\" that enables the treating team to replace the blood lost during preliminary attempts at hemostasis].</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Patient understands that he or she may reverse these restrictions at ANY time and accept blood. If this occurs, the care team will abide by all patient privacy standards and not discuss the acceptance of blood products in front of family or clergy without patient consent.</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Patient was given the option to allow blood transfusion in extremis if two physicians agree that death is likely eminent.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">Another health care provider was present during the consent process or, alternatively, was present when the patient verbally acknowledged the summary of acceptable and unacceptable products and interventions.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\"><span style=\"white-space: nowrap;\">Patient acceptance (Yes) or refusal (No) of the following items can be documented:</span></td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Allogenic human blood and blood components</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Whole blood </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Red blood cells </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Plasma </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Platelets </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>White blood cells (granulocytes) </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Blood from specific donor(s) </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Human blood fractions and medications that contain human blood fractions</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cryoprecipitate </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cryosupernatant (\"cryo-poor plasma\") </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Albumin </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Plasma protein fraction </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Human immunoglobulin (eg, Rh immune globulin, IVIG) </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Plasma-derived clotting factor concentrates (eg, fibrinogen, F8, F9) </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Tissue adhesives/fibrin glue </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Intravenous fluids and medications not derived from human blood</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hydroxyethyl starch (eg, hetastarch, pentastarch) </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Balanced salt solutions </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recombinant clotting factor concentrates (eg, F8, F9, recombinant F7a) </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recombinant erythropoietin </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Antifibrinolytic chemicals (eg, tranexamic acid, aminocaproic acid) </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Procoagulant chemicals (eg, desmopressin [DDAVP], vitamin K) </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"3\">Extracorporeal techniques for blood conservation or treatment</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Intraoperative hemodilution </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Intraoperative blood salvage (cell saver) </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Autologous banked blood (self donation) </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cardiopulmonary bypass </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Chest drainage autotransfusion </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Plasmapheresis </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hemodialysis </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Other: ____________________________________________ </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This information is for use with patients who desire to restrict the use of blood products. Refer to UpToDate content on the patient who refuses blood transfusion for further details.</div><div class=\"graphic_reference\">Courtesy of Kendall P Crookston, MD.</div><div id=\"graphicVersion\">Graphic 106229 Version 1.0</div></div></div>"},"106230":{"type":"graphic_figure","displayName":"Epidural spinal positioning device","title":"Epidural spinal positioning device","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Epidural spinal positioning device</div><div class=\"cntnt\"><img style=\"width:470px; height:574px;\" src=\"images/ANEST/106230_Epdrl_spnl_pstn_dvc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A neuraxial anesthesia positioning device such as the one shown can be used to provide stable patient support during spinal or epidural anesthesia placement.</div><div class=\"graphic_reference\">Reproduced with permission. Epidural Positioning Device (EPD Pkg 2). Copyright &copy; 2001 PHS Medical. All rights reserved. http://www.phsmedicalsolutions.com/store/Epidural-Positioning-Device-C132.aspx.</div><div id=\"graphicVersion\">Graphic 106230 Version 1.0</div></div></div>"},"106232":{"type":"graphic_figure","displayName":"Cervix anatomy histo","title":"Uterine cervix anatomy and histology","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">Uterine cervix anatomy and histology</div><div class=\"cntnt\"><img style=\"width:729px; height:490px;\" src=\"images/OBGYN/106232_Cervix_anatomy_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cell types comprising the transformation zone. The endocervix is lined by columnar epithelium. The ectocervix is lined with stratified squamous epithelium. The squamocolumnar junction marks the merging point of these two epithelial cell types.</div><div class=\"graphic_reference\">Asset provided by Anatomical Chart Company. Reproduced with permission from: Altered cells and tissue. In: Applied Pathophysiology: A Conceptual Approach to the Mechanisms of Disease, 3rd Edition, Braun CA, Anderson CM (eds), Philadelphia: Lippincott Williams &amp; Wilkins, 2017. Wolters Copyright &copy; 2017 Wolters Kluwer Health. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 106232 Version 1.0</div></div></div>"},"106233":{"type":"graphic_table","displayName":"IFCPC colposcopy cervix nomenclature","title":"2011 IFCPC cervical colposcopy nomenclature","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2011 IFCPC cervical colposcopy nomenclature</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>General assessment</strong></td> <td colspan=\"2\"> <ul class=\"decimal_heading\"> <li>Adequate/inadequate for the reason (ie, cervix obscured by inflammation, bleeding, scar) </li> <li>Squamocolumnar junction visibility: completely visible, partially visible, not visible </li> <li>Transformation zone types 1, 2, 3 </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Normal colposcopic findings</strong></td> <td colspan=\"2\">Original squamous epithelium <ul class=\"decimal_heading\"> <li>Mature </li> <li>Atrophic </li> </ul> Columnar epithelium <ul class=\"decimal_heading\"> <li>Ectopy </li> </ul> Metaplastic squamous epithelium <ul class=\"decimal_heading\"> <li>Nabothian cysts </li> <li>Crypt (gland) openings </li> </ul> Deciduosis in pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Abnormal colposcopic findings</strong></td> <td><strong>General principles</strong></td> <td colspan=\"2\"> <p><strong>Location of the lesion:</strong> inside or outside the T-zone, location of the lesion by clock position</p> <strong>Size of the lesion:</strong> number of cervical quadrants the lesion covers, size of the lesion in percentage of cervix</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><strong>Grade 1 (minor)</strong></td> <td> <p>Thin acetowhite epithelium</p> Irregular, geographic border</td> <td> <p>Fine mosaic</p> Fine punctuation</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><strong>Grade 2 (major)</strong></td> <td> <p>Dense acetowhite epithelium</p> <p>Rapid appearance of acetowhitening</p> Cuffed crypt (gland) openings</td> <td> <p>Coarse mosaic</p> <p>Coarse punctuation</p> <p>Sharp border</p> <p>Inner border sign</p> Ridge sign</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td><strong>Non-specific</strong></td> <td colspan=\"2\"> <p>Leukoplakia (keratosis, hyperkeratosis), erosion</p> Lugol's staining (Schiller's test): stained/non-stained</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Suspicious for invasion</strong></td> <td colspan=\"2\"> <p>Atypical vessels</p> <strong>Additional signs:</strong> fragile vessels, irregular surface, exophytic lesion, necrosis, ulceration (necrotic), tumor/gross neoplasm</td> </tr> <tr> <td colspan=\"2\"><strong>Miscellaneous finding</strong></td> <td> <p>Congenital transformation zone</p> <p>Condyloma</p> <p>Polyp (ectocervical/endocervical)</p> Inflammation</td> <td> <p>Stenosis</p> <p>Congenital anomaly</p> <p>Post-treatment consequence</p> Endometriosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IFCPC: International Federation for Cervical Pathology and Colposcopy.</div><div class=\"graphic_reference\">From: Bornstein J, Bentley J, Bosze P, et al. 2011 Colposcopic Terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 2012; 120:166. DOI: <a href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2012&amp;issue=07000&amp;article=00026&amp;type=abstract\" target=\"_blank\">10.1097/AOG.0b013e318254f90c</a>. Copyright &copy; 2012 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 106233 Version 1.0</div></div></div>"},"106234":{"type":"graphic_figure","displayName":"Positioning for neuraxial anesthesia","title":"Positioning for neuraxial anesthesia","html":"<div class=\"graphic\"><div style=\"width: 707px\" class=\"figure\"><div class=\"ttl\">Positioning for neuraxial anesthesia</div><div class=\"cntnt\"><img style=\"width:687px; height:379px;\" src=\"images/ANEST/106234_Pstn_nrxl_ansths.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sitting and lateral decubitus positions are used most commonly for spinal anesthesia. The sitting position may be particularly useful for larger patients, as the midline may be&nbsp;more easily estimated&nbsp;in this position if bony landmarks are not easily palpated. The patient should slouch symmetrically with shoulders over the hips to flex the spine.<br />For the lateral decubitus position, the thighs should be drawn up with the hips maximally flexed&nbsp;and&nbsp;the lower back rounded or pushed out.<br />The intercristal line (ie, a line between the iliac crests) is used as a rough guide for spinal needle placement. The needle should be inserted at or below this line to avoid spinal cord trauma.<br />For further details, refer to the topic on spinal anesthesia technique.</div><div class=\"graphic_reference\">Reproduced with permission from: Kleinman W, Mikhail M. Spinal, epidural, and caudal blocks. In: Clinical Anesthesiology, 4th ed, Morgan GE, Mikhail MS, Murray M (Eds), McGraw-Hill, New York 2006. p.289. Copyright &copy; 2006 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 106234 Version 2.0</div></div></div>"},"106235":{"type":"graphic_figure","displayName":"Hand position for neuraxial anesthesia","title":"Hand position for neuraxial anesthesia","html":"<div class=\"graphic\"><div style=\"width: 798px\" class=\"figure\"><div class=\"ttl\">Hand position for neuraxial anesthesia</div><div class=\"cntnt\"><img style=\"width:778px; height:488px;\" src=\"images/ANEST/106235_Hand_postn_neuraxial_injctn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When performing neuraxial anesthesia, the&nbsp;nondominant hand is used to stabilize the needle. One method for stabilizing the needle is shown in this graphic, with the knuckle of the index finger held against the patient's back. The index finger and thumb of the nondominant hand should be used to hold the needle hub when removing the loss of resistance syringe during epidural anesthesia, and when connecting the syringe during spinal anesthesia.</div><div class=\"graphic_reference\">Reproduced with permission from: Bernards CM, Hostetter LS. Epidural and spinal anesthesia. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 106235 Version 1.0</div></div></div>"},"106236":{"type":"graphic_figure","displayName":"Layers through which spinal needle goes","title":"Layers through which spinal needle goes","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Layers through which spinal needle goes</div><div class=\"cntnt\"><img style=\"width:533px; height:519px;\" src=\"images/ANEST/106236_Layers_through_which_spinal_needle_goes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For spinal anesthesia, the needle is inserted through the skin and subcutaneous tissue, the supraspinous and interspinous ligaments, the ligamentum flavum, the dura, and the epidural space before puncturing the dura to enter the subarachnoid space.&nbsp;CSF flow from the needle hub&nbsp;confirms correct needle placement.</div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid.</div><div id=\"graphicVersion\">Graphic 106236 Version 1.0</div></div></div>"},"106237":{"type":"graphic_figure","displayName":"Dermatome map","title":"Dermatome map","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Dermatome map</div><div class=\"cntnt\"><img style=\"width:540px; height:620px;\" src=\"images/ANEST/106237_Dermatome_map.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic depicts the dermatomes, or bands of sensory innervation of the skin, of cranial and spinal nerves. </div><div id=\"graphicVersion\">Graphic 106237 Version 1.0</div></div></div>"},"106238":{"type":"graphic_figure","displayName":"Change in intervertebral space with spine flexion","title":"Change in intervertebral space with spine flexion","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Change in intervertebral space with spine flexion</div><div class=\"cntnt\"><img style=\"width:507px; height:607px;\" src=\"images/ANEST/106238_Change_in_intervertebral_space_with_spine_flexion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For lumbar neuraxial anesthesia, the patient is optimally positioned with the lumbar spine flexed. As shown in this graphic, flexion&nbsp;opens the space for needle insertion between adjacent spinous processes. For further details, refer to the UpToDate topic on spinal anesthesia technique.</div><div id=\"graphicVersion\">Graphic 106238 Version 1.0</div></div></div>"},"106239":{"type":"graphic_figure","displayName":"Spinal needle tips","title":"Spinal needle tips","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Spinal needle tips</div><div class=\"cntnt\"><img style=\"width:490px; height:474px;\" src=\"images/ANEST/106239_Spinal_needle_tips.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Needles for spinal anesthesia or lumbar puncture can be classified according to the needle tip. Cutting-tip, or Quincke, needles have sharp, cutting tips, with the hole at the end of the needle. Whitacre and Sprotte needles are two types of pencil point, or noncutting tip needles. They have a closed tip shaped like a pencil, with the hole on the side of the needle near the tip.&nbsp;Pencil point needles are designed to minimize leak of cerebrospinal fluid after puncture and reduce the&nbsp;chance of postdural puncture headache.&nbsp;&nbsp;</div><div id=\"graphicVersion\">Graphic 106239 Version 1.0</div></div></div>"},"106240":{"type":"graphic_figure","displayName":"Paramedian neuraxial needle insertion","title":"Paramedian neuraxial needle insertion","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Paramedian&nbsp;neuraxial needle insertion</div><div class=\"cntnt\"><img style=\"width:471px; height:459px;\" src=\"images/ANEST/106240_Paramedian_spinal_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the paramedian approach to neuraxial needle placement, the needle is inserted&nbsp;10 to 15 degrees from midline, in a slightly&nbsp;cephalad direction. The aim is to puncture the dura in the&nbsp;midline. This approach is particularly useful for the patient with&nbsp;reduced space between adjacent transverse processes.&nbsp;</div><div id=\"graphicVersion\">Graphic 106240 Version 1.0</div></div></div>"},"106241":{"type":"graphic_figure","displayName":"Redirect spinal needle","title":"Redirect spinal needle","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Redirect spinal needle</div><div class=\"cntnt\"><img style=\"width:540px; height:356px;\" src=\"images/ANEST/106241_Redirect_spinal_needle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If the needle hits bone during spinal needle placement, note the depth, withdraw the needle into the introducer if one is used, and redirect and reinsert in a slightly cephalad direction. If bone is contacted again, the depth compared with the initial insertion will help determine further maneuvers. For further details, refer to UpToDate topic on midline approach to spinal anesthesia technique.</div><div id=\"graphicVersion\">Graphic 106241 Version 1.0</div></div></div>"},"106281":{"type":"graphic_table","displayName":"Bethesda system for reporting thyroid cytopathology","title":"Bethesda system diagnostic categories for reporting thyroid cytopathology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bethesda system diagnostic categories for reporting thyroid cytopathology</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Bethesda class</td> <td class=\"subtitle1\">Diagnostic category</td> <td class=\"subtitle1\">Cancer risk</td> </tr> <tr> <td>I</td> <td>Nondiagnostic (unsatisfactory)</td> <td>5 to 10%</td> </tr> <tr> <td>II</td> <td>Benign</td> <td>0 to 3%</td> </tr> <tr> <td>III</td> <td>Atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS)</td> <td>10 to 30%</td> </tr> <tr> <td>IV</td> <td>Follicular neoplasm (or suspicious for follicular neoplasm)</td> <td>25 to 40%</td> </tr> <tr> <td>V</td> <td>Suspicious for malignancy</td> <td>50 to 75%</td> </tr> <tr> <td>VI</td> <td>Malignant</td> <td>97 to 99%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid 2017; 27: 1341.</div><div id=\"graphicVersion\">Graphic 106281 Version 3.0</div></div></div>"},"106293":{"type":"graphic_table","displayName":"Effects of substances of abuse on sleep and wakefulness","title":"Effects of substances of abuse on sleep and wakefulness in substance use disorders*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effects of substances of abuse on sleep and wakefulness in substance use disorders*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"6\" width=\"10%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Substance of abuse</td> <td class=\"subtitle1\" colspan=\"3\">Sleep continuity</td> <td class=\"subtitle1\" colspan=\"3\">Sleep architecture</td> <td class=\"subtitle1\" rowspan=\"2\">Other aspects</td> </tr> <tr> <td class=\"subtitle2\">SL</td> <td class=\"subtitle2\">TST</td> <td class=\"subtitle2\">SE</td> <td class=\"subtitle2\">REM-L</td> <td class=\"subtitle2\">REM%</td> <td class=\"subtitle2\">SWS%</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"8\">Alcohol</td> </tr> <tr> <td class=\"indent2\">Intoxication</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8593;</td> <td class=\"divider_bottom\" rowspan=\"2\">&#8593; rates of sleep-related breathing disorders and periodic limb movements in sleep</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Withdrawal</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8593;</td> <td>&#8595;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"8\">Cannabis (marijuana)</td> </tr> <tr> <td class=\"indent2\">Intoxication</td> <td>&#8593; to &#8595;</td> <td>&#8596;</td> <td>&#8596;</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8593;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Withdrawal</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8593; rates of periodic limb movements in sleep</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"8\">Cocaine and other stimulants</td> </tr> <tr> <td class=\"indent2\">Intoxication</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8593; to &#8596;</td> <td>&#8595; daytime sleepiness on MSLT</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Withdrawal</td> <td>&#8595;</td> <td>&#8593;</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8593; daytime sleepiness on MSLT</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"8\">Heroin and other opioids</td> </tr> <tr> <td class=\"indent2\">Intoxication</td> <td>&#8593; to &#8596;</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8596; to &#8595;</td> <td rowspan=\"2\">&#8593; central sleep apnea and irregular breathing patterns with chronic opioid therapy</td> </tr> <tr> <td class=\"indent2\">Withdrawal</td> <td>0</td> <td>0</td> <td>&#8593;</td> <td>0</td> <td>&#8593;</td> <td>&#8593;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">&uarr;: increased compared with baseline; &darr;: decreased compared with baseline; &harr;: no change compared with baseline; 0: insufficient information; SL: sleep latency; TST: total sleep time; SE: sleep efficiency; REM-L: rapid eye movement latency; REM%: percent rapid eye movement sleep; SWS%: percent slow wave sleep; MSLT: multiple sleep latency test.<br />* Results reported are based on preponderance of data from laboratory studies in humans. Findings across individual studies frequently varied.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Aldrich MS, Brower KJ, Hall JM. Sleep-disordered breathing in alcoholics. Alcohol Clin Exp Res 1999; 23:134. </li>&#xD;&#xA;    <li>Gann H, Feige B, Fasihi S, et al. Periodic limb movements during sleep in alcohol dependent patients. Eur Arch Psychiatry Clin Neurosci 2002; 252:124.</li>&#xD;&#xA;    <li>Johanson CE, Roehrs T, Schuh K, Warbasse L. The effects of cocaine on mood and sleep in cocaine-dependent males. Exp Clin Psychopharmacol 1999; 7:338.</li>&#xD;&#xA;    <li>Walker JM, Farney RJ, Rhondeau SM, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007; 3:455.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 106293 Version 1.0</div></div></div>"},"106305":{"type":"graphic_table","displayName":"Sensory level required for operations under neuraxial anesthesia","title":"Sensory level required for surgical procedures commonly performed under neuraxial anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensory level required for surgical procedures commonly performed under&nbsp;neuraxial anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Surgical procedure</td> <td class=\"subtitle1\">Sensory dermatome level</td> </tr> <tr> <td>Cesarean delivery</td> <td>T4</td> </tr> <tr> <td>Postpartum tubal ligation</td> <td>T4</td> </tr> <tr> <td>Total hip arthroplasty</td> <td>T10</td> </tr> <tr> <td>Open reduction internal fixation of femur or hip fractures</td> <td>T10</td> </tr> <tr> <td>Cervical cerclage</td> <td>T10</td> </tr> <tr> <td>Urologic procedures</td> <td>T10</td> </tr> <tr> <td>Peri-anal procedure</td> <td>S1</td> </tr> <tr> <td>Total knee arthroplasty</td> <td>L1</td> </tr> <tr> <td>Knee arthroscopy</td> <td>L1</td> </tr> <tr> <td>Foot surgery</td> <td>L2 to L3</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 106305 Version 2.0</div></div></div>"},"106306":{"type":"graphic_table","displayName":"Spinal needle lengths and gauges","title":"Spinal needle lengths and gauges","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spinal needle lengths and gauges</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Needle type</td> <td class=\"subtitle1\">Gauge</td> <td class=\"subtitle1\">Length (inches)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Quincke</td> <td>18</td> <td>3.5, 6</td> </tr> <tr> <td>20</td> <td>1.5, 2.5, 3, 3.5, 6</td> </tr> <tr> <td>22</td> <td>1.5, 2.5, 3.5, 5, 7</td> </tr> <tr> <td>23</td> <td>3.5</td> </tr> <tr> <td>25</td> <td>1, 2, 3, 3.5, 4<span style=\"font-size: 9px;\"><sup>11</sup>&frasl;<sub>16</sub></span></td> </tr> <tr> <td>26</td> <td>3.5</td> </tr> <tr class=\"divider_bottom\"> <td>27</td> <td>3.5</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Whitacre</td> <td>22</td> <td>3.5</td> </tr> <tr> <td>24</td> <td>3.5</td> </tr> <tr> <td>25</td> <td>3.5, 4<span style=\"font-size: 9px;\"><sup>11</sup>&frasl;<sub>16</sub></span>, 5</td> </tr> <tr class=\"divider_bottom\"> <td>27</td> <td>3.5, 4<span style=\"font-size: 9px;\"><sup>11</sup>&frasl;<sub>16</sub></span>, 5</td> </tr> <tr> <td rowspan=\"6\">Sprotte</td> <td>20</td> <td>3.5</td> </tr> <tr> <td>21</td> <td>3.5</td> </tr> <tr> <td>22</td> <td>3.5, 4.75</td> </tr> <tr> <td>24</td> <td>1, 1.5, 3, 3.5, 4.75, 6</td> </tr> <tr> <td>25</td> <td>4</td> </tr> <tr> <td>27</td> <td>4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table shows the gauges and lengths available for several commonly used spinal needles.</div><div id=\"graphicVersion\">Graphic 106306 Version 1.0</div></div></div>"},"106307":{"type":"graphic_table","displayName":"Traditional febrile infant evaluation","title":"Traditional strategies for the evaluation of febrile young infants (younger than 90 days of age)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Traditional strategies for the evaluation of febrile young infants (younger than&nbsp;90 days of age)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Boston criteria</td> <td class=\"subtitle1\">Milwaukee criteria</td> <td class=\"subtitle1\">Philadelphia criteria</td> <td class=\"subtitle1\">Rochester criteria</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Age range</strong></td> <td> <ul> <li>28 to 89 days </li> </ul> </td> <td> <ul> <li>28 to 56 days </li> </ul> </td> <td> <ul> <li>29 to 60 days </li> </ul> </td> <td> <ul> <li>&#8804;60 days </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Temperature</strong></td> <td> <ul> <li>&#8805;38.0&#176;C </li> </ul> </td> <td> <ul> <li>&#8805;38.0&#176;C </li> </ul> </td> <td> <ul> <li>&#8805;38.2&#176;C </li> </ul> </td> <td> <ul> <li>&#8805;38.0&#176;C </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>History</strong>*</td> <td> <ul> <li>No immunizations within last 48 hours </li> <li>No antimicrobial within 48 hours </li> <li>Not dehydrated </li> </ul> </td> <td> <ul> <li>Not defined </li> </ul> </td> <td> <ul> <li>Not defined </li> </ul> </td> <td> <ul> <li>Term infant </li> <li>No perinatal antibiotics </li> <li>No underlying disease </li> <li>Not hospitalized longer than the mother </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Physical examination</strong>*</td> <td> <ul> <li>Well appearing </li> <li>No sign of focal infection (middle ear, soft tissue, bone/joint) </li> </ul> </td> <td> <ul> <li>Well appearing (normal breathing, alert, active, normal muscle tone) </li> <li>Not dehydrated </li> <li>No sign of focal infection (middle ear, soft tissue, bone/joint) </li> </ul> </td> <td> <ul> <li>Well appearing </li> <li>Unremarkable examination </li> </ul> </td> <td> <ul> <li>Well appearing </li> <li>No sign of focal infection (middle ear, soft tissue, bone/joint) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Laboratory parameters</strong>*</td> <td> <ul> <li>CSF &#60;10/mm<sup>3</sup> </li> <li>WBC &#60;20,000/mm<sup>3</sup> </li> <li>UA &#60;10 WBCs/hpf </li> <li>Chest radiograph: no infiltrate (if obtained) </li> </ul> </td> <td> <ul> <li>CSF &#60;10/mm<sup>3</sup> </li> <li>WBC &#60;15,000/mm<sup>3</sup> </li> <li>UA &#60;5 to 10 WBCs/hpf (no bacteria, negative LE/nitrite) </li> <li>Chest radiograph: no infiltrate (if obtained) </li> </ul> </td> <td> <ul> <li>CSF &#60;8/mm<sup>3</sup> </li> <li>WBC &#60;15,000/mm<sup>3</sup> </li> <li>UA &#60;10 WBCs/hpf </li> <li>Urine Gram stain negative </li> <li>CSF Gram stain negative </li> <li>Chest radiograph: no infiltrate </li> <li>Stool: no blood, few or no WBCs on smear (if indicated) </li> <li>Band-neutrophil ratio &#60;0.2 </li> </ul> </td> <td> <ul> <li>CSF: NA (no lumbar puncture is indicated) </li> <li>WBC &#62;5000 and &#60;15,000/mm<sup>3</sup> </li> <li>ABC &#60;1500 </li> <li>UA &#8804;10 WBCs/hpf </li> <li>Stool: &#8804;5 WBCs/hpf smear (if indicated) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Management strategy for low risk</strong></td> <td> <ul> <li>Home/outpatient </li> <li>Empiric antibiotics </li> <li>Follow-up required </li> </ul> </td> <td> <ul> <li>Reliable caretaker followup required </li> <li>IM ceftriaxone 50 mg/kg followed by re-evaluation within 24 hours </li> </ul> </td> <td> <ul> <li>Home/outpatient </li> <li>No antibiotics </li> <li>Followup required </li> </ul> </td> <td> <ul> <li>Home/outpatient </li> <li>No antibiotics </li> <li>Follow-up required </li> </ul> </td> </tr> <tr> <td><strong>Management strategy for high risk</strong></td> <td> <ul> <li>Hospitalize </li> <li>Empiric antibiotics </li> </ul> </td> <td> <ul> <li>Not defined </li> </ul> </td> <td> <ul> <li>Hospitalize </li> <li>Empiric antibiotics </li> </ul> </td> <td> <ul> <li>Hospitalize </li> <li>Empiric antibiotics </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ABC: absolute band count; C: Celsius; CSF: cerebrospinal fluid; hpf: high-power field; UA: urinalysis; WBC: white blood cells.<br />* The evaluation algorithms rate patients as normal/low risk versus high/not low risk for serious bacterial infection based on information in each of these domains. The example values in the table represent low risk.</div><div class=\"graphic_reference\">Reproduced from: Hui C, Neto G, Tsertsvadze A, et al. Diagnosis and management of febrile infants (0-3 months). Evid Rep Technol Assess 2012; (205):1. Available at: <A spellcheck=true href=\"http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=1016&amp;pageaction=displayproduct\" target=_blank>http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=1016&amp;pageaction=displayproduct</A> (Accessed September 1, 2016).</div><div id=\"graphicVersion\">Graphic 106307 Version 5.0</div></div></div>"},"106312":{"type":"graphic_table","displayName":"JAAM DIC scoring system","title":"Japanese Association for Acute Medicine (JAAM) scoring system for disseminated intravascular coagulation (DIC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Japanese Association for Acute Medicine (JAAM) scoring system for disseminated intravascular coagulation (DIC)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td colspan=\"2\"><strong>SIRS criteria met</strong>*<strong>:</strong></td> </tr> <tr> <td class=\"indent1\">&#8805;3</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">0 to 2</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\"><strong>Platelet count (per microL):</strong></td> </tr> <tr> <td class=\"indent1\">&#60;80 or &#62;50% decrease within 24 hours</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">81 to 120 or 30 to 50% decreased within 24 hours</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;120</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\"><strong>Prothrombin time (PT):</strong></td> </tr> <tr> <td class=\"indent1\">INR &#8805;1.2</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">INR &#60;1.2</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\"><strong>Fibrinogen level (mg/dL):</strong></td> </tr> <tr> <td class=\"indent1\">&#60;35</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;35</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\"><strong>Fibrin/fibrinogen degradation products (mcg/mL):</strong></td> </tr> <tr> <td class=\"indent1\">&#8805;25</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">10 to 24</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#60;10</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\"><strong>Score interpretation: DIC is diagnosed if total score is &#8805;4.</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">JAAM: Japanese Association for Acute Medicine; DIC: disseminated intravascular coagulation; SIRS: systemic inflammatory response syndrome; PT: prothrombin time; INR: international normalized ratio.<br />* SIRS criteria include abnormal (high or low) core temperature, tachycardia, tachypnea, and abnormal (high or low) leukocyte count. For details of SIRS criteria, refer to UpToDate topic reviews on sepsis and SIRS in adult and pediatric patients.</div><div class=\"graphic_reference\">Additional information from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gando S, Saitoh D, Ogura H, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 2008; 36:145.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006; 34:625. DOI: <a href=\"http://journals.lww.com/ccmjournal/pages/articleviewer.aspx?year=2006&amp;issue=03000&amp;article=00007&amp;type=abstract\" target=\"_blank\">10.1097/01.CCM.0000202209.42491.38</a>. Copyright &copy; 2006 Society of Critical Care Medicine. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 106312 Version 1.0</div></div></div>"},"106314":{"type":"graphic_picture","displayName":"Ladd bands in an adult","title":"Ladd bands in an adult","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Ladd bands in an adult</div><div class=\"cntnt\"><img style=\"width:716px; height:486px;\" src=\"images/SURG/106314_Ladd_bnd_adlt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adult patients typically have thick, vascular Ladd bands traveling from the duodenum to the lateral abdomen (arrow).</div><div class=\"graphic_reference\">Courtesy of Terry Buchmiller, MD.</div><div id=\"graphicVersion\">Graphic 106314 Version 1.0</div></div></div>"},"106315":{"type":"graphic_diagnosticimage","displayName":"CT \"Whirlpool\" sign of midgut volvulus","title":"CT \"Whirlpool\" sign of midgut volvulus","html":"<div class=\"graphic\"><div style=\"width: 755px\" class=\"figure\"><div class=\"ttl\">CT \"Whirlpool\" sign of midgut volvulus</div><div class=\"cntnt\"><img style=\"width:735px; height:370px;\" src=\"images/SURG/106315_CT_Whrlpl_sgn_mdgt_vlvl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This \"whirlpool\" sign of volvulus depicts blood vessels twisting around the base of the mesenteric pedicle on CT imaging.<br />(A) Axial image.<br />(B) Vascular 3D reconstruction.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Terry Buchmiller, MD.</div><div id=\"graphicVersion\">Graphic 106315 Version 2.0</div></div></div>"},"106316":{"type":"graphic_diagnosticimage","displayName":"Duodenum with \"corkscrew\" appearance in intestinal malrotation","title":"Duodenum with \"corkscrew\" appearance in intestinal malrotation","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Duodenum with \"corkscrew\" appearance in intestinal malrotation</div><div class=\"cntnt\"><img style=\"width:644px; height:559px;\" src=\"images/SURG/106316_Dd_crkscrw_appr_intst_mlrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On upper gastrointestinal contrast study, a \"corkscrew\" appearance of the duodenum is diagnostic of intestinal malrotation.</div><div class=\"graphic_reference\">Courtesy of Terry Buchmiller, MD.</div><div id=\"graphicVersion\">Graphic 106316 Version 1.0</div></div></div>"},"106319":{"type":"graphic_diagnosticimage","displayName":"Color Doppler of cord entanglement","title":"Color Doppler of cord entanglement","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Color Doppler of cord entanglement</div><div class=\"cntnt\"><img style=\"width:715px; height:612px;\" src=\"images/OBGYN/106319_Clr_dpplr_crd_entngl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color Doppler ultrasound shows blood vessels in umbilical cord. Pulsed Doppler arterial waveforms go in opposite directions and have different fetal heart rates, consistent with cord entanglement.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 106319 Version 2.0</div></div></div>"},"106320":{"type":"graphic_figure","displayName":"Manual stabilization of the adult spine","title":"Manual stabilization of the adult spine","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Manual stabilization of the adult spine</div><div class=\"cntnt\"><img style=\"width:465px; height:701px;\" src=\"images/ANEST/106320_Manual_stabilization_adult_spine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For manual in-line stabilization of the cervical spine, an assistant grasps the mastoid process with the fingertips, with the occiput in the palms of the hands, standing at the head of the&nbsp;bed beside the intubating clinician. Alternatively, the assistant may stand at the patient's shoulder, holding the mastoid with the palms and the occiput with the fingertips. Either way, the assistant should apply enough force to counter forces applied during laryngoscopy to keep the head and neck in a neutral position, without applying traction.</div><div id=\"graphicVersion\">Graphic 106320 Version 1.0</div></div></div>"},"106331":{"type":"graphic_diagnosticimage","displayName":"Idiopathic LV apical pseudoaneurysm","title":"Idiopathic left ventricular apical pseudoaneurysm","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Idiopathic left ventricular apical pseudoaneurysm</div><div class=\"cntnt\"><img style=\"width:725px; height:338px;\" src=\"images/CARD/106331_Idpthc_LV_apcl_psdnrysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An idiopathic left ventricular apical pseudoaneurysm in a 78-year-old-male.</div><div id=\"graphicVersion\">Graphic 106331 Version 1.0</div></div></div>"},"106339":{"type":"graphic_movie","displayName":"Askling hamstring exercises: The Diver","title":"Askling hamstring exercises: The Diver","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Askling&nbsp;hamstring exercises: The Diver</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/106339_Diverhamstringexercisvid.mp4\" style=\"width:608px;height:400px\"></div><img style=\"width:540px; height:404px;\" src=\"images/SM/106339_Diverhamstringexercisimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diver is a useful exercise for developing hamstring strength and is used during rehabilitation of hamstring muscle strains.</div><div class=\"graphic_reference\">From: Askling CM, Tengvar M, Thorstensson A. Acute hamstring injuries in Swedish elite football: a prospective randomised controlled clinical trial comparing two rehabilitation protocols. Br J Sports Med 2013; 47:953. Reproduced with permission from BMJ Publishing Group Ltd. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 106339 Version 2.0</div></div></div>"},"106340":{"type":"graphic_movie","displayName":"Askling hamstring exercises: The Glider","title":"Askling hamstring exercises: The Glider","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Askling&nbsp;hamstring exercises: The Glider</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/106340_Gliderhamstringexercsvid.mp4\" style=\"width:608px;height:400px\"></div><img style=\"width:540px; height:405px;\" src=\"images/SM/106340_Gliderhamstringexercsimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Glider is a challenging exercise used to develop hamstring strength,&nbsp;usually during the latter stages of rehabilitation from a muscle strain. It must be performed in a controlled manner.</div><div class=\"graphic_reference\">From: Askling CM, Tengvar M, Thorstensson A. Acute hamstring injuries in Swedish elite football: a prospective randomised controlled clinical trial comparing two rehabilitation protocols. Br J Sports Med 2013; 47:953. Reproduced with permission from BMJ Publishing Group Ltd. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 106340 Version 2.0</div></div></div>"},"106341":{"type":"graphic_picture","displayName":"Birt-Hogg-Dube lip","title":"Birt-Hogg-Dubé syndrome","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Birt-Hogg-Dub&eacute; syndrome</div><div class=\"cntnt\"><img style=\"width:715px; height:475px;\" src=\"images/DERM/106341_Birt_hogg_dube_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mucosal papules in a patient with Birth-Hogg-Dubé syndrome.</div><div class=\"graphic_reference\">Courtesy of Edward&nbsp;W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 106341 Version 2.0</div></div></div>"},"106345":{"type":"graphic_table","displayName":"Approach generalized lymphadenopathy in children","title":"Our step-wise approach to the evaluation and initial management of generalized lymphadenopathy in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Our step-wise approach to the evaluation and initial management of generalized lymphadenopathy in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>1. History and examination to look for obvious causes</td> </tr> <tr class=\"divider_bottom\"> <td>2. Early biopsy* of most abnormal node for children with: <ul class=\"decimal_heading\"> <li>Supraclavicular nodes </li> <li>Massively enlarged nodes (ie, &#62;4 cm [1.6 inches]) </li> <li>A group of nodes with a total diameter &#62;3 cm (1.2 inches) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>3. Initial testing typically includes: <ul class=\"decimal_heading\"> <li>CBC with differential, ESR/CRP </li> <li>Serology for CMV and EBV </li> <li>Serology for other viral illnesses as warranted by the history and examination<sup>&#182;</sup> </li> <li>TST </li> <li>Chest radiograph </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>4. Provide treatment or additional evaluation as indicated for conditions that are identified through initial history, examination, and testing</td> </tr> <tr class=\"divider_bottom\"> <td>5. When the cause remains uncertain after the initial evaluation, obtain the following second tier tests <strong>if there are indications based on the initial evaluation<sup>&#182;</sup></strong>: <ul class=\"decimal_heading\"> <li>Serology for <em>Bartonella henselae</em>, toxoplasmosis, histoplasmosis, coccidiomycosis, brucellosis, syphilis, HIV, and other viruses </li> <li>ANA </li> </ul> </td> </tr> <tr> <td>5. Obtain biopsy* of the most abnormal node within four weeks of initial evaluation if: <ul class=\"decimal_heading\"> <li>Any lymph nodes increase in size </li> <li>There is a lymph node &#8805;2 cm (0.8 inches) in diameter and <strong>either</strong> of the following: <ul> <li>The diagnosis remains uncertain after four weeks </li> <li>There is no response to therapy as indicated by the findings of initial or second tier tests </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; CMV: cytomegalovirus; EBV: Epstein-Barr virus; TST: tuberculin skin test; HIV: human immunodeficiency virus; ANA: antinuclear antibody.<br />* Excisional biopsy is preferred; fine needle aspirate biopsies usually are inadequate for evaluation of pediatric malignancies or infiltrative diseases.<br />¶ Refer to UpToDate topic on evaluation of peripheral lymphadenopathy in children for details.</div><div id=\"graphicVersion\">Graphic 106345 Version 2.0</div></div></div>"},"106346":{"type":"graphic_table","displayName":"Approach to axillary lymphadenopathy in children","title":"Our step-wise approach to the evaluation and initial management of axillary lymphadenopathy in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Our step-wise approach to the evaluation and initial management of axillary lymphadenopathy in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>1. History and examination to look for obvious causes or worrisome features*</td> </tr> <tr class=\"divider_bottom\"> <td>2. Refer children with worrisome features for early biopsy<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>3. Evaluate and treat causes that appear obvious based on initial evaluation</td> </tr> <tr class=\"divider_bottom\"> <td>4. When the cause remains uncertain after the initial evaluation:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Lymph node &#8805;2 cm (0.8 inches) in longest diameter: </li> </ul> </td> </tr> <tr> <td class=\"indent2\">a. Obtain CBC/differential, ESR/CRP <ul class=\"decimal_heading\"> <li>Worrisome features*: Proceed to biopsy<sup>&#182;</sup> </li> <li>No worrisome features*: <ul> <li>Signs of infection in lymph node or distal to lymph node: <ul> <li>Obtain cultures and other microbiologic studies as indicated<sup>&#916;</sup> </li> <li>Provide 10 to 14 day trial of antibiotic therapy, broadened as indicated<sup>&#9674;</sup> </li> </ul> </li> <li>No signs of infection: <ul> <li>Observe for two to three weeks </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent2\">b. Response to antibiotic therapy/broadened antibiotic therapy<sup>&#916;</sup> or observation <ul class=\"decimal_heading\"> <li>Regression in size: No additional evaluation or therapy </li> <li>No regression or increase: Biopsy<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Lymph node &#60;2 cm (0.8 inches) in longest diameter: </li> </ul> </td> </tr> <tr> <td class=\"indent2\">a. Initial management according to symptoms/signs of infection within or distal to node: <ul class=\"decimal_heading\"> <li>Symptoms or signs of infection: <ul> <li>Obtain cultures and other microbiologic studies as indicated<sup>&#916;</sup> </li> <li>Initiate a 10 to 14 day trial of antibiotic therapy, broadened as indicated<sup>&#9674;</sup> </li> </ul> </li> <li>No symptoms or signs of infection: <ul> <li>Observe for two to three weeks </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">b. Response to antibiotic therapy/broadened antibiotic therapy<sup>&#9674;</sup> or observation: <ul class=\"decimal_heading\"> <li>Regression in size: No additional evaluation or therapy </li> <li>No regression or increase: Obtain a CBC/differential, perform TST, and initiate or broaden antimicrobial therapy <ul> <li>CBC/differential concerning for malignancy (eg, lymphoblasts, cytopenias in more than one cell line): Biopsy<sup>&#182;</sup> </li> <li>TST positive: Additional evaluation as indicated for tuberculosis or nontuberculous mycobacteria </li> <li>TST negative and lymphadenopathy regresses in size: No additional evaluation or therapy </li> <li>TST negative and lymphadenopathy does not regress in size: Obtain ESR/CRP and serology for EBV, CMV, HIV, and <em>Bartonella henselae </em>(for children with exposure to cats or kittens); evaluate other conditions as indicated by the history and examination<sup>&#916;</sup> </li> </ul> </li> </ul> </td> </tr> <tr> <td>5. Obtain biopsy<sup>&#182;</sup> after four weeks if the diagnosis remains uncertain and the lymph node has not regressed in size or there is no response to antimicrobial therapy/broadened antimicrobial therapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TST: tuberculin skin test; EBV: Epstein-Barr virus; CMV: cytomegalovirus; HIV: human immunodeficiency virus; CA-MRSA: community-associated methicillin-resistant <EM>Staphylococcus aureus</EM>.<br />* Worrisome features include systemic symptoms (fever &gt;1 week, night sweats, weight loss [&gt;10% of body weight]); fixed nontender nodes in the absence of other symptoms; abnormal chest radiograph (eg, mediastinal mass or hilar adenopathy); abnormal CBC/differential; lack of upper respiratory tract symptoms; lymph nodes &gt;2 cm in diameter that have increased in size from baseline or have not responded to two weeks of antibiotic therapy; and persistently elevated ESR/CRP or rising ESR/CRP despite antibiotic therapy. Refer to UpToDate topic on evaluation of peripheral lymphadenopathy in children for details.<br />¶ Excisional biopsy is preferred; fine needle aspirate biopsies usually are inadequate for evaluation of pediatric malignancies or infiltrative diseases.<br />Δ Refer to UpToDate topic on evaluation of peripheral lymphadenopathy in children for details.<br /><FONT class=lozenge>◊</FONT> Empiric antibiotic therapy should include coverage for common pathogens such as group A <EM>Streptococcus </EM>and <EM>S. aureus </EM>(eg, clindamycin in areas with a high prevalence of CA-MRSA or a first-generation cephalosporin [eg, cephalexin] or amoxicillin-clavulanate in areas with a low prevalence of CA-MRSA). If the patient's systemic symptoms (eg, fever) do not improve within 72 hours or the lymph node increases in size (at any point during treatment), we broaden the antimicrobial coverage to include coverage for common pathogens that were not included initially (eg, CA-MRSA, <EM innerHtml>B. henselae </EM>[for children with exposure to cats or kittens]). Refer to UpToDate topic on evaluation of peripheral lymphadenopathy in children for details.</div><div id=\"graphicVersion\">Graphic 106346 Version 4.0</div></div></div>"},"106347":{"type":"graphic_table","displayName":"Approach to cervical lymphadenopathy in children","title":"Our step-wise approach to the evaluation and initial management of cervical lymphadenopathy in children that does not appear to be caused by an infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Our step-wise approach to the evaluation and initial management of cervical lymphadenopathy in children that does not appear to be caused by an infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>1. History and examination to look for obvious causes or worrisome features*</td> </tr> <tr class=\"divider_bottom\"> <td>2. Refer children with worrisome features for early biopsy<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>3. Evaluate and treat causes that appear obvious based on initial evaluation</td> </tr> <tr class=\"divider_bottom\"> <td>4. When the cause remains uncertain after the initial evaluation: <ul class=\"decimal_heading\"> <li>Lymph node &#60;2 cm (0.8 inches) in longest diameter: <ul> <li>Observe for 10 to 14 days: <ul> <li>Regression in size: No additional evaluation or therapy </li> <li>No regression in size: <ul> <li>Obtain CBC/differential; ESR/CRP; serology for EBV, CMV, and HIV; evaluate for Kawasaki disease and other uncommon causes of cervical lymphadenopathy as indicated by the history and examination<sup>&#916;</sup> </li> <li>Provide referral or treatment as indicated based upon results </li> </ul> </li> </ul> </li> </ul> </li> <li>Lymph node &#8805;2 cm (0.8 inches) in longest diameter <ul> <li>Obtain CBC, ESR/CRP, and CXR <ul> <li>Worrisome features*: Refer for biopsy </li> <li>No worrisome features and cause remains uncertain (including possible occult infection): Perform TST and provide 10 to 14 day trial of antibiotics<sup>&#9674;</sup> <ul> <li>TST positive: Additional testing may be necessary to establish diagnosis of tuberculosis or NTM </li> <li>TST negative and lymph node regresses in size: No additional evaluation or therapy </li> <li>TST negative and lymph node does not regress: <ul> <li>Obtain serology for EBV, CMV, and HIV; evaluate for Kawasaki disease and other uncommon causes of cervical lymphadenopathy as indicated by the history and examination<sup>&#916;</sup> </li> <li>Provide referral or treatment as indicated based upon results </li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td>5. Obtain biopsy<sup>&#182;</sup> after four weeks if the diagnosis remains uncertain and the lymph node has not regressed in size or there is no response to antimicrobial therapy/broadened antimicrobial therapy<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; EBV: Epstein-Barr virus; CMV: cytomegalovirus; HIV: human immunodeficiency virus; CXR: chest radiograph; TST: tuberculin skin test; CA-MRSA: community-associated methicillin-resistant <EM>Staphylococcus aureus</EM>.<br />* Worrisome features include: Systemic symptoms (fever &gt;1 week, night sweats, weight loss [&gt;10% of body weight]); fixed nontender nodes in the absence of other symptoms; abnormal chest radiograph (eg, mediastinal mass or hilar adenopathy); abnormal CBC/differential; lack of upper respiratory tract symptoms; lymph nodes &gt;2 cm in diameter that have increased in size from baseline or have not responded to two weeks of antibiotic therapy; and persistently elevated ESR/CRP or rising ESR/CRP despite antibiotic therapy.<br />¶ Excisional biopsy is preferred; fine needle aspirate biopsies usually are inadequate for evaluation of pediatric malignancies or infiltrative diseases.<br />Δ Refer to UpToDate topic on evaluation of peripheral lymphadenopathy in children for details.<br />◊ Empiric antibiotic therapy should include coverage for common pathogens such as group A <EM innerHtml>Streptococcus </EM>and <EM innerHtml>S. aureus </EM>(eg, clindamycin in areas with a high prevalence of CA-MRSA or a first-generation cephalosporin [eg, cephalexin] or amoxicillin-clavulanate in areas with a low prevalence of CA-MRSA). If the patient's systemic symptoms (eg, fever) do not improve within 72 hours or the lymph node increases in size (at any point during treatment), we broaden the antimicrobial coverage to include coverage for common pathogens that were not included initially (eg, CA-MRSA, <EM innerHtml>B. henselae </EM>[for children with exposure to cats or kittens]). Refer to UpToDate topic on evaluation of peripheral lymphadenopathy in children for details. <br />§ For lymph nodes &lt;2 cm (0.8 inches) in diameter, continued observation may be reasonable if there are no worrisome features. </div><div id=\"graphicVersion\">Graphic 106347 Version 3.0</div></div></div>"},"106348":{"type":"graphic_table","displayName":"Approach to inguinal lymphadenopathy in children","title":"Our step-wise approach to the evaluation and initial management of inguinal lymphadenopathy in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Our step-wise approach to the evaluation and initial management of inguinal lymphadenopathy in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>1. History and examination to look for obvious causes or worrisome features*</td> </tr> <tr class=\"divider_bottom\"> <td>2. Refer children with worrisome features for early biopsy<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>3. Evaluate and treat causes that appear obvious based on initial evaluation</td> </tr> <tr class=\"divider_bottom\"> <td>4. When the cause remains uncertain after the initial evaluation: <ul class=\"decimal_heading\"> <li>Lymph node &#8805;2 cm (0.8 inches) in longest diameter and tender: <ul> <li>Initiate 10 to 14 day trial of antibiotic therapy, broadened as indicated<sup>&#916;</sup> <ul> <li>Regression in size: No additional evaluation or therapy</li> <li>No regression in size: Obtain CBC/differential, ESR/CRP, CXR, TST, <em>Bartonella henselae</em> serology and provide referral or treatment based on the results</li> </ul> </li> </ul> </li> <li>Lymph node &#8805;2 cm (0.8 inches) in longest diameter, nontender, with symptoms/signs of infection within or distal to node <ul> <li>Obtain bacterial and fungal cultures or other fungal studies as indicated by the initial evaluation<sup>&#9674;</sup>, <em>B. henselae</em> serology, and provide a 10 to 14 day trial of antibiotic therapy, broadened as indicated<sup>&#916;</sup> <ul> <li>Regression in size: No additional evaluation or therapy</li> <li>No regression in size: Obtain CBC, ESR/CRP, and CXR to evaluate worrisome features*</li> </ul> </li> </ul> </li> <li>Lymph node &#8805;2 cm (0.8 inches) in longest diameter, nontender, no symptoms/signs of infection within or distal to node <ul> <li>Obtain CBC/differential, ESR/CRP, CXR and abdominal ultrasonography <ul> <li>Worrisome features*, abdominal mass, or abdominal lymphadenopathy: Proceed to biopsy<sup>&#182;</sup></li> <li>No worrisome features*, no abdominal mass or lymphadenopathy, and cause remains uncertain: Perform TST and provide a 10 to 14 day trial of antibiotic therapy broadened as indicated<sup>&#916;</sup> <ul> <li>TST positive: Additional testing may be necessary to establish diagnosis of tuberculosis or NTM</li> <li>TST negative and lymph node regresses in size: No additional evaluation or therapy</li> <li>TST negative, lymph node does not regress: Obtain additional microbiologic studies as indicated by the history and examination<sup>&#9674;</sup> and provide referral or treatment based on the results</li> </ul> </li> </ul> </li> </ul> </li> <li>Lymph node &#60;2 cm (0.8 inches) in longest diameter: <ul> <li>Worrisome features*: Proceed to biopsy<sup>&#182;</sup></li> <li>No worrisome features*: Continue to observe, even if the lymph node does not regress after four weeks</li> </ul> </li> </ul> </td> </tr> <tr> <td>5. For lymph nodes &#8805;2 cm (0.8 inches), obtain biopsy<sup>&#182;</sup> after four weeks if the diagnosis remains uncertain and the lymph node has not regressed in size or there is no response to antimicrobial therapy/broadened antimicrobial therapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; CXR: chest radiograph; TST: tuberculin skin test; EBV: Epstein-Barr virus; CMV: cytomegalovirus; NTM: nontuberculous mycobacteria; CA-MRSA: community-associated methicillin-resistant <EM>Staphylococcus aureus</EM>.<br />* Worrisome features include systemic symptoms (fever &gt;1 week, night sweats, weight loss [&gt;10% of body weight]); fixed nontender nodes in the absence of other symptoms; abnormal chest radiograph (eg, mediastinal mass or hilar adenopathy); abnormal CBC/differential; lack of upper respiratory tract symptoms; lymph nodes &gt;2 cm in diameter that have increased in size from baseline or have not responded to two weeks of antibiotic therapy; and persistently elevated ESR/CRP or rising ESR/CRP despite antibiotic therapy.<br />¶ Excisional biopsy is preferred; fine needle aspirate biopsies usually are inadequate for evaluation of pediatric malignancies or infiltrative diseases.<br />Δ Empiric antibiotic therapy should include coverage for common pathogens such as group A <EM>Streptococcus </EM>and <EM>S. aureus </EM>(eg, clindamycin in areas with a high prevalence of CA-MRSA or a first-generation cephalosporin [eg, cephalexin] or amoxicillin-clavulanate in areas with a low prevalence of CA-MRSA). If the patient’s systemic symptoms (eg, fever) do not improve within 72 hours or the lymph node increases in size (at any point during treatment), we broaden the antimicrobial coverage to include coverage for common pathogens that were not included initially (eg, CA-MRSA, <EM>B. henselae</EM>). Refer to UpToDate topic on diagnostic approach to peripheral lymphadenopathy in children for details.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate topic on evaluation of peripheral lymphadenopathy in children for details.</div><div id=\"graphicVersion\">Graphic 106348 Version 2.0</div></div></div>"},"106353":{"type":"graphic_figure","displayName":"Types of cecal volvulus","title":"Types of cecal volvulus","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Types of cecal volvulus</div><div class=\"cntnt\"><img style=\"width:531px; height:609px;\" src=\"images/SURG/106353_Types_of_cecal_volvulus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Type I: Axial cecal volvulus<br />B) Type II: Loop cecal volvulus<br />C) Type III: Cecal bascule<br />Black arrow denotes direction of rotation.</div><div id=\"graphicVersion\">Graphic 106353 Version 3.0</div></div></div>"},"106359":{"type":"graphic_figure","displayName":"TWiTCH trial results","title":"Transcranial Doppler (TCD) velocities in the TWiTCH trial ","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Transcranial Doppler (TCD) velocities in the TWiTCH trial </div><div class=\"cntnt\"><img style=\"width:574px; height:454px;\" src=\"images/HEME/106359_Primary_endpoint_anlyss_TCD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The TWiTCH trial&nbsp;randomly assigned children with&nbsp;sickle cell disease at high risk of stroke&nbsp;who had already received chronic transfusions for one or more years to receive continued transfusions (standard group) or to transition to hydroxyurea according to the trial protocol (alternative group). The primary endpoint was TCD velocity.&nbsp;Data in each group are shown as the mean plus or minus&nbsp;one standard deviation. Refer to UpToDate topic on stroke prevention in sickle cell disease for further interpretation, context, and approach.</div><div class=\"graphic_footnotes\">TCD: transcranial Doppler.</div><div class=\"graphic_reference\">Reproduced from: Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia&mdash;TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet 2015. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 106359 Version 1.0</div></div></div>"},"106369":{"type":"graphic_table","displayName":"Etiologic classification of renal infarction","title":"Etiologic classification of renal infarction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologic classification of renal infarction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Number</td> </tr> <tr> <td class=\"subtitle2_left\">Cardiogenic</td> <td class=\"subtitle2_left\">244</td> </tr> <tr> <td class=\"indent1\">Atrial fibrillation</td> <td class=\"indent1\">211</td> </tr> <tr> <td class=\"indent1\">Cardiomyopathy</td> <td class=\"indent1\">43</td> </tr> <tr> <td class=\"indent1\">Artificial valve</td> <td class=\"indent1\">19</td> </tr> <tr> <td class=\"indent1\">Endocarditis</td> <td class=\"indent1\">15</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Thrombi from suprarenal aorta or left ventricle</td> <td class=\"indent1\">7</td> </tr> <tr> <td class=\"subtitle2_left\">Renal artery injury</td> <td class=\"subtitle2_left\">33</td> </tr> <tr> <td class=\"indent1\">Renal artery dissection</td> <td class=\"indent1\">21</td> </tr> <tr> <td class=\"indent1\">Trauma</td> <td class=\"indent1\">9</td> </tr> <tr> <td class=\"indent1\">Marfan syndrome</td> <td class=\"indent1\">1</td> </tr> <tr> <td class=\"indent1\">Polyarteritis nodosa</td> <td class=\"indent1\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Compression from para-aortic lymph node</td> <td class=\"indent1\">1</td> </tr> <tr> <td class=\"subtitle2_left\">Hypercoagulable state</td> <td class=\"subtitle2_left\">29</td> </tr> <tr> <td class=\"indent1\">Malignancy</td> <td class=\"indent1\">18</td> </tr> <tr> <td class=\"indent1\">Antiphospholipid antibody syndrome</td> <td class=\"indent1\">4</td> </tr> <tr> <td class=\"indent1\">Hyperhomocysteinemia*</td> <td class=\"indent1\">5</td> </tr> <tr> <td class=\"indent1\">Nephrotic syndrome</td> <td class=\"indent1\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Paroxysmal nocturnal hemoglobinuria</td> <td class=\"indent1\">1</td> </tr> <tr> <td><strong>Idiopathic</strong></td> <td><strong>132</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Defined as homocysteine level &gt;15 micromol/L.</div><div class=\"graphic_reference\">Reproduced from: Oh YK, Yang CW, Kim YL, et al. Clinical characteristics and outcomes of renal infarction. Am J Kidney Dis 2016; 67:243. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 106369 Version 1.0</div></div></div>"},"106380":{"type":"graphic_figure","displayName":"Intestinal malrotation with and without midgut volvulus","title":"Intestinal malrotation with and without midgut volvulus","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Intestinal malrotation with and without midgut volvulus</div><div class=\"cntnt\"><img style=\"width:534px; height:568px;\" src=\"images/SURG/106380_Intestinal_malrotation_with_and_without_midgut_volvulus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;Intestinal malrotation without midgut volvulus.<br />(B) Intestinal malrotation with midgut volvulus.</div><div id=\"graphicVersion\">Graphic 106380 Version 2.0</div></div></div>"},"106381":{"type":"graphic_diagnosticimage","displayName":"Barium enema image of transverse colon cut-off due to midgut vol","title":"Barium enema image of transverse colon cut-off due to midgut volvulus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barium enema image of transverse colon cut-off due to midgut volvulus</div><div class=\"cntnt\"><img style=\"width:377px; height:409px;\" src=\"images/SURG/106381_Brm_enm_img_trns_cln_ct_off.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph obtained with a barium enema shows a beak-like disruption of the midtransverse colon (arrow). At surgery for reduction of the volvulus, the colon was located mostly on the left side, consistent with malrotation.</div><div class=\"graphic_reference\">Reproduced with permission from: Applegate K, Anderson J, Klatte E. Intestinal malrotation in children: a problem-solving approach to the upper gastrointestinal series. Radiographics 2006; 26:1485. Copyright &copy; 2006 The Radiological Society of North America (RSNA).</div><div id=\"graphicVersion\">Graphic 106381 Version 1.0</div></div></div>"},"106382":{"type":"graphic_figure","displayName":"Aedes distribution United States","title":"Estimated range of <EM>Aedes aegypti </EM>and <EM>Aedes albopictus </EM>in the United States","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Estimated range of <EM>Aedes aegypti </EM>and <EM>Aedes albopictus </EM>in the United States</div><div class=\"cntnt\"><img style=\"width:602px; height:806px;\" src=\"images/ID/106382_Aedes_distribution_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These maps show areas where mosquitoes are or have been previously found (based on a variety of sources) and reflect estimates of the potential range of <em>Aedes aegypti</em> and <em>Aedes albopictus</em> in the United States. These maps do not show exact locations or numbers of mosquitoes living in an area nor do they represent risk for spread of disease.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Zika Virus: Vector Surveillance and Control. Available at: <a href=\"http://www.cdc.gov/zika/vector/index.html\" target=\"_blank\">http://www.cdc.gov/zika/vector/index.html</a> (Accessed on March 31, 2016).</div><div id=\"graphicVersion\">Graphic 106382 Version 3.0</div></div></div>"},"106383":{"type":"graphic_diagnosticimage","displayName":"CD1a-positive cells in BAL fluid","title":"CD1a-positive cells in bronchoalveolar lavage fluid in pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 663px\" class=\"figure\"><div class=\"ttl\">CD1a-positive cells in bronchoalveolar lavage fluid in pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:643px; height:431px;\" src=\"images/PULM/106383_CD1a_pstv_clls_BAL_fld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagnosis of pulmonary Langerhans cell histiocytosis is supported by the finding of ≥5% CD1a-positive cells (Langerhans cells) in bronchoalveolar lavage (BAL) fluid.</div><div class=\"graphic_reference\">Courtesy of Anja C Roden, MD.</div><div id=\"graphicVersion\">Graphic 106383 Version 1.0</div></div></div>"},"106384":{"type":"graphic_figure","displayName":"Cause-specific mortality in incident dialysis patients","title":"Cause-specific mortality in incident dialysis patients after first dialysis session in a freestanding facility","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Cause-specific mortality in incident dialysis patients after first dialysis session in a freestanding facility</div><div class=\"cntnt\"><img style=\"width:496px; height:925px;\" src=\"images/NEPH/106384_Cs_spcfc_mrtl_incd_dlys_pt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">According to the Death Notification Form; 2011.</div><div class=\"graphic_reference\">Reproduced from: Weinhandl E, Constantini E, Everson S, et al. Peer kidney care initiative 2014 report: Dialysis care and outcomes in the United States. Am J Kidney Dis 2015; 65(6 Suppl 1): S1. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 106384 Version 1.0</div></div></div>"},"106385":{"type":"graphic_figure","displayName":"Distribution of causes of death during first year of dialysis","title":"Distribution of causes of death during the first year of dialysis","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Distribution of causes of death during the first year of dialysis</div><div class=\"cntnt\"><img style=\"width:565px; height:703px;\" src=\"images/NEPH/106385_Dstrbt_dth_dr_frst_yr_dlys.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">According to the Death Notification Form; 2011.</div><div class=\"graphic_reference\">Reproduced from: Weinhandl E, Constantini E, Everson S, et al. Peer kidney care initiative 2014 report: Dialysis care and outcomes in the United States. Am J Kidney Dis 2015; 65(6 Suppl 1): S1. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 106385 Version 1.0</div></div></div>"},"106387":{"type":"graphic_diagnosticimage","displayName":"Cicatrizing atelectasis","title":"Computed tomography of cicatrizing atelectasis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Computed tomography of cicatrizing atelectasis</div><div class=\"cntnt\"><img style=\"width:540px; height:508px;\" src=\"images/PULM/106387_Cctrz_atlcts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal multiplanar reformation of multislice computed tomographic scan is shown. Cicatrizing atelectasis of the left upper lobe with traction bronchiectases due to prior granulomatous disease is seen. The patient has also diffuse centrilobular emphysema.</div><div id=\"graphicVersion\">Graphic 106387 Version 1.0</div></div></div>"},"106388":{"type":"graphic_table","displayName":"SCD pain management plan","title":"Sickle cell disease acute and chronic pain management plan","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sickle cell disease acute and chronic pain management plan</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Chronic pain management plan and strategies to reduce pain episodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Take prescribed medications regularly, including long-acting opioid medications and/or methadone if appropriate </li> <li>Have short-acting opioids available (and a clear plan for their use) for breakthrough pain </li> <li>Maintain hydration </li> <li>Avoid extremes of temperature and stress </li> <li>Possible use of medications for neuropathic pain </li> <li>Discussion of hydroxyurea or other disease-modifying therapies when well (eg, as an outpatient) if appropriate </li> <li>Address psychosocial issues (eg, depression, social isolation) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Acute pain - prompt assessment and treatment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li><strong>Distinguish between acute vaso-occlusive pain events and non-SCD pain</strong> <ul> <li>Treat minor injuries with rest, heat, elevation, and over-the-counter analgesics (acetaminophen, NSAIDs) </li> <li>Treat pain preceded by fever, dehydration, temperature extremes, or other stresses as vaso-occlusive (sickle cell) pain <strong><span>​</span><strong> </strong></strong></li> </ul> </li> <li><strong>Treat with escalating therapy</strong> <ul> <li>Start with nonpharmacologic therapies (eg, relaxation/breathing exercises) </li> <li>Add non-opioid therapies (eg, acetaminophen, NSAIDs) if pain is not controlled </li> <li>Add short-acting opioids </li> </ul> </li> <li><strong>Avoid</strong> <ul> <li>Avoid application of ice or cold compresses, which can precipitate sickling </li> <li>Avoid ketorolac</li> </ul> </li> <li><strong>Identify and treat other potential SCD complications</strong> <ul> <li>Pain with fever or cough may indicate respiratory infection or early acute chest syndrome and requires pain management and communication with sickle cell clinic </li> <li>Pain with dyspnea, focal neurologic signs, splenic enlargement, and/or signs of severe anemia requires emergent medical attention and evaluation for possible acute chest syndrome, stroke, splenic sequestration, or aplastic crisis </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Management of&nbsp;opioid side effects</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Use stimulant laxatives for constipation; osmotic agents are not as effective in opioid-induced constipation&nbsp; </li> <li>Use non-sedating (H1-antagonist) antihistamines&nbsp;for pruritus if needed </li> <li>Use antiemetics for nausea if needed;&nbsp;a selective 5-HT<sub>3</sub> receptor antagonist such as ondansetron should be the first choice because of minimal CNS findings </li> <li>Treat insomnia with nonpharmacologic or pharmacologic approaches as needed </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content and other graphics on vaso-occlusive pain management for additional information.</div><div class=\"graphic_footnotes\">SCD: sickle cell disease; NSAIDs: nonsteroidal anti-inflammatory drugs; CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 106388 Version 3.0</div></div></div>"},"106446":{"type":"graphic_table","displayName":"Somatic Symptom Disorder-B Criteria Scale","title":"Somatic Symptom Disorder-B Criteria Scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Somatic Symptom Disorder-B Criteria Scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Never</td> <td class=\"subtitle1\">Rarely</td> <td class=\"subtitle1\">Sometimes</td> <td class=\"subtitle1\">Often</td> <td class=\"subtitle1\">Very Often</td> </tr> <tr> <td> <ol class=\"numbers_no_heading\"> <li>I think that my physical symptoms are signs of a serious illness (I).</li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"2\"> <li>I am very worried about my health (II).</li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"3\"> <li>My health concerns hinder me in everyday life (III).</li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"4\"> <li>I am convinced that my symptoms are serious (I).</li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"5\"> <li>My symptoms scare me (II).</li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"6\"> <li>My physical complaints occupy me for most of the day (III).</li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"7\"> <li>Others tell me that my physical problems are not serious (I).</li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"8\"> <li>I'm worried that my physical complaints will never stop (II).</li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"9\"> <li>My worries about my health take my energy (III).</li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"10\"> <li>I think that doctors do not take my physical complaints seriously (I).</li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"11\"> <li>I am worried that my physical symptoms will continue into the future (II).</li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> <tr> <td> <ol class=\"numbers_no_heading\" start=\"12\"> <li>Due to my physical complaints, I have poor concentration on other things (III).</li> </ol> </td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> <td class=\"centered\"><span class=\"primarybox_left\" style=\"vertical-align: middle; float: none;\">&nbsp;</span></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">(I): sub-criterion I (cognitive aspects); (II): sub-criterion II (affective aspects); (III): sub-criterion III (behavioral aspects).</div><div class=\"graphic_reference\">Published in: Toussaint A, Murray AM, Voigt K, et al. Development and validation of the Somatic Symptom Disorder-B Criteria Scale (SSD-12). Psychosom Med 2016; 78:5. Copyright © 2014 Bernd Löwe, Alexandra M Murray, Anne Toussaint, et al, Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Germany. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 106446 Version 1.0</div></div></div>"},"106448":{"type":"graphic_table","displayName":"Somatic Symptoms Experience Questionnaire (SSEQ)","title":"Somatic Symptoms Experience Questionnaire (SSEQ)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Somatic Symptoms Experience Questionnaire (SSEQ)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"8%\"></colgroup><colgroup width=\"44%\"></colgroup><colgroup span=\"6\" width=\"8%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"8\">This questionnaire focuses on thoughts and feelings you might have with regard to physical complaints and the way you usually cope with such complaints. Please read all questions in detail. There is a line in each sentence: _____. Please indicate which word fits best for you in the position of the line in each sentence.</td> </tr> <tr> <td class=\"divider_bottom\" colspan=\"2\"><strong>Example:</strong></td> <td class=\"subtitle2_left\">Never</td> <td class=\"subtitle2_left\">Very rarely</td> <td class=\"subtitle2_left\">Rarely</td> <td class=\"subtitle2_left\">Often</td> <td class=\"subtitle2_left\">Very often</td> <td class=\"subtitle2_left\">Always</td> </tr> <tr> <td>&nbsp;</td> <td>I _____ have cold feet.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"centered highlight_gray_text\"><span style=\"font-size:1.5em;\">☒</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\" style=\"text-align: right;\" colspan=\"4\">If you rarely have cold feet, check the box here:</td> <td class=\"centered highlight_gray_text\"><span style=\"font-size:1.5em;\">&#8593;</span></td> <td colspan=\"3\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_blue_text sublist1\" colspan=\"8\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\">&nbsp;</td> <td class=\"divider_bottom\"><strong>How often do these things happen to you?</strong></td> <td class=\"subtitle2_left\">Never</td> <td class=\"subtitle2_left\">Very rarely</td> <td class=\"subtitle2_left\">Rarely</td> <td class=\"subtitle2_left\">Often</td> <td class=\"subtitle2_left\">Very often</td> <td class=\"subtitle2_left\">Always</td> </tr> <tr> <td>1.</td> <td>I _____ feel ill.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td>2.</td> <td>When I have physical complaints, I _____ worry whether they will ever end.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td>3.</td> <td>When I go to see a doctor, I _____ feel as though my concerns are not really understood.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td>4.</td> <td>While I have physical complaints, I _____ have to think about them.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td>5.</td> <td>I _____ feel physically weak and sensitive.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td>6.</td> <td>I have _____ felt as though doctors think my health-related problems are exaggerated.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td>7.</td> <td>When I notice physical complaints, I _____ think that they are signs of a serious disease.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td>8.</td> <td>I _____ doubt that the diagnoses that doctors have given me are correct.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td>9.</td> <td>I _____ worry that something is not right with my health.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td>10.</td> <td>When I feel ill and doctors do not find anything, I _____ believe that something is nevertheless seriously wrong with my health.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"sublist1\" colspan=\"8\">&nbsp;</td> </tr> <tr> <td rowspan=\"2\">11.</td> <td> <p>During the last&nbsp;six months, I have _____ experienced physical complaints.</p> <span class=\"small\">For example: Headaches, back pain, stomach pain, digestive pain, dizziness, heart or blood-pressure problems.</span></td> <td class=\"indent1 highlight_gray_text\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1 highlight_green_text\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1 highlight_green_text\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1 highlight_green_text\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1 highlight_green_text\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1 highlight_green_text\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent1 highlight_gray_text\"> <ul> <li><strong>If you marked 'never' for question number 11, this is the end of the questionnaire for you. Thank you for responding to all the questions.</strong> </li> </ul> </td> <td class=\"indent1 highlight_gray_text\"><span style=\"font-size:1.5em;\">&#8593;</span></td> <td class=\"centered highlight_green_text\" colspan=\"5\"><strong>Please continue to question number 12</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\" colspan=\"8\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"8\">The following questions deal with other thoughts and feelings you might have with regard to your physical complaints and the way you've been coping with such complaints. You will again find a line ( _____ ) in each sentence. Please indicate which word seems to fit best in the position of the line. Please refer to your experiences over the last&nbsp;six months when answering these questions.</td> </tr> <tr> <td class=\"divider_bottom\">&nbsp;</td> <td class=\"divider_bottom\"><strong>How often has this happened to you?</strong></td> <td class=\"subtitle2_left\">Never</td> <td class=\"subtitle2_left\">Very rarely</td> <td class=\"subtitle2_left\">Rarely</td> <td class=\"subtitle2_left\">Often</td> <td class=\"subtitle2_left\">Very often</td> <td class=\"subtitle2_left\">Always</td> </tr> <tr> <td>12.</td> <td>Because of my physical complaints, I have _____ tried to spare certain body parts or go easy on them to avoid strain.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td>13.</td> <td>I have _____ felt desperate because of my physical complaints.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td>14.</td> <td>I have _____ been worried because I was impaired due to my physical complaints.</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"sublist1\" colspan=\"8\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>15.</td> <td>Please indicate here how often you have visited a doctor during the last&nbsp;six months:</td> <td class=\"indent1\" colspan=\"6\">_____ times</td> </tr> <tr> <td class=\"centered\" colspan=\"8\"><strong>Thank you for completing the questionnaire!</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Herzog A, Voigt K, Meyer B, et al. Psychological and interactional characteristics of patients with somatoform disorders: Validation of the Somatic Symptoms Experiences Questionnaire (SSEQ) in a clinical psychosomatic population. J Psychosom Res 2015; 78:553. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 106448 Version 1.0</div></div></div>"},"106459":{"type":"graphic_table","displayName":"Risk factors for drowsy driving","title":"Risk factors for drowsy driving","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for drowsy driving</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Youth (especially males aged 16 to 25 years)</td> </tr> <tr> <td>Obstructive sleep apnea and other sleep disorders</td> </tr> <tr> <td>Night or rotating shift work</td> </tr> <tr> <td>Sleep deprivation</td> </tr> <tr> <td>Use of sedating medications, substances, or alcohol</td> </tr> <tr> <td>High-risk occupations</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Commercial driving </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Law enforcement </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Medical house staff </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 106459 Version 2.0</div></div></div>"},"106460":{"type":"graphic_table","displayName":"Key elements of the history in patients with drowsy driving","title":"Key elements of the history in patients with drowsy driving","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key elements of the history in patients with drowsy driving</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Sleep disorders (eg, obstructive sleep apnea [OSA], narcolepsy)</td> </tr> <tr> <td>Medical or psychiatric conditions which may interfere with sleep continuity and sleep quality (eg, cardiopulmonary disorders, pain syndromes, mood disorders)</td> </tr> <tr> <td>Use of sedating medications (eg, benzodiazepines, nonbenzodiazepine hypnotics, opioids)&nbsp;or alcohol</td> </tr> <tr> <td>Driving conditions (eg, long distance, late at night, lone driving)</td> </tr> <tr> <td>Circadian factors (eg, night or rotating shift work, jet lag)</td> </tr> <tr> <td>Lifestyle factors (eg, working multiple jobs, parenting infants)</td> </tr> <tr> <td>Insufficient sleep</td> </tr> <tr> <td>History of fall-asleep crash or near-miss&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 106460 Version 3.0</div></div></div>"},"106463":{"type":"graphic_picture","displayName":"Vitiligo legs","title":"Vitiligo","html":"<div class=\"graphic\"><div style=\"width: 742px\" class=\"figure\"><div class=\"ttl\">Vitiligo</div><div class=\"cntnt\"><img style=\"width:722px; height:568px;\" src=\"images/DERM/106463_Vtlg_lgs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous white macules on the legs of this patient with generalized vitiligo.</div><div id=\"graphicVersion\">Graphic 106463 Version 3.0</div></div></div>"},"106464":{"type":"graphic_picture","displayName":"Vitiligo white hairs","title":"Vitiligo","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Vitiligo</div><div class=\"cntnt\"><img style=\"width:470px; height:710px;\" src=\"images/DERM/106464_Vtlg_wht_hrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large vitiligo patch is present on the leg of this patient. Note the depigmented hairs in the lesional skin.</div><div class=\"graphic_reference\">Courtesy of Pearl E Grimes, MD.</div><div id=\"graphicVersion\">Graphic 106464 Version 1.0</div></div></div>"},"106468":{"type":"graphic_table","displayName":"Cardiovascular screening and monitoring for TS","title":"Cardiovascular screening and monitoring algorithm for girls and women with Turner syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardiovascular screening and monitoring algorithm for girls and women with Turner syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Screening: All patients at time of diagnosis</td> </tr> <tr> <td class=\"indent1\">Evaluation by cardiologist with expertise in congenital heart disease</td> </tr> <tr> <td class=\"indent1\">Comprehensive exam including blood pressure in all extremities</td> </tr> <tr> <td class=\"indent1\">All require clear imaging of heart, aortic valve, aortic arch, and pulmonary veins</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Echocardiography is usually adequate for infants and young girls </li> <li>Magnetic resonance imaging (MRI) and echocardiography for older girls and adults </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Electrocardiogram (ECG)</td> </tr> <tr> <td class=\"subtitle1_single\">Monitoring: Follow-up depends on clinical situation</td> </tr> <tr> <td class=\"indent1\">For patients with apparently normal cardiovascular system and age-appropriate blood pressure</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Reevaluation with imaging at timely occasions (eg, at transition to adult clinic) before attempting pregnancy, or with appearance of hypertension. Girls that have only had echocardiography should undergo MRI when old enough to cooperate with the procedure </li> <li>Otherwise, imaging about every 5 to 10 years </li> </ul> </td> </tr> <tr> <td class=\"indent1\">For patients with cardiovascular pathology, treatment and monitoring determined by cardiologist</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; ECG: electrocardiogram.</div><div class=\"graphic_reference\">Republished with permission of The Endocrine Society, from: Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007; 92:10; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 106468 Version 2.0</div></div></div>"},"106469":{"type":"graphic_table","displayName":"Screening at diagnosis of Turner syndrome","title":"Screening at diagnosis of Turner syndrome in children and adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening at diagnosis of Turner syndrome in children and adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">All patients</td> </tr> <tr> <td class=\"indent1\">Cardiovascular evaluation by specialist</td> </tr> <tr> <td class=\"indent1\">Renal ultrasound</td> </tr> <tr> <td class=\"indent1\">Hearing evaluation by an audiologist</td> </tr> <tr> <td class=\"indent1\">Evaluation for scoliosis/kyphosis</td> </tr> <tr> <td class=\"indent1\">Evaluation for knowledge of Turner syndrome; referral to support groups</td> </tr> <tr> <td class=\"indent1\">Evaluation for growth and pubertal development</td> </tr> <tr> <td class=\"subtitle1_single\">Ages 0 to 4 years</td> </tr> <tr> <td class=\"indent1\">Eye exam by pediatric ophthalmologist (if age &#8805;1 year)</td> </tr> <tr> <td class=\"subtitle1_single\">Ages 4 to 10 years</td> </tr> <tr> <td class=\"indent1\">Thyroid function tests (T<sub>4</sub>, TSH) and celiac screen (tTG Ab)</td> </tr> <tr> <td class=\"indent1\">Educational/psychosocial evaluations</td> </tr> <tr> <td class=\"indent1\">Orthodontic evaluation (if age &#8805;7 years)</td> </tr> <tr> <td class=\"subtitle1_single\">Age &#62;10 years</td> </tr> <tr> <td class=\"indent1\">Thyroid function tests (T<sub>4</sub>, TSH) and celiac screen (tTG Ab)</td> </tr> <tr> <td class=\"indent1\">Educational and psychosocial evaluations</td> </tr> <tr> <td class=\"indent1\">Orthodontic evaluation</td> </tr> <tr> <td class=\"indent1\">Evaluation of ovarian function/estrogen replacement</td> </tr> <tr> <td class=\"indent1\">AST, ALT, fasting blood glucose, lipids, CBC, creatinine, BUN</td> </tr> <tr> <td class=\"indent1\">Bone mineral density&nbsp;(if age &#8805;18 years)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">T<SUB innerHtml>4</SUB>: thyroxine; TSH: thyroid-stimulating hormone; tTG Ab: tissue transglutaminase IgA antibody; AST: aspartate aminotransferase; ALT: alanine aminotransferase;&nbsp;CBC: complete blood count;&nbsp;BUN: blood urea nitrogen.</div><div class=\"graphic_reference\">Republished with permission of The Endocrine Society, from: Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007; 92:10; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 106469 Version 4.0</div></div></div>"},"106470":{"type":"graphic_table","displayName":"Ongoing monitoring in Turner syndrome","title":"Ongoing monitoring in Turner syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ongoing monitoring in Turner syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">All ages</td> </tr> <tr> <td class=\"indent1\">Cardiological evaluation as indicated</td> </tr> <tr> <td class=\"indent1\">Blood pressure annually</td> </tr> <tr> <td class=\"indent1\">ENT and audiology every 1 to 5 years</td> </tr> <tr> <td class=\"subtitle1_single\">Girls &#60;5 years</td> </tr> <tr> <td class=\"indent1\">Social skills evaluation at age 4 to 5 years</td> </tr> <tr> <td class=\"subtitle1_single\">School age</td> </tr> <tr> <td class=\"indent1\">Liver and thyroid screening annually</td> </tr> <tr> <td class=\"indent1\">Celiac screen every 2 to 5 years</td> </tr> <tr> <td class=\"indent1\">Educational and social progress annually</td> </tr> <tr> <td class=\"indent1\">Dental and orthodontic as needed</td> </tr> <tr> <td class=\"subtitle1_single\">Older girls and adults</td> </tr> <tr> <td class=\"indent1\">Fasting lipids and blood sugar <span style=\"color: black;\">annually, and/or hemoglobin A1C</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">BUN, creatinine</span>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Liver and thyroid screening annually</td> </tr> <tr> <td class=\"indent1\">Celiac screen as indicated<span style=\"color: black;\"> (tTg-IgA), generally every 2 to 5 years</span></td> </tr> <tr> <td class=\"indent1\">Age-appropriate evaluation of pubertal development and psychosexual adjustment</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ENT: ears, nose, and throat; BUN: blood urea nitrogen; tTG-IgA: Immunoglobulin A antibodies to tissue transglutaminase. </div><div class=\"graphic_reference\">Modified&nbsp;with permission of The Endocrine Society, from: Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007; 92:10; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 106470 Version 1.0</div></div></div>"},"106474":{"type":"graphic_table","displayName":"Definitions of the eight best practices of nuclear cardiology","title":"Definitions of the eight best practices of nuclear cardiology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of the eight best practices of nuclear cardiology</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td> <ol> <li><strong>Avoid thallium stress:</strong> No thallium stress tests were performed in patients &#8804;70 years old. SPECT MPI performed with thallium-201 is associated with a considerably higher radiation dose to patients than when it is performed with technetium-99m.<sup>[1]</sup> This excludes thallium rest-redistribution viability studies and stress-redistribution-reinjection stress-and-viability studies. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"2\"> <li><strong>Avoid dual isotope:</strong> No dual isotope (rest thallium and stress technetium) stress tests were performed in patients &#8804;70 years old. Dual isotope MPI is associated with the highest radiation dose of any protocol.<sup>[1]</sup> </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"3\"> <li><strong>Avoid too much technetium:</strong> No study was performed with administered activity &#62;1332 MBq (36 mCi) for an injection of technetium, and mean total effective dose was &#60;15 mSv for all studies using just technetium injections. 1332 MBq is the highest recommended activity in guidelines<sup>[2]</sup>, and 15 mSv is a high radiation dose for a study using technetium-99m. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"4\"> <li><strong>Avoid too much thallium:</strong> For each nuclear stress test involving thallium, no more than 129.5 MBq (3.5 mCi) was administered at stress. The expert committee maintained that no more than this activity is needed for patients who are good candidates to receive thallium MPI. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"5\"> <li><strong>Perform stress-only imaging:</strong> The laboratory performed at least one stress-only study, in which rest imaging was omitted, or the laboratory only does PET-based stress tests. If stress images are completely normal, subsequent rest imaging can be avoided to reduce radiation dose by up 80%. PET MPI studies have low radiation dose, the dosimetric advantage of stress-only is less, and there is less evidence regarding stress-only PET MPI. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"6\"> <li><strong>Use camera-based dose-reduction strategies:</strong> The laboratory performed at least one study using at least one of the following: <ul class=\"decimal_heading\"> <li>Attenuation correction (CT or line source) </li> <li>Imaging patients in multiple positions (eg, both supine and prone) </li> <li>High-technology software (eg, incorporating iterative reconstruction, resolution recovery, and noise reduction) </li> <li>High-technology hardware (eg, PET, a high-efficiency solid-state SPECT camera, or a cardiac-focused collimator) </li> </ul> Each of these approaches reduces the radiation dose needed or facilitates performance of stress-only imaging. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"7\"> <li><strong>Weight-based dosing for technetium:</strong> The laboratory had a statistically significant positive correlation between patient weight and administered activity (MBq), for injections of technetium. Tailoring the administered activity to the patient size offers an opportunity to reduce radiation dose. </li> </ol> </td> </tr> <tr> <td> <ol start=\"8\"> <li><strong>Avoid inappropriate dosing that can lead to 'shine through' artifact:</strong> The laboratory performed no SPECT MPI studies with technetium rest and stress injections on the same day, in which activity of the second injection was less than three times that of the first injection. Shine through occurs in two injection, single-day technetium studies when residual radioactivity from the first injection interferes with interpretation of images for the second injection. To avoid shine through, it is recommended in guidelines that the activity (mCi or MBq) imaged for the second injection be at least three to four times that of the first injection; in some cases, this can be achieved with a second injection that has less than four times the activity by waiting for some of the technetium-99 m to decay. Reflecting guidelines, we considered a second injection of less than three times the activity of the first injection to constitute dosing that can lead to shine through.<sup>[2-5]</sup> </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A committee of international experts convened at the International Atomic Energy Agency, including physicians and medical physicists, developed these criteria to be applied to nuclear cardiology laboratories.</div><div class=\"graphic_footnotes\">SPECT: single-photon emission computed tomography; MPI: myocardial perfusion imaging; MBq: megabecquerel; mCi: millicurie; PET: positron emission tomography; CT: computed tomography.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Einstein AJ, Moser KW, Thompson RC, et al. Radiation dose to patients from cardiac diagnostic imaging. Circulation 2007; 116:1290.</LI>&#xD;&#xA;<LI>Henzlova MJ, Cerqueira MD, Mahmarian JJ, Yao SS. Stress protocols and tracers. J Nucl Cardiol 2006; 13:e80.</LI>&#xD;&#xA;<LI>Hesse B, Tagil K, Cuocolo A, et al. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging 2005; 32:855.</LI>&#xD;&#xA;<LI>International Atomic Energy Agency. Nuclear Cardiology: Guidance and Recommendations for Implementation in Developing Countries. IAEA Human Health Series No. 23. Vienna: International Atomic Energy Agency; 2012.</LI>&#xD;&#xA;<LI>Depuey EG, Mahmarian JJ, Miller TD, et al. Patient-centered imaging. J Nucl Cardiol 2012; 19:185.</LI></OL>Reproduced from: Einstein AJ, Pascual TN, Mercuri M, et al. Current worldwide nuclear cardiology practices and radiation exposure: results from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS). Eur Heart J 2015; 36(26):1689-96, by permission of Oxford University Press on behalf of the European Society of Cardiology. Copyright © 2017.</div><div id=\"graphicVersion\">Graphic 106474 Version 2.0</div></div></div>"},"106494":{"type":"graphic_table","displayName":"Factors influencing pharmacokinetics of calcineurin inhibitors","title":"Factors influencing pharmacokinetics of calcineurin inhibitors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors influencing pharmacokinetics of calcineurin inhibitors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Absorption</td> </tr> <tr> <td class=\"indent1\">Interacting medications (eg, cholestyramine)</td> </tr> <tr> <td class=\"indent1\">Motility agents</td> </tr> <tr> <td class=\"indent1\">Diarrhea or constipation</td> </tr> <tr> <td class=\"indent1\">Presence or absence of food</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Brand versus generic, formulation</td> </tr> <tr> <td class=\"subtitle1_single\">Distribution</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hematocrit</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolism</td> </tr> <tr> <td class=\"indent1\">Interacting prescription medications</td> </tr> <tr> <td class=\"indent1\">Interacting over-the-counter medications</td> </tr> <tr> <td class=\"indent1\">Interacting herbal supplements</td> </tr> <tr> <td class=\"indent1\">Interacting beverages (eg, grapefruit juice)</td> </tr> <tr> <td class=\"indent1\">Genetic polymorphism in CYP3A5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hepatic impairment</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Timing of concentration</td> </tr> <tr> <td class=\"indent1\">Type of laboratory immunoassay</td> </tr> <tr> <td class=\"indent1\">Schedule and frequency</td> </tr> <tr> <td class=\"indent1\">Adherence</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Karen Hardinger, PharmD, BCPS.</div><div id=\"graphicVersion\">Graphic 106494 Version 1.0</div></div></div>"},"106510":{"type":"graphic_table","displayName":"Advice for healthcare providers caring for parents of stillborns","title":"Advice for healthcare providers caring for parents of stillborns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advice for healthcare providers caring for parents of stillborns</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Communicate in a warm, sensitive, and genuine manner.</td> </tr> <tr> <td>Provide information in understandable lay language, which may need to be repeated.</td> </tr> <tr> <td>Minimize delays in delivering information.</td> </tr> <tr> <td>Be aware of and respect parents' individual and changing emotional needs. Validate emotions. Continuity of caregivers can be helpful.</td> </tr> <tr> <td>Discuss timing of induction.</td> </tr> <tr> <td>Discuss what parents can expect (environment for delivery and postpartum care, physical condition of the baby, disposition of the baby).</td> </tr> <tr> <td>Provide options for intrapartum and postpartum procedures and care.</td> </tr> <tr> <td>Treat baby with respect.</td> </tr> <tr> <td>Respect individual preferences about seeing and holding the baby. Seeing the stillborn is validation and evidence of the baby's birth, existence, and death. Not seeing the baby may cause regret for some parents, but may be the right decision for others.</td> </tr> <tr> <td>Collect memorabilia for the parents (eg, photographs, hand and footprints, locks of hair, hospital wristbands).</td> </tr> <tr> <td>Provide information about referrals to psychologists, social workers, counselors, and support organizations that the parents can pursue if and when desired.</td> </tr> <tr> <td>Provide information about practical issues, such as lactation, registration of the death and funeral preparation, contraception, when to expect results of testing, and future pregnancies.</td> </tr> <tr> <td>Provide extra support during a subsequent pregnancy, particularly around the time of the previous loss.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Lisy K, Peters MD, Riitano D, et al. Provision of meaningful care at diagnosis, birth, and after stillbirth: A qualitative synthesis of parents' experiences. Birth 2016.</div><div id=\"graphicVersion\">Graphic 106510 Version 1.0</div></div></div>"},"106512":{"type":"graphic_table","displayName":"Zika vs dengue vs chikungunya","title":"Clinical features: Zika virus compared with dengue and chikungunya","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features: Zika virus compared with dengue and chikungunya</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"55%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Features</td> <td class=\"subtitle1\">Zika</td> <td class=\"subtitle1\">Dengue</td> <td class=\"subtitle1\">Chikungunya</td> </tr> <tr> <td>Fever</td> <td class=\"centered\">++</td> <td class=\"centered\">+++</td> <td class=\"centered\">+++</td> </tr> <tr> <td>Rash</td> <td class=\"centered\">+++</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> </tr> <tr> <td>Conjunctivitis</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Arthralgia</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> </tr> <tr> <td>Myalgia</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> </tr> <tr> <td>Headache</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> </tr> <tr> <td>Hemorrhage</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Shock</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Zika virus - What clinicians need to know? Clinician Outreach and Communication Activity (COCA) Call, January 26, 2016. Available at: <a href=\"http://emergency.cdc.gov/coca/ppt/2016/01_26_16_zika.pdf\" target=\"_blank\">http://emergency.cdc.gov/coca/ppt/2016/01_26_16_zika.pdf</a> (Accessed February 1, 2016).</div><div id=\"graphicVersion\">Graphic 106512 Version 1.0</div></div></div>"},"106515":{"type":"graphic_table","displayName":"Features of common extraglottic devices (EGDs)","title":"Features of common extraglottic devices (EGDs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of common extraglottic devices (EGDs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Device</td> <td class=\"subtitle1\">Glottic location</td> <td class=\"subtitle1\">Ability to pass OG tube</td> <td class=\"subtitle1\">Ability to intubate blindly</td> </tr> <tr> <td>LMA Classic</td> <td>Supraglottic (laryngeal mask)</td> <td>No (1st generation EGD)</td> <td>Yes (variable success)<sup>[1,2]</sup></td> </tr> <tr> <td>LMA ProSeal</td> <td>Supraglottic (laryngeal mask)</td> <td>Yes (2nd generation EGD)</td> <td>No</td> </tr> <tr> <td>LMA Supreme</td> <td>Supraglottic (laryngeal mask)</td> <td>Yes (2nd generation EGD)</td> <td>No</td> </tr> <tr> <td>LMA Fastrach</td> <td>Supraglottic (laryngeal mask)</td> <td>No (1st generation EGD)</td> <td>Yes (good success)<sup>[3-13]</sup></td> </tr> <tr> <td>Aura-i</td> <td>Supraglottic (laryngeal mask)</td> <td>No (1st generation EGD)</td> <td>Yes (limited data)</td> </tr> <tr> <td>Aura-Gain</td> <td>Supraglottic (laryngeal mask)</td> <td>Yes (2nd generation EGD)</td> <td>Yes (limited data)</td> </tr> <tr> <td>Air-Q</td> <td>Supraglottic (laryngeal mask)</td> <td>Yes (only blocker version)</td> <td>Yes (good success)<sup>[11-14]</sup></td> </tr> <tr> <td>i-Gel</td> <td>Supraglottic (laryngeal mask)</td> <td>Yes (2nd generation EGD)</td> <td>Yes (variable success)<sup>[5,6]</sup></td> </tr> <tr> <td>Combitube</td> <td>Retroglottic (laryngeal tube)</td> <td>Yes (2nd generation EGD)</td> <td>No</td> </tr> <tr> <td>King LT</td> <td>Retroglottic (laryngeal tube)</td> <td>Yes (only LTS version)</td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD, and Aaron Bair, MD.<br /><br />References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Asai T. Blind tracheal intubation through the laryngeal mask. Can J Anaesth 1996; 43:1275. </LI>&#xD;&#xA;<LI>Lim SL, Tay DH, Thomas E. A comparison of three types of tracheal tube for use in laryngeal mask assisted blind orotracheal intubation. Anaesthesia 1994; 49:255. </LI>&#xD;&#xA;<LI>Ferson DZ, Rosenblatt WH, Johansen MJ, et al. Use of the intubating LMA-Fastrach in 254 patients with difficult-to-manage airways. Anesthesiology 2001; 95:1175. </LI>&#xD;&#xA;<LI>Rich JM. Recognition and management of the difficult airway with special emphasis on the intubating LMA-Fastrach/whistle technique: a brief review with case reports. Proceedings (Baylor University Medical Center) 2005; 18:220. </LI>&#xD;&#xA;<LI>Halwagi AE, Massicotte N, Lallo A, et al. Tracheal intubation through the I-gel™ supraglottic airway versus the LMA Fastrach™: a randomized controlled trial. Anesth Analg 2012; 114:152. </LI>&#xD;&#xA;<LI>Sastre JA1, López T, Garzón JC. [Blind tracheal intubation through two supraglottic devices: i-gel versus Fastrach intubating laryngeal mask airway (ILMA)]. Rev Esp Anestesiol Reanim 2012; 59:71. </LI>&#xD;&#xA;<LI>Shah VR, Bhosale GP, Mehta T, Parikh GP. A comparison of conventional endotracheal tube with silicone wire-reinforced tracheal tube for intubation through intubating laryngeal mask airway. Saudi J Anaesth 2014; 8:183. </LI>&#xD;&#xA;<LI>Kundra P, Sujata N, Ravishankar M. Conventional tracheal tubes for intubation through the intubating laryngeal mask airway. Anesth Analg 2005; 100:284. </LI>&#xD;&#xA;<LI>Kanazi GE, El-Khatib M, Nasr VG, et al. A comparison of a silicone wire-reinforced tube with the Parker and polyvinyl chloride tubes for tracheal intubation through an intubating laryngeal mask airway in patients with normal airways undergoing general anesthesia. Anesth Analg 2008; 107:994. </LI>&#xD;&#xA;<LI>Khan MU. Endotracheal intubation in patients with unstable cervical spine using LMA-Fastrach and gum elastic bogie. J Coll Physicians Surg Pak 2014; 24:4. </LI>&#xD;&#xA;<LI>Erlacher W, Tiefenbrunner H, Kastenbauer T, et al. CobraPLUS and Cookgas air-Q versus Fastrach for blind endotracheal intubation: a randomised controlled trial. Eur J Anaesthesiol 2011; 28:181. </LI>&#xD;&#xA;<LI>Karim YM, Swanson DE. Comparison of blind tracheal intubation through the intubating laryngeal mask airway (LMA Fastrach™) and the Air-Q™. Anaesthesia 2011; 66:185. </LI>&#xD;&#xA;<LI>Yang D, Deng XM, Tong SY, et al. [Roles of Cookgas and Fastrach intubating laryngeal mask airway for anticipated difficult tracheal intubation]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2013; 35:207. </LI>&#xD;&#xA;<LI>Garzón Sánchez JC, López Correa T, Sastre Rincón JA. [Blind tracheal intubation with the air-Q® (ILA-Cookgas) mask. A comparison with the ILMA-Fastrach™ laryngeal intubation mask]. Rev Esp Anestesiol Reanim 2014; 61:190.</LI></OL></div><div id=\"graphicVersion\">Graphic 106515 Version 1.0</div></div></div>"},"106516":{"type":"graphic_picture","displayName":"Superficial cervical plexus probe","title":"Superficial cervical plexus block ultrasound probe placement","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Superficial cervical plexus block ultrasound&nbsp;probe placement</div><div class=\"cntnt\"><img style=\"width:530px; height:712px;\" src=\"images/ANEST/106516_Sprf_crvcl_plxs_prb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided superficial cervical plexus block, the ultrasound probe is placed in a transverse orientation at the posterior border of the sternocleidomastoid muscle, midway between the mastoid process and the C6 transverse process. For further details on this block, refer to the UpToDate topic on nerve blocks of the scalp, neck, and trunk.</div><div id=\"graphicVersion\">Graphic 106516 Version 2.0</div></div></div>"},"106517":{"type":"graphic_table","displayName":"Pros and cons of prostate cancer treatment PI","title":"Advantages and disadvantages of the primary treatment approaches for early prostate cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of the primary treatment approaches for early prostate cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"42%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td>Prostatectomy</td> <td> <ul> <li>Possibility of permanently curing your cancer</li> <li>If your doctor needs to remove lymph nodes for testing, this can be done during the same surgery</li> </ul> </td> <td> <ul> <li>Risk of erectile dysfunction or urinary incontinence</li> <li>Risk of complications associated with any surgical procedure (such as bleeding, pain, or infection)</li> <li>Requires time to recover before returning to work/activities</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>External beam radiation therapy (EBRT)</td> <td> <ul> <li>Possibility of permanently curing your cancer</li> <li>You can continue your normal activities during treatment</li> </ul> </td> <td> <ul> <li>Side effects may include erectile dysfunction, needing to urinate urgently, urinary incontinence, bladder pain, or proctitis (swelling and pain in the rectum)</li> <li>Requires committing to treatment 5 days a week for 5-8 weeks</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Brachytherapy</td> <td> <ul> <li>Possibility of permanently curing your cancer</li> <li>Unlike EBRT, usually only requires one treatment session</li> </ul> </td> <td> <ul> <li>Requires anesthesia to have the radiation-emitting device(s) implanted</li> <li>Depending on the type of brachytherapy, may require that you stay in the hospital for 1-2 days</li> <li>Side effects may include erectile dysfunction urinary urgency and frequency, burning with urination, or trouble emptying the bladder</li> <li>Less common side effects include bowel urgency and frequency, rectal bleeding, and rectal ulcers</li> </ul> </td> </tr> <tr> <td>Active surveillance or \"watchful waiting\"</td> <td> <ul> <li>Avoids or delays all risks and side effects associated with treatment</li> </ul> </td> <td> <ul> <li>The cancer could grow or spread, making it harder (or impossible) to treat</li> <li>Knowing that you have cancer but aren't treating it might cause stress or anxiety</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Vogelzang NJ, Scardino PT, Shipley WU, et al. Comprehensive textbook of genitourinary oncology, 3rd Ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 106517 Version 1.0</div></div></div>"},"106519":{"type":"graphic_algorithm","displayName":"Echocardiography for NVE","title":"An approach to use of echocardiography for diagnosis of native valve infective endocarditis","html":"<div class=\"graphic\"><div style=\"width: 857px\" class=\"figure\"><div class=\"ttl\">An approach to use of echocardiography for diagnosis of native valve infective endocarditis</div><div class=\"cntnt\"><img style=\"width:837px; height:591px;\" src=\"images/ID/106519_Echocardiography_NVE.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Issues related to clinical manifestations, diagnosis, and treatment of IE are discussed further in the text (refer to the UpToDate topics on clinical manifestations, diagnosis, and treatment of infective endocarditis). Issues related to diagnosis of prosthetic valve endocarditis and cardiac device infections are discussed in the text (refer to the UpToDate topics on prosthetic valve endocarditis and cardiac device infections).</div><div class=\"graphic_footnotes\">IE: infective endocarditis; TTE: transthoracic echocardiogram; TEE: transesophageal echocardiogram.<br />* The diagnosis of IE should be suspected in patients with fever (with or without bacteremia) and/or relevant cardiac risk factors (prior IE, presence of a prosthetic valve or cardiac device, history of valvular or congenital heart disease) or noncardiac risk factors (intravenous drug use, indwelling intravenous lines, immunosuppression, or a recent dental or surgical procedure).<br />&para; Low risk/low suspicion for IE: for example, patient with fever and previously known cardiac murmur and no other stigmata of IE.<br />&Delta; High risk/high suspicion for IE: for example, <em>S. aureus</em> bacteremia, new murmur, prior IE, congenital heart disease. Patients with prosthetic heart valve or intracardiac device are also high risk; the approach to diagnosis of IE in these circumstances is discussed further separately (refer to the UpToDate topics on prosthetic valve endocarditis and cardiac device infections).<br /><span class=\"lozenge\">&loz;</span> High-risk clinical features include new atrioventricular block (prolonged PR interval), persistent fever despite appropriate antimicrobial therapy, and <em>Staphylococcus aureus</em> bacteremia; high-risk echocardiographic features include large or mobile vegetations, valvular insufficiency, suggestion of paravalvular extension, or ventricular dysfunction.<br />&sect; Patients with high suspicion for paravalvular complications (such as prolonged PR interval) and indeterminate or negative TEE may warrant additional imaging such as cardiac computed tomography; refer to text for further discussion.</div><div class=\"graphic_reference\">Modified from: Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</div><div id=\"graphicVersion\">Graphic 106519 Version 2.0</div></div></div>"},"106520":{"type":"graphic_table","displayName":"Perinatal depression screening tools","title":"Perinatal depression screening tools","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Perinatal depression screening tools</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Screening tool</td> <td class=\"subtitle1\">Number of items</td> <td class=\"subtitle1\">Time to complete (minutes)</td> <td class=\"subtitle1\">Sensitivity and specificity</td> <td class=\"subtitle1\">Spanish available</td> </tr> <tr class=\"divider_bottom\"> <td>Edinburgh Postnatal Depression Scale</td> <td class=\"centered\">10</td> <td class=\"centered\">Less than 5</td> <td> <p>Sensitivity 59 to 100%</p> Specificity 49 to 100%</td> <td class=\"centered\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td>Postpartum Depression Screening Scale</td> <td class=\"centered\">35</td> <td class=\"centered\">5 to 10</td> <td> <p>Sensitivity 91 to 94%</p> Specificity 72 to 98%</td> <td class=\"centered\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td>Patient Health Questionnaire 9</td> <td class=\"centered\">9</td> <td class=\"centered\">Less than 5</td> <td> <p>Sensitivity 75%</p> Specificity 90%</td> <td class=\"centered\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td>Beck Depression Inventory</td> <td class=\"centered\">21</td> <td class=\"centered\">5 to 10</td> <td> <p>Sensitivity 47.6 to 82%</p> Specificity 85.9 to 89%</td> <td class=\"centered\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td>Beck Depression Inventory-II</td> <td class=\"centered\">21</td> <td class=\"centered\">5 to 10</td> <td> <p>Sensitivity 56 to 57%</p> Specificity 97 to 100%</td> <td class=\"centered\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td>Center for Epidemiologic Studies Depression Scale</td> <td class=\"centered\">20</td> <td class=\"centered\">5 to 10</td> <td> <p>Sensitivity 60%</p> Specificity 92%</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Zung self-rating Depression Scale</td> <td class=\"centered\">20</td> <td class=\"centered\">5 to 10</td> <td> <p>Sensitivity 45 to 89%</p> Specificity 77 to 88%</td> <td class=\"centered\">No</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Committee on Obstetric Practice. The American College of Obstetricians and Gynecologists Committee Opinion no. 630. Screening for perinatal depression. Obstet Gynecol 2015; 125:1268. DOI: <a href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2015&amp;issue=05000&amp;article=00047&amp;type=abstract\" target=\"_blank\">10.1097/01.AOG.0000465192.34779.dc</a>. Copyright &copy; 2015 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 106520 Version 1.0</div></div></div>"},"106522":{"type":"graphic_algorithm","displayName":"Approach to febrile infants 29 to 60 days of age","title":"Approach to febrile infants 29 to 60 days of age*","html":"<div class=\"graphic\"><div style=\"width: 1284px\" class=\"figure\"><div class=\"ttl\">Approach to febrile infants 29 to 60 days of age*</div><div class=\"cntnt\"><img style=\"width:1264px; height:1071px;\" src=\"images/EM/106522_Apprfbrlinfnt2960dyag.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GA: gestational age; RSV: respiratory syncytial virus; PCR: polymerase chain reaction; CBC: complete blood count; UTI: urinary tract infection; WBC: white blood cell count; CSF: cerebrospinal fluid; ANC: absolute neutrophil count.<br />* For definition of fever and interpretation of report of tactile fever or fever by methods other than rectal measurement, refer to UpToDate topics on definition of fever in infants younger than 90 days of age.<br />&para; For empiric antibiotic recommendations, refer to UpToDate topics on the management of febrile infants younger than 90 days of age.<br />&Delta; If the social situation suggests that follow-up within 24 hours is problematic (eg, transportation problems or other concerns regarding parental adherence), then the infant should be admitted to the hospital for observation.<br /><span class=\"lozenge\">&loz;</span> Depending upon the setting and when the examining physician has extensive pediatric experience, cerebrospinal fluid studies may be omitted for selected infants. For well-appearing infants 6 weeks and older who have received immunizations within the past 48 hours and for whom close follow-up is assured, urine testing only or no testing (if immunizations were within 24 hours) are potential options, especially in the primary care setting.<br />&sect; Refer to UpToDate topics on management of UTI in infants for specific antibiotic recommendations. Some clinicians may choose to give the first dose of antibiotics parenterally.<br />&yen; Refer to UpToDate topics on treatment of seasonal influenza in children.<br />&Dagger; Because the risk of meningitis is low in febrile infants 29 to 60 days of age with a UTI, some experts choose NOT to perform an LP in patients who do not have a recognizable viral illness but do have abnormal WBC, elevated band count, or elevated inflammatory markers.<br />&dagger; Empiric antibiotics should be adjusted based upon susceptibility of organisms in the region. Refer to UpToDate topics on treatment of UTI in infants and children and management of febrile young infants.</div><div id=\"graphicVersion\">Graphic 106522 Version 4.0</div></div></div>"},"106530":{"type":"graphic_figure","displayName":"Classification of angioedema without wheals","title":"Classification of angioedema without wheals","html":"<div class=\"graphic\"><div style=\"width: 771px\" class=\"figure\"><div class=\"ttl\">Classification of angioedema without wheals</div><div class=\"cntnt\"><img style=\"width:751px; height:413px;\" src=\"images/ALLRG/106530_Class_angioedema_wo_wheals.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACE inhibitors: angiotensin-converting enzyme inhibitors; C1INH deficiency: C1 inhibitor deficiency.<br />* Mutations in the genes encoding factor XII, angiopoietin-1, and plasminogen are associated with hereditary angioedema (HAE).</div><div class=\"graphic_reference\">From: Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69:602. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/all.12380/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/all.12380/abstract</a>. Copyright &copy; 2014 European Academy of Allergy and Clinical Immunology. Modified with permission of John Wiley &amp; Sons, Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared, or emailed. Please contact Wiley's Permissions Department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href=\"http://www.onlinelibrary.wiley.com/\" target=\"_blank\">www.onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 106530 Version 2.0</div></div></div>"},"106531":{"type":"graphic_table","displayName":"Post-exposure prophylaxis to HBV after nonoccupational exposure","title":"Post-exposure prophylaxis to hepatitis B virus after a nonoccupational exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Post-exposure prophylaxis to hepatitis B virus after a nonoccupational exposure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Vaccination and/or antibody response status of exposed person*</td> <td class=\"subtitle1\" colspan=\"2\">Treatment when source patient is:</td> </tr> <tr> <td class=\"subtitle2\">HBsAg-positive/source unknown or not available for testing</td> <td class=\"subtitle2\">HBsAg-negative<sup>&#182;</sup></td> </tr> <tr> <td>Unvaccinated/nonimmune</td> <td>HBIG<sup>&#916;</sup> &times; 1; initiate HBV vaccine series</td> <td>Initiate HBV vaccine series</td> </tr> <tr> <td>Previously vaccinated<sup>&#9674;</sup>, known responder<sup>&#167;</sup></td> <td>No treatment</td> <td>No treatment</td> </tr> <tr> <td>Previously vaccinated<sup>&#9674;</sup>, known nonresponder<sup>&#167;</sup></td> <td>HBIG<sup>&#916;</sup> &times; 1 and initiate revaccination<sup>&#165;</sup> or HBIG<sup>&#916;</sup> &times; 2</td> <td>No treatment</td> </tr> <tr> <td>Previously vaccinated<sup>&#9674;</sup>, antibody response unknown<sup>&#135;</sup></td> <td>Single vaccine booster dose</td> <td>No treatment</td> </tr> <tr> <td>If still undergoing vaccination</td> <td>HBIG<sup>&#916;</sup> &times; 1; complete series</td> <td>Complete series</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">anti-HBc: antibody to hepatitis B core antigen; anti-HBs: antibody to hepatitis B surface antigen; HBsAg: hepatitis B surface antigen; HBIG: hepatitis B immune globulin; HBV: hepatitis B virus.<br />* Persons who have previously been infected with HBV are immune to reinfection and do not require post-exposure prophylaxis.<br />¶ A source is considered HBsAg-negative if at the time of exposure they are known to have either of the following: anti-HBs ≥10 milli-international units/mL after immunization or resolved HBV (anti-HBs-positive and anti-HBc-positive).<br />Δ For specific recommendations on dosing and administration of HBIG, refer to the&nbsp;topic that discusses post-exposure prophylaxis after a nonoccupational exposure to HBV and the drug information topic within UpToDate.<br />◊ Vaccinated with full three-dose series.<br /><FONT class=lozenge>§</FONT> Based on information available at presentation. Responder is defined as person with previously documented adequate levels of serum antibody to HBsAg (serum anti-HBs ≥10 milli-international units/mL); nonresponder is a person with previously documented inadequate response to vaccination (serum anti HBs&lt;10 milli-international units/mL). It is recommended that decision-making <STRONG>not</STRONG> be delayed while testing for anti-HBs at presentation.<br />¥ The option of giving one dose of HBIG and reinitiating the vaccine series is preferred for nonresponders who have not completed a second three-dose vaccine series. For persons who previously completed a second vaccine series but failed to respond, two doses of HBIG are preferred.<br />‡ The need for additional prophylaxis (eg, hepatitis B vaccine and HBIG) depends upon serologic testing performed at the time of the initial evaluation. Refer to the UpToDate topic that discusses post-exposure prophylaxis for HBV.</div><div class=\"graphic_reference\">References:&nbsp;<br /><OL>&#xD;&#xA;<LI>HIV Clinical Resource. UPDATE: HIV prophylaxis following non-occupational exposure. Available at: <A spellcheck=true href=\"http://www.hivguidelines.org/clinical-guidelines/post-exposure-prophylaxis/hiv-prophylaxis-following-non-occupational-exposure/\" target=_blank>http://www.hivguidelines.org/clinical-guidelines/post-exposure-prophylaxis/hiv-prophylaxis-following-non-occupational-exposure/</A> (Accessed on February 2, 2016). Copyright © 2014 New York State Department of Health AIDS Institute's Clinical Guidelines Development Program.</LI>&#xD;&#xA;<LI>CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management. MMWR Recomm Rep 2013; 62:1.</LI>&#xD;&#xA;<LI>Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</LI></OL></div><div id=\"graphicVersion\">Graphic 106531 Version 2.0</div></div></div>"},"106533":{"type":"graphic_figure","displayName":"Retropharangeal calcific tendonitis","title":"Retropharangeal calcific tendonitis","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Retropharangeal calcific tendonitis</div><div class=\"cntnt\"><img style=\"width:524px; height:533px;\" src=\"images/ID/106533_Rtrphrngl_clcfc_tndnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced computed tomography (CT)&nbsp;scan showing prevertebral calcifications (arrows)&nbsp;in a 40-year-old man with low-grade fever and acute neck pain.</div><div class=\"graphic_reference\">Reproduced with permission from: Tagashira Y, Watanuki S. Acute calcific retropharyngeal tendonitis. CMAJ 2015; 187:995. Copyright &copy; 2015 Canadian Medical Association. This work is protected by copyright and the making of this copy was with the permission of Access Copyright. Any alteration of its content or further copying in any form whatsoever is strictly prohibited unless otherwise permitted by law.</div><div id=\"graphicVersion\">Graphic 106533 Version 2.0</div></div></div>"},"106536":{"type":"graphic_table","displayName":"IRd for MM","title":"Ixazomib, lenalidomide, and dexamethasone (IRd) for multiple myeloma<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ixazomib, lenalidomide, and dexamethasone (IRd) for multiple myeloma<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 28 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Ixazomib</strong></td> <td>4 mg by mouth</td> <td>Take at least one hour prior to or two hours following a meal. Swallow capsule whole; do not break, open, or chew.</td> <td>Days 1, 8, and 15</td> </tr> <tr> <td><strong>Lenalidomide</strong>*</td> <td>25 mg by mouth</td> <td>Take with water. Swallow capsule whole; do not break, open, or chew.</td> <td>Daily, on days 1 through 21</td> </tr> <tr> <td><strong>Dexamethasone</strong></td> <td>40 mg by mouth</td> <td>Take with food (after meals or with food or milk) in the morning.</td> <td>Days 1, 8, 15, and 22</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations: </td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Antithrombotic prophylaxis:</strong> Routine antithrombotic prophylaxis is warranted. The risk of thromboembolism was over 10% with another lenalidomide and high-dose dexamethasone (RD) regimen<sup>[3]</sup>. Refer to UpToDate topic on \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong></p> <p><strong><em>Ixazomib:</em></strong> Reduce ixazomib dose to 3 mg orally on days 1, 8, and 15 in patients with moderate (total bilirubin greater than 1.5 to 3 times ULN) or severe (total bilirubin greater than 3 times ULN) hepatic impairment and in those with severe renal impairment (creatinine clearance &#60;30 mL/min) or end-stage renal disease requiring dialysis. Since the drug is not dialyzable, it may be administered without regard to the timing of dialysis.</p> <strong><em>Lenalidomide:</em></strong> Dose adjustment is recommended for patients with CrCl &#60;60 mL/min. Suggested initial doses for patients with renal insufficiency are: for patients with CrCl 30 to 60 mL/min, start at 10 mg every 24 hours. For patients with CrCl &#60;30 mL/min not requiring dialysis, start at 15 mg every 48 hours. For patients with CrCl &#60;30 mL/min requiring dialysis, start at 5 mg once daily. On dialysis days, administer the dose following dialysis. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count at baseline, every seven days for the first two cycles, days 1 and 15 in cycle 3, and every 28 days thereafter<sup>[4]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Electrolytes, renal, and hepatic function at baseline and the start of each cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assessment for peripheral neuropathy and/or neuropathic pain at baseline and prior to the start of each cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for signs of hypovolemia secondary to diarrhea and/or vomiting prior to each cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for rash prior to each cycle.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelosuppression:</strong> A cycle of IRd should not be started unless the ANC is &#8805;1000 cells/microL and the platelet count is &#8805;75,000/microL<sup>[2]</sup>. If platelets are &#60;30,000/microL and/or the ANC is &#60;500 cells/microL, hold ixazomib and lenalidomide until platelet count is at least 30,000/mm<sup>3</sup> and the ANC is at least 500/mm<sup>3</sup>. Consider prophylactic G-CSF in subsequent cycles for those with ANC &#60;500 cells/microL. Following recovery, reduce lenalidomide dose by 5 mg and resume ixazomib at its most recent dose<sup>[4]</sup>. If platelet count and/or ANC falls to this level again, withhold both ixazomib and lenalidomide. Following recovery, reduce ixazomib by one dose level (from 4 mg to 3 mg; from 3 mg to 2.3 mg) and resume lenalidomide at its most recent dose<sup>[2]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Rash:</strong> If grade 2 or 3, withhold lenalidomide until rash recovers to grade 1 or lower. Following recovery, reduce lenalidomide dose by 5 mg. If grade 2 or 3 rash recurs, withhold lenalidomide and ixazomib. Following recovery to grade 1 or lower, resume ixazomib at next lower dose (from 4 mg to 3 mg; from 3 mg to 2.3 mg) and lenalidomide at its most recent dose. If grade 4 rash develops, discontinue treatment regimen<sup>[2]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Peripheral neuropathy:</strong> If grade 1 with pain or grade 2, withhold ixazomib until neuropathy recovers to grade 1 or lower without pain or patient's baseline, and resume ixazomib at its most recent dose. For grade 2 with pain or grade 3, withhold ixazomib until recovery to patient's baseline condition or grade 1 or lower, and resume ixazomib at a dose reduced by one dose level (from 4 mg to 3 mg; from 3 mg to 2.3 mg). For grade 4 peripheral neuropathy, discontinue treatment regimen<sup>[2]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Other non-hematologic toxicities:</strong> If grade 3 or 4, withhold ixazomib and upon recovery to patient's baseline or grade 1 or lower, resume ixazomib at its most recent dose. If toxicity believed to be attributable to ixazomib, resume at next lower dose (from 4 mg to 3 mg; from 3 mg to 2.3 mg).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">ULN: upper limit of normal; CBC: complete blood count; ANC: absolute neutrophil count; CrCl: creatinine clearance.<br />* In the United States, the use of lenalidomide is subject to the REVLIMID REMS Program (<A href=\"http://www.revlimidrems.com/\" target=_blank>www.revlimidrems.com</A>) developed in an attempt to minimize the potential for pregnancy among patients taking this medication and associated with birth defects.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 374:1621.</LI>&#xD;&#xA;<LI>NINLARO (ixazomib) capsules. United States Prescribing Information. US National Library of Medicine. (Available online at <A href=\"http://www.dailymed.nlm.nih.gov/\" target=_blank>www.dailymed.nlm.nih.gov</A>, accessed on January 19, 2016.)</LI>&#xD;&#xA;<LI>Rajkumar SV, Jacobus S, Callander NS,&nbsp;et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11:29.</LI>&#xD;&#xA;<LI>REVLIMID (lenalidomide) capsules. United States Prescribing Information. US National Library of Medicine. (Available online at <A href=\"http://www.dailymed.nlm.nih.gov/\" target=_blank>www.dailymed.nlm.nih.gov</A>, accessed on January 19, 2016.)</LI></OL></div><div id=\"graphicVersion\">Graphic 106536 Version 4.0</div></div></div>"},"106538":{"type":"graphic_algorithm","displayName":"FHR monitoring after maternal trauma","title":"Type and duration of fetal heart rate monitoring after maternal trauma","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Type and duration of fetal heart rate monitoring after maternal trauma</div><div class=\"cntnt\"><img style=\"width:552px; height:472px;\" src=\"images/OBGYN/106538_FHR_monitor_maternal_trauma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetal heart rate and uterine monitoring are performed, when feasible. This monitoring should not interfere with the acute emergency care required to stabilize the mother. The 24 weeks of gestation decision point assumes that this is the gestational age at which delivery for fetal indications and aggressive neonatal resuscitation will be considered. Some clinicians and patients may choose a lower or higher threshold&nbsp;or may use the information as a maternal vital sign, even if delivery would not be considered. </div><div id=\"graphicVersion\">Graphic 106538 Version 1.0</div></div></div>"},"106539":{"type":"graphic_picture","displayName":"Transversus abdominis plane (TAP) probe","title":"Transversus abdominis plane (TAP) block ultrasound probe placement","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Transversus abdominis plane (TAP) block ultrasound&nbsp;probe placement</div><div class=\"cntnt\"><img style=\"width:716px; height:532px;\" src=\"images/ANEST/106539_Trnsv_abdm_pln_TAP_prb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided transversus abdominis plane (TAP)&nbsp;block, the ultrasound probe is placed in a transverse position, parallel to the iliac crest, immediately posterior to the midaxillary line, at or above the level of the umbilicus. For details of the TAP block technique,&nbsp;refer to&nbsp;the UpToDate topic on nerve blocks of the scalp, neck, and trunk.</div><div id=\"graphicVersion\">Graphic 106539 Version 2.0</div></div></div>"},"106540":{"type":"graphic_picture","displayName":"Subcostal transversus abdominis plane (TAP) probe","title":"Subcostal transversus abdominis plane (TAP) block ultrasound probe position","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Subcostal transversus abdominis plane (TAP) block ultrasound probe position</div><div class=\"cntnt\"><img style=\"width:716px; height:535px;\" src=\"images/ANEST/106540_Sbcstl_trnvr_abdmn_pln_TAP_prb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the subcostal transversus abdominis plane block, the probe is initially placed along the costal margin with the medial edge at the xiphoid process. The probe is then moved laterally along the costal margin, as shown in this photo, until the tranversus muscle is clearly visualized on ultrasound. For further details, refer to UpToDate topic on nerve blocks of the scalp, neck, and trunk.</div><div id=\"graphicVersion\">Graphic 106540 Version 3.0</div></div></div>"},"106541":{"type":"graphic_table","displayName":"IV adjuvant agents for induction of general anesthesia","title":"Intravenous adjuvant agents used during induction of general anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous adjuvant agents used during induction of general anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Suggested dose</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Potential adverse effects</td> </tr> <tr class=\"divider_bottom\"> <td>Opioids</td> <td> <ul> <li>Fentanyl:&nbsp;25 to 100 mcg (or 0.5 to&nbsp;1 mcg/kg): may be administered in divided doses </li> <li>Sufentanil: <span style=\"color: black;\">0.05 to 0.1</span> mcg/kg:&nbsp;may be administered in divided doses&nbsp;&nbsp; </li> </ul> <p>&nbsp;</p> (Reduce dose in older adults [&#8805;70 years]; reduce or avoid dose in patients with hemodynamic instability.)</td> <td> <ul> <li>Suppresses airway reflexes to prevent coughing and/or bronchospasm during laryngoscopy and intubation </li> <li>Attenuates stress response to prevent tachycardia and hypertension during laryngoscopy and intubation </li> <li>Minimizes pain caused by IV injection of induction agent </li> <li>Supplements sedation and reduces dose requirement of IV induction agent </li> </ul> </td> <td> <ul> <li>Dose-dependent respiratory depression; possible apnea </li> <li>Pruritus </li> <li>Postoperative nausea and vomiting </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Lidocaine</td> <td> <ul> <li><span style=\"color: black;\">0.5</span><span style=\"color: black;\">&nbsp;to 1.5 mg/kg for suppression of airway reflexes (or 0.5 to </span>1 mg/kg in older adults [&#8805;70 years]) </li> <li>20 to 30 mg total is used to reduce pain on injection of other agents&nbsp; </li> </ul> <p>&nbsp;</p> (Reduce or avoid dose in patients with hemodynamic instability.)</td> <td> <ul> <li>Suppresses airway reflexes to prevent coughing during laryngoscopy and intubation </li> <li>Reduces airway responsiveness to noxious stimuli; reduces airway responsiveness to drugs that cause bronchospasm </li> <li>Minimizes pain caused by IV injection of induction agent </li> <li>Supplements sedation and reduces dose requirement of IV induction agent </li> </ul> </td> <td> <ul> <li>Mild increases in airway tone </li> <li>Increases ventricular rate in patients with atrial fibrillation (avoid in patients with Wolff-Parkinson-White syndrome or high-grade heart block) </li> </ul> </td> </tr> <tr> <td>Midazolam</td> <td> <ul> <li>1 to 4 mg, administered in 1-mg increments </li> <li>Older adults (&#8805;70 years): 0.5-mg increments up to 2 mg </li> </ul> <p>&nbsp;</p> (Reduce or avoid dose in patients with hemodynamic instability.)</td> <td> <ul> <li>Reduces anxiety and produces amnesia; typically administered in the immediate preoperative period </li> <li>Supplements sedation and reduces dose requirement of IV induction agent </li> <li>Anticonvulsant </li> </ul> </td> <td> <ul> <li>Mild systemic vasodilation and decreased cardiac output; may cause severe hypotension in hemodynamically unstable or hypovolemic patients </li> <li>Dose-dependent respiratory depression; possible apnea, particularly if coadministered with an opioid </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.</div><div id=\"graphicVersion\">Graphic 106541 Version 6.0</div></div></div>"},"106549":{"type":"graphic_table","displayName":"Germline mutations associated with pheo and paraganglioma","title":"Germline mutations associated with pheochromocytoma and paraganglioma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Germline mutations associated with pheochromocytoma and paraganglioma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome/name</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Typical tumor location and other associations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Hypoxic pathway &ndash; Cluster 1*</td> </tr> <tr> <td class=\"indent1\"><em>SDHD</em> mutation (familial paraganglioma <span style=\"white-space: nowrap;\">type 1)<sup>&#182;</sup></span></td> <td><em>SDHD</em></td> <td>Primarily skull base and neck; occasionally adrenal medulla, mediastinum, abdomen, pelvis; GIST; possible pituitary adenoma</td> </tr> <tr> <td class=\"indent1\"><em>SDHAF2</em> mutation (familial paraganglioma <span style=\"white-space: nowrap;\">type 2)<sup>&#182;</sup></span></td> <td><em>SDHAF2</em></td> <td>Primarily skull base and neck; occasionally abdomen and pelvis</td> </tr> <tr> <td class=\"indent1\"><em>SDHC</em> mutation (familial paraganglioma type 3)</td> <td><em>SDHC</em></td> <td>Primarily skull base and neck; occasionally abdomen and pelvis; GIST; possible pituitary adenoma</td> </tr> <tr> <td class=\"indent1\"><em>SDHB</em> mutation (familial paraganglioma type 4)</td> <td><em>SDHB</em></td> <td>Abdomen, pelvis and mediastinum; rarely adrenal medulla, skull base, and neck; GIST; possible pituitary adenoma</td> </tr> <tr> <td class=\"indent1\"><em>SDHA</em> mutation</td> <td><em>SDHA</em></td> <td>Primarily skull base and neck; occasionally abdomen and pelvis; GIST; possible pituitary adenoma</td> </tr> <tr> <td class=\"indent1\">VHL disease</td> <td><em>VHL</em></td> <td>Adrenal medulla, frequently bilateral; occasionally paraganglioma that may be localized from skull base to pelvis</td> </tr> <tr> <td class=\"indent1\">Hereditary leiomyomatosis and renal cell carcinoma (Reed's syndrome) &ndash; fumarate hydratase mutation</td> <td><em>FH</em></td> <td>Multifocal and metastatic; associated with hereditary leiomyomatosis, uterine fibroids, and renal cell cancer</td> </tr> <tr> <td class=\"indent1\">Hypoxia inducible factor 2-alpha</td> <td><em>HIF-2&#945;</em></td> <td>Paraganglioma, polycythemia, and rarely somastostatinoma</td> </tr> <tr> <td class=\"indent1\">Familial erythrocytosis associated with mutation in prolyl hydroxylase isoform 1 (PDH1)</td> <td><em>EGLN2</em></td> <td>Polycythemia associated with pheochromocytoma and paraganglioma</td> </tr> <tr> <td class=\"indent1\">Familial erythrocytosis associated with mutation in prolyl hydroxylase isoform 2 (PDH2)</td> <td><em>EGLN1</em></td> <td>Polycythemia associated with pheochromocytoma and paraganglioma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>KIF1B</em></td> <td><em>KIF1B</em></td> <td>Neuroblastoma</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Kinase signaling pathway &ndash; Cluster 2<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">MEN2A and MEN2B</td> <td><em>RET</em></td> <td>Adrenal medulla, frequently bilateral</td> </tr> <tr> <td class=\"indent1\">Neurofibromatosis type 1</td> <td><em>NF1</em></td> <td>Adrenal or peri-adrenal</td> </tr> <tr> <td class=\"indent1\"><em>MAX</em><sup>&#182;</sup></td> <td><em>MAX</em></td> <td>Adrenal medulla</td> </tr> <tr> <td class=\"indent1\">Familial pheochromocytoma</td> <td><em>TMEM127</em></td> <td>Adrenal medulla; possible renal cell carcinoma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GIST: gastrointestinal stromal tumor; MEN2: multiple endocrine neoplasia type 2; SDH: succinate dehydrogenase; VHL: von Hippel-Lindau.<br />* Cluster 1 tumors are mostly extra-adrenal paragangliomas (except in VHL where most tumors are localized to the adrenal) and nearly all have a noradrenergic biochemical phenotype.<br />&para; Associated with maternal imprinting.<br />&Delta; Cluster 2 tumors are usually adrenal pheochromocytomas with an adrenergic biochemical phenotype.</div><div class=\"graphic_reference\">Original figure modified for this publication. Young WF. Endocrine hypertension. In: Williams Textbook of Endocrinology, Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (Eds), 13th ed, Elsevier Inc, Philadelphia 2015. p.556. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 106549 Version 1.0</div></div></div>"},"106561":{"type":"graphic_diagnosticimage","displayName":"Slipped capital femoral epiphysis: Anteroposterior radiograph","title":"Slipped capital femoral epiphysis: Anteroposterior radiograph","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Slipped capital femoral epiphysis: Anteroposterior radiograph</div><div class=\"cntnt\"><img style=\"width:720px; height:559px;\" src=\"images/PEDS/106561_SCFEAPrdgrph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph of right slipped capital femoral epiphysis demonstrates widening, lucency, and irregularity of the physis (arrow), blurring of the junction between the metaphysis and the growth plate, diminished height of the epiphysis (double arrow), and increased density in the proximal femoral neck (arrowhead, the \"blanch sign of Steel\"). In addition, note that Klein line (dashed line) passes along the superior edge of the epiphysis of the femoral head rather than intersecting the lateral portion (as on the left).</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 106561 Version 3.0</div></div></div>"},"106562":{"type":"graphic_diagnosticimage","displayName":"Slipped capital femoral epiphysis: Frog-leg lateral radiograph","title":"Slipped capital femoral epiphysis: Frog-leg lateral radiograph","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Slipped capital femoral epiphysis: Frog-leg lateral radiograph</div><div class=\"cntnt\"><img style=\"width:710px; height:558px;\" src=\"images/PEDS/106562_SCFEfrglegrdgr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This frog-leg lateral radiograph of right slipped capital femoral epiphysis demonstrates widening and irregularity of the capital femoral physis (arrow), osteopenia, and increased density of the metaphysis, as well as posterior displacement and step-off of the epiphysis on the femoral neck (arrowhead).</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 106562 Version 2.0</div></div></div>"},"106563":{"type":"graphic_diagnosticimage","displayName":"Undisplaced SCFE","title":"Left-sided, early, undisplaced (\"preslip\") slipped capital femoral epiphysis","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Left-sided, early, undisplaced (\"preslip\") slipped capital femoral epiphysis</div><div class=\"cntnt\"><img style=\"width:726px; height:300px;\" src=\"images/PEDS/106563_UndisplacedSCFE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this patient with left-sided, early, undisplaced (\"pre-slip\") slipped capital femoral epiphysis (SCFE), the anteroposterior (A) and lateral (B) radiographs show only widening of the capital femoral physis (arrows). This finding is easier to detect in pelvic (rather than isolated hip) radiographs, which permit comparison with the opposite side. In the anteroposterior view, Klein line (dashed yellow line) appropriately intersects the lateral portion of the femoral head; as SCFE progresses and the femoral head is displaced, Klein line no longer intersects the lateral portion of the femoral head.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 106563 Version 2.0</div></div></div>"},"106564":{"type":"graphic_diagnosticimage","displayName":"Coxa valga radiograph","title":"Coxa valga radiograph","html":"<div class=\"graphic\"><div style=\"width: 712px\" class=\"figure\"><div class=\"ttl\">Coxa valga radiograph</div><div class=\"cntnt\"><img style=\"width:692px; height:546px;\" src=\"images/PEDS/106564_Coxavlgrdgrph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiographic findings of bilateral coxa valga that are depicted above include an increased angle between the femoral neck and shaft, which is normally between 120 and 135°, and deformities of the femoral head and acetabulum, including&nbsp;disruption of Shenton line (solid lines), incomplete femoral head coverage, and acetabular dysplasia.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 106564 Version 2.0</div></div></div>"},"106569":{"type":"graphic_table","displayName":"Contraceptive options for menstrual manipulation","title":"Contraceptive options for menstrual manipulation in patients with disabilities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraceptive options for menstrual manipulation in patients with disabilities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> <td class=\"subtitle1\">Concerns</td> </tr> <tr> <td>Nonsteroidal antiinflammatory drugs</td> <td> <p>Decreases flow</p> Nonhormonal</td> <td>Gastrointestinal intolerance</td> <td> <p>Not for daily use</p> Use as needed</td> </tr> <tr> <td>Combined oral contraceptives</td> <td> <p>Decreases flow</p> Extended regimen</td> <td> <p>Increased risk of deep vein thrombosis</p> Breakthrough bleeding</td> <td> <p>Increased DVT risk with immobility</p> Must&nbsp;be taken daily</td> </tr> <tr> <td>Contraceptive patch</td> <td>Weekly</td> <td>Deep vein thrombosis risk greater than with combined oral contraceptives Weight limit</td> <td> <p>Increased DVT risk with immobility</p> Accidental or deliberate removal before expiration</td> </tr> <tr> <td>Contraceptive ring</td> <td> <p>Monthly</p> May reduce bleeding</td> <td>Risk of deep vein thrombosis</td> <td> <p>Increased DVT risk with immobility</p> Need assistance for use</td> </tr> <tr> <td>Progestin-only pills</td> <td>Can be used by women with contraindications to estrogen</td> <td>Irregular bleeding</td> <td>Must be taken daily</td> </tr> <tr> <td>Depot medroxyprogesterone acetate</td> <td>Four times a year</td> <td> <p>May decrease bone density</p> <p>Weight gain</p> Intramuscular injection</td> <td> <p>Bone density monitoring</p> </td> </tr> <tr> <td>Levonorgestrel-releasing intrauterine device (IUD)</td> <td> <p>Lasts up to 3 or 5 years</p> Amenorrhea after six months with 5 year IUD</td> <td>Irregular bleeding initially</td> <td>Requires procedure for insertion and removal</td> </tr> <tr> <td>Implant</td> <td>Three years</td> <td>Irregular bleeding</td> <td>Requires procedure for insertion and removal</td> </tr> <tr> <td>Ablation</td> <td>Nonhormonal</td> <td> <p>Not studied in teenagers</p> <p>Irregular bleeding</p> Irreversible</td> <td> <p>Not indicated or recommended in teenagers</p> <p>Consent issues</p> Risk of anesthesia</td> </tr> <tr> <td>Hysterectomy</td> <td>Amenorrhea</td> <td> <p>Surgery</p> Irreversible</td> <td> <p>Sterilization</p> <p>Consent issues</p> <p>Rarely indicated in teenagers</p> Risk of general anesthesia</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">DVT: deep venous thrombosis. IUD: intrauterine device</div><div class=\"graphic_reference\">From: American College of Obstetricians and Gynecologists Committee on Adolescent Health Care. ACOG Committee Opinion No. 448: Menstrual manipulation for adolescents with disabilities. Obstet Gynecol 2009; 114:1428. DOI: <a href=\"http://journals.lww.com/greenjournal/Citation/2009/12000/ACOG_Committee_Opinion_No__448__Menstrual.52.aspx\" spellcheck=\"true\" target=\"_blank\">10.1097/AOG.0b013e3181c6f922</a>. Copyright &copy; 2009 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 106569 Version 2.0</div></div></div>"},"106590":{"type":"graphic_diagnosticimage","displayName":"MRI early neonatal HSV CNS disease","title":"Brain magnetic resonance imaging of an infant with HSV CNS disease","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Brain magnetic resonance imaging of an infant with HSV CNS disease</div><div class=\"cntnt\"><img style=\"width:556px; height:640px;\" src=\"images/PEDS/106590_MRI_erly_nntl_HSV_CNS_dss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T2 weighted post-contrast MRI of the brain in a two week-old term infant with early HSV encephalitis showing focal subacute hemorrhage and inflammation within cortex and overlying subarachnoid space of the left front lobe (arrow).<br />The infant presented with lethargy, poor feeding, seizure-like activity, and one small facial vesicular skin lesion. HSV PCR testing of blood and CSF was positive for HSV type 2 DNA. She was treated with 21 days of IV acyclovir followed by oral suppressive therapy for six months. At two years of age she had motor disabilities with hemiparesis but normal speech and language abilities.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; HSV: herpes simplex virus; CNS: central nervous system; PCR: polymerase chain reaction; CSF: cerebrospinal fluid; DNA: deoxyribonucleic acid; IV: intravenous.</div><div id=\"graphicVersion\">Graphic 106590 Version 1.0</div></div></div>"},"106592":{"type":"graphic_table","displayName":"Knee motion required for some basic activities","title":"Knee motion required for some basic activities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Knee motion required for some basic activities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Activity</td> <td class=\"subtitle1\">Approximate knee flexion required*</td> </tr> <tr> <td>Walking without a limp on flat ground</td> <td>75&#176;</td> </tr> <tr> <td>Stair climbing</td> <td>90&#176;</td> </tr> <tr> <td>Cycling</td> <td>90&#176;</td> </tr> <tr> <td>Jogging</td> <td>105&#176;</td> </tr> <tr> <td>Running</td> <td>120&#176;</td> </tr> <tr> <td>Sprinting</td> <td>140&#176;</td> </tr> <tr> <td>Getting out of a car</td> <td>135&#176;</td> </tr> <tr> <td>Getting in or out of a&nbsp;bathtub</td> <td>135&#176;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The knee flexion measurement is determined from a starting position of full extension, which is 0&deg;.</div><div class=\"graphic_reference\">Adapted from: Rowe PJ, Myles CM, Walker C, Nutton R. Knee joint kinematics in gait and other functional activities measured using flexible electrogoniometry: how much knee motion is sufficient for normal daily life? Gait Posture 2000; 12:143.</div><div id=\"graphicVersion\">Graphic 106592 Version 1.0</div></div></div>"},"106595":{"type":"graphic_table","displayName":"Infectious screening US blood","title":"Infectious agents for which donated blood is screened in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious agents&nbsp;for which donated blood is screened in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Infectious agent</td> <td class=\"subtitle1\">Comments on testing</td> </tr> <tr> <td>HIV 1 and 2</td> <td>All units; immunoassay for antibody (with further confirmation testing if reactive) and nucleic acid minipool testing for viral RNA</td> </tr> <tr> <td>HTLV-I and II</td> <td>All units; immunoassay for antibody</td> </tr> <tr> <td>Hepatitis C virus</td> <td>All units; immunoassay for antibody (with further confirmation testing if reactive) and nucleic acid minipool testing for viral RNA</td> </tr> <tr> <td>Hepatitis B virus</td> <td>All units; immunoassay for HBsAg and HBc antibody and nucleic acid minipool testing for viral DNA</td> </tr> <tr> <td>West Nile virus</td> <td>All units; nucleic acid minipool or individual donation testing for viral RNA</td> </tr> <tr> <td><em>Treponema pallidum</em> (syphilis)</td> <td>All units; immunoassay</td> </tr> <tr> <td><em>Trypanosoma cruzi</em> (Chagas disease)</td> <td>Initial donation from all donors; immunoassay for antibody (with further confirmation testing if reactive)</td> </tr> <tr> <td><em>Babesia microti </em>(babesiosis)</td> <td>Many units in high-risk&nbsp;regions of the US;&nbsp;either with an antibody assay alone&nbsp;or with an&nbsp;antibody assay and a PCR assay&nbsp;&nbsp;</td> </tr> <tr> <td>Cytomegalovirus</td> <td>Selected units to establish a CMV-negative inventory for at-risk recipients; immunoassay for antibody</td> </tr> <tr> <td>Zika virus</td> <td>All units; nucleic acid individual donation testing for viral RNA</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content on laboratory testing of donated blood&nbsp;for further information. Additional donor screening and self-deferral are used to address other infectious risks. In addition to this testing, platelets, which are stored at room temperature, also undergo bacterial testing, the details of which vary by institution.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; HTLV: human T-lymphotropic virus; HBsAg: hepatitis B surface antigen; HBc: hepatitis B core antigen; PCR: polymerase chain reaction. </div><div id=\"graphicVersion\">Graphic 106595 Version 3.0</div></div></div>"},"106596":{"type":"graphic_picture","displayName":"Vitiligo histo","title":"Histopathologic features of vitiligo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of vitiligo</div><div class=\"cntnt\"><img style=\"width:434px; height:576px;\" src=\"images/DERM/106596_Vtlg_hst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Nonlesional skin and&nbsp;(B) lesional skin&nbsp;showing an absence of melanin and melanocytes. Hematoxylin and eosin stain.</div><div class=\"graphic_reference\">Courtesy of Pearl E Grimes, MD.</div><div id=\"graphicVersion\">Graphic 106596 Version 3.0</div></div></div>"},"106597":{"type":"graphic_figure","displayName":"Sleep duration recommendations by age","title":"Sleep duration recommendations by age from the National Sleep Foundation*","html":"<div class=\"graphic\"><div style=\"width: 967px\" class=\"figure\"><div class=\"ttl\">Sleep duration recommendations by age from the National Sleep Foundation*</div><div class=\"cntnt\"><img style=\"width:947px; height:590px;\" src=\"images/SLEEP/106597_Slp_drt_rcmmnd_age.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* These recommendations are very similar, but not identical to those from the American Academy of Sleep Medicine (AASM).<SUP>[1,2]</SUP></div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>Paruthi S, Brooks LJ, D'Ambrosio C, et al. Recommended amount of sleep for pediatric populations: A statement of the American Academy of Sleep Medicine. J Clin Sleep Med 2016; 12:785.</LI>&#xD;&#xA;<LI>Consensus Conference Panel, Watson NF, Badr MS, et al. Recommended amount of sleep for a healthy adult: A Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society. J Clin Sleep Med 2015; 11:591.</LI></OL>Republished with permission of National Sleep Foundation, 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 106597 Version 3.0</div></div></div>"},"106603":{"type":"graphic_picture","displayName":"Nevus depigmentosus 2","title":"Nevus depigmentosus","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Nevus depigmentosus</div><div class=\"cntnt\"><img style=\"width:712px; height:649px;\" src=\"images/DERM/106603_Nvs_dpgmnts_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nevus depigmentosus presenting as a hypopigmented, quasi-dermatomal lesion of the left forehead.</div><div class=\"graphic_reference\">Courtesy of Pearl E Grimes, MD.</div><div id=\"graphicVersion\">Graphic 106603 Version 2.0</div></div></div>"},"106609":{"type":"graphic_picture","displayName":"Hypopigmented mycosis fungoides 2","title":"Hypopigmented mycosis fungoides","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Hypopigmented mycosis fungoides</div><div class=\"cntnt\"><img style=\"width:609px; height:712px;\" src=\"images/DERM/106609_Hyppgmnt_mycs_fngd_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypopigmented and scaly patches are present on the legs of this patient. Biopsy showed cutaneous T cell lymphoma.</div><div class=\"graphic_reference\">Courtesy of Pearl E Grimes, MD.</div><div id=\"graphicVersion\">Graphic 106609 Version 2.0</div></div></div>"},"106610":{"type":"graphic_table","displayName":"Surveillance for PML during natalizumab therapy","title":"Surveillance for progressive multifocal leukoencephalopathy during natalizumab therapy for patients with multiple sclerosis and no prior immunosuppressive treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surveillance for progressive multifocal leukoencephalopathy during natalizumab therapy for patients with multiple sclerosis and no prior immunosuppressive treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">JCV antibody status*</td> <td class=\"subtitle1\">PML risk with natalizumab</td> <td class=\"subtitle1\">Suggested monitoring*</td> <td class=\"subtitle1\">Management issues*</td> </tr> <tr class=\"divider_bottom\"> <td>Anti-JCV antibody negative</td> <td>&#60;1:10,000</td> <td>Anti-JCV antibody every 6 months; obtain brain MRI scan<sup>&#182;</sup> at baseline and every 12 months</td> <td>Natalizumab continued as indicated for MS</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Anti-JCV antibody positive and anti-JCV antibody index &#60;0.9</p> </td> <td> <p>&#60;1:10,000&nbsp;for months 1 to 24</p> <p>~1:748 for &#62;24 months</p> </td> <td>Anti-JCV antibody index every 6 months; brain MRI scan<sup>&#182;</sup> every 12 months</td> <td>Patient and clinician should review the benefits and risks of continuing natalizumab beyond 24 months</td> </tr> <tr> <td> <p>Anti-JCV antibody positive and anti-JCV antibody index &#8805;0.9</p> </td> <td> <p>~1:1062 for months 1 to 24</p> <p>~1:101 for &#62;24 months</p> </td> <td>Further anti-JCV antibody index testing not required; brain MRI scan<sup>&#182;</sup> at one year and then every 6 months beginning at 18 months<sup>&#916;</sup></td> <td>We suggest discontinuing natalizumab after 24 months due to mounting risk of PML</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table is intended to provide guidance for clinicians about the risk of PML associated with natalizumab therapy for patients with relapsing-remitting MS without prior immunosuppressant treatment (beta interferons or glatiramer acetate are not considered immunosuppressants in this paradigm). However, the risks of PML are estimates and subject to change as more data accrue. The surveillance steps outlined here may not apply to all patients; clinical judgement and vigilance are required at all times.</div><div class=\"graphic_footnotes\">JCV: JC virus; MRI: magnetic resonance imaging; MS: multiple sclerosis; PML: progressive multifocal leukoencephalopathy.<br />* PML monitoring and management suggestions are based on the patient's current JCV antibody status, which should be assessed at baseline and reassessed periodically. A baseline brain MRI scan should be obtained prior to initiating therapy with natalizumab.<br />¶ Natalizumab should be discontinued in any patient with MRI findings suggestive of PML.<br />Δ Some experts recommend MRI scanning every&nbsp;3 to 4 months after 18 months of therapy for patients with an anti-JCV index ≥0.9.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016; 87:117. </LI>&#xD;&#xA;<LI>Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76:802. </LI>&#xD;&#xA;<LI>Kuesters G, Plavina T, Lee S, et al. Anti-JC virus (JCV) antibody index differentiates risk of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated multiple sclerosis (MS) patients with no prior immunosuppressant (IS) use: An updated analysis. Poster presentation, 67th American Academy of Neurology Annual Meeting, April 22, 2015 Washington DC, USA. www.abstracts2view.com/aan/view.php?nu=AAN15L1_P4.031 (Accessed on February 04, 2016).</LI>&#xD;&#xA;<LI>Schwab N, Schneider-Hohendorf T, Melzer N, et al. Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification. Neurology 2017; 88:1197.</LI></OL></div><div id=\"graphicVersion\">Graphic 106610 Version 2.0</div></div></div>"},"106616":{"type":"graphic_table","displayName":"Serious illness conversation guide","title":"Serious illness conversation guide","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serious illness conversation guide</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Conversation flow</td> <td class=\"subtitle1\">Patient-tested language</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1. Set up the conversation</strong> <ul class=\"decimal_heading\"> <li>Introduce purpose </li> <li>Prepare for future decisions </li> <li>Ask permission </li> </ul> </td> <td>\"I'd like to talk about what is ahead with your illness and do some thinking in advance about what is important to you so that I can make sure we provide you with the care you want&#8212;<strong>is this okay?</strong>\" </td> </tr> <tr class=\"divider_bottom\"> <td><strong>2. Assess understanding and preferences</strong> </td> <td> <p>\"What is your <strong>understanding</strong> now of where you are with your illness?\"</p> \"How much <strong>information</strong> about what is likely to be ahead with your illness would you like from me?\" </td> </tr> <tr class=\"divider_bottom\"> <td><strong>3. Share prognosis</strong> <ul class=\"decimal_heading\"> <li>Share prognosis </li> <li>Frame as a \"wish...worry,\" \"hope...worry\" statement </li> <li>Allow silence, explore emotion </li> </ul> </td> <td> <p>\"I want to share with you <strong>my understanding</strong> of where things are with your illness...\"</p> <p>Uncertain: \"It can be difficult to predict what will happen with your illness. I <strong>hope</strong> you will continue to live well for a long time, but I'm <strong>worried</strong> that you could get sick quickly, and I think it is important to prepare for that possibility.\"</p> <p>OR</p> <p>Time: \"I <strong>wish</strong> we were not in this situation, but I am <strong>worried</strong> that time may be as short as ___ (express as a range, eg, days to weeks, weeks to months, months to a year).\"</p> <p>OR</p> Function: \"I <strong>hope</strong> that this is not the case, but I'm <strong>worried</strong> that this may be as strong as you will feel, and things are likely to get more difficult.\" </td> </tr> <tr class=\"divider_bottom\"> <td><strong>4. Explore key topics</strong> <ul class=\"decimal_heading\"> <li>Goals </li> <li>Fears and worries </li> <li>Sources of strength </li> <li>Critical abilities </li> <li>Tradeoffs </li> <li>Family </li> </ul> </td> <td> <p>\"What are your most important <strong>goals</strong> if your health situation worsens?\"</p> <p>\"What are your biggest <strong>fears and worries</strong> about the future with your health?\"</p> <p>\"What gives you <strong>strength</strong> as you think about the future with your illness?\"</p> <p>\"What <strong>abilities</strong> are so critical to your life that you can't imagine living without them?\"</p> <p>\"If you become sicker, <strong>how much are you willing to go through</strong> for the possibility of gaining more time?\"</p> \"How much does your <strong>family</strong> know about your priorities and wishes?\" </td> </tr> <tr class=\"divider_bottom\"> <td><strong>5. Close the conversation</strong> <ul class=\"decimal_heading\"> <li>Summarize </li> <li>Make a recommendation </li> <li>Check in with patient </li> <li>Affirm commitment </li> </ul> </td> <td> <p>\"I've heard you say that ___ is really important to you. Keeping that in mind, and what we know about your illness, I <strong>recommend</strong> that we ___. This will help us make sure that your treatment plans reflect what's important to you.\"</p> <p>\"How does this plan seem to you?\"</p> \"I will do everything I can to help you through this.\" </td> </tr> <tr class=\"divider_bottom\"> <td><strong>6. Document your conversation</strong> </td> <td>&nbsp;</td> </tr> <tr> <td><strong>7. Communicate with key clinicians</strong> </td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Serious Illness Conversation Guide (Accessed on October 16, 2017). This material has been modified by UpToDate. The original content can be found at <A href=\"https://portal.ariadnelabs.org/\" target=_blank>https://portal.ariadnelabs.org</A> and is licensed by Ariadne Labs under the <A href=\"https://creativecommons.org/licenses/by-nc-sa/4.0/\" target=_blank>Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License</A>. Ariadne Labs licenses the original content as-is and as-available, and makes no representations or warranties of any kind concerning the original content or concerning this material, which Ariadne Labs has not reviewed or endorsed.</div><div id=\"graphicVersion\">Graphic 106616 Version 5.0</div></div></div>"},"106621":{"type":"graphic_figure","displayName":"Lateral decubitus position","title":"Standard lateral decubitus position","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">Standard lateral decubitus position</div><div class=\"cntnt\"><img style=\"width:786px; height:544px;\" src=\"images/ANEST/106621_Lateral_decubitus_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proper head support, axillary roll, and leg pillow arrangement are depicted. The downside leg is flexed at the hip and knee to stabilize the torso.</div><div class=\"graphic_reference\">Illustration by Kiran Guthikonda, MD, PhD, Dartmouth-Hitchcock Medical Center.</div><div id=\"graphicVersion\">Graphic 106621 Version 3.0</div></div></div>"},"106622":{"type":"graphic_figure","displayName":"Flexed lateral decubitus position","title":"Flexed lateral decubitus position","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Flexed lateral decubitus position</div><div class=\"cntnt\"><img style=\"width:720px; height:405px;\" src=\"images/ANEST/106622_Flexed_lateral_decubts_pstn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proper head support, axillary roll, and leg pillow arrangement are depicted. The iliac crest at the proper flexion point and proper positioning of the elevated transverse rest allow the best possible expansion of the downside lung.</div><div class=\"graphic_reference\">Illustration by Kiran Guthikonda, MD, PhD, Dartmouth-Hitchcock Medical Center.</div><div id=\"graphicVersion\">Graphic 106622 Version 1.0</div></div></div>"},"106623":{"type":"graphic_table","displayName":"Comparison of reversible and permanent contraceptive methods","title":"Comparison of highly effective reversible and permanent contraceptive methods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of highly effective&nbsp;reversible and permanent contraceptive methods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Reversible (for couples who want the option of future fertility OR like other features of these methods)</td> <td class=\"subtitle1\">Permanent (for couples who have definitely completed their childbearing)</td> </tr> <tr class=\"divider_bottom\"> <td>Levonorgestrel-releasing IUD (Liletta, Mirena, Skyla) <ul class=\"decimal_heading\"> <li>Placed during an office visit </li> <li>Small amount of hormone released </li> <li>Effective for at least three to five years, depending on IUD type, but can be removed at any time </li> <li>May make periods irregular or lighter </li> <li>Sometimes results in no periods </li> </ul> </td> <td>Male sterilization <ul class=\"decimal_heading\"> <li>In-office procedure for male partner </li> <li>Usually done under local anesthesia </li> <li>Back-up method of birth control needed, usually for three months, until testing confirms success </li> <li>Simpler and safer than female sterilization </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Copper IUD (ParaGard) <ul class=\"decimal_heading\"> <li>Placed during an office visit </li> <li>Small amount of copper released, no hormones </li> <li>Effective for at least 10 years but can be removed at any time </li> <li>May make periods heavier </li> <li>May make periods irregular </li> </ul> </td> <td>Incisional female sterilization <ul class=\"decimal_heading\"> <li>Female sterilization done in operating room </li> <li>Usually with general anesthesia </li> <li>Tubes are either cut, tied, or burned </li> </ul> </td> </tr> <tr> <td>Implant/Nexplanon <ul class=\"decimal_heading\"> <li>Placed during an office visit </li> <li>Effective for at least three years </li> <li>Inserted under the skin of the upper arm </li> <li>Releases a hormone </li> <li>May make periods irregular </li> </ul> </td> <td>Hysteroscopic female sterilization <ul class=\"decimal_heading\"> <li>Done in the office under local anesthesia or in the operating room </li> <li>Puts inserts in the tubes to block permanently </li> <li>Back-up method of birth control needed for the first three months until testing confirms success </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IUD: intrauterine device.</div><div id=\"graphicVersion\">Graphic 106623 Version 2.0</div></div></div>"},"106663":{"type":"graphic_table","displayName":"Antiseizure drugs that may worsen generalized seizures","title":"Antiseizure drugs with the potential to worsen generalized seizure types","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antiseizure drugs with the potential to worsen generalized seizure types</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Seizure type and patient population</td> <td class=\"subtitle1\">Drugs with potential to precipitate or aggravate seizures*</td> </tr> <tr> <td>Generalized-onset tonic-clonic seizures in children and adults</td> <td>Carbamazepine, phenytoin</td> </tr> <tr> <td>Absence seizures in children</td> <td>Carbamazepine, oxcarbazepine, phenobarbital, phenytoin, tiagabine, and vigabatrin</td> </tr> <tr> <td>Absence seizures, myoclonic seizures, and in some cases generalized-onset tonic-clonic seizures in patients with juvenile myoclonic epilepsy</td> <td>Carbamazepine, gabapentin, lamotrigine<sup>&#182;</sup>, oxcarbazepine, phenytoin, tiagabine, vigabatrin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Low quality evidence, based primarily on scattered reports.<br />¶ Myoclonic seizures only, also reported in other generalized epilepsy syndromes.</div><div class=\"graphic_reference\">Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54:551-63; 2013.</div><div id=\"graphicVersion\">Graphic 106663 Version 2.0</div></div></div>"},"106668":{"type":"graphic_picture","displayName":"Light microscopy spermatocytic tumor","title":"Spermatocytic tumor","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Spermatocytic tumor</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/ONC/106668_Lght_mcrscp_sprmtcy_tmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the tumor cells of three distinct sizes in the lesion: small tumor cells that resemble the size of a lymphocyte, medium size tumor cells, and large tumor cells with spireme (speckled) nuclear features.</div><div class=\"graphic_reference\">Courtesy of Dr. Michelle S. Hirsch, Department of Pathology, Brigham and Womens Hospital, Boston, MA.</div><div id=\"graphicVersion\">Graphic 106668 Version 3.0</div></div></div>"},"106673":{"type":"graphic_table","displayName":"Bowel Function Index","title":"Bowel Function Index<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bowel Function Index<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Bowel Function Index (BFI)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Please complete all items in this assessment.</td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_to_nine\"> <li>Ease of defecation (based upon a numeric analog scale [NAS]) during the last 7 days according to patient assessment: </li> </ol> </td> </tr> <tr> <td style=\"text-align: right;\">0 = easy/no difficulty<br /> 100 = severe difficulty</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1 highlight_gray_text\" colspan=\"2\"><strong>Ask the subject:</strong> <em>\"During the last 7 days, how would you rate your ease of defecation on a scale from 0 to 100, where 0 = easy or no difficulty and 100 = severe difficulty?\"</em><br /> <strong>If the subject requires clarification, ask:</strong> <em>\"During the last 7 days, how easy or difficult was it to have a bowel movement on a scale from 0 to 100, where 0 = easy or no difficulty and 100 = severe difficulty?\"</em></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Feeling of incomplete bowel evacuation (NAS) during the last 7 days according to patient assessment: </li> </ol> </td> </tr> <tr> <td style=\"text-align: right;\">0 = not at all<br /> 100 = very strong</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1 highlight_gray_text\" colspan=\"2\"><strong>Ask the subject:</strong> <em>\"During the last 7 days, how would you rate any feeling of incomplete bowel evacuation on a scale from 0 to 100, where 0 = no feeling of incomplete evacuation and 100 = a very strong feeling of incomplete evacuation?\"</em><br /> <strong>If the subject requires clarification, ask:</strong> <em>\"During the last 7 days, how strongly did you feel that you did not empty your bowels completely? Please indicate how strong this feeling was on a scale from 0 to 100, where 0 = not at all and 100 = very strong.\"</em></td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_to_nine\" start=\"3\"> <li>Personal judgement of patient (NAS) regarding constipation during the last 7 days: </li> </ol> </td> </tr> <tr> <td style=\"text-align: right;\">0 = not at all <br /> 100 = very strong </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\" colspan=\"2\"><strong>Ask the subject:</strong> <em>\"During the last 7 days, how would you rate your constipation on a scale from 0 to 100, where 0 = not at all and 100 = very strong?\"</em><br /> <strong>If the subject requires clarification, ask:</strong> <em>\"During the last 7 days, how would you rate how constipated you felt on a scale from 0 to 100, where 0 = not at all and 100 = very strong?\"</em></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>The Bowel Function Index (BFI) is a three-item questionnaire to measure constipation from the patient's perspective. Study personnel should ask subjects the BFI questions. The BFI is not intended to be given to the subject for completion on their own (self-administration), not even if study personnel explain how the measure should be completed. The BFI should always be administered to the subject by study personnel.</li>&#xD;&#xA;    <li>Instructions for administering each item of the BFI are indicated in the grey sections below each item.</li>&#xD;&#xA;    <li>Ask subjects each question. If the subject does not understand the question, study personnel may provide clarification as indicated below each question in the grey sections of the measure below. Study personnel should enter each answer provided by the subject in the appropriate section of the case record form (CRF). To avoid any form of response bias, study personnel must not lead the subjects in their answers (eg, study personnel should not provide examples of answers to a given question).</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">NAS: numeric analogue scale.</div><div class=\"graphic_reference\">Reference:&nbsp;&#xD;&#xA;<OL>&#xD;&#xA;<LI>Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12:371</LI></OL>© 2002 Mundipharma Laboratories GmbH, used with permission.</div><div id=\"graphicVersion\">Graphic 106673 Version 2.0</div></div></div>"},"106687":{"type":"graphic_diagnosticimage","displayName":"Bronchopulmonary sequestration CT","title":"CT scan showing bronchopulmonary sequestration","html":"<div class=\"graphic\"><div style=\"width: 681px\" class=\"figure\"><div class=\"ttl\">CT scan showing bronchopulmonary sequestration</div><div class=\"cntnt\"><img style=\"width:661px; height:495px;\" src=\"images/PEDS/106687_Brnchplmn_sqst_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four images from a contrast-enhanced computed tomography (CT) study of a two month old infant with bronchopulmonary sequestration (BPS). The top images demonstrate abnormal lung tissue (arrows), consistent with BPS, in the posterior right lower lobe. The lower two images demonstrate an extremely large feeding artery arising from the thoracic aorta just above the diaphragm (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography; BPS: bronchopulmonary sequestration.</div><div class=\"graphic_reference\">Courtesy of Christopher Oermann, MD.</div><div id=\"graphicVersion\">Graphic 106687 Version 1.0</div></div></div>"},"106688":{"type":"graphic_diagnosticimage","displayName":"Bronchopulmonary sequestration 3D reconstruction","title":"Bronchopulmonary sequestration 3-dimensional vascular reconstruction","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Bronchopulmonary sequestration 3-dimensional vascular reconstruction</div><div class=\"cntnt\"><img style=\"width:512px; height:512px;\" src=\"images/PEDS/106688_Brnchplm_sqst_3D_rcnst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) angiography with 3-dimensional reconstruction showing an extralobar bronchopulmonary sequestration in a two-month old infant. The study demonstrates the large thoracic feeding artery (arrow) and communication with the dilated right inferior pulmonary vein (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Christopher Oermann, MD.</div><div id=\"graphicVersion\">Graphic 106688 Version 1.0</div></div></div>"},"106689":{"type":"graphic_table","displayName":"PSQI questionnaire","title":"Pittsburgh Sleep Quality Index (PSQI) questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pittsburgh Sleep Quality Index (PSQI) questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"5\"><strong>Name:</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>ID#:</strong></td> <td colspan=\"2\"><strong>Date:</strong></td> <td><strong>Age:</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"><strong>INSTRUCTIONS:</strong> The following questions relate to your usual sleep habits during the past month <em>only</em>. Your answers should indicate the most accurate reply for the <em>majority</em> of days and nights in the past month.<br /> Please answer all questions.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"> <ol> <li> <p>During the past month, when have you usually gone to bed at night?</p> USUAL BED TIME ____________________ </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"> <ol start=\"2\"> <li> <p>During the past month, how long (in minutes) has it usually take you to fall asleep each night?</p> NUMBER OF MINUTES ____________________ </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"> <ol start=\"3\"> <li> <p>During the past month, when have you usually gotten up in the morning?</p> USUAL GETTING UP TIME ____________________ </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"> <ol start=\"4\"> <li> <p>During the past month, how many hours of <em>actual sleep</em> did you get at night? (This may be different than the number of hours you spend in bed.)</p> HOURS OF SLEEP PER NIGHT ____________________ </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"><strong>INSTRUCTIONS:</strong> For each of the remaining questions, check the one best response.<br /> Please answer <em>all</em> questions.</td> </tr> <tr> <td> <ol start=\"5\"> <li>During the past month, how often have you had trouble sleeping because you... </li> </ol> </td> <td><strong>Not during the past month</strong></td> <td><strong>Less than once a week</strong></td> <td><strong>Once or twice a week</strong></td> <td><strong>Three or more times a week</strong></td> </tr> <tr> <td class=\"indent3\">(a) ...cannot get to sleep within 30 minutes</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\">(b) ...wake up in the middle of the night or early morning</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\">(c) ...have to get up to use the bathroom</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\">(d) ...cannot breathe comfortably</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\">(e) ...cough or snore loudly</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\">(f) ...feel too cold</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\">(g) ...feel too hot</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\">(h) ...had bad dreams</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\">(i) ...have pain</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\"> <p>(j) Other reason(s), please describe:</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> <td colspan=\"4\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">How often during the past month have you had trouble sleeping because of this?</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"highlight_gray_text\">&nbsp;</td> <td><strong>Very good</strong></td> <td><strong>Fairly good</strong></td> <td><strong>Fairly bad</strong></td> <td><strong>Very bad</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"6\"> <li>During the past month, how would you rate your sleep quality overall? </li> </ol> </td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"highlight_gray_text\">&nbsp;</td> <td><strong>Not during the past month</strong></td> <td><strong>Less than once a week</strong></td> <td><strong>Once or twice a week</strong></td> <td><strong>Three or more times a week</strong></td> </tr> <tr> <td> <ol start=\"7\"> <li>During the past month, how often have you taken medicine (prescribed or \"over the counter\") to help you sleep? </li> </ol> </td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"8\"> <li>During the past month, how often have you had trouble staying awake while driving, eating meals, or engaging in social activity? </li> </ol> </td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"highlight_gray_text\">&nbsp;</td> <td><strong>No problem at all</strong></td> <td><strong>Only a very slight problem</strong></td> <td><strong>Somewhat of a problem</strong></td> <td><strong>A very big problem</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"9\"> <li>During the past month, how much of a problem has it been for you to keep up enough enthusiasm to get things done? </li> </ol> </td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"highlight_gray_text\">&nbsp;</td> <td><strong>No bed partner or roommate</strong></td> <td><strong>Partner/roommate in other room</strong></td> <td><strong>Partner in same room, but not same bed</strong></td> <td><strong>Partner in same bed</strong></td> </tr> <tr> <td> <ol start=\"10\"> <li>Do you have a bed partner or roommate? </li> </ol> </td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\">If you have a roommate or bed partner, ask him/her how often in the past month have you had...</td> <td><strong>Not during the past month</strong></td> <td><strong>Less than once a week</strong></td> <td><strong>Once or twice a week</strong></td> <td><strong>Three or more times a week</strong></td> </tr> <tr> <td class=\"indent3\">(a) ...loud snoring</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\">(b) ...long pauses between breaths while asleep</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\">(c) ...legs twitching or jerking while you sleep</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\">(d) ...episodes of disorientation or confusion during sleep</td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3 divider_bottom\" rowspan=\"2\"> <p>(e) ...other restlessness while you sleep; please describe</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: A New Instrument for Psychiatric Practice and Research. Psychiatry Res 1989; 28:193. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 106689 Version 1.0</div></div></div>"},"106690":{"type":"graphic_waveform","displayName":"Transition from NREM 2 to REM sleep","title":"Transition from NREM 2 to REM sleep","html":"<div class=\"graphic\"><div style=\"width: 1120px\" class=\"figure\"><div class=\"ttl\">Transition from NREM 2 to REM sleep</div><div class=\"cntnt\"><img style=\"width:1100px; height:226px;\" src=\"images/SLEEP/106690_60_PSG_epch_trnst_NREM_2_REM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two 30-second epochs of sleep recorded in a 14-year-old during overnight PSG.&nbsp;The second epoch (labeled 768) is easily scored as REM sleep, because it contains all of the typical&nbsp;PSG features of REM sleep (rapid eye movements, low voltage mixed frequency EEG, and chin muscle atonia). Scoring of the first epoch (labeled 767) is more complex. In the epoch before (not shown), chin muscle tone was preserved, sleep spindles were seen, and it was scored as NREM 2. In epoch 767, a 3-second&nbsp;arousal is seen (diffuse 14 Hz activity), and there are no sleep spindles. Beginning 3 seconds into epoch 767, the chin EMG increases after the arousal, then drops to its lowest amplitude in the sleep study. Epoch 767 is therefore best scored as NREM 1 sleep, and epoch 768 as REM sleep. An arousal such as this one&nbsp;often occurs in the transition from NREM 2 to REM sleep.</div><div class=\"graphic_footnotes\">REM: rapid eye movement; EEG: electroencephalography; NREM: non-REM; PSG: polysomnogram; LEOG: left electrooculography; REOG: right electrooculography; EMG: surface electromyography; EKG: electrocardiography.</div><div id=\"graphicVersion\">Graphic 106690 Version 1.0</div></div></div>"},"106691":{"type":"graphic_picture","displayName":"Paravertebral block technique","title":"Thoracic paravertebral block technique","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Thoracic paravertebral block technique</div><div class=\"cntnt\"><img style=\"width:716px; height:474px;\" src=\"images/ANEST/106691_Prvrtbrl_blck_tchnq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paravertebral blocks are typically done using ultrasound guidance to precisely localize the injection and&nbsp;improve success, and to avoid the pain of needle contact with bone (not shown). An anatomic landmark approach is an alternative technique,&nbsp;as shown here,&nbsp;with placement of a&nbsp;paravertebral block between the T4 and T5 transverse processes. For further details, please refer to UpToDate topics addressing nerve blocks of the trunk, including the thoracic paravertebral block.</div><div class=\"graphic_reference\">Reproduced with permission from: Daly DJ, Myles PS. Update on the role of paravertebral blocks for thoracic surgery: Are they worth it? Curr Opin Anaesthesiol 2009; 22:38. DOI: <a href=\"http://journals.lww.com/co-anesthesiology/pages/articleviewer.aspx?year=2009&amp;issue=02000&amp;article=00008&amp;type=abstract\" target=\"_blank\">10.1097/ACO.0b013e32831a4074</a>. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 106691 Version 2.0</div></div></div>"},"106706":{"type":"graphic_picture","displayName":"Grover disease chest","title":"Grover's disease","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Grover's disease</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/106706_Grvr_dss_chst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules involving the central area of the chest in a patient with Grover's disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 106706 Version 1.0</div></div></div>"},"106747":{"type":"graphic_table","displayName":"Estimated corrections for converting VBGs to ABGs","title":"Estimated corrections for converting venous blood gasses to arterial blood gasses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated corrections for converting venous blood gasses to arterial blood gasses</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Central</td> <td class=\"subtitle1\">Peripheral</td> </tr> <tr> <td><strong>pH</strong></td> <td>Add 0.03 to 0.05 units</td> <td>Add 0.02 to 0.04 pH units</td> </tr> <tr> <td><strong>pCO<sub>2</sub></strong></td> <td>Subtract 4 to 5 mmHg</td> <td>Subtract 3 to 8 mmHg</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">pCO<sub>2</sub>: partial pressure of carbon dioxide.</div><div id=\"graphicVersion\">Graphic 106747 Version 1.0</div></div></div>"},"106748":{"type":"graphic_picture","displayName":"Circumferential bronchomalacia","title":"Circumferential bronchomalacia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circumferential bronchomalacia</div><div class=\"cntnt\"><img style=\"width:362px; height:369px;\" src=\"images/PULM/106748_Crcmfrntl_brnchmlc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circumferential bronchomalacia is seen during bronchoscopy in the left main stem bronchus in a 57 year old man with relapsing polychondritis. The image is taken during expiration and shows involvement of the entire bronchial wall.</div><div class=\"graphic_reference\">Courtesy of A Majid, MD.</div><div id=\"graphicVersion\">Graphic 106748 Version 1.0</div></div></div>"},"106749":{"type":"graphic_diagnosticimage","displayName":"Tracheobronchomegaly","title":"Tracheobronchomegaly","html":"<div class=\"graphic\"><div style=\"width: 818px\" class=\"figure\"><div class=\"ttl\">Tracheobronchomegaly</div><div class=\"cntnt\"><img style=\"width:798px; height:232px;\" src=\"images/PULM/106749_Trchbrnchmgly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Flexible bronchoscopy in a 28 year old man with Mounier-Kuhn syndrome reveals a widened diameter of the trachea and mainstem bronchi consistent with congenital tracheobronchomegaly.<br />(B) Dynamic airway computed tomographic (CT) image taken at end-inspiration in the same man, confirming increased size of the trachea.<br />(C) CT image taken at end-expiration confirms the finding of tracheal collapse (ie, tracheomalacia).</div><div class=\"graphic_reference\">Courtesy of A Majid, MD.</div><div id=\"graphicVersion\">Graphic 106749 Version 1.0</div></div></div>"},"106750":{"type":"graphic_picture","displayName":"Focal tracheomalacia","title":"Focal tracheomalacia from a tracheostomy tube","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Focal tracheomalacia from a tracheostomy tube</div><div class=\"cntnt\"><img style=\"width:726px; height:254px;\" src=\"images/PULM/106750_Fcl_trchmlc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Bronchoscopic image taken during expiration of a 75 year old man with post-tracheostomy focal tracheomalacia (TM).<br />(B and C) The TM was successfully treated using a Montgomery T-tube stent.</div><div class=\"graphic_reference\">Courtesy of A Majid, MD.</div><div id=\"graphicVersion\">Graphic 106750 Version 1.0</div></div></div>"},"106751":{"type":"graphic_figure","displayName":"FVL characteristics in TM","title":"Flow volume loop characteristics in tracheomalacia","html":"<div class=\"graphic\"><div style=\"width: 908px\" class=\"figure\"><div class=\"ttl\">Flow volume loop characteristics in tracheomalacia</div><div class=\"cntnt\"><img style=\"width:888px; height:525px;\" src=\"images/PULM/106751_FVLcharacteristicsTM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Flow volume loop in a patient with tracheomalacia demonstrating biphasic morphology with typical obstructive pattern.<br />(B) A notched expiratory loop in a different patient is shown.<br />(C) Expiratory oscillations from a third patient are shown.</div><div class=\"graphic_reference\">Reproduced with permission of the American Association for Respiratory Care, from: Majid A, Sosa AF, Ernst A, et al. Pulmonary function and flow-volume loop patterns in patients with tracheobronchomalacia. Respir Care 2013; 58:1521; permission conveyed through Copyright Clearance Center, Inc. Copyright © 2013.</div><div id=\"graphicVersion\">Graphic 106751 Version 3.0</div></div></div>"},"106752":{"type":"graphic_algorithm","displayName":"Evaluation of primary amenorrhea","title":"Evaluation of primary amenorrhea","html":"<div class=\"graphic\"><div style=\"width: 1528px\" class=\"figure\"><div class=\"ttl\">Evaluation of primary amenorrhea</div><div class=\"cntnt\"><img style=\"width:1508px; height:724px;\" src=\"images/ENDO/106752_Evaluatn_primary_amenorrhea.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; FSH: follicle-stimulating hormone; TSH: thyroid-stimulating hormone; PRL: prolactin; T: testosterone; DHT: dihydrotestosterone;&nbsp;LH: luteinizing hormone; GnRH: gonadotropin-releasing hormone; MRI: magnetic resonance imaging; PCOS: polycystic ovary syndrome.<br />* In addition to primary amenorrhea: hypertension (which can be severe), absence of secondary sexual characteristics, or minimal body hair. Refer to UpToDate topics on uncommon congenital adrenal hyperplasias.<br />¶ Refer to UpToDate topics on the evaluation of secondary amenorrhea for discussion of hyperprolactinemia, thyroid disease, and PCOS.<br />Δ Pituitary MRI not required in those with clear explanation for their hypogonadotropic amenorrhea, eg, celiac disease or type 1 diabetes mellitus. Refer to UpToDate topics on the evaluation and management of secondary amenorrhea.</div><div id=\"graphicVersion\">Graphic 106752 Version 3.0</div></div></div>"},"106762":{"type":"graphic_table","displayName":"Canadian FASD nomenclature and diagnostic criteria","title":"Canadian nomenclature and diagnostic criteria for fetal alcohol spectrum disorder (2015)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Canadian nomenclature and diagnostic criteria for fetal alcohol spectrum disorder (2015)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnostic criteria for FASD</td> </tr> <tr> <td class=\"subtitle2_single\">FASD with sentinel facial features:</td> </tr> <tr> <td class=\"indent1\">All of the following:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Prenatal alcohol exposure<sup>&#182;</sup> confirmed or unknown </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>All three sentinel facial features<sup>&#916;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Meets criteria for CNS involvement: <ul> <li>Any age: Severe impairment<sup>&#9674;</sup> in &#8805;3 neurodevelopmental domains<sup>&#167;</sup> </li> <li>For children &#8804;6 years: Microcephaly </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">FASD without sentinel facial features:</td> </tr> <tr> <td class=\"indent1\">Both of the following:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Confirmed prenatal alcohol exposure<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Severe impairment<sup>&#9674;</sup> in &#8805;3 neurodevelopmental domains<sup>&#167;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Special designation (not a diagnosis)</td> </tr> <tr> <td class=\"subtitle2_single\">At risk for neurodevelopmental disorder and FASD, associated with prenatal alcohol exposure (whether or not child has all three sentinel facial features<sup>&#916;</sup>):</td> </tr> <tr> <td class=\"indent1\">All three of the following:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Confirmed prenatal alcohol exposure<sup>&#182;</sup>, <strong>and</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Some indication of neurodevelopmental disorder, but does <strong>not</strong> meet CNS criteria as described above, <strong>and</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Plausible explanation for lack of meeting CNS criteria (eg, incomplete evaluation, child is too young for adequate assessment) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FASD: fetal alcohol spectrum disorder; CNS: central nervous system.<br />* Nomenclature and diagnostic criteria vary geographically. Refer to UpToDate topic on diagnosis of fetal alcohol spectrum disorder for details.<br />¶ Via reliable clinical observation; self-report; reports by a reliable source; medical record documentation of positive blood alcohol concentrations; alcohol treatment; or other social, legal, or medical problems related to drinking alcohol during pregnancy. Estimated dose of alcohol consumption must be at a level known to be associated with neurodevelopmental effects.<br />Δ Palpebral fissure length &lt;3<SUP>rd</SUP> percentile; philtrum rated 4 or 5 on University of Washington Lip-Philtrum Guide; upper lip rated 4 or 5 on University of Washington Lip-Philtrum Guide.<br /><FONT class=lozenge>◊</FONT> Global score or a major subdomain score on a standardized neurodevelopmental measure that is ≥2 standard deviations below the mean, with appropriate allowance for test error.<br />§ Motor skills; neuroanatomy/neurophysiology; cognition; language; academic achievement; memory; attention; executive function, including impulse control and hyperactivity; affect regulation; adaptive behavior, social skills, or social communication.</div><div class=\"graphic_reference\">Data from: Cook JL, Green CR, Lilley CM, et al. Fetal alcohol spectrum disorder:&nbsp;A guideline for diagnosis across the lifespan. CMAJ 2015.</div><div id=\"graphicVersion\">Graphic 106762 Version 2.0</div></div></div>"},"106775":{"type":"graphic_table","displayName":"SAPS 3","title":"Simplified acute physiologic score 3 (SAPS 3)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Simplified acute physiologic score 3 (SAPS 3)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"42%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Range</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Patient age</td> <td>&#60;40 years</td> <td>0</td> </tr> <tr> <td>40-59 years</td> <td>5</td> </tr> <tr> <td>60-69 years</td> <td>9</td> </tr> <tr> <td>70-74 years</td> <td>13</td> </tr> <tr> <td>75-79 years</td> <td>15</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;80 years</td> <td>18</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Temperature</td> <td>&#60;35&#176;C, &#60;102.2&#176;F</td> <td>7</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;35&#176;C, &#8805;102.2&#176;F</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Systolic blood pressure</td> <td>&#8805;120 mmHg</td> <td>0</td> </tr> <tr> <td>70-119 mmHg</td> <td>3</td> </tr> <tr> <td>40-69 mmHg</td> <td>8</td> </tr> <tr class=\"divider_bottom\"> <td>&#60;40 mmHg</td> <td>11</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Heart rate</td> <td>&#8805;160 bpm</td> <td>7</td> </tr> <tr> <td>120-159 bpm</td> <td>5</td> </tr> <tr> <td>&#60;120 bpm</td> <td>0</td> </tr> <tr class=\"divider_bottom\"> <td>&#60;120 bpm</td> <td>5</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Glasgow coma scale </td> <td>&#60;2</td> <td>0</td> </tr> <tr> <td>2-5</td> <td>4</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;6</td> <td>5</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">White blood cell count (g/L)</td> <td>&#60;15</td> <td>0</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;15</td> <td>2</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Platelet count (g/L)</td> <td>&#60;20</td> <td>13</td> </tr> <tr> <td>20-49</td> <td>8</td> </tr> <tr> <td>50-99</td> <td>5</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;100</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Hydrogen ion concentration (pH)</td> <td>&#8804;7.25</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;7.25</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Creatinine</td> <td>&#60;106.1 micromol/L, &#60;1.2 mg/dL</td> <td>0</td> </tr> <tr> <td>106.1-176.7 mmol/L, 1.2-1.9 mg/dL</td> <td>2</td> </tr> <tr> <td>176.8-309.3 micromol/L, 2-3.4 mg/dL</td> <td>7</td> </tr> <tr class=\"divider_bottom\"> <td>309.4 micromol/L, &#62;3.5 mg/dL</td> <td>8</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Bilirubin level</td> <td>&#60;2 mg/dL, &#60;34.2 micromol/L</td> <td>0</td> </tr> <tr> <td>2-5 mg/dL, 34.2-102.6 micromol/L</td> <td>4</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;6 mg/dL, &#8805;102.6 micromol/L</td> <td>5</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">PaO<sub>2</sub>/FiO<sub>2</sub> (on mechanical ventilation)</td> <td>&#60;100 mmHg</td> <td>11</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;100</td> <td>7</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">PaO<sub>2</sub> (no mechanical ventilation)</td> <td>&#60;60</td> <td>5</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;60</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Length of stay before ICU admission</td> <td>&#60;14 days</td> <td>0</td> </tr> <tr> <td>14-27 days</td> <td>6</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;28 days</td> <td>7</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Co-morbidities </td> <td>Cancer therapy</td> <td>3</td> </tr> <tr> <td>Chronic heart failure, hematologic malignancy</td> <td>6</td> </tr> <tr> <td>Cirrhosis, AIDS</td> <td>8</td> </tr> <tr class=\"divider_bottom\"> <td>Cancer</td> <td>11</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Intrahospital location before ICU admission </td> <td>Emergency room</td> <td>5</td> </tr> <tr> <td>Other ICU</td> <td>7</td> </tr> <tr class=\"divider_bottom\"> <td>Other</td> <td>8</td> </tr> <tr class=\"divider_bottom\"> <td>Use of other major therapeutic options before ICU admission</td> <td>Vasoreactive drugs</td> <td>3</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">ICU admission</td> <td>Planned</td> <td>0</td> </tr> <tr class=\"divider_bottom\"> <td>Unplanned</td> <td>3</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"10\">Reason for admission*</td> <td>Cardiovascular: Rhythm disturbances</td> <td>&ndash;5</td> </tr> <tr> <td>Neurologic: Seizures</td> <td>&ndash;4</td> </tr> <tr> <td>Cardiovascular: Hypovolemic hemorrhagic shock, hypovolemic non hemorrhagic shock. Digestive: Acute abdomen, Other</td> <td>3</td> </tr> <tr> <td>Neurologic: Coma, stupor, obtunded patient, vigilance disturbances, confusion, agitation, delirium</td> <td>4</td> </tr> <tr> <td>Cardiovascular: Septic shock./Cardiovascular: Anaphylactic shock, mixed and undefined shock</td> <td>5</td> </tr> <tr> <td>Hepatic: Liver failure</td> <td>6</td> </tr> <tr> <td>Neurologic: Focal neurologic deficit</td> <td>7</td> </tr> <tr> <td>Digestive: Severe pancreatitis</td> <td>9</td> </tr> <tr> <td>Neurologic: Intracranial mass effect</td> <td>10</td> </tr> <tr class=\"divider_bottom\"> <td>All others</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Surgical status</td> <td>Scheduled</td> <td>0</td> </tr> <tr> <td>No surgery</td> <td>5</td> </tr> <tr class=\"divider_bottom\"> <td>Emergency</td> <td>6</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Anatomical site of surgery</td> <td>Transplantation surgery: Liver, kidney, pancreas, kidney and pancreas, transplantation other</td> <td>&ndash;11</td> </tr> <tr> <td>Trauma: Other, isolated (includes thorax, abdomen, limb); Trauma: Multiple</td> <td>&ndash;8</td> </tr> <tr> <td>Cardiac surgery: CABG without valvular repair</td> <td>&ndash;6</td> </tr> <tr> <td>Neurosurgery: Cerebrovascular accident</td> <td>5</td> </tr> <tr class=\"divider_bottom\"> <td>All others</td> <td>0</td> </tr> <tr> <td rowspan=\"2\">Acute infection</td> <td>Nosocomial</td> <td>4</td> </tr> <tr> <td>Respiratory</td> <td>5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">bpm: beats per minute; PaO<SUB>2</SUB>: partial pressure of arterial oxygen; FiO<SUB>2</SUB>: fraction of inspired oxygen.<br />* Every patient gets 16 points for an admission with the indicated points added or subtracted for each diagnosis.</div><div class=\"graphic_reference\">Reprinted by permission from: Springer: Intensive Care Medicine. Moreno RP, Metnitz PG, Almeida E, et al. SAPS 3--From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med 2005; 31:1345. Copyright © 2005. <A spellcheck=true href=\"https://link.springer.com/journal/134\" target=_blank>https://link.springer.com/journal/134</A>.</div><div id=\"graphicVersion\">Graphic 106775 Version 3.0</div></div></div>"},"106776":{"type":"graphic_table","displayName":"MPM0-III","title":"Mortality prediction model III (MPM<SUB>0</SUB>-III)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mortality prediction model III (MPM<SUB>0</SUB>-III)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"76%\"></colgroup><colgroup span=\"2\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Response</td> <td class=\"subtitle1\">Points</td> </tr> <tr class=\"divider_bottom\"> <td>Patient age*</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Medical or unscheduled surgical admission?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cardiopulmonary resuscitation prior to admission?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Coma (Glasgow coma scale 3-5)?</p> (Does not include patients whose coma is due to overdose or who received neuromuscular blocking agents)</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Heart rate &#8805;150 bpm?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Systolic blood pressure &#8804;90 mmHg?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Mechanical ventilation?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Acute renal failure?</p> (Does not include pre-renal azotemia)</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cardiac dysrhythmias?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cerebrovascular accident?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Intracranial mass effect?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Gastrointestinal bleeding?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Metastatic carcinoma?</p> (Distant metastases only; does not include local lymph node involvement)</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cirrhosis?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Chronic renal insufficiency?</p> (Creatinine &#62;2 mg/dL chronically)</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">In acute or chronic care facility before admission to ICU</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Time between hospital and ICU admission &#62;1 day</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> <tr> <td rowspan=\"2\">Full resuscitation status</td> <td class=\"centered\">Yes</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"centered\">No</td> <td class=\"centered\">0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patient age does not receive points when calculating the severity score; however, it is used in the formula to calculate predicted mortality.</div><div class=\"graphic_reference\">Source: Higgins TL, Teres D, Copes WS, et al. Assessing contemporary intensive care unit outcome: an updated Mortality Probability Admission Model (MPM0-III). Crit Care Med 2007; 35:827.</div><div id=\"graphicVersion\">Graphic 106776 Version 1.0</div></div></div>"},"106782":{"type":"graphic_table","displayName":"Classification of central sleep apnea syndromes","title":"Classification of central sleep apnea syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of central sleep apnea syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Central sleep apnea with predominant hyperventilation</td> </tr> <tr> <td class=\"indent1\">1. Central sleep apnea with Cheyne-Stokes breathing</td> </tr> <tr> <td class=\"indent1\">2. Central sleep apnea due to high altitude periodic breathing</td> </tr> <tr> <td class=\"indent1\">3. Treatment-emergent central sleep apnea</td> </tr> <tr> <td class=\"subtitle1_single\">Central sleep apnea with predominant hypoventilation</td> </tr> <tr> <td class=\"indent1\">1. Central apnea due to a medical disorder without Cheyne-Stokes breathing</td> </tr> <tr> <td class=\"indent1\">2. Central sleep apnea due to a medication or substance</td> </tr> <tr> <td class=\"indent1\">3. Primary central sleep apnea</td> </tr> <tr> <td class=\"indent1\">4. Primary central sleep apnea of infancy*</td> </tr> <tr> <td class=\"indent1\">5. Primary central sleep apnea of prematurity*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In pediatric population.</div><div class=\"graphic_reference\">Data from: American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, American Academy of Sleep Medicine, Darien, IL 2014.</div><div id=\"graphicVersion\">Graphic 106782 Version 1.0</div></div></div>"},"106783":{"type":"graphic_table","displayName":"Examination findings for penetrating neck injury","title":"Key examination points for patient with penetrating neck injury (PNI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key examination points for patient with penetrating neck injury (PNI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Examination</td> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Concern</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">General appearance</td> <td> <ul> <li>Declining mental status </li> </ul> </td> <td> <ul> <li>Vascular injury or cerebral hypoperfusion (eg, hemorrhage, hypotension) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Stroke-like syndrome </li> </ul> </td> <td> <ul> <li>Vascular injury; stroke; spinal cord injury </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Distress (eg, agitation, respiratory distress) </li> </ul> </td> <td> <ul> <li>Hypoxia from airway occlusion or tension pneumothorax </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Oropharyngeal examination</td> <td> <ul> <li>Blood in saliva </li> </ul> </td> <td> <ul> <li>Pharyngoesophageal injury </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Hemoptysis, hematemesis, dysphagia, odynophagia </li> </ul> </td> <td> <ul> <li>Pharyngoesophageal or laryngotracheal injury </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Voice</td> <td> <ul> <li>Stridor </li> </ul> </td> <td> <ul> <li>Airway occlusion from multiple sources (expanding hematoma, laryngotracheal injury) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Dysphonia </li> </ul> </td> <td> <ul> <li>Laryngotracheal injury </li> <li>Laryngeal nerve injury </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Tracheal position</td> <td class=\"divider_bottom\" rowspan=\"2\"> <ul> <li>Shifted trachea </li> </ul> </td> <td> <ul> <li>Visceral injury or vascular injury producing mass effect </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Tension pneumothorax (most&nbsp;commonly associated&nbsp;with Zone I PNI) </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Neck appearance, palpation, auscultation</td> <td> <ul> <li>Expanding hematoma, thrill, or bruit </li> </ul> </td> <td> <ul> <li>Vascular injury </li> </ul> </td> </tr> <tr> <td> <ul> <li>Crepitus </li> </ul> </td> <td> <ul> <li>Airway leak, pneumothorax, laryngotracheal or pharyngoesophageal injury </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Anterior neck tenderness </li> </ul> </td> <td> <ul> <li>Laryngotracheal injury </li> </ul> </td> </tr> <tr> <td rowspan=\"2\">Neurologic examination</td> <td> <ul> <li>Focal neurologic deficit </li> </ul> </td> <td> <ul> <li>Spinal nerve or cranial nerve injury (neuropraxia versus nerve transection) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Horner's syndrome (miosis, ptosis, anhidrosis) </li> </ul> </td> <td> <ul> <li>Sympathetic chain injury (consider adjacent vascular injury due to proximity) </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 106783 Version 3.0</div></div></div>"},"106792":{"type":"graphic_diagnosticimage","displayName":"CT tuberculous empyema","title":"Tuberculous empyema","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Tuberculous empyema</div><div class=\"cntnt\"><img style=\"width:461px; height:461px;\" src=\"images/ID/106792_CT_tbrcl_empym.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomography demonstrating tuberculous empyema. The loculated pleural fluid collection is associated with a thick, calcific pleural rind and ipsilateral rib thickening.</div><div class=\"graphic_reference\">Reproduced with permission from: Huggins JT. Chylothorax and cholesterol pleural effusion. Semin Respir Crit Care Med 2010; 31:743. Copyright &copy; 2010 Georg Thieme Verlag KG.</div><div id=\"graphicVersion\">Graphic 106792 Version 1.0</div></div></div>"},"106793":{"type":"graphic_table","displayName":"Adjunctive treatments for opioid withdrawal symptoms","title":"Adjunctive treatments for opioid withdrawal symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjunctive&nbsp;treatments for opioid withdrawal symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"17%\"></colgroup><colgroup width=\"49%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Usual effective dose range (adult)</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Anxiety</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Anxiety, irritability, restlessness</td> <td>Diphenhydramine*</td> <td>50 to 100 mg orally every 4 to 6 hours as needed (maximum 300 mg daily)</td> <td> <ul> <li>May also treat nausea </li> <li>Use reduced dose in hepatic impairment </li> <li>IV and IM administration available </li> </ul> </td> </tr> <tr> <td>Hydroxyzine</td> <td>25 to 100 mg orally every 6 to 8 hours as needed (maximum 400 mg daily)</td> <td> <ul> <li>May also treat lacrimation and rhinorrhea </li> <li>Use reduced dose (50%) in renal or hepatic impairment </li> <li>IM administration available </li> </ul> </td> </tr> <tr> <td>Clonazepam<sup>&#182;</sup></td> <td>0.5 to 1.5 mg orally every 6 to 8 hours as needed (maximum 6 mg daily)</td> <td> <ul> <li>Use with caution and reduce dose in mild hepatic or renal impairment; active metabolites can accumulate </li> <li>Avoid in moderate to severe hepatic impairment or hepatic encephalopathy </li> </ul> </td> </tr> <tr> <td>Lorazepam<sup>&#182;</sup></td> <td>1 mg orally every 4 to 6 hours as needed (maximum 6 mg daily)</td> <td> <ul> <li>Relatively safe in mild to moderate hepatic impairment; use of reduced dose may be needed </li> <li>Avoid in severe hepatic impairment or hepatic encephalopathy </li> <li>IV and IM administration available; use caution in renal impairment due to propylene glycol diluent </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Oxazepam<sup>&#182;</sup></td> <td>15 to 30 mg orally every 6 to 8 hours as needed (maximum 120 mg daily)</td> <td> <ul> <li>Relatively safe in mild to moderate hepatic or renal impairment </li> <li>Use with caution in severe renal impairment </li> <li>Avoid in severe hepatic impairment or hepatic encephalopathy </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Gastrointestinal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Abdominal cramping</td> <td>Dicyclomine*</td> <td>10 to 20 mg orally every 6 to 8 hours as needed (maximum 160 mg daily)</td> <td> <ul> <li>IM administration available (lower doses are used) </li> <li>Use with caution and reduce dose in renal or hepatic impairment </li> </ul> </td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Diarrhea</td> <td>Bismuth*</td> <td>~524 mg orally every 30 to 60 minutes as needed (up to 4200 mg daily)</td> <td class=\"divider_bottom\" rowspan=\"2\"> <ul> <li>Monitor for dehydration and maintain fluid levels with oral and/or IV hydration </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Loperamide</td> <td>4 mg orally followed by 2 mg after each loose stool (maximum 16 mg daily)</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Nausea/vomiting</td> <td>Ondansetron*<sup>&#916;</sup></td> <td>4 to 8 mg orally or IV every 12 hours as needed (maximum 16 mg/day)</td> <td> <ul> <li>Monitor for dehydration and maintain fluid levels with oral and/or IV hydration </li> <li>Dose-dependent QT interval prolongation; risk of rare, potentially fatal,&nbsp;ventricular arrhythmia; use with caution (eg, monitor&nbsp;baseline and post-dose ECG) or avoid in patients&nbsp;with features of&nbsp;elevated&nbsp;risk<sup>&#916;</sup> </li> <li>Use caution and reduced dose (50%) in severe hepatic impairment </li> </ul> </td> </tr> <tr> <td>Prochlorperazine</td> <td>5 to 10 mg orally three times daily before meals or every six hours as needed (maximum 40 mg/day)</td> <td> <ul> <li>Monitor for dehydration and maintain fluid levels with oral and/or IV hydration </li> <li>Use with caution in mild to moderate hepatic impairment; avoid in severe hepatic impairment </li> <li>IV and rectal administration available </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Promethazine</td> <td>25 mg orally every 4 to 6 hours as needed (maximum 50 mg/day)</td> <td> <ul> <li>Monitor for dehydration and maintain fluid levels with oral and/or IV hydration </li> <li>Use with caution in mild to moderate hepatic impairment; avoid in severe hepatic impairment </li> <li>IM and rectal administration available (IV use not recommended) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Insomnia, pain, muscle spasm, and restless legs</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Insomnia</td> <td>Trazodone*</td> <td>25 to 100 mg orally at bedtime</td> <td> <ul> <li>May titrate nightly up to 300 mg at bedtime if needed </li> <li>Use with caution in severe hepatic or renal impairment </li> </ul> </td> </tr> <tr> <td>Doxepin</td> <td>6 to 50 mg orally at bedtime</td> <td> <ul> <li>Use with caution and reduce dose in severe hepatic impairment </li> </ul> </td> </tr> <tr> <td>Mirtazapine</td> <td>7.5 to 15 mg orally at bedtime</td> <td> <ul> <li>May need to use lower dose in moderate to severe hepatic or renal impairment </li> </ul> </td> </tr> <tr> <td>Quetiapine</td> <td>50 to 100 mg orally at bedtime</td> <td> <ul> <li>Use lower initial dose (25 mg) in hepatic impairment and adjust based on response </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Zolpidem<sup>&#182;</sup></td> <td>5 to 10 mg orally at bedtime</td> <td> <ul> <li>A dose of 5 mg is usually appropriate for female patients, and those with mild or moderate hepatic impairment </li> <li>Avoid in severe hepatic impairment or hepatic encephalopathy </li> </ul> </td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Muscle aches<sup>&#9674;</sup>, joint pain, headache</td> <td>Ibuprofen*<sup>&#167;</sup></td> <td>400 mg orally every 4 to 6 hours as needed (maximum 2400 mg daily)</td> <td> <ul> <li>Patient should be well hydrated and without significant kidney disease </li> <li>Use with caution in mild to moderate hepatic or renal impairment </li> <li>Avoid all NSAIDs in severe renal or hepatic impairment or cirrhosis </li> </ul> </td> </tr> <tr> <td>Acetaminophen</td> <td>650 to 1000 mg orally every 4 to 6 hours as needed (maximum 4000 mg daily)</td> <td> <ul> <li>Appropriate analgesic for most patients </li> <li>Use reduced dose (ie, 2000 mg daily) or avoid in hepatic impairment or if malnourished </li> </ul> </td> </tr> <tr> <td>Ketorolac<sup>&#167;</sup></td> <td>15 to 30 mg IV or IM every 6 hours as needed (maximum 120 mg daily)</td> <td> <ul> <li>Patient should be well hydrated and without significant kidney disease </li> <li>Limit use to 5 days or less </li> <li>Use with caution and reduce dose (50%) in older adults and patients with mild to moderate renal impairment </li> <li>Use with caution in mild to moderate hepatic impairment </li> <li>Contraindicated in severe renal or hepatic impairment or volume depletion </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Naproxen<sup>&#167;</sup></td> <td>500 mg orally twice daily with meals</td> <td> <ul> <li>Patient should be well hydrated and without significant kidney disease </li> <li>Use with caution in mild to moderate hepatic or renal impairment </li> <li>Avoid all NSAIDs in severe renal or hepatic impairment or cirrhosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Muscle spasm<sup>&#9674;</sup>, restless legs</td> <td>Cyclobenzaprine*</td> <td>5 to 10 mg orally every 8 hours as needed (maximum 30 mg daily)</td> <td> <ul> <li>Use reduced dose in mild hepatic impairment </li> <li>Avoid in moderate to severe haptic impairment </li> </ul> </td> </tr> <tr> <td>Baclofen</td> <td>5 to 10 mg orally every 8 hours as needed (maximum 60 mg daily)</td> <td> <ul> <li>Use reduced dose in renal impairment </li> </ul> </td> </tr> <tr> <td>Diazepam<sup>&#182;</sup></td> <td>5 to 10 mg orally every 6 to 12 hours as needed (maximum 40 mg daily)</td> <td> <ul> <li>Use with caution in hepatic or renal impairment </li> <li>Avoid in severe hepatic impairment or hepatic encephalopathy </li> <li>IM and IV administration available </li> </ul> </td> </tr> <tr> <td>Methocarbamol</td> <td>750 to 1500 mg orally every 8 hours as needed (maximum 6 g daily)</td> <td> <ul> <li>Use with caution in hepatic or renal impairment </li> <li>IM and IV administration available (lower doses are used); avoid parenteral formulation in renal impairment (propylene glycol additive) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>A calm quiet environment with supportive and reassuring staff can be instrumental for helping patients overcome most symptoms of acute opioid withdrawal and decreases the need for pharmacologic interventions.</li>&#xD;&#xA;    <li>Patients who have diarrhea, vomiting, or sweating should be monitored for dehydration and fluid levels maintained with oral and/or intravenous fluids.</li>&#xD;&#xA;    <li>The role of opioid replacement therapies and alpha-2 agonists (eg, clonidine) in management of acute opioid withdrawal and maintenance pharmacotherapy in opioid use disorder is discussed separately; refer to accompanying text.</li>&#xD;&#xA;    <li>This is not a complete list of cautionary information or dose adjustments in organ impairment. For additional information refer to the Lexicomp drug monographs included within UpToDate.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">IV: intravenous; IM: intramuscular; NSAID: nonsteroidal anti-inflammatory drug.<br />* Author's first choice.<br />¶ Use of benzodiazepines and benzodiazepine agonists (eg, zolpidem) is NOT recommended in patients receiving methadone or buprenorphine therapy unless under close medical supervision. Patients who resume heroin (diamorphine) use after a period of abstinence are at high risk of fatally overdosing, particularly if heroin use is resumed in combination with benzodiazepines, alcohol, or other drugs with sedative characteristics (eg, quetiapine). The use of benzodiazepines should be limited to 5 to 10 days in total and tapered. They are not recommended for use in supervised outpatient withdrawal and should be reserved for inpatient settings where frequent clinical monitoring is provided.<br />Δ &nbsp;Risk of QTc prolongation or torsades de pointes is also elevated with advanced age, female sex, heart disease, congenital long QT syndrome, hypokalemia or hypomagnesemia,&nbsp;overly rapid IV administration,&nbsp;and combination of drugs with QTc prolonging effects (eg, methadone). Refer to topic on acquired long QT syndrome.<br /><FONT class=lozenge>◊ </FONT>Warm baths, rehydration, and gentle stretching are also helpful for relieving muscle aches and cramps.<br />§ Safety concerns of NSAID use in older adults and patients with, or at elevated risk for, cardiovascular disease, gastrointestinal bleeding, organ dysfunction, or thrombotic events are addressed separately in UpToDate.</div><div class=\"graphic_reference\">Prepared with data from Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 106793 Version 4.0</div></div></div>"},"106801":{"type":"graphic_figure","displayName":"Endovascular repair of acute type B aortic dissection","title":"Endovascular repair of acute type B aortic dissection","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Endovascular repair of acute type B aortic dissection</div><div class=\"cntnt\"><img style=\"width:529px; height:680px;\" src=\"images/SURG/106801_Endovascular_repair_of_acute_type_B_aortic_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For endovascular repair descending (type B) aortic dissection, the stent-graft is positioned to cover the tear, while avoiding obstructing flow to the left subclavian artery. </div><div id=\"graphicVersion\">Graphic 106801 Version 1.0</div></div></div>"},"106811":{"type":"graphic_picture","displayName":"US transducer position hip examination sagittal oblique plane","title":"US transducer position for hip examination in sagittal oblique plane","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US transducer position for hip examination in sagittal oblique plane</div><div class=\"cntnt\"><img style=\"width:353px; height:710px;\" src=\"images/SM/106811_US_trnsdcr_pst_hip_exm_sgttl_oblq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows proper ultrasound&nbsp;transducer position to begin the evaluation of&nbsp;the hip joint in the sagittal oblique plane.</div><div class=\"graphic_footnotes\">Rectangle: probe position.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106811 Version 2.0</div></div></div>"},"106812":{"type":"graphic_diagnosticimage","displayName":"US hip sagittal oblique view","title":"US hip sagittal oblique view","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US hip sagittal oblique view</div><div class=\"cntnt\"><img style=\"width:715px; height:357px;\" src=\"images/SM/106812_US_hip_sgtl_oblq_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound scan&nbsp;shows the hip joint in the sagittal oblique plane.</div><div class=\"graphic_footnotes\">FH: femoral head; Ac: acetabulum; *: acetabular labrum; arrows: articular cartilage; arrowheads: anterior joint capsule.<br />Left side of image: cranial; right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106812 Version 1.0</div></div></div>"},"106813":{"type":"graphic_picture","displayName":"US transducer position iliopsoas tendon transverse oblique view","title":"US transducer position hip examination iliopsoas tendon transverse oblique view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US transducer position hip examination iliopsoas tendon transverse oblique view</div><div class=\"cntnt\"><img style=\"width:352px; height:710px;\" src=\"images/SM/106813_US_trnsd_ilps_tndn_trnsv_oblq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows proper&nbsp;position of the ultrasound transducer to evaluate the iliopsoas tendon in the transverse oblique plane.</div><div class=\"graphic_footnotes\">Rectangle: probe position.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106813 Version 1.0</div></div></div>"},"106814":{"type":"graphic_diagnosticimage","displayName":"US iliopsoas tendon transverse oblique view","title":"US hip examination iliopsoas tendon in transverse oblique view","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">US hip examination iliopsoas tendon in transverse oblique view</div><div class=\"cntnt\"><img style=\"width:714px; height:341px;\" src=\"images/SM/106814_US_iips_tndn_trnsv_oblq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image&nbsp;shows&nbsp;the iliopsoas tendon in a transverse oblique plane&nbsp;(short-axis view).</div><div class=\"graphic_footnotes\">AIIS: anterior superior iliac spine; IP: iliopectineal eminence; arrows: iliopsoas muscle; arrowheads: iliopsoas tendon; dotted circle: femoral nerve; A: femoral artery.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106814 Version 1.0</div></div></div>"},"106815":{"type":"graphic_diagnosticimage","displayName":"US doppler femoral nerve artery vein transverse oblique view","title":"US doppler femoral nerve artery vein in transverse oblique view","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">US doppler femoral nerve artery vein in transverse oblique view</div><div class=\"cntnt\"><img style=\"width:792px; height:183px;\" src=\"images/SM/106815_US_dpplr_fem_nrv_artry_vn_oblq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The images above&nbsp;are transverse oblique plane ultrasound scans of the femoral nerve, artery, and vein in short-axis. Both&nbsp;grey-scale (left side image)&nbsp;and color Doppler (right side image) are shown. Note the&nbsp;diminished resolution with color Doppler imaging.</div><div class=\"graphic_footnotes\">Left image: greyscale image; right image: color Doppler image; A: femoral artery; V: femoral vein; red: femoral artery; blue: femoral vein; dotted circle: femoral nerve; arrows: iliopsoas tendon; IP: iliopectineal eminence.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106815 Version 1.0</div></div></div>"},"106817":{"type":"graphic_table","displayName":"Dermatome level of visceral innervation","title":"Dermatome level of visceral innervation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dermatome level of visceral innervation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organ</td> <td class=\"subtitle1\">Dermatome</td> </tr> <tr> <td>Upper abdomen</td> <td>T1</td> </tr> <tr> <td>Lower abdomen</td> <td>T6</td> </tr> <tr> <td>Uterus</td> <td>T4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows the upper dermatomal level of neuraxial blockade required for visceral anesthesia. </div><div id=\"graphicVersion\">Graphic 106817 Version 1.0</div></div></div>"},"106822":{"type":"graphic_picture","displayName":"Prone popliteal block ultrasound probe placement","title":"Prone popliteal block ultrasound probe placement","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Prone popliteal block ultrasound probe placement</div><div class=\"cntnt\"><img style=\"width:656px; height:587px;\" src=\"images/ANEST/106822_Prn_ppltl_blck_ultrsnd_prb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the ultrasound-guided posterior approach to popliteal nerve block, the patient is positioned prone, and the probe is placed transverse to the thigh in the popliteal crease. For further details, refer to the UpToDate topic on lower extremity nerve block techniques.</div><div id=\"graphicVersion\">Graphic 106822 Version 1.0</div></div></div>"},"106823":{"type":"graphic_picture","displayName":"Obturator block ultrasound probe placement","title":"Obturator block ultrasound probe placement","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Obturator block ultrasound probe placement</div><div class=\"cntnt\"><img style=\"width:713px; height:473px;\" src=\"images/ANEST/106823_Obtrtr_blck_ultrsnd_prb_plc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided obturator nerve block, the tranducer is placed in the inguinal crease. For further details, refer to the UpToDate topic on lower extremity nerve block techniques.</div><div id=\"graphicVersion\">Graphic 106823 Version 1.0</div></div></div>"},"106824":{"type":"graphic_picture","displayName":"Femoral block ultrasound probe placement","title":"Femoral block ultrasound probe placement","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Femoral block ultrasound probe placement</div><div class=\"cntnt\"><img style=\"width:715px; height:513px;\" src=\"images/ANEST/106824_Fmrl_blck_ultrsnd_prb_plc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided femoral nerve block, the probe is placed in the inguinal crease. For further details, refer to UpToDate topic on lower extremity nerve block techniques.</div><div id=\"graphicVersion\">Graphic 106824 Version 2.0</div></div></div>"},"106826":{"type":"graphic_picture","displayName":"Adductor canal block ultrasound probe placement","title":"Adductor canal block ultrasound probe placement","html":"<div class=\"graphic\"><div style=\"width: 690px\" class=\"figure\"><div class=\"ttl\">Adductor canal block ultrasound probe placement</div><div class=\"cntnt\"><img style=\"width:670px; height:507px;\" src=\"images/ANEST/106826_Abdutr_cnl_blck_ultr_prb_plc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided adductor canal block, the transducer is placed perpendicular to the thigh at the midpoint between the anterior superior iliac spine and the distal end of the femur. For further details, refer to the UpToDate topic on lower extremity nerve block techniques.</div><div id=\"graphicVersion\">Graphic 106826 Version 2.0</div></div></div>"},"106827":{"type":"graphic_picture","displayName":"US transducer position anterior superior iliac spine transverse","title":"US transducer position to view anterior superior iliac spine in transverse plane","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US transducer position to view anterior superior iliac spine in transverse plane</div><div class=\"cntnt\"><img style=\"width:389px; height:783px;\" src=\"images/SM/106827_US_trns_pst_antrr_spr_ilc_trnsvr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photographs shows&nbsp;the proper ultrasound transducer&nbsp;position to image the anterior superior iliac spine, tensor fascia latae, and sartorius muscles in the transverse plane.</div><div class=\"graphic_footnotes\">Rectangle: probe position.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106827 Version 1.0</div></div></div>"},"106829":{"type":"graphic_diagnosticimage","displayName":"US hip ASIS sartorius TFL transverse view","title":"US anterior hip ASIS sartorius TFL in transverse view","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US anterior hip ASIS sartorius TFL in transverse view</div><div class=\"cntnt\"><img style=\"width:715px; height:304px;\" src=\"images/SM/106829_US_hip_ASIS_srtr_TFL_trnsvrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows&nbsp;the anterior superior iliac spine (ASIS) and sartorius and tensor fasciae latae tendons in the transverse plane (short-axis view).</div><div class=\"graphic_footnotes\">Arrows: tensor fasciae latae muscle tendon; arrowheads: sartorius muscle tendon.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106829 Version 1.0</div></div></div>"},"106830":{"type":"graphic_diagnosticimage","displayName":"US hip TFL sartorius rectus femoris transverse view","title":"US hip TFL sartorius and rectus femoris in transverse view","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US hip TFL sartorius and rectus femoris in transverse view</div><div class=\"cntnt\"><img style=\"width:715px; height:263px;\" src=\"images/SM/106830_US_hip_TFL_srtrs_rcts_fmr_trnsvrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the tensor fasciae latae and sartorius muscles in the transverse plane&nbsp;(short-axis view).</div><div class=\"graphic_footnotes\">TFL: tensor fasciae latae; SA: sartorius; RF; rectus femoris.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106830 Version 1.0</div></div></div>"},"106831":{"type":"graphic_figure","displayName":"Branched-chain amino acid breakdown pathway","title":"Branched-chain amino acid breakdown pathway","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Branched-chain amino acid breakdown pathway</div><div class=\"cntnt\"><img style=\"width:518px; height:414px;\" src=\"images/ALLRG/106831_Brnchd_chn_amin_acid_brkdwn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CoA: coenzyme A; BCKD: branched-chain ketoacid dehydrogenase.<br />* Regulatory enzymes: BCKD phosphatase and&nbsp;BCKD kinase.</div><div class=\"graphic_reference\">Courtesy of Olaf A Bodamer, MD, PhD, FAAP, FACMG.</div><div id=\"graphicVersion\">Graphic 106831 Version 1.0</div></div></div>"},"106832":{"type":"graphic_diagnosticimage","displayName":"US hip TFL origin sagittal view","title":"US hip TFL origin in sagittal view","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US hip TFL origin in sagittal view</div><div class=\"cntnt\"><img style=\"width:716px; height:313px;\" src=\"images/SM/106832_US_hip_TFL_orgn_sgttl_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the tensor fascia latae muscle and tendon in the sagittal plane&nbsp;(long-axis view) as it inserts onto the ASIS.</div><div class=\"graphic_footnotes\">TFL: tensor fasciae latae muscle; arrowheads: tensor fasciae latae tendon; ASIS: anterior superior iliac spine; GMI: gluteus minimus muscle.<br />Right side of image: cranial; left of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106832 Version 1.0</div></div></div>"},"106834":{"type":"graphic_diagnosticimage","displayName":"US hip sartorius origin sagittal view","title":"US hip sartorius origin in sagittal view","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US hip sartorius origin in sagittal view</div><div class=\"cntnt\"><img style=\"width:715px; height:281px;\" src=\"images/SM/106834_US_hip_srtrs_orgn_sgttl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the sartorius muscle and tendon in the sagittal plane&nbsp;(long-axis view) as it inserts onto the ASIS.</div><div class=\"graphic_footnotes\">SA: sartorius muscle; arrows: sartorius tendon; ASIS: anterior superior iliac spine; I: iliopsoas muscle.<br />Left of image: cranial; right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106834 Version 1.0</div></div></div>"},"106835":{"type":"graphic_diagnosticimage","displayName":"US hip lateral cutaneous nerve transverse view","title":"US hip lateral cutaneous nerve in transverse view","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US hip lateral cutaneous nerve in transverse view</div><div class=\"cntnt\"><img style=\"width:716px; height:345px;\" src=\"images/SM/106835_US_hip_ltrl_ctn_nrv_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the lateral cutaneous nerve of the thigh in the transverse plane&nbsp;(short-axis view).</div><div class=\"graphic_footnotes\">Arrows: lateral cutaneous nerve of the thigh; SA: sartorius muscle; TFL: tensor fasciae latae muscle; RF: rectus femoris muscle.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106835 Version 1.0</div></div></div>"},"106837":{"type":"graphic_figure","displayName":"Ligaments of pelvis and hip joint","title":"Ligaments of pelvis and hip joint","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Ligaments of pelvis and hip joint</div><div class=\"cntnt\"><img style=\"width:620px; height:648px;\" src=\"images/SM/106837_Ligaments_pelvis_hip_joint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Weight transfer from the vertebral column to the pelvic girdle is a function of the sacro-iliac ligaments. Weight transfer at the hip joint is accomplished primarily by the disposition of the bones, with the ligaments limiting the range of movement and adding stability.<br />(B) Articulating surfaces of hip joint and sites of attachment and tendinous relationships of iliofemoral ligaments and joint capsule.<br />(C) Iliofemoral ligament.<br />(D) The ischiofemoral ligament. Because the joint capsule does not attach to the posterior aspect of the femur, the synovial membrane protrudes from the joint capsule, forming the obturator externus bursa to facilitate movement of the tendon of the obturator externus (show in part C) over the bone.</div><div class=\"graphic_footnotes\">* Thin area of joint capsule (floor of iliopectineal bursa) has been removed here.</div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 106837 Version 1.0</div></div></div>"},"106838":{"type":"graphic_picture","displayName":"Contraceptive sponge","title":"Contraceptive sponge","html":"<div class=\"graphic\"><div style=\"width: 796px\" class=\"figure\"><div class=\"ttl\">Contraceptive sponge</div><div class=\"cntnt\"><img style=\"width:776px; height:313px;\" src=\"images/OBGYN/106838_Cntrcptv_spng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images of Today brand contraceptive sponge.<br />(A) Packaging containing contraceptive sponge.<br />(B) Contraceptive sponge: dimpled surface that faces toward cervix.<br />(C) Contraceptive sponge: back surface with removal loop.</div><div class=\"graphic_reference\">Reproduced with permission from Bedsider.org. Copyright &copy; 2016 Bedsider. All rights reserved.</div><div id=\"graphicVersion\">Graphic 106838 Version 1.0</div></div></div>"},"106839":{"type":"graphic_diagnosticimage","displayName":"US hip proximal rectus femoris transverse view","title":"US hip proximal rectus femoris in transverse view","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US hip proximal rectus femoris in transverse view</div><div class=\"cntnt\"><img style=\"width:716px; height:329px;\" src=\"images/SM/106839_US_hp_prxml_rct_fmr_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the proximal rectus femoris muscle in the transverse plane&nbsp;(short-axis view).</div><div class=\"graphic_footnotes\">RF: rectus femoris muscle; SA: sartorius muscle.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106839 Version 1.0</div></div></div>"},"106840":{"type":"graphic_diagnosticimage","displayName":"US hip rectus femoris direct indirect tendons transverse view","title":"US hip rectus femoris direct and indirect tendons in transverse view","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">US hip rectus femoris direct and indirect tendons in transverse view</div><div class=\"cntnt\"><img style=\"width:712px; height:450px;\" src=\"images/SM/106840_US_hp_rct_fmr_drct_indrct_tndn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the direct and indirect heads of the rectus femoris tendon in the transverse plane&nbsp;(short-axis view).</div><div class=\"graphic_footnotes\">Arrows: direct head of rectus femoris tendon; *: indirect head of rectus femoris tendon; arrowheads: posterior acoustic shadowing of indirect head of rectus femoris tendon; SA: sartorius muscle; TFL: tensor fasciae latae muscle.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106840 Version 1.0</div></div></div>"},"106842":{"type":"graphic_diagnosticimage","displayName":"US hip rectus femoris tendon direct head transverse view","title":"US hip rectus femoris tendon direct head in transverse view","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">US hip rectus femoris tendon direct head in transverse view</div><div class=\"cntnt\"><img style=\"width:713px; height:406px;\" src=\"images/SM/106842_US_hp_rct_fmr_tndn_drct_hd_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the direct head of the rectus femoris tendon in the transverse plane&nbsp;(short-axis view) at its origin on the AIIS.</div><div class=\"graphic_footnotes\">Arrows: direct head of rectus femoris tendon; AIIS: anterior inferior iliac spine; SA: sartorius muscle.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106842 Version 1.0</div></div></div>"},"106843":{"type":"graphic_diagnosticimage","displayName":"US hip rectus femoris direct tendon sagittal view","title":"US hip rectus femoris direct tendon in sagittal view","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US hip rectus femoris direct tendon in sagittal view</div><div class=\"cntnt\"><img style=\"width:716px; height:377px;\" src=\"images/SM/106843_US_hip_rct_fmr_drct_tndn_sgttl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the direct head of the rectus femoris tendon in the sagittal plane&nbsp;(long-axis view) at its origin on the anterior inferior iliac spine.</div><div class=\"graphic_footnotes\">Arrows: direct head of rectus femoris tendon; IC: iliocapsularis muscle; SA: sartorius muscle; AIIS: anterior inferior iliac spine.<br />Left of image: cranial; right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106843 Version 1.0</div></div></div>"},"106844":{"type":"graphic_diagnosticimage","displayName":"US hip rectus femoris indirect tendon refraction shadow coronal","title":"US hip rectus femoris indirect tendon refraction shadow in coronal view","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US hip rectus femoris indirect tendon refraction shadow in coronal view</div><div class=\"cntnt\"><img style=\"width:716px; height:408px;\" src=\"images/SM/106844_US_hip_rct_fmr_indr_tndn_rfrct_crn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan, taken in the coronal plane,&nbsp;shows a&nbsp;refraction shadow from the indirect head of the rectus femoris tendon (arrows).</div><div class=\"graphic_footnotes\">Left of image: cranial; right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106844 Version 1.0</div></div></div>"},"106845":{"type":"graphic_diagnosticimage","displayName":"US hip rectus femoris indirect tendon sagittal view","title":"US hip rectus femoris indirect tendon in sagittal view","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US hip rectus femoris indirect tendon in sagittal view</div><div class=\"cntnt\"><img style=\"width:715px; height:425px;\" src=\"images/SM/106845_US_hip_rct_fmr_indrct_tndn_sgttl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the indirect head of the rectus femoris tendon&nbsp;(arrows)&nbsp;in the coronal oblique plane&nbsp;(long-axis view).</div><div class=\"graphic_footnotes\">AC: acetabulum.<br />Left of image: cranial; right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106845 Version 1.0</div></div></div>"},"106846":{"type":"graphic_movie","displayName":"US hip snapping iliopsoas tendon","title":"US hip snapping iliopsoas tendon","html":"<div class=\"graphic normal\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">US hip snapping iliopsoas tendon</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/106846_UShipsnapiliopsoasvid.mp4\" style=\"width:560px;height:416px\"></div><img style=\"width:468px; height:350px;\" src=\"images/SM/106846_UShipsnapiliopsoasimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows the abrupt movement of the iliopsoas tendon, which gives the patient the sensation of a \"snapping hip.\"</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106846 Version 1.0</div></div></div>"},"106848":{"type":"graphic_figure","displayName":"Standard alcoholic drink PI","title":"What is a standard drink?","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">What is a standard drink?</div><div class=\"cntnt\"><img style=\"width:604px; height:644px;\" src=\"images/PI/106848_Standard_alcoholic_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">oz. = ounces.<br />* It can be difficult to estimate the number of standard drinks in a single mixed drink made with hard liquor. Depending on factors such as the type of spirits and the recipe, a mixed drink can contain from one to three or more standard drinks.</div><div class=\"graphic_reference\">Reproduced with content from: National Institutes on Alcohol Abuse and Alcoholism. Rethinking Drinking: Alcohol and your health. Available at: <a href=\"http://rethinkingdrinking.niaaa.nih.gov/\" target=\"_blank\">http://rethinkingdrinking.niaaa.nih.gov</a>.</div><div id=\"graphicVersion\">Graphic 106848 Version 1.0</div></div></div>"},"106849":{"type":"graphic_table","displayName":"Clinical relevance of RBC antigens","title":"Clinical importance of blood group antigens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical importance of blood group antigens</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Blood group system</td> <td class=\"subtitle1\">Commonly recognized antigens</td> <td class=\"subtitle1\">Function</td> <td class=\"subtitle1\">Tissue distribution</td> <td class=\"subtitle1\">Clinical importance of antigen</td> <td class=\"subtitle1\">Clinical importance of antibodies</td> </tr> <tr class=\"divider_bottom\"> <td>ABO</td> <td>A, B, H</td> <td>&nbsp;</td> <td>RBCs, platelets, endothelial and epithelial tissues</td> <td>Matched for tissue transplantation</td> <td>HTR</td> </tr> <tr class=\"divider_bottom\"> <td>Rh</td> <td>D, C, c, E, e</td> <td>&nbsp;</td> <td>RBCs, platelets</td> <td>&nbsp;</td> <td>HTR, HDFN</td> </tr> <tr class=\"divider_bottom\"> <td>Glob</td> <td>P, LKE</td> <td>&nbsp;</td> <td>RBCs, epithelial and non-hematopoietic tissues</td> <td>Receptor for Shiga toxins, <em>E. coli</em>, <em>S. Suis</em> (brucellosis), parvovirus B19</td> <td>Paroxysmal cold hemoglobinuria resulting from autoantibodies to P</td> </tr> <tr class=\"divider_bottom\"> <td>I</td> <td>I, I</td> <td>&nbsp;</td> <td>All cell membranes</td> <td>&nbsp;</td> <td>Autoimmune hemolytic anemia following infectious illness</td> </tr> <tr class=\"divider_bottom\"> <td>MNSs</td> <td>M or N, S or s</td> <td>Chaperonin</td> <td>RBCs</td> <td>Receptor for malaria species <em>P. falciparum</em></td> <td>HTR, HDFN</td> </tr> <tr class=\"divider_bottom\"> <td>Kell</td> <td>K (KEL1), k (KEL2)</td> <td>&nbsp;</td> <td>RBCs</td> <td>&nbsp;</td> <td>HTR, HDFN</td> </tr> <tr class=\"divider_bottom\"> <td>Duffy</td> <td>FY1 (Fy<sup>a</sup>), FY2 (Fy<sup>b</sup>)</td> <td>Chemokine receptor</td> <td>RBCs, endothelial and some epithelial cells (lung, kidney), Purkinje cells of cerebellum</td> <td>Receptor for certain malaria species (<em>Plasmodium vivax</em>, <em>P. knowlesi</em>)</td> <td>HTR, HDFN</td> </tr> <tr class=\"divider_bottom\"> <td>Kidd</td> <td>JK1 (Jk<sup>a</sup>), JK2 (Jk<sup>b</sup>)</td> <td>Urea transporter</td> <td>RBCs, renal medulla</td> <td>&nbsp;</td> <td>HTR, HDFN (rare)</td> </tr> <tr class=\"divider_bottom\"> <td>Lutheran</td> <td>LU1 (LU<sup>a</sup>), LU2 (LU<sup>b</sup>), LU6/LU9, LU8/LU14</td> <td>&nbsp;</td> <td>RBCs, endothelium, basal layer of epithelium</td> <td>Possible role in RBC adhesion in sickle cell disease</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content on blood group antigens and antibodies for further information.</div><div class=\"graphic_footnotes\">RBC: red blood cell; HTR: hemolytic transfusion reaction; HDFN: hemolytic disease of the fetus and newborn.</div><div class=\"graphic_reference\">Adapted from:&nbsp;<br /><OL>&#xD;&#xA;<LI>Daniels G, Reid ME. Blood groups: the past 50 years. Transfusion 2010; 50:281. </LI>&#xD;&#xA;<LI>Denomme GA. The structure and function of the molecules that carry human red blood cell and platelet antigens. Transfus Med Rev 2004; 18:203. </LI>&#xD;&#xA;<LI>Flegel WA. Pathogenesis and mechanisms of antibody-mediated hemolysis. Transfusion 2015; 55 Suppl 2:S47.</LI></OL></div><div id=\"graphicVersion\">Graphic 106849 Version 1.0</div></div></div>"},"106852":{"type":"graphic_table","displayName":"US ABO and Rh(D) haplotypes","title":"ABO and Rh(D) haplotype frequencies in the US population","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ABO and Rh(D) haplotype frequencies in the US population</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">ABO and Rh(D) type</td> <td class=\"subtitle1\">Caucasian Americans</td> <td class=\"subtitle1\">African Americans</td> <td class=\"subtitle1\">Hispanic Americans</td> <td class=\"subtitle1\">Asian Americans</td> </tr> <tr class=\"highlight_green_text\"> <td class=\"subtitle2_left\">O</td> <td class=\"subtitle2_left\">45%</td> <td class=\"subtitle2_left\">51%</td> <td class=\"subtitle2_left\">57%</td> <td class=\"subtitle2_left\">40%</td> </tr> <tr> <td class=\"indent1\">O positive</td> <td> <ul class=\"decimal_heading\"> <li>37% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>47% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>53% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>39% </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">O negative</td> <td> <ul class=\"decimal_heading\"> <li>8% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>4% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>4% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>1% </li> </ul> </td> </tr> <tr class=\"highlight_green_text\"> <td class=\"subtitle2_left\">A</td> <td class=\"subtitle2_left\">40%</td> <td class=\"subtitle2_left\">26%</td> <td class=\"subtitle2_left\">31%</td> <td class=\"subtitle2_left\">28%</td> </tr> <tr> <td class=\"indent1\">A positive</td> <td> <ul class=\"decimal_heading\"> <li>33% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>24% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>29% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>27% </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A negative</td> <td> <ul class=\"decimal_heading\"> <li>7% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>2% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>2% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>0.5% </li> </ul> </td> </tr> <tr class=\"highlight_green_text\"> <td class=\"subtitle2_left\">B</td> <td class=\"subtitle2_left\">11%</td> <td class=\"subtitle2_left\">19%</td> <td class=\"subtitle2_left\">10%</td> <td class=\"subtitle2_left\">25%</td> </tr> <tr> <td class=\"indent1\">B positive</td> <td> <ul class=\"decimal_heading\"> <li>9% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>18% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>9% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>25% </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">B negative</td> <td> <ul class=\"decimal_heading\"> <li>2% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>1% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>1% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>0.4% </li> </ul> </td> </tr> <tr class=\"highlight_green_text\"> <td class=\"subtitle2_left\">AB</td> <td class=\"subtitle2_left\">4%</td> <td class=\"subtitle2_left\">4%</td> <td class=\"subtitle2_left\">2%</td> <td class=\"subtitle2_left\">7%</td> </tr> <tr> <td class=\"indent1\">AB positive</td> <td> <ul class=\"decimal_heading\"> <li>3% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>4% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>2% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>7% </li> </ul> </td> </tr> <tr> <td class=\"indent1\">AB negative</td> <td> <ul class=\"decimal_heading\"> <li>1% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>0.3% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>0.2% </li> </ul> </td> <td> <ul class=\"decimal_heading\"> <li>0.1% </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These percentages are approximate and apply only to a United States population. Refer to UpToDate information on pretransfusion testing and red blood cell antigens and antibodies for further information.</div><div class=\"graphic_reference\">Data from the American Red Cross, <a href=\"http://www.redcrossblood.org/learn-about-blood/blood-types\" target=\"_blank\">http://www.redcrossblood.org/learn-about-blood/blood-types</a>.</div><div id=\"graphicVersion\">Graphic 106852 Version 1.0</div></div></div>"},"106869":{"type":"graphic_picture","displayName":"US transducer position for lateral hip examination","title":"US transducer position for examination of lateral hip region","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US transducer position for examination of lateral hip region</div><div class=\"cntnt\"><img style=\"width:432px; height:711px;\" src=\"images/SM/106869_US_trnsdcr_pst_ltrl_hp_exm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photographs shows&nbsp;how the&nbsp;US transducer&nbsp;is positioned&nbsp;to&nbsp;examine the lateral hip in the transverse plane.</div><div class=\"graphic_footnotes\">Rectangle: ultrasound transducer; A: initial position; B: position to evaluate greater trochanter region; arrow: direction transducer is translated to visualize greater trochanter.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106869 Version 1.0</div></div></div>"},"106870":{"type":"graphic_diagnosticimage","displayName":"US hip gluteal tendon insertion greater trochanter transverse","title":"US lateral hip gluteal tendon insertion on greater trochanter in transverse view","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US lateral hip gluteal tendon insertion on greater trochanter in transverse view</div><div class=\"cntnt\"><img style=\"width:715px; height:275px;\" src=\"images/SM/106870_US_hp_gltl_tndn_insrt_grt_trchn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound&nbsp;image shows the&nbsp;gluteal tendons&nbsp;at their insertion onto the&nbsp;greater trochanter in the transverse plane (short-axis view).</div><div class=\"graphic_footnotes\">*: apex of greater trochanter; 1: anterior facet; 2: lateral facet; arrows: gluteus minimus tendon; arrowheads: gluteus medius tendon; +: iliotibial band; open arrowheads: musculotendinous transition of gluteus maximus muscle; a: gluteus medius muscle.<br />Left side of image: posterior; right side of image: anterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106870 Version 1.0</div></div></div>"},"106871":{"type":"graphic_diagnosticimage","displayName":"US hip gluteus minimus tendon insertion transverse view","title":"US hip gluteus minimus tendon insertion in transverse view","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US hip gluteus minimus tendon insertion in transverse view</div><div class=\"cntnt\"><img style=\"width:716px; height:329px;\" src=\"images/SM/106871_US_hp_glt_mnm_tndn_insrt_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the&nbsp;gluteus minimus tendon insertion onto the greater trochanter&nbsp;in&nbsp;the transverse oblique plane&nbsp;(short-axis view).</div><div class=\"graphic_footnotes\">Arrows: gluteus minimus tendon; arrowheads: iliotibial band; A: anterior facet of greater trochanter; B: lateral facet of greater trochanter; C: gluteus medius muscle.<br />Left side of image: posterior; right side of image: anterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106871 Version 1.0</div></div></div>"},"106872":{"type":"graphic_diagnosticimage","displayName":"US hip gluteus minimus insertion sagittal view","title":"US hip gluteus minimus tendon insertion in sagittal view","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US hip gluteus minimus tendon insertion in sagittal view</div><div class=\"cntnt\"><img style=\"width:715px; height:401px;\" src=\"images/SM/106872_US_hp_glt_mnm_insrt_sgttl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound&nbsp;image shows the&nbsp;gluteus minimus tendon insertion onto the greater trochanter in the sagittal oblique plane&nbsp;(long-axis view).</div><div class=\"graphic_footnotes\">Arrows: gluteus minimus tendon; *: gluteus minimus muscle; large arrowheads: iliotibial band; A: anterior facet of greater trochanter; B: gluteus medius muscle. Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106872 Version 1.0</div></div></div>"},"106873":{"type":"graphic_diagnosticimage","displayName":"US hip gluteus medius tendon insertion transverse view","title":"US hip gluteus medius tendon insertion in transverse view","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US hip gluteus medius tendon insertion in transverse view</div><div class=\"cntnt\"><img style=\"width:715px; height:334px;\" src=\"images/SM/106873_US_hp_glts_md_tndn_insrt_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound&nbsp;image shows the&nbsp;gluteus medius tendon insertion onto the greater trochanter&nbsp;in the transverse plane&nbsp;(short-axis).</div><div class=\"graphic_footnotes\">Arrows: gluteus medius tendon; arrowheads: gluteus minimus tendon; +: iliotibial band; *: musculotendinous portion of gluteus maximus muscle; A: anterior facet of greater trochanter; B: lateral facet of greater trochanter; C: superior posterior facet of greater trochanter; D: gluteus maximus muscle.<br />Left side of image: posterior; right side of picture: anterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106873 Version 1.0</div></div></div>"},"106874":{"type":"graphic_diagnosticimage","displayName":"US hip gluteus medius tendon insertion sagittal view","title":"US hip gluteus medius tendon insertion in sagittal view","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US hip gluteus medius tendon insertion in sagittal view</div><div class=\"cntnt\"><img style=\"width:716px; height:269px;\" src=\"images/SM/106874_US_hp_glt_md_tndn_insrt_sgttl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the&nbsp;gluteus medius tendon insertion onto the greater trochanter&nbsp;in the sagittal plane&nbsp;(long-axis view).</div><div class=\"graphic_footnotes\">Arrows: gluteus medius tendon; arrowheads: iliotibial band; A: lateral facet of greater trochanter; B: gluteus medius muscle.<br />Left side of image: cranial; right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106874 Version 1.0</div></div></div>"},"106875":{"type":"graphic_diagnosticimage","displayName":"US hip gluteus medius insertion sup post facet transverse","title":"US hip gluteus medius insertion onto superior posterior facet in transverse view","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US hip gluteus medius insertion onto superior posterior facet in transverse view</div><div class=\"cntnt\"><img style=\"width:715px; height:244px;\" src=\"images/SM/106875_US_hp_glt_md_insrt_sp_pst_fct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the&nbsp;gluteus medius tendon insertion onto the greater trochanter in the transverse plane&nbsp;(short-axis view).</div><div class=\"graphic_footnotes\">Arrows: subgluteus maximus bursa (trochanteric bursa); arrowheads: gluteus medius tendon; A: superior posterior facet of greater trochanter; B: musculotendinous transition of gluteus maximus muscle; C: gluteus maximus muscle.<br />Left side of image: posterior; right side of image: anterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106875 Version 1.0</div></div></div>"},"106876":{"type":"graphic_movie","displayName":"US snapping hip involving iliotibial band","title":"US snapping hip involving iliotibial band","html":"<div class=\"graphic normal\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">US snapping hip involving iliotibial band</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/106876_USsnaphipiliotibialvid.mp4\" style=\"width:576px;height:448px\"></div><img style=\"width:596px; height:438px;\" src=\"images/SM/106876_USsnaphipiliotibialimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video shows abrupt movement of the iliotibial band over the greater trochanter, which the patient may describe as a \"snapping hip.\"</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106876 Version 1.0</div></div></div>"},"106883":{"type":"graphic_table","displayName":"Causes of unintentional weight loss","title":"Causes of unintentional weight loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of unintentional weight loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major causes of unintentional weight loss</td> </tr> <tr> <td class=\"indent1\">Malignancy (eg, gastrointestinal, lung, lymphoma, renal, and prostate cancers)</td> </tr> <tr> <td class=\"indent1\">Nonmalignant gastrointestinal diseases (eg, peptic ulcer disease, celiac disease, inflammatory bowel disease)</td> </tr> <tr> <td class=\"indent1\">Psychiatric disorders (particularly depression), also eating disorders, food-related delusional manifestations of other psychiatric disorders</td> </tr> <tr> <td class=\"indent1\">Endocrinopathies (eg, hyperthyroidism, diabetes, adrenal insufficiency)</td> </tr> <tr> <td class=\"indent1\">Infectious diseases (eg, HIV, viral hepatitis, tuberculosis, chronic fungal or bacterial disease, chronic helminth infection) </td> </tr> <tr> <td class=\"indent1\">Advanced chronic disease (eg, cardiac cachexia from heart failure, pulmonary cachexia, renal failure)</td> </tr> <tr> <td class=\"indent1\">Neurologic diseases (eg, stroke, dementia, Parkinson disease, amyotrophic lateral sclerosis)</td> </tr> <tr> <td class=\"indent1\">Medications/substances</td> </tr> <tr> <td class=\"indent1\">Rheumatologic diseases (eg, severe rheumatoid arthritis, giant cell vasculitis)</td> </tr> <tr> <td class=\"indent1\">Chronic vigorous exercise (eg, distance running, ballet dancing, gymnastics) </td> </tr> <tr> <td class=\"subtitle1_single\">Medication/substances associated with weight loss</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> <tr> <td class=\"indent1\">Amphetamines</td> </tr> <tr> <td class=\"indent1\">Drug withdrawal syndromes (withdrawal after chronic high-dose psychotropic medications or cannabis)</td> </tr> <tr> <td class=\"indent1\">Tobacco</td> </tr> <tr> <td class=\"indent1\">Adverse effects of prescription drugs (eg, anticonvulsants diabetes medications, thyroid medication)*</td> </tr> <tr> <td class=\"indent1\">Herbal and other nonprescription drugs (5-hydroxytryptophan, aloe, caffeine, cascara, chitosan, chromium, dandelion, ephedra, garcinia, glucomannan, guarana, guar gum, herbal diuretics, nicotine, pyruvate, St. John's wort)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.<br />* Refer to the UpToDate topic on the approach to the patient with unintentional weight loss.</div><div id=\"graphicVersion\">Graphic 106883 Version 2.0</div></div></div>"},"106885":{"type":"graphic_figure","displayName":"Hemodynamic response to aortic crossclamping","title":"Hemodynamic response to aortic crossclamping","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemodynamic response to aortic crossclamping</div><div class=\"cntnt\"><img style=\"width:446px; height:418px;\" src=\"images/ANEST/106885_Hmdnmc_rspns_artc_crssclmpn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Systemic hemodynamic response to aortic crossclamping. Preload does not necessarily increase. If during infrarenal aortic crossclamping blood volume shifts into the splanchnic vasculature, preload does not increase.</div><div class=\"graphic_footnotes\">AoX: aortic crossclamping; Ao: aortic; R art: arterial resistance; CO: cardiac output; &uarr;: increase; &darr;: decrease.<br />* Different patterns are possible.</div><div class=\"graphic_reference\">Reproduced from: Gelman S. The pathophysiology of aortic cross-clamping and unclamping. Anesthesiology 1995; 82:1026. Copyright &copy; 1995 American Society of Anesthesiologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 106885 Version 1.0</div></div></div>"},"106886":{"type":"graphic_figure","displayName":"Blood volume redistribution with aortic crossclamping","title":"Blood volume redistribution with aortic crossclamping","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Blood volume redistribution with aortic crossclamping</div><div class=\"cntnt\"><img style=\"width:524px; height:528px;\" src=\"images/ANEST/106886_Bld_vlm_rdstrbtn_artc_crss.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood volume redistribution during aortic crossclamping (AoX). This schedule depicts the reason for the decrease in venous capacity, which results in blood volume redistribution from the vasculature distal-to-aortic occlusion to the vasculature proximal-to-aortic occlusion. If the aorta is occluded above the splanchnic system, the blood volume travels to the heart, increasing preload and blood volume in all organs and tissues proximal to the clamp. However, if the aorta is occluded below the splanchnic system, blood volume may shift into the splanchnic system or into the vasculature of other tissues proximal to the clamp. The distribution of this blood volume between the splanchnic and nonsplanchnic vasculature determines changes in preload.</div><div class=\"graphic_footnotes\">&uarr;: increase; &darr;: decrease.</div><div class=\"graphic_reference\">Reproduced from: Gelman S. The pathophysiology of aortic cross-clamping and unclamping. Anesthesiology 1995; 82:1026. Copyright &copy; 1995 American Society of Anesthesiologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 106886 Version 1.0</div></div></div>"},"106887":{"type":"graphic_figure","displayName":"Hemodynamic response to aortic unclamping","title":"Hemodynamic response to aortic unclamping","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemodynamic response to aortic unclamping</div><div class=\"cntnt\"><img style=\"width:398px; height:620px;\" src=\"images/ANEST/106887_Hmdynmc_rspns_artc_unclmpng.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Systemic hemodynamic response to aortic unclamping. Preload does not necessarily increase.</div><div class=\"graphic_footnotes\">AoX: aortic crossclamping; Cven: venous capacitance; R art: arterial resistance; PVR: pulmonary vascular resistance; &uarr;: increase; &darr;: decrease.</div><div class=\"graphic_reference\">Reproduced from: Gelman S. The pathophysiology of aortic cross-clamping and unclamping. Anesthesiology 1995; 82:1026. Copyright &copy; 1995 American Society of Anesthesiologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 106887 Version 1.0</div></div></div>"},"106889":{"type":"graphic_table","displayName":"Contraindications to lung transplantation","title":"Contraindications to lung transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to lung transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Absolute contraindications to lung transplantation</td> </tr> <tr> <td class=\"indent1\">Uncontrolled or untreatable pulmonary or extrapulmonary infection</td> </tr> <tr> <td class=\"indent1\">Active <em>Mycobacterium tuberculosis</em> infection</td> </tr> <tr> <td class=\"indent1\">Malignancy in the last two years</td> </tr> <tr> <td class=\"indent1\">Significant dysfunction of other vital organs (eg, heart, liver, kidney, brain)</td> </tr> <tr> <td class=\"indent1\">Significant coronary heart disease not amenable to revascularization</td> </tr> <tr> <td class=\"indent1\">Uncorrectable bleeding diathesis</td> </tr> <tr> <td class=\"indent1\">Significant chest wall/spinal deformity expected to cause severe restriction after transplantation</td> </tr> <tr> <td class=\"indent1\">Class II or III obesity: body mass index (BMI) &#8805;35 kg/m<sup>2</sup></td> </tr> <tr> <td class=\"indent1\">Active tobacco smoking</td> </tr> <tr> <td class=\"indent1\">Drug or alcohol dependency</td> </tr> <tr> <td class=\"indent1\">Unresolved psychosocial problems or noncompliance with medical therapy</td> </tr> <tr> <td class=\"subtitle1_single\">Relative contraindications</td> </tr> <tr> <td class=\"indent1\">Age &#62;65 years in association with low physiologic reserve or other relative contraindications</td> </tr> <tr> <td class=\"indent1\">Class I obesity: BMI 30 to 34.9 kg/m<sup>2</sup></td> </tr> <tr> <td class=\"indent1\">Severe or progressive malnutrition</td> </tr> <tr> <td class=\"indent1\">Severe, symptomatic osteoporosis</td> </tr> <tr> <td class=\"indent1\">Extensive prior thoracic surgery with lung resection</td> </tr> <tr> <td class=\"indent1\">Colonization or infection with highly resistant or highly virulent bacteria, fungi, and certain strains of mycobacteria</td> </tr> <tr> <td class=\"indent1\">HIV infection</td> </tr> <tr> <td class=\"indent1\">Ongoing hepatitis B or C viral infection</td> </tr> <tr> <td class=\"indent1\">Absence of a consistent or reliable social support system</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 106889 Version 1.0</div></div></div>"},"106903":{"type":"graphic_figure","displayName":"RBC blood group antigens diagram","title":"Major types of RBC blood group antigens and their relationship to the RBC membrane","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Major&nbsp;types of RBC blood group antigens and their relationship to the RBC membrane</div><div class=\"cntnt\"><img style=\"width:518px; height:680px;\" src=\"images/HEME/106903_RBC_antigens_diagram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The three major types of RBC blood group antigens are illustrated, showing their&nbsp;structure and interaction with the plasma membrane. Blue&nbsp;denotes protein; green, sugars; and yellow, GPI. The dark blue protein covalently linked to Kell is the XK protein, required for Kell expression. Refer to UpToDate content on RBC antigens for further information and clinical relevance. </div><div class=\"graphic_footnotes\">N: protein amino terminus; C: protein carboxyl terminus; GPI: glycophosphatidylinositol; RBC: red blood cell. </div><div class=\"graphic_reference\">Modified from: The Blood Group Antigen FactsBook. Reid ME, Lomas-Francis C (Eds), Academic Press Harcourt Brace &amp; Co, 1997.</div><div id=\"graphicVersion\">Graphic 106903 Version 2.0</div></div></div>"},"106917":{"type":"graphic_table","displayName":"Example of epinephrine infusion (1 microgram/mL) - Adult","title":"Example of epinephrine infusion (1 microgram/mL) - Adult","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of epinephrine infusion (1 microgram/mL) - Adult</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Example of preparation of epinephrine infusion for refractory symptoms of anaphylaxis (adult patient) for emergency/critical care units</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"3\"> <p>Final concentration: Epinephrine 1 mcg/mL</p> Add 1 mg (1000 mcg) of epinephrine to 1 liter bag of 0.9% normal saline (NS)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Preparation</td> </tr> <tr> <td colspan=\"3\"> <ol> <li><strong>CHECK</strong> vial strength. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"> <ol start=\"2\"> <li>To prepare epinephrine infusion for a final concentration of 1 mcg/mL, dilute <strong>10 mL</strong> of <strong>0.1 mg/mL</strong> epinephrine (may also be labeled 1:10,000) in 1 liter bag of 0.9% NS <strong>OR 1 mL</strong> of <strong>1 mg/mL</strong> epinephrine (may also be labeled 1:1000) in 1 liter bag of 0.9% NS.* </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\"> <p>&nbsp;Administration</p> </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"> <ul> <li>Start the epinephrine infusion at <strong>0.1 mcg/kg/minute</strong>&nbsp;using a programmable infusion pump while continuously monitoring the patient's cardiac rhythm and blood pressure (ie, approximately 6 to 10 mcg/minute in most adults). </li> <li> <p>Using a body weight of 70 kg as an example, you can determine the infusion rate to deliver a dose of 0.1 mcg/kg/minute from a 1 mcg/mL bag as follows:&nbsp;</p> <p>1. Multiply 0.1 mcg/kg/minute dose by 70 kg body weight to determine dose in mcg/minute (= 7 mcg/minute).&nbsp;<br /> 2. Use this table to convert<span style=\"color: #ff0000;\">&nbsp;</span>7 mcg/minute to infusion rate&nbsp;of<span style=\"color: #ff0000;\">&nbsp;</span>7&nbsp;mL/minute (= 420 mL/hour).</p> </li> <li> <p>Every two to three minutes, increase the infusion rate by approximately one-half of the starting rate until the blood pressure and perfusion improve. For more detail, refer to&nbsp;the UpToDate topic on emergency treatment of anaphylaxis.</p> </li> <li> <p>In morbidly obese adults, we suggest initiating the infusion using a standard, ie, non-weight-based dose (eg, up to 10 mcg/minute initially) and titrating to effect.</p> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2\">Adult infusion dose</td> <td class=\"subtitle2\" colspan=\"2\">Administration rate for infusion pump to deliver adult dose shown</td> </tr> <tr> <td class=\"subtitle3\">mcg per minute</td> <td class=\"subtitle3\">mL per minute</td> <td class=\"subtitle3\">mL per hour</td> </tr> <tr class=\"centered\"> <td>1</td> <td>1</td> <td>60</td> </tr> <tr class=\"highlight_blue_text centered\"> <td>2</td> <td>2</td> <td>120</td> </tr> <tr class=\"centered\"> <td>3</td> <td>3</td> <td>180</td> </tr> <tr class=\"highlight_blue_text centered\"> <td>4</td> <td>4</td> <td>240</td> </tr> <tr class=\"centered\"> <td>5</td> <td>5</td> <td>300</td> </tr> <tr class=\"highlight_blue_text centered\"> <td>6</td> <td>6</td> <td>360</td> </tr> <tr class=\"centered\"> <td>7</td> <td>7</td> <td>420</td> </tr> <tr class=\"highlight_blue_text centered\"> <td>8</td> <td>8</td> <td>480</td> </tr> <tr class=\"centered\"> <td>9</td> <td>9</td> <td>540</td> </tr> <tr class=\"highlight_blue_text centered\"> <td>10</td> <td>10</td> <td>600</td> </tr> <tr class=\"centered\"> <td>11</td> <td>11</td> <td>660</td> </tr> <tr class=\"highlight_blue_text centered\"> <td>12</td> <td>12</td> <td>720</td> </tr> <tr class=\"centered\"> <td>13</td> <td>13</td> <td>780</td> </tr> <tr class=\"highlight_blue_text centered\"> <td>14</td> <td>14</td> <td>840</td> </tr> <tr class=\"centered\"> <td>15</td> <td>15</td> <td>900</td> </tr> <tr class=\"highlight_blue_text divider_bottom\"> <td class=\"centered\">16</td> <td class=\"centered\">16</td> <td class=\"centered\">960</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The above table is provided as an example. There are other acceptable concentrations. <FONT color=black>If there is a risk of volume overload,&nbsp;this dilute solution should only be used as a temporizing measure until a more concentrated solution (eg, 4 mcg/mL)&nbsp;is available.</FONT></LI>&#xD;&#xA;<LI>Intravenous epinephrine, like all vasopressors, can cause life-threatening hypertension, cardiac ischemia, and ventricular arrhythmias. It should be administered ONLY by clinicians trained and experienced in dose titration of intravenous epinephrine using continuous noninvasive electronic monitoring of heart rate and blood pressure.</LI>&#xD;&#xA;<LI>Epinephrine is an ischemia-causing agent and vesicant. Monitor infusion site for extravasation. Central venous catheter administration is preferred when available. Refer to the&nbsp;Lexicomp drug reference for information on managing extravasation including infiltration of phentolamine.</LI>&#xD;&#xA;<LI>To reduce the risk of making a medication error, we suggest that centers have available an institutionally approved protocol for epinephrine infusion that includes steps on how to prepare and administer the infusion by programmable infusion pump and standard concentration(s).</LI></UL></div><div class=\"graphic_footnotes\">* Unused diluted solutions should be discarded within 24 hours or less of preparation, depending on local standards.<br /></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gahart BL, Nazareno AR, Ortega MQ. Gahart's 2016 Intravenous Medications: A Handbook for Nurses and Health Professionals, 32nd ed, Elsevier-Mosby, St. Louis, MO 2016.</LI>&#xD;&#xA;<LI>Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126:477.</LI></OL></div><div id=\"graphicVersion\">Graphic 106917 Version 2.0</div></div></div>"},"106922":{"type":"graphic_table","displayName":"Tests for bacterial infection in febrile young infants","title":"Identification of serious bacterial infection in well-appearing febrile young infants: Test characteristics of inflammatory marker criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Identification of serious bacterial infection in well-appearing febrile young infants: Test characteristics of inflammatory marker criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"5\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Sensitivity<br /> (range, %)</td> <td class=\"subtitle1\">Specificity<br /> (range, %)</td> <td class=\"subtitle1\">PPV<br /> (range, %)*</td> <td class=\"subtitle1\">NPV<br /> (range, %)*</td> <td class=\"subtitle1\">ROC<br /> (AUC, %)</td> </tr> <tr class=\"divider_bottom\"> <td>C-reactive protein &#62;20 mg/L</td> <td class=\"centered\">48 to 100</td> <td class=\"centered\">84 to 96</td> <td class=\"centered\">55 to 71</td> <td class=\"centered\">84 to 100</td> <td class=\"centered\">74 to 85</td> </tr> <tr class=\"divider_bottom\"> <td>Procalcitonin (semi-quantitative) &#62;0.3 ng/mL<sup>&#182;</sup></td> <td class=\"centered\">90</td> <td class=\"centered\">78</td> <td class=\"centered\">NR</td> <td class=\"centered\">NR</td> <td class=\"centered\">81 (91 for IBI)</td> </tr> <tr class=\"divider_bottom\"> <td>Procalcitonin (semi-quantitative) &#62;0.5 ng/mL</td> <td class=\"centered\">63 to 86</td> <td class=\"centered\">87 to 93</td> <td class=\"centered\">35 to 59</td> <td class=\"centered\">89 to 99</td> <td class=\"centered\">73 to 77</td> </tr> <tr> <td colspan=\"6\">Absolute band count</td> </tr> <tr> <td class=\"indent1\">&#62;250/microL</td> <td class=\"centered\">93</td> <td class=\"centered\">44</td> <td class=\"centered\">13</td> <td class=\"centered\">99</td> <td class=\"centered\">81</td> </tr> <tr> <td class=\"indent1\">&#62;500/microL</td> <td class=\"centered\">80 to 88</td> <td class=\"centered\">61</td> <td class=\"centered\">16</td> <td class=\"centered\">98</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">&#62;1000/microL</td> <td class=\"centered\">74</td> <td class=\"centered\">80</td> <td class=\"centered\">24</td> <td class=\"centered\">97</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">&#62;1500/microL<sup>&#182;</sup></td> <td class=\"centered\">50</td> <td class=\"centered\">96</td> <td class=\"centered\">NR</td> <td class=\"centered\">NR</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">&#62;3000/microL</td> <td class=\"centered\">19</td> <td class=\"centered\">98</td> <td class=\"centered\">47</td> <td class=\"centered\">93</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;5000/microL</td> <td class=\"centered\">80</td> <td class=\"centered\">57</td> <td class=\"centered\">17</td> <td class=\"centered\">96</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Absolute neutrophil count &#62;10,000/microL</td> <td class=\"centered\">20 to 80</td> <td class=\"centered\">95 to 100</td> <td class=\"centered\">71 to 100</td> <td class=\"centered\">78 to 98.2</td> <td class=\"centered\">71 to 78</td> </tr> <tr> <td colspan=\"6\">WBC</td> </tr> <tr> <td class=\"indent1\">5000 to 15,000/microL</td> <td class=\"centered\">28 to 80</td> <td class=\"centered\">72 to 91</td> <td class=\"centered\">2 to 44</td> <td class=\"centered\">78 to 99.5</td> <td class=\"centered\">59 to 72</td> </tr> <tr> <td class=\"indent1\">&#62;15,000/microL</td> <td class=\"centered\">20 to 50</td> <td class=\"centered\">74 to 88</td> <td class=\"centered\">2 to 21</td> <td class=\"centered\">91 to 99.3</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">&#62;20,000/microL</td> <td class=\"centered\">16 to 24</td> <td class=\"centered\">93 to 97</td> <td class=\"centered\">3 to 35</td> <td class=\"centered\">93 to 99.1</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operator curve; AUC: area under the curve; WBC: white blood cell count; NR: not reported.<br />* Prevalence of SBI in well-appearing febrile young infants varies by age with highest prevalence in infants 28 days of age and younger. Range of prevalence in large observational studies is 7 to 10% for urinary tract infection and is similar for all infants up to 90 days of age. The prevalence of bacteremia and meningitis is higher in the youngest infants with an overall range of 1 to 2.5% for bacteremia, and 0.1 to 0.5% for meningitis.<br />​¶ Results from one cohort. Positive and negative predictive values were not provided.</div><div class=\"graphic_reference\">Data from: Hui C, Neto G, Tsertsvadze A, et al. Diagnosis and Management of Febrile Infants (0-3 months). Evidence Report/Technology Assessment No. 205 (Prepared by the University of Ottawa: Evidence-based Practice Center under Contract No. HHSA 290-2007-10059-I). AHRQ Publication No. 12-E004-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2012. Available at <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK92690/\" target=\"_blank\">http://www.ncbi.nlm.nih.gov/books/NBK92690/</a> (Accessed July 29, 2016).</div><div id=\"graphicVersion\">Graphic 106922 Version 3.0</div></div></div>"},"106923":{"type":"graphic_picture","displayName":"US transducer position to begin examination of medial hip","title":"US transducer position to begin examination of medial hip","html":"<div class=\"graphic\"><div style=\"width: 661px\" class=\"figure\"><div class=\"ttl\">US transducer position to begin examination of medial hip</div><div class=\"cntnt\"><img style=\"width:641px; height:708px;\" src=\"images/SM/106923_US_trnsd_pst_bgn_exm_mdl_hp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the starting position of the ultrasound probe for examination of the medial hip in the transverse plane.</div><div class=\"graphic_footnotes\">Rectangle: ultrasound probe.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106923 Version 1.0</div></div></div>"},"106924":{"type":"graphic_diagnosticimage","displayName":"US medial hip proximal adductors transverse plane","title":"US medial hip showing proximal adductors in transverse plane","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">US medial hip showing proximal adductors in transverse plane</div><div class=\"cntnt\"><img style=\"width:581px; height:708px;\" src=\"images/SM/106924_US_mdl_hp_prx_addct_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the proximal portion of the hip adductors in the transverse plane (short-axis view).</div><div class=\"graphic_footnotes\">AL: adductor longus; AB: adductor brevis; AM: aductor magnus.<br />Left side of image: anterior; right side of image: posterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106924 Version 1.0</div></div></div>"},"106925":{"type":"graphic_diagnosticimage","displayName":"US hip adductor insertion coronal plane","title":"US hip adductor insertion in coronal plane","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">US hip adductor insertion in coronal plane</div><div class=\"cntnt\"><img style=\"width:783px; height:610px;\" src=\"images/SM/106925_US_hp_addct_inst_crnl_pln.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound scan shows the origin of the hip adductors from the pubic tubercle in the coronal plane (long-axis view).</div><div class=\"graphic_footnotes\">AL: adductor longus; AB: adductor brevis; AM: aductor magnus; PT: pubic tubercle.<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106925 Version 2.0</div></div></div>"},"106926":{"type":"graphic_diagnosticimage","displayName":"US hip pubic tubercle with adductor and rectus abdominus tendons","title":"US hip pubic tubercle with adductor and rectus abdominus tendon insertions","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US hip pubic tubercle with adductor and rectus abdominus tendon insertions</div><div class=\"cntnt\"><img style=\"width:716px; height:256px;\" src=\"images/SM/106926_US_hp_-pbc_tub_addct_abdm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the insertion of the rectus abdominus tendon onto the pubic tubercle in the coronal plane (long-axis view).</div><div class=\"graphic_footnotes\">Arrows: rectus abdominus tendon; arrowheads: adductor tendons (origin); PT: pubic tubercle.<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106926 Version 1.0</div></div></div>"},"106927":{"type":"graphic_diagnosticimage","displayName":"US hip rectus abdominus transverse plane","title":"US hip rectus abdominus muscles in transverse plane","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">US hip rectus abdominus muscles in transverse plane</div><div class=\"cntnt\"><img style=\"width:711px; height:404px;\" src=\"images/SM/106927_US_hp_rct_abdm_trnsv_pln.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound&nbsp;image shows the&nbsp;rectus abdominus muscles in the transverse plane&nbsp;(short-axis view).</div><div class=\"graphic_footnotes\">RAr: right rectus abdominus muscle; RAl: left rectus abdominus muscle; arrows: linea alba.<br />Left side of image: right side of midline; right side of image: left of midline.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106927 Version 1.0</div></div></div>"},"106928":{"type":"graphic_diagnosticimage","displayName":"US hip pubic symphysis transverse plane","title":"US hip pubic symphysis transverse plane","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US hip pubic symphysis transverse plane</div><div class=\"cntnt\"><img style=\"width:716px; height:291px;\" src=\"images/SM/106928_US_hp_pbc_smphs_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the pubic symphysis in the transverse plane.</div><div class=\"graphic_footnotes\">RAr: right rectus abdominus muscle; RAl: left rectus abdominus muscle; Pr: right pubic bone; Pl: left pubic bone.<br />Left side of image: right side of midline; right side of image: left of midline.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106928 Version 1.0</div></div></div>"},"106929":{"type":"graphic_picture","displayName":"US transducer position iliopsoas insertion coronal view","title":"US transducer position to examine iliopsoas insertion in coronal view","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">US transducer position to examine iliopsoas insertion in coronal view</div><div class=\"cntnt\"><img style=\"width:570px; height:712px;\" src=\"images/SM/106929_US_trnsd_pst_ilps_insrt_crnl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photographs shows the proper ultrasound transducer and patient positions to examine the insertion of the iliopsoas tendon in the coronal oblique plane.</div><div class=\"graphic_footnotes\">Rectangle: ultrasound probe.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106929 Version 1.0</div></div></div>"},"106930":{"type":"graphic_diagnosticimage","displayName":"US hip iliopsoas tendon insertion lesser trochanter coronal","title":"US hip iliopsoas tendon insertion onto lesser trochanter in coronal oblique view","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">US hip iliopsoas tendon insertion onto lesser trochanter in coronal oblique view</div><div class=\"cntnt\"><img style=\"width:712px; height:460px;\" src=\"images/SM/106930_US_hp_ilps_tndn_insrt_lss_trchnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the distal iliopsoas tendon as it inserts onto the lesser trochanter in a coronal oblique plane (long-axis view).</div><div class=\"graphic_footnotes\">Arrows: iliopsoas tendon; LT: lesser trochanter.<br />Left side of image: cranial; right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106930 Version 1.0</div></div></div>"},"106931":{"type":"graphic_picture","displayName":"US transducer start position hamstrings posterior hip","title":"US transducer start position for examination of the hamstrings and posterior hip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US transducer start position for examination of the hamstrings and posterior hip</div><div class=\"cntnt\"><img style=\"width:440px; height:710px;\" src=\"images/SM/106931_US_trnsd_strt_pst_hmstr_pst_hp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photographs shows the starting position of the ultrasound transducer for examination of the hamstring muscles and posterior hip.</div><div class=\"graphic_footnotes\">Rectangle: ultrasound probe.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106931 Version 1.0</div></div></div>"},"106940":{"type":"graphic_diagnosticimage","displayName":"US hamstring muscles extended field transverse view","title":"US hamstring muscles extended field transverse view","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US hamstring muscles extended field transverse view</div><div class=\"cntnt\"><img style=\"width:716px; height:338px;\" src=\"images/SM/106940_US_hmstr_mscl_extnd_fld_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound scan provides an extended field of view of the hamstring muscles in the transverse plane (short-axis view) at mid-thigh.</div><div class=\"graphic_footnotes\">ST: semitendinosus muscle; SM: semimembranosus muscle; BFL: long head of biceps femoris muscle; BFS: short head of biceps femoris muscle; G: gracilis muscle; AD: adductor muscles; dotted ellipse: sciatic nerve.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106940 Version 1.0</div></div></div>"},"106942":{"type":"graphic_diagnosticimage","displayName":"US proximal hamstring conjoint tendon transverse view","title":"US proximal hamstring and conjoint tendon in transverse view","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US proximal hamstring and conjoint tendon in transverse view</div><div class=\"cntnt\"><img style=\"width:716px; height:357px;\" src=\"images/SM/106942_US_prx_hmstr_cnjnt_tnd_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound scan shows the proximal hamstring musculotendinous junction and conjoint tendon&nbsp;in the transverse plane (short-axis view).</div><div class=\"graphic_footnotes\">Arrows: semimembranous tendon; arrowheads: conjoint tendon; dotted ellipse: sciatic nerve.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106942 Version 1.0</div></div></div>"},"106943":{"type":"graphic_diagnosticimage","displayName":"US posterior hip quadratus femoris gluteus maximus transverse","title":"US posterior hip showing gluteus maximus and quadratus femoris and other external rotators in transverse plane","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">US posterior hip showing gluteus maximus and quadratus femoris and other external rotators in transverse plane</div><div class=\"cntnt\"><img style=\"width:712px; height:465px;\" src=\"images/SM/106943_US_pst_hp_qd_fmr_glts_mx_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the quadratus femoris muscle, as well as other hip external rotators and the gluteus maximus, in the transverse plane (long-axis view).</div><div class=\"graphic_footnotes\">QF: quadratus femoris muscle; IT: ischial tuberosity; LT: lesser trochanter; CJ: conjoint tendon; SM: semimembranosus tendon; Gmax: gluteus maximus muscle; OBe: obturator externus muscle; dotted ellipse: sciatic nerve.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106943 Version 1.0</div></div></div>"},"106944":{"type":"graphic_diagnosticimage","displayName":"US posterior hip piriformis transverse plane","title":"US posterior hip showing piriformis in transverse plane","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US posterior hip showing piriformis in transverse plane</div><div class=\"cntnt\"><img style=\"width:715px; height:424px;\" src=\"images/SM/106944_US_pst_hp_prfm_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the piriformis muscle in the sciatic foramen in the transverse plane.</div><div class=\"graphic_footnotes\">GT: greater trochanter; Gmax: gluteus maximus muscle; PI: piriformis muscle; ISCH: ischium.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 106944 Version 1.0</div></div></div>"},"106945":{"type":"graphic_picture","displayName":"Complete repair of bladder exstrophy","title":"Complete repair of bladder exstrophy in a two-month-old girl","html":"<div class=\"graphic\"><div style=\"width: 924px\" class=\"figure\"><div class=\"ttl\">Complete repair of bladder exstrophy in a two-month-old girl</div><div class=\"cntnt\"><img style=\"width:904px; height:342px;\" src=\"images/PEDS/106945_Cmplt_rpr_blddr_exstrph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Frontal view of two-month-old girl immediately following complete primary repair of bladder exstrophy (CPRBE).<br />(B) Picture of same two-month-old girl immediately immobilized in a spica cast following CPRBE.</div><div id=\"graphicVersion\">Graphic 106945 Version 1.0</div></div></div>"},"106946":{"type":"graphic_table","displayName":"Evaluation of potential lung transplant recipients","title":"Evaluation of potential lung transplant recipients*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of potential lung transplant recipients*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Laboratory testing</td> </tr> <tr> <td class=\"indent1\">Complete blood count and differential</td> </tr> <tr> <td class=\"indent1\">Coagulation studies (INR, PTT)</td> </tr> <tr> <td class=\"indent1\">Iron, TIBC, ferritin</td> </tr> <tr> <td class=\"indent1\">Glucose, hemoglobin A1C</td> </tr> <tr> <td class=\"indent1\">Complete metabolic panel (electrolytes, liver function tests, BUN, creatinine)</td> </tr> <tr> <td class=\"indent1\">Pregnancy test in women of childbearing age</td> </tr> <tr> <td class=\"indent1\">Urinalysis</td> </tr> <tr> <td class=\"indent1\">Brain natriuretic peptide<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Vitamin D level</td> </tr> <tr> <td class=\"indent1\">Type and cross match (ABO)</td> </tr> <tr> <td class=\"indent1\">Highly sensitive, solid-phase assays for HLA I and II antibodies</td> </tr> <tr> <td class=\"indent1\">Serum/urine cotinine</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Toxicology screen in patients with prior or suspected illicit drug use</td> </tr> <tr> <td class=\"subtitle1_single\">Assessment for prior/current infections</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus (CMV) IgG/IgM</td> </tr> <tr> <td class=\"indent1\">Epstein Barr virus (EBV) IgG/IgM</td> </tr> <tr> <td class=\"indent1\">Hepatitis B and C serologies</td> </tr> <tr> <td class=\"indent1\">Herpes simplex (HSV) IgG/IgM</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus (HIV)</td> </tr> <tr> <td class=\"indent1\">Varicella zoster (VZV) IgG/IgM</td> </tr> <tr> <td class=\"indent1\">Coccidioides IgG/IgM<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Toxoplasma IgG/IgM<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Strongyloides IgG<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Tuberculin skin test<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sputum gram stain and culture</td> </tr> <tr> <td class=\"subtitle1_single\">Breathing tests</td> </tr> <tr> <td class=\"indent1\">Spirometry pre and post bronchodilator</td> </tr> <tr> <td class=\"indent1\">Lung volumes by plethysmography</td> </tr> <tr> <td class=\"indent1\">Diffusing capacity for carbon monoxide</td> </tr> <tr> <td class=\"indent1\">Six-minute walk test</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Arterial blood gas</td> </tr> <tr> <td class=\"subtitle1_single\">Imaging</td> </tr> <tr> <td class=\"indent1\">Chest radiograph</td> </tr> <tr> <td class=\"indent1\">Chest computed tomography</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Quantitative nuclear ventilation perfusion scan</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiac tests</td> </tr> <tr> <td class=\"indent1\">Electrocardiogram</td> </tr> <tr> <td class=\"indent1\">Echocardiogram or radionuclide ventriculography (RVG)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cardiac catheterization (right and left heart) for patients over age 45<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Health maintenance review to ensure the candidate is up to date on these screening tests</td> </tr> <tr> <td class=\"indent1\">DEXA bone density test (within two years)</td> </tr> <tr> <td class=\"indent1\">Colonoscopy (within 10 years, if over age 50 years)</td> </tr> <tr> <td class=\"indent1\">Mammogram and Pap smear (for women) in the past year</td> </tr> <tr> <td class=\"indent1\">Prostate specific antigen and digital rectal examination of prostate (for men)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dental examination</td> </tr> <tr> <td class=\"subtitle1_single\">Assessment of gastric esophageal reflux and gastric emptying<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Barium swallow</td> </tr> <tr> <td class=\"indent1\">Impedance pH probe monitoring</td> </tr> <tr> <td class=\"indent1\">Esophageal manometry</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Esophagogastroduodenoscopy (EGD) if concerns about Barrett esophagus, reflux esophagitis</td> </tr> <tr> <td class=\"subtitle1_single\">Vaccinations</td> </tr> <tr> <td class=\"indent1\">Hepatitis A and B (if not already immune)</td> </tr> <tr> <td class=\"indent1\">Pneumococcal pneumonia vaccines (pneumococcal conjugate vaccine [13-valent], pneumococcal polysaccharide vaccine [PPS23])</td> </tr> <tr> <td class=\"indent1\">Seasonal influenza vaccine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">INR: international normalized ratio; PTT: partial thromboplastin time; TIBC: total iron binding capacity; A1C: glycated hemoglobin; BUN: blood urea nitrogen; HLA: human leukocyte antigen; DEXA: dual-energy x-ray absorptiometry.<br />* This table provides an overview of testing of potential lung transplant candidates, but the exact tests performed depend on the specific patient's history and the practice of the individual lung transplant center.<br />¶ Some centers use a noninvasive test for cardiac ischemia in patients without risk factors for coronary disease and reserve catheterization for patients with risk factors or a positive noninvasive test.<br />Δ Testing varies among centers based on geographic location or clinical history. As examples, some centers may only assess brain natriuretic peptide in patients with pulmonary hypertension, Coccidioides serology in patients who have resided in the southwestern United States, TST in patients from TB endemic areas, or tests for gastroesophageal reflux in patients with a history of reflux or symptoms suggestive of esophageal dysmotility.</div><div id=\"graphicVersion\">Graphic 106946 Version 1.0</div></div></div>"},"106948":{"type":"graphic_table","displayName":"Antibiotic regimens for low-risk intra-abdominal infections","title":"Empiric antibiotic regimens for low-risk community-acquired intra-abdominal infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric antibiotic regimens for low-risk community-acquired intra-abdominal infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Single-agent regimen</td> </tr> <tr> <td class=\"indent1\">Ertapenem</td> <td>1 g IV once daily</td> </tr> <tr> <td class=\"indent1\">Piperacillin-tazobactam</td> <td>3.375 g IV every 6 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ticarcillin-clavulanate</td> <td>3.1 g IV every 4 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Combination regimen with metronidazole</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">ONE of the following: </td> </tr> <tr> <td class=\"indent2\">Cefazolin</td> <td>1 to 2 g IV every 8 hours</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\">OR</td> </tr> <tr> <td class=\"indent2\">Cefuroxime</td> <td>1.5 g IV every 8 hours</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\">OR</td> </tr> <tr> <td class=\"indent2\">Ceftriaxone</td> <td>2&nbsp;g IV once daily</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\">OR</td> </tr> <tr> <td class=\"indent2\">Cefotaxime</td> <td>2 g IV every 8 hours</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\">OR</td> </tr> <tr> <td class=\"indent2\">Ciprofloxacin</td> <td> <p>400 mg IV every 12 hours or</p> 500 mg PO every 12 hours</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\">OR</td> </tr> <tr> <td class=\"indent2\">Levofloxacin</td> <td>750 mg IV or PO once daily</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">PLUS:</td> </tr> <tr> <td class=\"indent2\">Metronidazole</td> <td>500 mg IV or PO every 8 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Low-risk community-acquired intra-abdominal infections are those that are of mild-to-moderate severity (including perforated appendix or appendiceal abscess) in the absence of risk factors for antibiotic resistance or treatment failure. Such risk factors include recent travel to areas of the world with high rates of antibiotics-resistant organisms, known colonization with such organisms, advanced age, immunocompromising conditions, or other major medical comorbidities. Refer to other UpToDate content on the antimicrobial treatment of intra-abdominal infections for further discussion of these risk factors.<br />For empiric therapy of low-risk community-acquired intra-abdominal infections, we cover streptococci, Enterobacteriaceae, and anaerobes.<br />The antibiotic doses listed are for adult patients with normal renal function.</div><div class=\"graphic_footnotes\">IV: intravenously; PO: orally.</div><div id=\"graphicVersion\">Graphic 106948 Version 7.0</div></div></div>"},"106949":{"type":"graphic_table","displayName":"Antibiotic regimens for high-risk intra-abdominal infections","title":"Empiric antibiotic regimens for high-risk community-acquired intra-abdominal infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric antibiotic regimens for high-risk community-acquired intra-abdominal infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Single-agent regimen</td> </tr> <tr> <td class=\"indent1\">Imipenem-cilastatin</td> <td>500 mg IV every six hours</td> </tr> <tr> <td class=\"indent1\">Meropenem</td> <td>1 g IV every eight hours</td> </tr> <tr> <td class=\"indent1\">Doripenem</td> <td>500 mg IV every eight hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Piperacillin-tazobactam</td> <td>4.5 g IV every six hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Combination regimen with metronidazole</td> </tr> <tr> <td class=\"indent1\">ONE of the following:</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Cefepime</td> <td colspan=\"2\">2 g IV every eight hours</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\">OR</td> </tr> <tr> <td class=\"indent2\">Ceftazidime</td> <td>2 g IV every eight hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">PLUS:</td> </tr> <tr> <td class=\"indent2\">Metronidazole</td> <td>500 mg IV every eight hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">High-risk community-acquired intra-abdominal infections are those that are severe or in patients at high risk for adverse outcomes or antimicrobial resistance. These include patients with&nbsp;recent travel to areas of the world with high rates of antibiotics-resistant organisms, known colonization with such organisms, advanced age, immunocompromising conditions,&nbsp;or other major medical comorbidities. Refer to the topic on the antimicrobial treatment of intra-abdominal infections for further discussion of these risk factors. <br /><br />For empiric therapy of high-risk community-acquired intra-abdominal infections, we cover streptococci, Enterobacteriaceae resistant to third-generation cephalosporins, <EM>Pseudomonas aeruginosa</EM>, and anaerobes. Empiric antifungal therapy is usually not warranted, but is reasonable for critically ill patients with an upper gastrointestinal source. <br /><br />Local rates of resistance should inform antibiotic selection (ie, agents for which there is &gt;10 percent resistance among Enterobacteriaceae should be avoided). If the patient is at risk for infection with an extended-spectrum beta-lactamase (ESBL)-producing organism (eg, known colonization or prior infection with an ESBL-producing organism), a carbapenem should be chosen. When beta-lactams or carbapenems are chosen for patients who are critically ill or are at high risk of infection with drug-resistant pathogens, we favor a prolonged infusion dosing strategy. Refer to other UpToDate content on prolonged infusions of beta-lactam antibiotics. <br /><br />The combination of vancomycin, aztreonam, and metronidazole is an alternative for those who cannot use beta-lactams or carbapenems (eg, because of severe reactions).<br /><br />The antibiotic doses listed are for adult patients with normal renal function.</div><div id=\"graphicVersion\">Graphic 106949 Version 4.0</div></div></div>"},"106950":{"type":"graphic_table","displayName":"Antibiotics for healthcare-associated intra-abdominal infections","title":"Empiric antibiotic regimens for health care-associated intra-abdominal infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric antibiotic regimens for health care-associated intra-abdominal infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Single-agent regimen</td> </tr> <tr> <td class=\"indent1\">Imipenem-cilastatin</td> <td>500 mg IV every six hours</td> </tr> <tr> <td class=\"indent1\">Meropenem</td> <td>1 g IV every eight hours</td> </tr> <tr> <td class=\"indent1\">Doripenem</td> <td>500 mg IV every eight hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Piperacillin-tazobactam</td> <td>4.5 g IV every six hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Combination regimen</td> </tr> <tr> <td class=\"indent1\">ONE of the following: &nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Cefepime</td> <td>2 g IV every eight hours</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\">OR</td> </tr> <tr> <td class=\"indent2\">Ceftazidime</td> <td>2 g IV every eight hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">PLUS:</td> </tr> <tr> <td class=\"indent2\">Metronidazole</td> <td>500 mg IV every eight hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">PLUS ONE of the following (in some cases*): &nbsp;</td> </tr> <tr> <td class=\"indent2\">Ampicillin</td> <td>2 g IV every&nbsp;four hours</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\">OR</td> </tr> <tr> <td class=\"indent2\">Vancomycin</td> <td>15-20 mg/kg IV every eight to twelve hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For empiric therapy of health care-associated intra-abdominal infections, we cover streptococci, enterococci, Enterobacteriaceae that are resistant to third-generation cephalosporins and fluoroquinolones, <EM>Pseudomonas aeruginosa</EM>, and anaerobes. We include coverage against methicillin-resistant <EM>Staphylococcus aureus </EM>(MRSA) with vancomycin&nbsp;in those who are known to be colonized, those with prior treatment failure, and those with significant prior antibiotic exposure. Empiric antifungal coverage is appropriate for patients at risk for infection with Candida spp, including those with upper gastrointestinal perforations, recurrent bowel perforations, surgically treated pancreatitis, heavy colonization with Candida spp, and/or yeast identified on Gram stain of samples from infected peritoneal fluid or tissue. Refer to other UpToDate content on treatment of invasive candidiasis.<br /><br />If the patient is at risk for infection with an extended-spectrum beta-lactamase (ESBL)-producing organism (eg, known colonization or prior infection with an ESBL-producing organism), a carbapenem should be chosen. For patients who are known to be colonized with highly resistant gram-negative bacteria, the addition of an aminoglycoside, polymyxin, or novel beta-lactam combination (ceftolozane-tazobactam or ceftazidime-avibactam) to an empiric regimen may be warranted. In such cases, consultation with an expert in infectious diseases is advised.&nbsp;<br /><br />When beta-lactams or carbapenems are chosen for patients who are critically ill or are at high risk of infection with drug-resistant pathogens, we favor a prolonged infusion dosing strategy. Refer to other UpToDate content on prolonged infusions of beta-lactam antibiotics. <br /><br />The combination of vancomycin, aztreonam, and metronidazole is an alternative for those who cannot use beta-lactams or carbapenems (eg, because of severe reactions).<br /><br />The antibiotic doses listed are for adult patients with normal renal function.</div><div class=\"graphic_footnotes\">* We add ampicillin or vancomycin to a cephalosporin-based regimen to provide enterococcal coverage, particularly in those with postoperative infection, prior use of antibiotics that select for <EM>Enterococcus</EM>, immunocompromising condition, valvular heart disease, or prosthetic intravascular materials. Coverage against vancomycin-resistant enterococci (VRE) is generally not recommended, although it is reasonable in patients who have a history of VRE colonization or in liver transplant recipients who have an infection of hepatobiliary source.</div><div id=\"graphicVersion\">Graphic 106950 Version 5.0</div></div></div>"},"106958":{"type":"graphic_table","displayName":"Diagnostic criteria for minor depression","title":"Diagnostic criteria for minor depression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for minor depression</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">We suggest diagnosing minor depressive episodes according to all of the following criteria (A through F).</td> </tr> <tr> <td class=\"indent1\">A. Two to four of the following symptoms have been present during the same two-week period:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ol class=\"numbers_to_nine\"> <li>Dysphoria &ndash; Depressed mood most of the day, nearly every day </li> <li>Anhedonia &ndash; Markedly diminished interest or pleasure most of the day, nearly every day </li> <li>Significant appetite or weight change </li> <li>Insomnia or hypersomnia nearly every day </li> <li>Psychomotor agitation or retardation (observable by others) </li> <li>Anergia &ndash; Fatigue nearly every day </li> <li>Thoughts of worthlessness or inappropriate guilt nearly every day </li> <li>Impaired concentration or memory nearly every day </li> <li>Recurrent thoughts of death or suicide, or suicide attempt </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">B. At least one of the symptoms includes dysphoria or anhedonia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">C. The symptoms cause clinically significant distress of psychosocial impairment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">D. The symptoms are not due to the physiologic effects of a substance, medication, or general medical condition</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">E. Persistent depressive disorder (dysthymia) and cyclothymic disorder are not present</td> </tr> <tr> <td class=\"indent1\">F. The mood disturbance does not occur exclusively during a psychotic disorder</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These criteria for minor depression are similar to the criteria that are used in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for the diagnosis, \"Other specified depressive disorder, depressive episode with insufficient symptoms\" (ie, the depressive episode is characterized by an insufficient number of symptoms to meet criteria for major depression).</div><div class=\"graphic_reference\"><EM>Reference: </EM>&#xD;&#xA;<OL>&#xD;&#xA;<LI><EM>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington 2013.</EM></LI></OL></div><div id=\"graphicVersion\">Graphic 106958 Version 1.0</div></div></div>"},"106961":{"type":"graphic_table","displayName":"Medications associated with seizures","title":"Medications associated with seizures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications associated with seizures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Examples</td> </tr> <tr class=\"divider_bottom\"> <td>Analgesics</td> <td> <p>NSAIDs</p> <p>Opioids (eg, hydromorphone, meperidine, pentazocine, propoxyphene*, tramadol)</p> Triptans</td> </tr> <tr class=\"divider_bottom\"> <td>Anesthetics</td> <td> <p>Intravenous or inhalation anesthetics (eg, alfentanil, enflurane, ketamine, methohexital, propofol, sevoflurane, sufentanil)</p> Local anesthetics (eg, bupivacaine, cocaine, lidocaine, procaine, ropivacaine)</td> </tr> <tr class=\"divider_bottom\"> <td>Anticancer drugs<sup>&#182;</sup></td> <td> <p>Busulfan</p> <p>Chlorambucil</p> <p>Cytarabine</p> <p>Doxorubicin</p> <p>Etoposide</p> <p>Fluorouracil</p> <p>Interferon alfa</p> <p>Methotrexate</p> <p>Mitoxantrone</p> <p>Nelarabine</p> <p>Platinum-based drugs (eg, cisplatin)</p> <p>Vinblastine</p> Vincristine</td> </tr> <tr class=\"divider_bottom\"> <td>Anticholinergics</td> <td> <p>Oxybutynin</p> Scopolamine</td> </tr> <tr class=\"divider_bottom\"> <td>Antiemetics</td> <td> <p>Dronabinol</p> <p>Metoclopramide</p> <p>Ondansetron</p> <p>Phenothiazines (eg, prochlorperazine)</p> Scopolamine</td> </tr> <tr class=\"divider_bottom\"> <td>Antihistamines</td> <td> <p>Diphenhydramine</p> Hydroxyzine</td> </tr> <tr class=\"divider_bottom\"> <td>Antimicrobials<sup>&#916;</sup></td> <td> <p>Antimalarials (eg, hydroxychloroquine, mefloquine)</p> <p>Antiretrovirals</p> <p>Antivirals</p> <p>Carbapenems (eg, imipenem)</p> <p>Cephalosporins</p> <p>Fluoroquinolones (eg, ciprofloxacin)</p> <p>Isoniazid<sup>&#9674;</sup></p> <p>Ivermectin</p> <p>Linezolid</p> <p>Metronidazole</p> Penicillins</td> </tr> <tr class=\"divider_bottom\"> <td>Anti-Parkinson agents</td> <td> <p>Dopamine agonists (eg, amantadine)</p> <p>Rasagiline</p> Selegiline</td> </tr> <tr class=\"divider_bottom\"> <td>Cardiovascular agents</td> <td> <p>Antiarrhythmics</p> Beta-blockers</td> </tr> <tr class=\"divider_bottom\"> <td>Cholinesterase inhibitors</td> <td> <p>Donepezil</p> <p>Galantamine</p> Rivastigmine</td> </tr> <tr class=\"divider_bottom\"> <td>Contrast agents, iodinated</td> <td> <p>Iohexol</p> Iopamidol</td> </tr> <tr class=\"divider_bottom\"> <td>Erectile dysfunction</td> <td>Phosphodiesterase-5 inhibitors (eg, sildenafil, tadalafil, others)</td> </tr> <tr class=\"divider_bottom\"> <td>Hypoglycemic agents</td> <td>Potentially any antidiabetic agent that can cause hypoglycemia</td> </tr> <tr class=\"divider_bottom\"> <td>Immunosuppressants</td> <td> <p>Azathioprine</p> <p>Cyclosporine</p> <p>Glucocorticoids</p> <p>Mycophenolate</p> Tacrolimus</td> </tr> <tr class=\"divider_bottom\"> <td>Muscle relaxants</td> <td> <p>Baclofen</p> <p>Carisoprodol</p> <p>Cyclobenzaprine</p> <p>Dantrolene</p> Tizanidine</td> </tr> <tr class=\"divider_bottom\"> <td>Psychiatric medications</td> <td> <p>Antipsychotics<sup>&#167;</sup></p> <p>Atomoxetine&nbsp;</p> <p>Bupropion</p> <p>Buspirone</p> <p>Lithium</p> <p>Monoamine oxidase inhibitors<sup>&#165;</sup></p> <p>Selective serotonin reuptake inhibitors<sup>&#135;</sup></p> <p>Serotonin norepinephrine reuptake inhibitors<sup>&#135;</sup></p> <p>Serotonin modulators</p> Tricyclic antidepressants (eg, amoxapine, clomipramine,&nbsp;maprotiline)</td> </tr> <tr class=\"divider_bottom\"> <td>Pulmonary drugs</td> <td> <p>Albuterol (salbutamol)</p> <p>Aminophylline</p> <p>Montelukast</p> <p>Terbutaline</p> Theophylline</td> </tr> <tr class=\"divider_bottom\"> <td>Stimulants</td> <td> <p>Amphetamines</p> Methylphenidate</td> </tr> <tr class=\"divider_bottom\"> <td>Sympathomimetics and decongestants</td> <td> <p>Anorexiants (eg, diethylpropion, phentermine, nonprescription diet aids)</p> <p>Caffeine</p> <p>Phenylephrine</p> Pseudoephedrine</td> </tr> <tr> <td>Others</td> <td> <p>Epoetin</p> <p>Flumazenil</p> <p>Isotretinoin</p> <p>Memantine</p> <p>Nicotine</p> <p>Sodium oxybate</p> Ticlopidine</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The magnitude of risk of seizure for various categories and individual agents is not well established. Factors that may contribute to the risk of seizure with medications include overdose, alcohol abuse, organ dysfunction, drug interactions, older age, and a history of seizures. Illicit drugs use, herbs/natural remedies (eg, guarana), nonprescription supplements, and abrupt withdrawal from chronic alcohol use and certain prescription medicines (eg, antiepileptic drugs, baclofen, benzodiazepines) are also associated with seizure.<br />This table is not all-inclusive. For detailed prescribing information, including reported adverse effects, readers should refer to the individual drug information topics within UpToDate. Comprehensive information on drug interactions can be determined using the Lexi-Interact tool included within UpToDate.</div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs.<br />* Removed from market in most countries.<br />¶ For more details and additional anti-cancer drugs that have been associated with seizures, refer to UpToDate topic reviews on the neurologic complications of anticancer therapies.<br />Δ Among antibiotics, evidence for an association is strongest for unsubstituted penicillins, fourth-generation cephalosporins, imipenem, and ciprofloxacin in combination with renal dysfunction, brain lesions, and epilepsy<SUP>[1]</SUP>.<br />◊ Seizures are a manifestation of pyridoxal-5-phosphate deficiency; they respond to pyridoxine and benzodiazepine treatment. Refer to UpToDate topic review on isoniazid poisoning.&nbsp;<br />§&nbsp;Clozapine has a higher risk of seizure than most other antipsychotics<SUP>[2]</SUP>; refer to UpToDate topic review on guidelines for prescribing clozapine in schizophrenia for more information.<br />¥&nbsp;Monoamine oxidase inhibitors include: furazolidone, isocarboxazid, linezolid, moclobemide, pargyline, phenelzine, procarbazine, rasagiline, selegiline, tranylcypromine.<br />‡ Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors&nbsp;do not increase seizure risk in patients with epilepsy when used in therapeutic doses, but may be proconvulsant at toxic doses<SUP innerHtml>[3,4]</SUP>.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Sutter S, Ruegg S, Tschudin-Sutter S, Seizures as adverse events of antibiotic drugs: A systematic review. Neurology 2015; 1332.</LI>&#xD;&#xA;<LI>Hitchings AW, Drugs that lower the seizure threshold. Adverse Drug Reaction Bulletin 2016; 1151.</LI>&#xD;&#xA;<LI>Kanner AM, Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: A review of the evidence. Epilepsy Behav 2016;282.</LI>&#xD;&#xA;<LI>Landmark CJ, Henning O, Johannessen SI. Proconvulsant effects of antidepressants&nbsp;- What is the current evidence? Epilepsy Behav 2016;287.</LI></OL></div><div id=\"graphicVersion\">Graphic 106961 Version 6.0</div></div></div>"},"106962":{"type":"graphic_table","displayName":"Allele frequencies of MVK mutations","title":"Allele frequencies of mevalonate kinase (<em>MVK</em>) mutations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Allele frequencies of mevalonate kinase (<em>MVK</em>) mutations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mutation</td> <td class=\"subtitle1\">Allele frequency (%)</td> </tr> <tr> <td>V377I</td> <td>50</td> </tr> <tr> <td>I268T</td> <td>14.7</td> </tr> <tr> <td>H20P/N</td> <td>4.4</td> </tr> <tr> <td>P167L</td> <td>2.4</td> </tr> <tr> <td>H380R</td> <td>1.5</td> </tr> <tr> <td>R215Q</td> <td>1.5</td> </tr> <tr> <td>W188X</td> <td>1.5</td> </tr> <tr> <td>25 other mutations and deletions</td> <td>All &#60;1</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: van der Hilst JC, Bodar EJ, Barron KS, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008; 87:301. DOI: <a href=\"http://journals.lww.com/md-journal/pages/articleviewer.aspx?year=2008&amp;issue=11000&amp;article=00001&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/MD.0b013e318190cfb7</a>. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 106962 Version 1.0</div></div></div>"},"106965":{"type":"graphic_algorithm","displayName":"Algorithm for NTM-PD in CF","title":"Algorithm for investigation of nontuberculous mycobacteria pulmonary disease (NTM-PD) in patients with cystic fibrosis (CF)","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Algorithm for investigation of nontuberculous mycobacteria pulmonary disease (NTM-PD) in patients with cystic fibrosis (CF)</div><div class=\"cntnt\"><img style=\"width:688px; height:482px;\" src=\"images/PEDS/106965_Algorithm_NTM_PD_CF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An algorithm for the investigation of individuals with clinical suspicion of NTM-PD, suggested by the US Cystic Fibrosis Foundation and the European Cystic Fibrosis Society.</div><div class=\"graphic_footnotes\">NTM-PD: nontuberculous mycobacteria pulmonary disease; CF: cystic fibrosis; AFB: acid-fast bacilli; FEV<sub>1</sub>: forced expiratory volume in one second; HRCT: high-resolution computed tomography; CT: computed tomography.</div><div class=\"graphic_reference\">From: Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71:i1. Reproduced through the <a href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution (CC BY 4.0) license</a>.</div><div id=\"graphicVersion\">Graphic 106965 Version 2.0</div></div></div>"},"106967":{"type":"graphic_table","displayName":"Normal values for 2D TEE LV size","title":"Normal values for 2D TEE LV size","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal values for 2D TEE LV size</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"34%\"></colgroup><colgroup span=\"4\" width=\"16.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Parameter</td> <td class=\"subtitle1\" colspan=\"2\">Male</td> <td class=\"subtitle1\" colspan=\"2\">Female</td> </tr> <tr> <td class=\"subtitle2\">Mean &#177; SD</td> <td class=\"subtitle2\">2-SD range</td> <td class=\"subtitle2\">Mean &#177; SD</td> <td class=\"subtitle2\">2-SD range</td> </tr> <tr> <td colspan=\"5\"><strong>LV internal dimension</strong></td> </tr> <tr> <td class=\"indent1\">Diastolic dimension (mm)</td> <td class=\"centered\">50.2 &#177; 4.1</td> <td class=\"centered\">42.0 to 58.4</td> <td class=\"centered\">45.0 &#177; 3.6</td> <td class=\"centered\">37.8 to 52.2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Systolic dimension (mm)</td> <td class=\"centered\">32.4 &#177; 3.7</td> <td class=\"centered\">25.0 to 39.8</td> <td class=\"centered\">28.2 &#177; 3.3</td> <td class=\"centered\">21.6 to 34.8</td> </tr> <tr> <td colspan=\"5\"><strong>LV volumes (biplane)</strong></td> </tr> <tr> <td class=\"indent1\">LV EDV (mL)</td> <td class=\"centered\">106 &#177; 22</td> <td class=\"centered\">62 to 150</td> <td class=\"centered\">76 &#177; 15</td> <td class=\"centered\">46 to 106</td> </tr> <tr> <td class=\"indent1\">LV ESV (mL)</td> <td class=\"centered\">41 &#177; 10</td> <td class=\"centered\">21 to 61</td> <td class=\"centered\">28 &#177; 7</td> <td class=\"centered\">14 to 42</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Normal values for 2D echocardiographic parameters of LV size according to gender.</div><div class=\"graphic_footnotes\">2D: two-dimensional; LV: left ventricle; EDV: end-diastolic volume; ESV: end-systolic volume.</div><div class=\"graphic_reference\">Original figure modified for this publication. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults. J Am Soc Echocardiogr 2015; 28:1. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 106967 Version 1.0</div></div></div>"},"106968":{"type":"graphic_figure","displayName":"Transmitral flow propagation velocity (Vp)","title":"Transmitral flow propagation velocity (Vp)","html":"<div class=\"graphic\"><div style=\"width: 1022px\" class=\"figure\"><div class=\"ttl\">Transmitral flow propagation velocity (Vp)</div><div class=\"cntnt\"><img style=\"width:1002px; height:662px;\" src=\"images/ANEST/106968_Transmitrl_flw_prpgtn_vlcty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">Color M-mode propagation velocity (Vp). It is&nbsp;measured during the early rapid filling phase&nbsp;of the left ventricle and is used to assess the active diastolic relaxation of the left ventricle. The M-mode scan line is placed through the center of the LV inflow blood column from the mitral valve to the LV&nbsp;apex. The Nyquist limit&nbsp;is lowered so that the central highest-velocity jets are red and yellow (refer to UpToDate topic on principles of Doppler echocardiography). Flow propagation velocity is measured as the slope of the first aliasing velocity during early filling, and is measured from the mitral valve plane to 4 cm distally into the LV cavity. Vp &gt;50 cm/second is considered normal. </SPAN></div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium</div><div id=\"graphicVersion\">Graphic 106968 Version 2.0</div></div></div>"},"106970":{"type":"graphic_waveform","displayName":"Opioid-induced ataxic and cluster breathing","title":"Opioid-induced ataxic and cluster breathing","html":"<div class=\"graphic\"><div style=\"width: 768px\" class=\"figure\"><div class=\"ttl\">Opioid-induced ataxic and cluster breathing</div><div class=\"cntnt\"><img style=\"width:748px; height:571px;\" src=\"images/SLEEP/106970_Opd_indc_atxc_clstr_brth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This respiratory pattern during sleep&nbsp;is characterized by a highly irregular rhythm, varying in rate and amplitude, as originally described by MC Biot. There are a few scattered central apneas with a \"cluster\" pattern.</div><div class=\"graphic_footnotes\">SpO<sub>2</sub>: oxygen saturation.</div><div class=\"graphic_reference\">From: Correa D, Farney RJ, Chung F, et al. Chronic opioid use and central sleep apnea: A review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg 2015; 120:1273. DOI: <a href=\"http://journals.lww.com/anesthesia-analgesia/pages/articleviewer.aspx?year=2015&amp;issue=06000&amp;article=00017&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1213/ANE.0000000000000672</a>. Copyright &copy; 2015 International Anesthesia Research Society. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 106970 Version 1.0</div></div></div>"},"106972":{"type":"graphic_diagnosticimage","displayName":"Rapid development of cardiac allograft vasculopathy","title":"Rapid development of cardiac allograft vasculopathy","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">Rapid development of cardiac allograft vasculopathy</div><div class=\"cntnt\"><img style=\"width:723px; height:337px;\" src=\"images/CARD/106972_Rpd_dvl_allgrft_vsclpthy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A. Coronary angiogram obtained at year&nbsp;two post-transplant.<br />B. Coronary angiogram obtained&nbsp;three months later showing rapid development of severe diffuse coronary artery disease.</div><div class=\"graphic_reference\">Courtesy of Hannah Valantine, MD.</div><div id=\"graphicVersion\">Graphic 106972 Version 1.0</div></div></div>"},"106973":{"type":"graphic_figure","displayName":"Handling the mesentery during resection of colon cancer","title":"Handling the mesentery during resection of colon cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Handling the mesentery during resection of colon cancer</div><div class=\"cntnt\"><img style=\"width:440px; height:477px;\" src=\"images/SURG/106973_Handling_the_mesentery_during_resection_of_colon_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When colectomies are performed for malignancy, the mesenteric vessels are ligated close to their root for optimal resection of lymphovascular tissue. </div><div id=\"graphicVersion\">Graphic 106973 Version 1.0</div></div></div>"},"106975":{"type":"graphic_table","displayName":"Potential triggers for end of life communication","title":"Potential triggers for communication about end of life in a variety of illnesses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential triggers for communication about end of life in a variety of illnesses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cancer<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">Prognosis-related triggers</td> </tr> <tr> <td class=\"indent2\">\"Would you be surprised if this patient died in the next year?\"</td> </tr> <tr> <td class=\"indent1\">Disease-based/condition-based criteria</td> </tr> <tr> <td class=\"indent2\">All patients with non-small cell lung cancer, pancreatic cancer, glioblastoma</td> </tr> <tr> <td class=\"indent2\">Patients older than 70 years with acute myelogenous leukemia</td> </tr> <tr> <td class=\"indent1\">Treatment-based identification</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Third-line chemotherapy</td> </tr> <tr> <td class=\"subtitle1_single\">Chronic obstructive pulmonary disease<sup>[2]</sup></td> </tr> <tr> <td class=\"indent1\">Lack of further treatment options</td> </tr> <tr> <td class=\"indent1\">Functional decline</td> </tr> <tr> <td class=\"indent1\">Symptom exacerbation</td> </tr> <tr> <td class=\"indent1\">Ongoing oxygen requirement</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hospitalizations</td> </tr> <tr> <td class=\"subtitle1_single\">Congestive heart failure<sup>[3]</sup></td> </tr> <tr> <td class=\"indent1\">Increased symptoms</td> </tr> <tr> <td class=\"indent1\">Reduced function</td> </tr> <tr> <td class=\"indent1\">Hospitalization</td> </tr> <tr> <td class=\"indent1\">Progressive increase in diuretic need</td> </tr> <tr> <td class=\"indent1\">Hypotension</td> </tr> <tr> <td class=\"indent1\">Azotemia</td> </tr> <tr> <td class=\"indent1\">Initiation of inotrope therapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">First or recurrent shock</td> </tr> <tr> <td class=\"subtitle1_single\">End-stage renal disease<sup>[4,5]</sup></td> </tr> <tr> <td class=\"indent1\">Prognosis-related triggers</td> </tr> <tr> <td class=\"indent2\">\"Would you be surprised if this patient died in the next year?\"</td> </tr> <tr> <td class=\"indent1\">Albumin level less than 3.5 g/dL</td> </tr> <tr> <td class=\"indent1\">Age (as a continuous variable)</td> </tr> <tr> <td class=\"indent1\">Dementia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Peripheral vascular disease</td> </tr> <tr> <td class=\"subtitle1_single\">General</td> </tr> <tr> <td class=\"indent1\">Older than 80 years and hospitalized<sup>[6]</sup></td> </tr> <tr> <td class=\"indent1\">Prognosis-based criteria (http://www.eprognosis.org)<sup>[7]</sup></td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Moss AH, Lunney JR, Culp S, et al. Prognostic significance of the \"surprise\" question in cancer patients. J Palliat Med 2010; 13:837.</li>&#xD;&#xA;    <li>Janssen DJ, Spruit MA, Schols JM, et al. Predicting changes in preferences for life-sustaining treatment among patients with advanced chronic organ failure. Chest 2012; 141:1251.</li>&#xD;&#xA;    <li>Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 2012; 125:1928.</li>&#xD;&#xA;    <li>Davison SN, Torgunrud C. The creation of an advance care planning process for patients with ESRD. Am J Kidney Dis 2007; 49:27.</li>&#xD;&#xA;    <li>Moss AH, Ganjoo J, Sharma S, et al. Utility of the \"surprise\" question to identify dialysis patients with high mortality. Clin J Am Soc Nephrol 2008; 3:1379.</li>&#xD;&#xA;    <li>Detering KM, Hancock AD, Reade MC, Silvester W. The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. BMJ 2010; 340:c1345.</li>&#xD;&#xA;    <li>Yourman LC, Lee SJ, Schonberg MA, et al. Prognostic indices for older adults: a systematic review. JAMA 2012; 307:182.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Bernacki RE, Block SD, for the American College of Physicians High Value Care Task Force. Communication about serious illness care goals: A review and synthesis of best practices. JAMA Intern Med 2014; 174(12):1994-2003. Copyright &copy; 2014 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 106975 Version 3.0</div></div></div>"},"106977":{"type":"graphic_table","displayName":"Medications that may contribute to unintentional weight loss","title":"Examples of medications that may contribute to unintentional weight loss*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of medications that may contribute to unintentional weight loss*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Adverse effect</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Analgesic and sedative</td> <td>Benzodiazepines</td> <td>Impaired cognition, anorexia</td> </tr> <tr> <td>NSAIDs (including aspirin and COX-2 selective)</td> <td>Nausea, gastrointestinal distress, dysphagia</td> </tr> <tr class=\"divider_bottom\"> <td>Opioids</td> <td>Nausea, vomiting</td> </tr> <tr class=\"divider_bottom\"> <td>Anti-infectives</td> <td>Erythromycin, lamivudine, metronidazole, trimethoprim-sulfamethoxazole</td> <td>Anorexia, altered taste, nausea, vomiting</td> </tr> <tr class=\"divider_bottom\"> <td>Anticholinergics (antimuscarinics)<sup>&#182;</sup></td> <td>Benztropine, oxybutynin, tolterodine</td> <td>Dry mouth, nausea</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"10\">Cardiovascular</td> <td>ACE inhibitors</td> <td>Altered taste or smell</td> </tr> <tr> <td>Aspirin</td> <td>Nausea, gastrointestinal distress, dysphagia </td> </tr> <tr> <td>Calcium channel blockers</td> <td>Altered taste or smell</td> </tr> <tr> <td>Clonidine</td> <td>Dry mouth</td> </tr> <tr> <td>Digoxin</td> <td>Nausea, vomiting (particularly as serum levels increase)</td> </tr> <tr> <td>Loop diuretics</td> <td>Dry mouth</td> </tr> <tr> <td>Propranolol</td> <td>Altered taste or smell</td> </tr> <tr> <td>Spironolactone</td> <td>Altered taste or smell</td> </tr> <tr> <td>Statins</td> <td>Nausea, vomiting</td> </tr> <tr class=\"divider_bottom\"> <td>Thiazide diuretics</td> <td>Dry mouth</td> </tr> <tr class=\"divider_bottom\"> <td>Chemotherapy<sup>&#916;</sup></td> <td>Cisplatin, cyclophosphamide, carboplatin, cytarabine, doxorubicin</td> <td>Nausea, vomiting, anorexia (varies by agent and combination)<sup>&#916;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Endocrine</td> <td>Antidiabetic (eg, metformin)</td> <td>Anorexia</td> </tr> <tr> <td>Hormones (eg, estrogens)</td> <td>Nausea</td> </tr> <tr class=\"divider_bottom\"> <td>Osteoporosis (eg, bisphosphonates)</td> <td>Dysphagia, nausea</td> </tr> <tr class=\"divider_bottom\"> <td>H1 antihistamines</td> <td>Diphenhydramine</td> <td>Dry mouth</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Neurologic</td> <td>Alzheimer&nbsp;medications (eg, donepezil)</td> <td>Nausea</td> </tr> <tr> <td>Antiparkinson&nbsp;medications (eg, amantadine, carbidopa-levodopa, selegiline)</td> <td>Altered taste or smell, nausea, anorexia</td> </tr> <tr class=\"divider_bottom\"> <td>Antiseizure (eg, topiramate)</td> <td>Anorexia</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Psychiatric</td> <td>Antipsychotics</td> <td>Anorexia, nausea (varies by agent; several associated with weight gain)</td> </tr> <tr> <td>Bupropion</td> <td>Anorexia</td> </tr> <tr> <td>Lithium</td> <td>Nausea, vomiting (particularly as serum levels increase)</td> </tr> <tr> <td>SSRI antidepressants (eg, fluoxetine, paroxetine, sertraline)</td> <td>Anorexia, nausea (generally short-lived)</td> </tr> <tr class=\"divider_bottom\"> <td>Tricyclic antidepressants</td> <td>Dry mouth, nausea</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Rheumatologic</td> <td>Antigout (eg, allopurinol, colchicine)</td> <td>Altered taste or smell (allopurinol)<br /> Anorexia, nausea, vomiting (colchicine)</td> </tr> <tr class=\"divider_bottom\"> <td>Rheumatoid arthritis (eg, hydroxychloroquine)</td> <td>Anorexia, nausea, vomiting</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Supplements</td> <td>Iron</td> <td>Nausea, dysphagia, vomiting</td> </tr> <tr class=\"divider_bottom\"> <td>Potassium</td> <td>Nausea, dysphagia, vomiting</td> </tr> <tr class=\"divider_bottom\"> <td>Sympathomimetics</td> <td>Decongestants</td> <td>Anorexia</td> </tr> <tr> <td rowspan=\"2\">Other</td> <td>Alcohol</td> <td>Anorexia, gastrointestinal distress, impaired cognition, liver disease</td> </tr> <tr> <td>Nicotine</td> <td>Anorexia</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Commonly used drugs associated with loss of appetite and unintentional weight loss. Most drugs can cause nausea or vomiting. This list is not exhaustive. Increasing dose and additive effect from simultaneous use of several medicines (polypharmacy) can increase appetite suppression.</div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal antiinflammatory drugs; COX-2: cyclooxygenase-2; ACE: angiotensin-converting enzyme; SSRI: selective serotonin reuptake inhibitor.<br />* Some of the medications listed in this table are considered inappropriate for use in older adults. For additional information and potential alternatives, refer to the UpToDate topic review on drug prescribing in older adults.<br />¶ Anticholinergic activity of medications is reviewed separately. Refer to the UpToDate topic review on drug prescribing in older adults, section on anticholinergic activity and accompanying table.<br />Δ Chemotherapy drug emetogenicity, including delayed effects, is reviewed separately. Refer to the UpToDate topic review of prevention and treatment of chemotherapy-induced nausea and vomiting.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Stajkovic S, Aitken Em, Holroyd-Leduc J. Unintentional weight loss in older adults. CMAJ 2011; 183:443.</LI>&#xD;&#xA;<LI>Gaddey H, Holder K. Unintentional weight loss in older adults. Am Fam Physician 2014; 89:718.</LI>&#xD;&#xA;<LI>McMinn J, Steel C, Bowman A. Investigation and management of unintentional weight loss in older adults. BMJ 2011 Mar 29; 342:d1732.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 106977 Version 4.0</div></div></div>"},"106979":{"type":"graphic_picture","displayName":"Rigid bronchoscope II","title":"Stent placed using rigid bronchoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stent placed using rigid bronchoscopy</div><div class=\"cntnt\"><img style=\"width:388px; height:276px;\" src=\"images/PULM/106979_Stnt_plcmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows a silicone stent (arrow) and the beveled edge of the rigid scope (arrowhead) in the airway.</div><div id=\"graphicVersion\">Graphic 106979 Version 1.0</div></div></div>"},"106983":{"type":"graphic_table","displayName":"Causes of elevated triglycerides","title":"Causes of elevated triglycerides","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of elevated triglycerides</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Secondary causes</td> </tr> <tr> <td>Type 2 diabetes mellitus, if poorly controlled</td> </tr> <tr> <td>Excessive alcohol consumption</td> </tr> <tr> <td>Hypothyroidism</td> </tr> <tr> <td>Pregnancy</td> </tr> <tr> <td>Obesity</td> </tr> <tr> <td>Nephrotic syndrome</td> </tr> <tr> <td>Renal failure</td> </tr> <tr> <td>Multiple myeloma</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Drugs (eg, estrogen, tamoxifen, glucocorticoids, beta blockers, protease inhibitors)</td> </tr> <tr> <td>Glycogen storage disease</td> </tr> <tr> <td class=\"subtitle1_single\">Primary disorders of triglyceride-rich lipoprotein metabolism</td> </tr> <tr> <td>Familial dysbetalipoproteinemia</td> </tr> <tr> <td>Familial combined hyperlipidemia</td> </tr> <tr> <td>Lipoprotein lipase deficiency</td> </tr> <tr> <td>Apolipoprotein CII deficiency</td> </tr> <tr> <td>Apolipoprotein C-III overproduction</td> </tr> <tr> <td>ANGPLT<sub>3</sub> overproduction</td> </tr> <tr> <td>Cholesteryl ester storage disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANGPLT<SUB>3</SUB>: Angiopoietin-like protein 3.</div><div id=\"graphicVersion\">Graphic 106983 Version 1.0</div></div></div>"},"106986":{"type":"graphic_figure","displayName":"TEE schematic of Doppler mitral inflow velocity","title":"TEE schematic of Doppler mitral inflow velocity","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">TEE schematic of Doppler mitral inflow velocity</div><div class=\"cntnt\"><img style=\"width:461px; height:225px;\" src=\"images/ANEST/106986_TEE_schm_dpp_mtrl_inflw_vlc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mitral inflow pattern, with E-wave, A-wave, and DT labeled. This pattern of blood flow can be used to evaluate diastolic function by obtaining a mid-esophageal four-chamber view and applying a pulse-wave Doppler at the tips of the mitral leaflets in diastole. Blood flow in the early diastolic period is the E-wave, and flow in the late phase of filling is the A wave. The A-wave follows atrial contraction. A basic assessment of this inflow pattern is made by obtaining peak E- and A-wave velocities, then measuring the time from peak E-wave to baseline (DT).</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; DT: deceleration time.</div><div id=\"graphicVersion\">Graphic 106986 Version 3.0</div></div></div>"},"106987":{"type":"graphic_table","displayName":"Grading severity of mitral regurgitation by echocardiography","title":"Grading severity of mitral regurgitation by echocardiography","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading severity of mitral regurgitation by echocardiography</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mild (1+)</td> <td class=\"subtitle1\">Moderate (2+)</td> <td class=\"subtitle1\">Severe (3 to 4+)</td> </tr> <tr> <td><strong>Jet size (percent left atrium)</strong></td> <td>&#60;20%</td> <td>20 to 40%</td> <td>&#62;40% for a central jet or variable size for an eccentric wall-impinging jet</td> </tr> <tr> <td><strong>Jet duration</strong></td> <td>Often brief (ie, mid-late systolic jet)</td> <td>Variable (includes late systolic eccentric jet)</td> <td>Holosystolic jet</td> </tr> <tr> <td><strong>Vena contracta (mm)</strong></td> <td>&#60;3</td> <td>3 to 6.9</td> <td>&#8805;7</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">TEE variables used to assess mitral regurgitation. The above criteria apply to chronic mitral regurgitation (MR). In acute MR, the MR jet velocity may be lower, the jet area may not be large, and the jet is often markedly eccentric; thus acute MR may&nbsp;be underestimated or not appreciated.&nbsp;Presence of the combination of a flail leaflet or ruptured papillary muscle, pulmonary vein flow reversal, and a hyperdynamic left ventricle with low systemic output by Doppler suggest acute MR.</div><div class=\"graphic_footnotes\">MR: mitral regurgitation.</div><div id=\"graphicVersion\">Graphic 106987 Version 3.0</div></div></div>"},"106988":{"type":"graphic_diagnosticimage","displayName":"Vena contracta measurement in aortic insufficiency","title":"Vena contracta measurement in aortic insufficiency","html":"<div class=\"graphic\"><div style=\"width: 892px\" class=\"figure\"><div class=\"ttl\">Vena contracta measurement in aortic insufficiency</div><div class=\"cntnt\"><img style=\"width:872px; height:316px;\" src=\"images/ANEST/106988_VCM_aortic_insufficiency.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">From the mid-esophageal aortic valve long-axis view, a color-flow video&nbsp;loop of the regurgitant jet through the aortic valve should be captured in diastole. The video should be cycled through until the peak diastolic flow is observed in a still frame (shown here). To make a valid measurement, the frame must contain the hemisphere of flow acceleration on the aortic valve side of the outflow tract, a clear image of the narrowest neck of the jet, and the jet itself in the left ventricular outflow tract. Aliasing velocities should be between 40 and 60 cm/s, and the focus should be at the level of the valve. The vena contracta is measured at the narrowest neck of the jet (illustrated&nbsp;in the image on the right). This measurement is reproducible and relatively independent of load, making it an attractive tool for quantifying the severity of aortic regurgitation using intraoperative TEE.</SPAN></div><div id=\"graphicVersion\">Graphic 106988 Version 3.0</div></div></div>"},"106994":{"type":"graphic_table","displayName":"Clinical Opioid Withdrawal Scale (COWS)","title":"Clinical Opioid Withdrawal Scale (COWS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical Opioid Withdrawal Scale (COWS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient's name:_______________</td> <td class=\"subtitle1\">Date and time:___/___/___:______</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Reason for this assessment:_________________________</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Resting pulse rate:</strong>__________beats/minute<br /> Measured after patient is sitting or lying for one minute</td> <td class=\"indent2\"><strong>GI upset:</strong> Over last&nbsp;half-hour</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"> <p>0 pulse rate 80 or below</p> <p>1 pulse rate 81 to 100</p> <p>2 pulse rate 101 to 120</p> 4 pulse rate greater than 120</td> <td class=\"indent3\"> <p>0 no GI symptoms</p> <p>1 stomach cramps</p> <p>2 nausea or loose stool</p> <p>3 vomiting or diarrhea</p> 5 multiple episodes of diarrhea or vomiting</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Sweating:</strong> Over past&nbsp;half-hour not accounted for by room temperature or patient activity</td> <td class=\"indent2\"><strong>Tremor:</strong> Observation of outstretched hands</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"> <p>0 no report of chills or flushing</p> <p>1 subjective report of chills or flushing</p> <p>2 flushed or observable moistness on face</p> <p>3 beads of sweat on brow or face</p> 4 sweat streaming off face</td> <td class=\"indent3\"> <p>0 no tremor</p> <p>1 tremor can be felt, but not observed</p> <p>2 slight tremor observable</p> 4 gross tremor or muscle twitching</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Restlessness:</strong> Observation during assessment</td> <td class=\"indent2\"><strong>Yawning:</strong> Observation during assessment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"> <p>0 able to sit still</p> <p>1 reports difficulty sitting still, but is able to do so</p> <p>3 frequent shifting or extraneous movements of legs/arms</p> 5 unable to sit stil l for more than a few seconds</td> <td class=\"indent3\"> <p>0 no yawning</p> <p>1 yawning once or twice during assessment</p> <p>2 yawning three or more times during assessment</p> 4 yawning several times/minute</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Pupil size</strong></td> <td class=\"indent2\"><strong>Anxiety or irritability</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"> <p>0 pupils pinned or normal size for room light</p> <p>1 pupils possibly larger than normal for room light</p> <p>2 pupils moderately dilated</p> 5 pupils so dilated that only the rim of the iris is visible</td> <td class=\"indent3\"> <p>0 none</p> <p>1 patient reports increasing irritability or anxiousness</p> <p>2 patient obviously irritable or anxious</p> 4 patient so irritable or anxious that participation in the assessment is difficult</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Bone or joint aches:</strong> If patient was having pain previously, only the additional component attributed to opiates withdrawal is scored</td> <td class=\"indent2\"><strong>Gooseflesh skin</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"> <p>0 not present</p> <p>1 mild diffuse discomfort</p> <p>2 patient reports severe diffuse aching of joints/muscles</p> 4 patient is rubbing joints or muscles and is unable to sit still because of discomfort</td> <td class=\"indent3\"> <p>0 skin is smooth</p> <p>3 piloerrection of skin can be felt or hairs standing up on arms</p> 5 prominent piloerrection</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Runny nose or tearing:</strong> Not accounted for by cold symptoms or allergies</td> <td class=\"indent2\"><strong>Total score:__________</strong><br /> The total score is the sum of all 11 items</td> </tr> <tr> <td class=\"indent3\"> <p>0 not present</p> <p>1 nasal stuffiness or unusually moist eyes</p> <p>2 nose running or tearing</p> 4 nose constantly running or tears streaming down cheeks</td> <td class=\"indent3\"> <p>Initials of person</p> completing assessment:__________</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Score: 5 to 12 = mild; 13 to 24 = moderate; 25 to 36 = moderately severe; more than 36 = severe withdrawal.</div><div class=\"graphic_footnotes\">GI: gastrointestinal.</div><div class=\"graphic_reference\">Reproduced from: Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003; 35:253.</div><div id=\"graphicVersion\">Graphic 106994 Version 1.0</div></div></div>"},"106995":{"type":"graphic_figure","displayName":"HIT probability from 4 Ts score and immunoassay","title":"Approach to estimating the probability of HIT based on 4 Ts score and immunoassay results","html":"<div class=\"graphic\"><div style=\"width: 706px\" class=\"figure\"><div class=\"ttl\">Approach to estimating the probability of HIT based on 4 Ts score and immunoassay results</div><div class=\"cntnt\"><img style=\"width:686px; height:292px;\" src=\"images/HEME/106995_HITprobability.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Probability of HIT estimated from 4 Ts score and immunoassay (a&nbsp;Bayesian approach). The pre-test&nbsp;odds of HIT, based on the 4 Ts score, is derived from Cuker et al.<SUP>[1]</SUP> For likelihood ratios for various immunoassays, see Table 2 in the article by Nagler et al.<SUP innerHtml>[2] </SUP>The likelihood ratios for the polyspecific ELISA (low threshold) are shown as an example. These values can be used to calculate the post-test odds and post-test probability of HIT: Post-test odds = pre-test odds x likelihood ratio; post-test probability = post-test odds/(post-test odds + 1).</div><div class=\"graphic_footnotes\">HIT: heparin-induced thrombocytopenia.<br />* Post-test odds = pre-test odds x likelihood ratio.<br />¶ Post-test probability = (post-test odds/[post-test odds + 1]&nbsp;x 100.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>​Cuker A, Gimotty PA, Crowther MA, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012; 120:160.</LI>&#xD;&#xA;<LI>Nagler M, Bachmann LM, ten Cate H, et al. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2016; 127:546.</LI></OL>Republished with permission from the American Society of Hematology, from: Cuker A. Does my patient have HIT? There should be an app for that. Blood 2016; 127:522. Copyright © 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 106995 Version 4.0</div></div></div>"},"106996":{"type":"graphic_table","displayName":"Dutch-English LEMS Tumor Association prediction score","title":"Dutch-English LEMS Tumor Association prediction score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dutch-English LEMS Tumor Association prediction score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Abbreviation</td> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"3\">D</td> <td colspan=\"2\">Dysarthria, dysphagia, chewing, neck weakness: bulbar weakness</td> </tr> <tr> <td class=\"indent1\">Absent</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Present</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"5\">E</td> <td colspan=\"2\">Erectile dysfunction</td> </tr> <tr> <td class=\"indent1\">Female</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Male</td> </tr> <tr> <td class=\"indent2\">Absent</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Present</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"3\">L</td> <td colspan=\"2\">Loss of weight</td> </tr> <tr> <td class=\"indent1\">Absent or &#60;5%</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;5%</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"3\">T</td> <td colspan=\"2\">Tobacco use at onset</td> </tr> <tr> <td class=\"indent1\">Absent</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Present</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"3\">A</td> <td colspan=\"2\">Age of onset, years</td> </tr> <tr> <td class=\"indent1\">&#60;50</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;50</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"3\">P</td> <td colspan=\"2\">Karnofsky performance score</td> </tr> <tr> <td class=\"indent1\">70 to 100</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">0 to 60</td> <td class=\"centered\">1</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\"><strong>&nbsp;</strong></td> <td><strong>DELTA-P score</strong></td> <td class=\"centered\"><strong>0 to 6</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LEMS: Lambert-Eaton myasthenic syndrome; DELTA-P: Dutch-English LEMS Tumor Association Prediction.</div><div class=\"graphic_reference\">From: Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011; 29(7):902-8. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 106996 Version 3.0</div></div></div>"},"106997":{"type":"graphic_table","displayName":"Grading severity of aortic regurgitation by echocardiography","title":"Grading severity of aortic regurgitation by echocardiography","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading severity of aortic regurgitation by echocardiography</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\" span=\"4\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mild (1+)</td> <td class=\"subtitle1\">Moderate (2+)</td> <td class=\"subtitle1\">Severe (3 to 4+)</td> </tr> <tr> <td><strong>Vena contracta width</strong></td> <td>&#60;0.3 cm</td> <td>0.3 to 0.6 cm</td> <td>&#62;0.6 cm</td> </tr> <tr> <td><strong>Jet width/LVOT ratio (for central&nbsp;jets)</strong></td> <td>&#60;25%</td> <td>25 to 64%</td> <td>&#8805;65%</td> </tr> <tr> <td><strong>Pressure half time</strong></td> <td>&#62;500 ms</td> <td>200 to 500 ms</td> <td>&#60;200 ms</td> </tr> <tr> <td><strong>Diastolic flow reversal in descending aorta</strong></td> <td>Brief early diastolic flow reversal</td> <td>Intermediate</td> <td>Prominent holodiastolic flow reversal</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Echocardiographic&nbsp;variables used to assess aortic regurgitation. With acute aortic regurgitation, there is early closure of the mitral valve (before the R wave) and flow reversal in the proximal descending aorta may not be holodiastolic.</div><div class=\"graphic_footnotes\">LVOT: left ventricular outflow tract.</div><div id=\"graphicVersion\">Graphic 106997 Version 3.0</div></div></div>"},"106998":{"type":"graphic_diagnosticimage","displayName":"Holodiastolic flow reversal AI","title":"Holodiastolic flow reversal AI","html":"<div class=\"graphic\"><div style=\"width: 840px\" class=\"figure\"><div class=\"ttl\">Holodiastolic flow reversal AI</div><div class=\"cntnt\"><img style=\"width:820px; height:595px;\" src=\"images/ANEST/106998_Holodiastolic_flow_rvrsl_AI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Holodiastolic flow reversal seen in the descending aorta, suggesting severe aortic regurgitation. Note the presence of the ECG, which can be used to time systole and diastole.</div><div class=\"graphic_footnotes\">AI: aortic insufficiency; ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 106998 Version 1.0</div></div></div>"},"106999":{"type":"graphic_table","displayName":"Grading severity of aortic stenosis by echocardiography","title":"Grading severity of aortic stenosis by echocardiography","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading severity of aortic stenosis by echocardiography</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\" span=\"4\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> </tr> <tr> <td><strong>Valve area (cm<sup>2</sup>)</strong></td> <td>&#62;1.5</td> <td>1.1 to 1.5</td> <td>&#60;=1</td> </tr> <tr> <td><strong>Mean gradient (mmHg)</strong></td> <td>&#60;20</td> <td>20 to 39</td> <td>&#62;=40</td> </tr> <tr> <td><strong>Jet velocity (m/second)</strong></td> <td>2.6 to 2.9</td> <td>3 to 3.9</td> <td>&#62;=4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Echocardiographic variables used to assess aortic stenosis.</div><div id=\"graphicVersion\">Graphic 106999 Version 3.0</div></div></div>"}};